<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PATDOC SYSTEM "ST32-US-Grant-025xml.dtd" [
<!ENTITY US06461629-20021008-D00001.TIF SYSTEM "US06461629-20021008-D00001.TIF" NDATA TIF>
<!ENTITY US06461629-20021008-D00002.TIF SYSTEM "US06461629-20021008-D00002.TIF" NDATA TIF>
<!ENTITY US06461629-20021008-D00003.TIF SYSTEM "US06461629-20021008-D00003.TIF" NDATA TIF>
<!ENTITY US06461629-20021008-D00004.TIF SYSTEM "US06461629-20021008-D00004.TIF" NDATA TIF>
<!ENTITY US06461629-20021008-D00005.TIF SYSTEM "US06461629-20021008-D00005.TIF" NDATA TIF>
<!ENTITY US06461629-20021008-D00006.TIF SYSTEM "US06461629-20021008-D00006.TIF" NDATA TIF>
<!ENTITY US06461629-20021008-D00007.TIF SYSTEM "US06461629-20021008-D00007.TIF" NDATA TIF>
<!ENTITY US06461629-20021008-D00008.TIF SYSTEM "US06461629-20021008-D00008.TIF" NDATA TIF>
<!ENTITY US06461629-20021008-D00009.TIF SYSTEM "US06461629-20021008-D00009.TIF" NDATA TIF>
<!ENTITY US06461629-20021008-D00010.TIF SYSTEM "US06461629-20021008-D00010.TIF" NDATA TIF>
]>
<PATDOC DTD="2.5" STATUS="Build 20020918">
<SDOBI>
<B100>
<B110><DNUM><PDAT>06461629</PDAT></DNUM></B110>
<B130><PDAT>B1</PDAT></B130>
<B140><DATE><PDAT>20021008</PDAT></DATE></B140>
<B190><PDAT>US</PDAT></B190>
</B100>
<B200>
<B210><DNUM><PDAT>09562813</PDAT></DNUM></B210>
<B211US><PDAT>09</PDAT></B211US>
<B220><DATE><PDAT>20000501</PDAT></DATE></B220>
</B200>
<B500>
<B510>
<B511><PDAT>A61F  200</PDAT></B511>
<B512><PDAT>A61F  204</PDAT></B512>
<B516><PDAT>7</PDAT></B516>
</B510>
<B520>
<B521><PDAT>424422</PDAT></B521>
<B522><PDAT>424423</PDAT></B522>
<B522><PDAT>424426</PDAT></B522>
<B522><PDAT>623 12</PDAT></B522>
</B520>
<B540><STEXT><PDAT>Method of nerve regeneration using biopolymer rods with oriented fibrils</PDAT></STEXT></B540>
<B560>
<B561>
<PCIT>
<DOC><DNUM><PDAT>3114372</PDAT></DNUM>
<DATE><PDAT>19631200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Griset, Jr. et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>4018906</PDAT></DNUM>
<DATE><PDAT>19770400</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Ostendorf</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>4485096</PDAT></DNUM>
<DATE><PDAT>19841100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Bell</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>4546500</PDAT></DNUM>
<DATE><PDAT>19851000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Bell</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>4835102</PDAT></DNUM>
<DATE><PDAT>19890500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Bell et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>4837379</PDAT></DNUM>
<DATE><PDAT>19890600</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Weinberg</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>4863668</PDAT></DNUM>
<DATE><PDAT>19890900</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Griffiths et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>4955893</PDAT></DNUM>
<DATE><PDAT>19900900</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Yannas et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>606154</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5256418</PDAT></DNUM>
<DATE><PDAT>19931000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Kemp et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 89/10728</PDAT></DNUM>
<DATE><PDAT>19891100</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 93/24155</PDAT></DNUM>
<DATE><PDAT>19931200</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 95/20359</PDAT></DNUM>
<DATE><PDAT>19950800</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B562><NCIT><STEXT><PDAT>Echizenya et al., &ldquo;Mineralization and Biodegradation of CSF Shunting Systems&rdquo;, J. Neurosurgery 67 (4): 584-91 (1987).* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Azuma, T. et al., &ldquo;A rheological approach to the architecture of arterial walls&rdquo;, </PDAT><HIL><ITALIC><PDAT>Japan J. Physiol.</PDAT></ITALIC></HIL><PDAT>, 21(1):27-47 (Feb. 1971). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Barocas, V. H. et al, &ldquo;The fibroblast-populated collagen microsphere assay of cell traction force&mdash;Part 2: Measurement of the cell traction parameter&rdquo;, </PDAT><HIL><ITALIC><PDAT>Journal of Biomechanical Engineering</PDAT></ITALIC></HIL><PDAT>, 117:161-170 (May 1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Barocas, V. H. et al., &ldquo;An anisotropic biphasic theory of tissue-equivalent mechanics: The interplay among cell traction, fibrillar network deformation, fibril alignment, and cell contact guidance&rdquo;, </PDAT><HIL><ITALIC><PDAT>Journal of Biomechanical Engineering </PDAT></ITALIC></HIL><PDAT>119(2):137-145 (May 1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Barocas, V. H. et al., &ldquo;Biphasic theory and in vitro assays of cell-fibril mechanical interactions in tissue-equivalent collagen gels&rdquo;, in </PDAT><HIL><ITALIC><PDAT>Cell Mechanics and Cellular Engineering</PDAT></ITALIC></HIL><PDAT>, ed. V. C. Mow, Springer-Verlag; pp. 185-209 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Bell, E. et al., &ldquo;Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro&rdquo;, </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA</PDAT></ITALIC></HIL><PDAT>, 76(3):1274-1278 (Mar. 1979). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Bergel, D. H., &ldquo;The dynamic elastic properties of the arterial wall&rdquo;, </PDAT><HIL><ITALIC><PDAT>J. Physiol</PDAT></ITALIC></HIL><PDAT>. 156(3):458-469 (May 1961). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Burton, A., &ldquo;Relation of structure to function of the tissues of the wall of blood vessels&rdquo;, </PDAT><HIL><ITALIC><PDAT>Physiol. Rev.</PDAT></ITALIC></HIL><PDAT>, 34(4):619-642 (Oct. 1954). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Buschmann, M. D. et al., &ldquo;Chondrocytes in agarose culture synthesize a mechanically functional extracellular matrix&rdquo;, </PDAT><HIL><ITALIC><PDAT>J. Orthop. Res.</PDAT></ITALIC></HIL><PDAT>, 10(6):745-758 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Carr et al., &ldquo;The Effect of Low Cycle Fatigue on a Novel Synthetic Collagen Vascular Graft&rdquo; </PDAT><HIL><ITALIC><PDAT>Society for Biomaterials</PDAT></ITALIC></HIL><PDAT>, 20th Annual Meeting, Boxton, MA, p. 486 (Apr. 5-9, 1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Chen et al., &ldquo;The Use of Collagen Polymer Tube and Fibrin Clot in Peripheral Nerve Repair&rdquo;, </PDAT><HIL><ITALIC><PDAT>Proceedings of the National Science Coundil, ROC</PDAT></ITALIC></HIL><PDAT>, 18(2):58-63 (Apr., 1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Dickinson, R. B. et al., &ldquo;Biased cell migration of fibroblasts exhibiting contact guidance in oriented collagen gels&rdquo;, </PDAT><HIL><ITALIC><PDAT>Annals of Biomedical Engineering,</PDAT></ITALIC></HIL><PDAT>, 22(4):342-356 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Diglio, C. A. et al., &ldquo;Rat cerebral microvascular smooth muscle cells in culture&rdquo;, </PDAT><HIL><ITALIC><PDAT>Journal of Cellular Physiology</PDAT></ITALIC></HIL><PDAT>, 129:131-141 (1986). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Dubuisson et al., &ldquo;Sciatic Nerve Regeneration Across Gaps Within Collagen Chambers: The Influence of Epidermal Growth Factor&rdquo;, </PDAT><HIL><ITALIC><PDAT>Journal of Reconstructive Microsurgery</PDAT></ITALIC></HIL><PDAT>, 9(5):341-347 (Sep., 1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Flinn, R. A. et al. (Eds.), </PDAT><HIL><ITALIC><PDAT>Engineering Materials and Their Applications</PDAT></ITALIC></HIL><PDAT>, 3d Ed., pp. 75-78; Houghton Mifflin Company, Boston, Publ. (1986). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Fung, Y. C., &ldquo;5.14 The hypothesis of a solid-like cell content&rdquo;, from </PDAT><HIL><ITALIC><PDAT>Biomechanics&mdash;Mechanical Properties of Living Tissues</PDAT></ITALIC></HIL><PDAT>, Second Ed., Springer-Verlag New York, Inc. (1993); pp. 210-213. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Guenard et al., &ldquo;Syngeneic Schwann Cells Derived from Adult Nerves Seeded in Semipermeable Guidance Channels Enhance Peripheral Nerve Regeneration&rdquo;, </PDAT><HIL><ITALIC><PDAT>The Journal of Neuroscience</PDAT></ITALIC></HIL><PDAT>, 12(9):3310-3320 (Sep., 1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Guido et al., &ldquo;A Methodology for the Systematic and Quantative Study of Cell Contact Guidance in Oriented Collagen Gels. Correlation of Fibroblast Orientation and Gel Birefringence&rdquo;, </PDAT><HIL><ITALIC><PDAT>Journal of Cell Science</PDAT></ITALIC></HIL><PDAT>, 105:317-331 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Hirai et al., &ldquo;Highly Oriented, Tubular Hybrid Vascular Tissue for a Low Pressure Circulatory System&rdquo;, </PDAT><HIL><ITALIC><PDAT>ASAIO Journal</PDAT></ITALIC></HIL><PDAT>, M383-M388 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Huang, D. et al., &ldquo;Mechanisms and dynamics of mechanical strengthening in ligament-equivalent fibroblast-populated collagen matrices&rdquo;, </PDAT><HIL><ITALIC><PDAT>Annals of Biomedical Engineering</PDAT></ITALIC></HIL><PDAT>, 21(3):289-305 (May/Jun. 1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Ioku et al., &ldquo;The Effect of Collagen Gel Matrix on Regeneration of Severed Rat Sciatic Nerve&mdash;Electromyographical and Morphological Study&rdquo;, </PDAT><HIL><ITALIC><PDAT>Electromyography and Clinical Neurophysiology</PDAT></ITALIC></HIL><PDAT>, 28 (7-8) 369-372 (Nov.-Dec. 1988). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Ives, C. L. et al., &ldquo;Mechanical effects on endothelial cell morphology: In vitro assessment&rdquo;, </PDAT><HIL><ITALIC><PDAT>In Vitro Cellular </PDAT></ITALIC></HIL><PDAT>&amp; </PDAT><HIL><ITALIC><PDAT>Developmental Biology</PDAT></ITALIC></HIL><PDAT>, 22(9):500-507 (Sep. 1986). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Jain, M. K. et al., &ldquo;Mechanical stress and cellular metabolism in living soft tissue composites&rdquo;, </PDAT><HIL><ITALIC><PDAT>Biomaterials</PDAT></ITALIC></HIL><PDAT>, 11(7):465-472 (Sep. 1990). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kanda et al., &ldquo;Mechanical Stress Induced Cellular Orientation and Phenotypic Modulation of 3-D Cultured Smooth Muscle Cells&rdquo;, </PDAT><HIL><ITALIC><PDAT>ASAIO Journal</PDAT></ITALIC></HIL><PDAT>, M686-M690 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kanda, K. et al., &ldquo;In vitro reconstruction of hybrid vascular tissue&rdquo;, </PDAT><HIL><ITALIC><PDAT>ASAIO Journal</PDAT></ITALIC></HIL><PDAT>, 39(3):M561-M565 (Jul.-Sep. 1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Keeley et al., &ldquo;Peripheral Nerve Regeneration Across 14-mm Gaps: A Comparison of Autograft and Entubulation Repair Methods in the Rat&rdquo;, </PDAT><HIL><ITALIC><PDAT>Journal of Reconstructive Microsurgery</PDAT></ITALIC></HIL><PDAT>, 9(5):349-358 (Sep., 1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kim et al., Labeled Schwann Cell Transplants Versus Sural Nerve Grafts in Nerve Repair, </PDAT><HIL><ITALIC><PDAT>Journal of Neurosurgery</PDAT></ITALIC></HIL><PDAT>, 80(2):254-260 (Feb., 1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kiyotani et al., &ldquo;Experimental study of nerves regeneration in a biodegradable tube made from collagen and plyglycolic acid&rdquo;, </PDAT><HIL><ITALIC><PDAT>Asaio J.</PDAT></ITALIC></HIL><PDAT>, 41(3):M657-61 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Langer et al., &ldquo;Tissue Engineering&rdquo;, </PDAT><HIL><ITALIC><PDAT>Science</PDAT></ITALIC></HIL><PDAT>, 260:920-926 (May 14, 1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Lefebvre, F. et al., &ldquo;New artificial connective matrix-like structure made of elastin solubilized peptides and collagens: elaboration, biochemical and structural properties&rdquo;, </PDAT><HIL><ITALIC><PDAT>Biomaterials</PDAT></ITALIC></HIL><PDAT>, 13(1):28-33 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Liu, Z.-Q. et al., &ldquo;Analysis directional features in images using gabor filters&rdquo;, </PDAT><HIL><ITALIC><PDAT>Third Annual IEEE Symnposium on Computer-Based Medical Systems</PDAT></ITALIC></HIL><PDAT>, pp. 68-74 (Jun. 1990). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Madison et al., &ldquo;Point Sources of Schwann Cells Result in Growth into a Nerve Entubulation Repair Site in the Absence of Axons: Effects of Freeze-Thawing&rdquo;, </PDAT><HIL><ITALIC><PDAT>Experimental Neurology</PDAT></ITALIC></HIL><PDAT>, 128(2):266-275 (Aug., 1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Marchand et al., &ldquo;Evaluation of Two Cross-Linked Collagen Gels Implanted in the Transected Spinal Cord&rdquo;, </PDAT><HIL><ITALIC><PDAT>Brain Research Bulletin</PDAT></ITALIC></HIL><PDAT>, 30:415-422 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Moon, A.G. et al., &ldquo;Fibroblast-populated collagen microsphere assay of cell traction force: Part 1. Continuum Model&rdquo;, </PDAT><HIL><ITALIC><PDAT>AIChE Journal</PDAT></ITALIC></HIL><PDAT>, 39(1):163-177 (Jan. 1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Paino et al., &ldquo;Regrowth of axons in lesioned adult rat spinal cord: promotion by implants of cultured Schwann cells&rdquo;, </PDAT><HIL><ITALIC><PDAT>J. Neurocytology</PDAT></ITALIC></HIL><PDAT>, 23(7):433-52 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Patterson et al., Design and Evaluation of a Sensory Feedback System that Provides Grasping Pressure in a Myoelectric Hand, </PDAT><HIL><ITALIC><PDAT>Journal of Rehabilitation Research and Development</PDAT></ITALIC></HIL><PDAT>, 29(1):1-8 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Rosen et al., &ldquo;Artificial Nerve Graft Using Collagen as an Extracellular Matrix for Nerve Repair Compared with Sutured Autograft in a Rat Model&rdquo;, </PDAT><HIL><ITALIC><PDAT>Annals of Plastic Surgery</PDAT></ITALIC></HIL><PDAT>, 25(5):375-387 (Nov. 1990). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Sumpio, B. E. et al., &ldquo;Response of porcine aortic smooth muscle cells to cyclic tensional deformation in culture&rdquo;, </PDAT><HIL><ITALIC><PDAT>Journal of Surgical Research</PDAT></ITALIC></HIL><PDAT>, 44:696-701 (1988). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Sumpio, B. et la., &ldquo;Enhanced collagen production by smooth muscle cells during repetitive mechanical stretching&rdquo;, </PDAT><HIL><ITALIC><PDAT>Arch. Surg</PDAT></ITALIC></HIL><PDAT>. 123(10):1233-1236 (Oct. 1988). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Torbet et al., &ldquo;Magnetic Alignment of Collagen During Self-Assembly&rdquo;, </PDAT><HIL><ITALIC><PDAT>Biochem Journal</PDAT></ITALIC></HIL><PDAT>, 219:1056-1059 (1984). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Torbet, &ldquo;Fibrin Assembly in Human Plasma and Fibrinogen/Albumin Mixtures&rdquo;, </PDAT><HIL><ITALIC><PDAT>Biochemistry</PDAT></ITALIC></HIL><PDAT>, 25(18):4979-5350 (Sep. 9, 1986). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Tranquillo et al., 1996, </PDAT><HIL><ITALIC><PDAT>Biomaterials</PDAT></ITALIC></HIL><PDAT>, vol. 7, No. 3, pp. 349-357 &ldquo;Magnetically Orientated Tissue-Equivalent Tubes: Application to a Circumferentially Orientated Media-Equivalent&rdquo;. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Utley et al., &ldquo;Brain-Derived Neurotrophic Factor and Collagen Tubulization Enhance Functional Recovery After Peripheral Nerve Trransection and Repair&rdquo;, </PDAT><HIL><ITALIC><PDAT>Arch. Otolaryngol. Head Neck Surg.</PDAT></ITALIC></HIL><PDAT>, 122:407-413 (Apr. 1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Valentini et al., &ldquo;Collagen-and Laminin-Containing Gels Impede Peripheral Nerve Regeneration through Semipermeable Nerve Guidance Channels&rdquo;, </PDAT><HIL><ITALIC><PDAT>Experimental Neurology</PDAT></ITALIC></HIL><PDAT>, 98:350-356 (1987). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Weinberg et al., &ldquo;A Blood Vessel Model Constructed from Collagen and Cultured Vascular Cells&rdquo;, </PDAT><HIL><ITALIC><PDAT>Science</PDAT></ITALIC></HIL><PDAT>, 231:397-400 (Jan. 24, 1986). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Williams, 1987, </PDAT><HIL><ITALIC><PDAT>Neurochemical Research</PDAT></ITALIC></HIL><PDAT>, vol. 12, No. 10, pp. 851-860 &ldquo;Exogenous Fibrin Matrix Precursors Stimulate the Temporal Progress of Nerve Regeneration Within a Silicon Chamber&rdquo;. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Wolinsky, H. et al., &ldquo;Structural basis for the static mechanical properties of the aortic media&rdquo;, </PDAT><HIL><ITALIC><PDAT>Circulation Research</PDAT></ITALIC></HIL><PDAT>, 14:400-413 (Jan.-Jun. 1964). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Yannas et al., &ldquo;Regeneration of Sciatic Nerve Across 15mm Gap by Use of a Polymeric Template,&rdquo; </PDAT><HIL><ITALIC><PDAT>Advances in Biomedical Polymers</PDAT></ITALIC></HIL><PDAT>, Plenum Press: 1-9 (&copy;1987).</PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
</B560>
<B570>
<B577><PDAT>9</PDAT></B577>
<B578US><PDAT>1</PDAT></B578US>
</B570>
<B580>
<B582><PDAT>606152</PDAT></B582>
<B582><PDAT>623 12</PDAT></B582>
<B582><PDAT>424422</PDAT></B582>
<B582><PDAT>424423</PDAT></B582>
<B582><PDAT>424426</PDAT></B582>
</B580>
<B590><B595><PDAT>10</PDAT></B595><B596><PDAT>18</PDAT></B596></B590>
</B500>
<B600>
<B630><B631><PARENT-US><CDOC><DOC><DNUM><PDAT>09/562813</PDAT></DNUM></DOC></CDOC><PDOC><DOC><DNUM><PDAT>08/725916</PDAT></DNUM><DATE><PDAT>19961004</PDAT></DATE><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>00</PDAT></KIND></DOC></PDOC><PSTA><PDAT>01</PDAT></PSTA><PPUB><DOC><DNUM><PDAT>6057137</PDAT></DNUM><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>A </PDAT></KIND></DOC></PPUB></PARENT-US></B631></B630>
<B630><B632><PARENT-US><CDOC><DOC><DNUM><PDAT>08/725916</PDAT></DNUM></DOC></CDOC><PDOC><DOC><DNUM><PDAT>08/703928</PDAT></DNUM><DATE><PDAT>19960828</PDAT></DATE><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>00</PDAT></KIND></DOC></PDOC><PSTA><PDAT>01</PDAT></PSTA><PPUB><DOC><DNUM><PDAT>5948654</PDAT></DNUM><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>A </PDAT></KIND></DOC></PPUB></PARENT-US></B632></B630>
<B630><B631><PARENT-US><CDOC><DOC><DNUM><PDAT>08/703928</PDAT></DNUM></DOC></CDOC><PDOC><DOC><DNUM><PDAT>08/319291</PDAT></DNUM><DATE><PDAT>19941006</PDAT></DATE><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>00</PDAT></KIND></DOC></PDOC><PSTA><PDAT>03</PDAT></PSTA></PARENT-US></B631></B630>
</B600>
<B700>
<B720>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Robert T.</PDAT></FNM><SNM><STEXT><PDAT>Tranquillo</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Roseville</PDAT></CITY>
<STATE><PDAT>MN</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Stefano</PDAT></FNM><SNM><STEXT><PDAT>Guido</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Naples</PDAT></CITY>
<CTRY><PDAT>IT</PDAT></CTRY>
</ADR>
</PARTY-US>
</B721>
</B720>
<B730>
<B731>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Regents of the University of Minnesota</PDAT></STEXT></ONM></NAM>
<ADR><CITY><PDAT>Minneapolis</PDAT></CITY><STATE><PDAT>MN</PDAT></STATE></ADR>
</PARTY-US>
</B731>
<B732US>
<PDAT>02</PDAT>
</B732US>
</B730>
<B740>
<B741>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Merchant &amp; Gould P.C.</PDAT></STEXT></ONM></NAM>
</PARTY-US>
</B741>
</B740>
<B745>
<B746>
<PARTY-US>
<NAM><FNM><PDAT>Sandra</PDAT></FNM><SNM><STEXT><PDAT>Saucier</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B746>
<B748US><PDAT>1651</PDAT></B748US>
</B745>
</B700>
</SDOBI>
<SDOAB>
<BTEXT>
<PARA ID="P-00001" LVL="0"><PTEXT><PDAT>Tissue-equivalent and biopolymer tubes and rods include fibrils which are oriented (aligned) by a magnetic field. These oriented fibrils provide enhanced mechanical and cell guidance properties to the tissue-equivalent and biopolymer tubes. One such tissue-equivalent tube includes a body of collagen gel with mammalian tissue cells interspersed therein. The collagen fibrils are circumferentially oriented within the tubular body by a magnetic field, thereby inducing circumferential orientation of the cells. One such biopolymer rod includes collagen fibrils longitudinally oriented along the rod axis by a magnetic field that guides invasion of cells. Methods of making magnetically oriented tissue-equivalent and biopolymer tubes and rods are also disclosed.</PDAT></PTEXT></PARA>
</BTEXT>
</SDOAB>
<SDODE>
<RELAPP>
<BTEXT>
<PARA ID="P-00002" LVL="0"><PTEXT><PDAT>This application is a Continuation of application Ser. No. 08/725,916, filed Oct. 4, 1996 now U.S. Pat. No. 6,057,137, which is a Continuation-In-Part of application Ser. No. 08/703,928, filed Aug. 28, 1996 now U.S. Pat. No. 5,948,654, Continuation of application Ser. No. 08/319,291, filed Oct. 6, 1994, now abandoned. These applications are incorporated herein by reference.</PDAT></PTEXT></PARA>
</BTEXT>
</RELAPP>
<GOVINT>
<BTEXT>
<H LVL="1"><STEXT><PDAT>GOVERNMENT SUPPORT</PDAT></STEXT></H>
<PARA ID="P-00003" LVL="0"><PTEXT><PDAT>This invention was made with Government support under Presidential Young Investigator Award BCS-8957736 and BES-9522758, awarded by the National Science Foundation. The Government has certain rights in the invention.</PDAT></PTEXT></PARA>
</BTEXT>
</GOVINT>
<BRFSUM>
<BTEXT>
<H LVL="1"><STEXT><PDAT>FIELD OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00004" LVL="0"><PTEXT><PDAT>This invention relates to oriented tissue-equivalent and biopolymer tubes and in particular bioartificial arteries made of Type I collagen formed into tubes having collagen fibrils circumferentially oriented by a magnetic field. The present invention additionally relates to tissue regeneration structures, and in particular tissue-equivalent and biopolymer rods for nerve regeneration.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>BACKGROUND OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00005" LVL="0"><PTEXT><PDAT>The demand for artificial blood vessels, and in particular, artificial arteries is great. This is due to the fact that over 600,000 surgical procedures involving large and small blood vessels are conducted annually.</PDAT></PTEXT></PARA>
<PARA ID="P-00006" LVL="0"><PTEXT><PDAT>Arteries are complex structures, as the cellular and extracellular components of the artery wall are not uniformly distributed. Rather, these cellular and extracellular components are organized into discrete layers. These discrete layers have a trilaminant structure of an intima, a media and an adventitia.</PDAT></PTEXT></PARA>
<PARA ID="P-00007" LVL="0"><PTEXT><PDAT>The mechanical properties of the artery wall are largely due to components of the vessel media layer. Elastin is the most extensible component of the vessel media, whereas collagen is relatively stiff. The presence of smooth muscle cells is important for two reasons. First, the smooth muscle cells synthesize the elastin and collagen present in the vessel media and second, they are capable of contraction and relaxation in response to various external stimuli including vasoactive substances in the blood and sympathetic and parasympathetic nerve impulses. These smooth muscle cells are thus an important source of structural protein that contribute directly to the strength and elasticity of the vessel wall and represent a component of variable elasticity participating in the regulation of vessel tone.</PDAT></PTEXT></PARA>
<PARA ID="P-00008" LVL="0"><PTEXT><PDAT>The elastin and collagen components confer a non-linear stress-strain relationship, in which the elastic modulus of the vessel wall increases (the vessel becomes stiffer) as the vessel is distended. The importance of organization to mechanical function in the arterial wall is clearly seen when arteries are compared to veins of similar size. In arteries, the circumferentially or (helically) oriented smooth muscle cells and associated elastin and collagen of the media, provide the mechanical strength necessary to withstand the higher pressures that exist in the arterial circulation. In contrast, the media layer of a vein of similar size is reduced in thickness, contains fewer smooth muscle cells, less elastin, and lastly little circumferential orientation of smooth muscle collagen and elastin seen as in the arteries.</PDAT></PTEXT></PARA>
<PARA ID="P-00009" LVL="0"><PTEXT><PDAT>Several attempts have been made at creating a completely bioartificial artery. Weinberg and Bell, &ldquo;A Blood Vessel Model Construction from Collagen and Cultured Vascular Cells&rdquo; in </PDAT><HIL><ITALIC><PDAT>Science</PDAT></ITALIC></HIL><PDAT>, Vol. 231 (1986), pp. 397-400, reported production of an artery involving smooth muscle cells and fibroblasts in layers of reconstituted Type I collagen that approximate the laminate structure, but not the circumferential orientation of natural arteries. These vessel analogs lacked the mechanical strength necessary to withstand the stress associated with pulsatile blood flow in vivo. To increase the strength, proponents of the Weinberg and Bell approach were forced to reinforce these arteries with synthetic polymer sheaths, such as Dacron&reg;. These bioartificial arteries exhibit a severe drawback in that biocompatability problems can ultimately lead to graft failure as reported by Langer and Vacanti, &ldquo;Tissue Engineering&rdquo; in </PDAT><HIL><ITALIC><PDAT>Science</PDAT></ITALIC></HIL><PDAT>, Vol. 260 (1993), pp. 920-926. Kanada et al., &ldquo;Mechanical Stress Induced Cellular Orientation and Phenotypic Modulation of 3-D Cultured Smooth Muscle Cells&rdquo; in </PDAT><HIL><ITALIC><PDAT>ASAIO Journal</PDAT></ITALIC></HIL><PDAT>, (1993), pp. M686-M690, reported a biohybrid vessel which includes polyurethane in order to obtain the appropriate mechanical properties.</PDAT></PTEXT></PARA>
<PARA ID="P-00010" LVL="0"><PTEXT><PDAT>The orientation of fibrils and cells in collagen has been studied. For example, Torbet and Ronziere, &ldquo;Magnetic Alignment of Collagen During Self-Assembly&rdquo; in </PDAT><HIL><ITALIC><PDAT>Biochem. J</PDAT></ITALIC></HIL><PDAT>., Vol. 219 (1984), pp. 1057-1059, reported collagen fibril orientation in the presence of a magnetic field. Additionally, Guido and Tranquillo, &ldquo;A Methodology for the Systematic and Quantitative Study of Cell Contact Guidance in Oriented Collagen Gels&rdquo; in </PDAT><HIL><ITALIC><PDAT>Journal of Cell Science</PDAT></ITALIC></HIL><PDAT>, Vol. 105 (1993), pp. 317-331, reported that cells orient in the same direction as the oriented collagen fibrils, under the phenomen known as &ldquo;cell contact guidance&rdquo;.</PDAT></PTEXT></PARA>
<PARA ID="P-00011" LVL="0"><PTEXT><PDAT>Despite the study of fibril and cell orientation, there remains the need to provide a tissue-equivalent tube that has mechanical properties that enable it-to better withstand distention, typically associated with pulsatile blood flow in arteries, without reinforcing synthetic materials.</PDAT></PTEXT></PARA>
<PARA ID="P-00012" LVL="0"><PTEXT><PDAT>Additionally, regeneration of severed peripheral nerves commonly results in permanent damage and disability because mature neurons do not normally replicate. Once severed, the severed ends of the neurons usually grow in a misdirected manner, such that they do not reestablish the original connection. Numerous attempts have been made to reestablish the connections, including the placement of a tube filled with a matrix for bridging the nerve endings. For Example, Rosen, &ldquo;Artificial Nerve Graft Using Collagen as an Extracelluar Matrix for Nerve Repair Compared with Suture Autograft in a Rat Model&rdquo;, in </PDAT><HIL><ITALIC><PDAT>Annals of Plastic Surgery</PDAT></ITALIC></HIL><PDAT>, 25:375-387 (1990) reported slightly inferior nerve regeneration using tubes filled with collagen gel as compared to nerve autografts, whereas Valentini, et al., &ldquo;Collagen and Laminin Containing Gels Impede Peripheral Nerve Regeneration through Semipermeable Nerve Guidance Channels&rdquo;, in </PDAT><HIL><ITALIC><PDAT>Experimental Neurology</PDAT></ITALIC></HIL><PDAT>, 98:350-356 (1987) reported greatly inferior nerve regeneration as compared to saline-filled tubes.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SUMMARY OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00013" LVL="0"><PTEXT><PDAT>The present invention comprises a tissue-equivalent tube that has a cylindrical body made of a reconstituted collagen network with smooth muscle cells interspersed therein. The collagen network is comprised of fibrils that orient circumferentially within the tubular body. The cells are induced by the oriented fibrils to also orient circumferentially. The circumferential orientation of fibrils and cells is characteristic of a native artery and results in improved mechanical properties.</PDAT></PTEXT></PARA>
<PARA ID="P-00014" LVL="0"><PTEXT><PDAT>The tissue-equivalent tube is formed by a tubular mold having a central rod and a concentric outer member, aligned to provide a cavity between the central rod and the outer member. The mold includes a longitudinal axis, extending the length of the mold. The cavity is then filled with a solution of collagen and mammalian tissue cells. In one embodiment, the filled tubular mold is then placed into a high strength magnetic field such that the longitudinal axis of the tubular mold is substantially parallel to the direction of the magnetic field. The magnetic field orients the forming collagen fibrils normal to the direction of the magnetic field, such that the collagen fibrils are oriented circumferentially with respect to the tube.</PDAT></PTEXT></PARA>
<PARA ID="P-00015" LVL="0"><PTEXT><PDAT>The invention additionally comprises tissue-equivalent and biopolymer rods, along with methods for their manufacture and use. In particular, these tissue-equivalent and biopolymer rods include axially (longitudinally) aligned collagen fibrils that provide a guidance field to exploit the contact response in growth cones at the tips of severed nerve endings (neurite tips) to effectively direct nerve cell growth across the gap between severed nerve endings, regenerating mature nerves.</PDAT></PTEXT></PARA>
<PARA ID="P-00016" LVL="0"><PTEXT><PDAT>The tissue-equivalent rods are formed by using a cylindrical (rod-shaped) mold with a cavity therein, including a longitudinal axis extending the length of, the mold and a transverse axis extending the width of the mold. The cavity is then filled with a solution of collagen and mammalian tissue cells, preferably Schwann Cells. In one embodiment, the filled cylindrical mold is then placed into a high strength magnetic field such that the longitudinal axis of the tubular mold is substantially perpendicular to the direction of the magnetic field. The magnetic field aligns (orients) the forming collagen fibrils normal (perpendicular) to the direction of the magnetic field, such that the collagen fibrils are aligned (oriented) substantially parallel to the direction of the longitudinal axis.</PDAT></PTEXT></PARA>
<PARA ID="P-00017" LVL="0"><PTEXT><PDAT>The biopolymer rods are formed by using a cylindrical mold with a cavity therein, including a longitudinal axis extending the length of the mold and a transverse axis extending the width of the mold. The cavity is then filled with a solution of collagen and polymer beads, that include encapsulated neurotrophic factors. In one embodiment, the filled cylindrical mold is then placed into a high strength magnetic field such that the longitudinal axis of the cylindrical mold is substantially perpendicular to the direction of the magnetic field. The magnetic field aligns (orients) the forming collagen fibrils normal (perpendicular) to the direction of the magnetic field, such that the collagen fibrils are aligned (oriented) substantially parallel to the direction of the longitudinal axis.</PDAT></PTEXT></PARA>
</BTEXT>
</BRFSUM>
<DRWDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BRIEF DESCRIPTION OF THE DRAWINGS</PDAT></STEXT></H>
<PARA ID="P-00018" LVL="0"><PTEXT><PDAT>The present invention will be described with reference to the accompanying drawings, wherein like reference numerals identify like components.</PDAT></PTEXT></PARA>
<PARA ID="P-00019" LVL="0"><PTEXT><PDAT>In the drawings:</PDAT></PTEXT></PARA>
<PARA ID="P-00020" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT> is a side view of the tubular mold of the present invention;</PDAT></PTEXT></PARA>
<PARA ID="P-00021" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> is an illustration of a control tissue-equivalent tube;</PDAT></PTEXT></PARA>
<PARA ID="P-00022" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> is an illustration of a circumferentially oriented tissue-equivalent tube of the present invention;</PDAT></PTEXT></PARA>
<PARA ID="P-00023" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT> is an illustration of an axially oriented biopolymer tube of the present invention;</PDAT></PTEXT></PARA>
<PARA ID="P-00024" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 5</PDAT></FGREF><PDAT> is a micrograph of the control tissue-equivalent tube;</PDAT></PTEXT></PARA>
<PARA ID="P-00025" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 6</PDAT></FGREF><PDAT> is a micrograph of the circumferentially oriented tissue-equivalent tube of the present invention;</PDAT></PTEXT></PARA>
<PARA ID="P-00026" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 7</PDAT></FGREF><PDAT> is a chart of a creep test in the circumferential direction on the control tissue-equivalent tube and the circumferentially oriented tissue-equivalent tube of the present invention.</PDAT></PTEXT></PARA>
<PARA ID="P-00027" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 8</PDAT></FGREF><PDAT> is a perspective view of a cylindrical mold of the invention;</PDAT></PTEXT></PARA>
<PARA ID="P-00028" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 9</PDAT></FGREF><PDAT> is a perspective view of the cylindrical mold of the invention having been filled with a collagen solution that is forming collagen fibrils in the presence of a magnetic field (B);</PDAT></PTEXT></PARA>
<PARA ID="P-00029" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 10</PDAT></FGREF><PDAT> is a perspective view of an axially aligned biopolymer or tissue-equivalent (collagen gel) rod of the present invention;</PDAT></PTEXT></PARA>
<PARA ID="P-00030" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 11</PDAT></FGREF><HIL><ITALIC><PDAT>a </PDAT></ITALIC></HIL><PDAT>is a perspective view of a severed nerve;</PDAT></PTEXT></PARA>
<PARA ID="P-00031" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 11</PDAT></FGREF><HIL><ITALIC><PDAT>b </PDAT></ITALIC></HIL><PDAT>is a perspective view of the axially aligned biopolymer or tissue-equivalent (collagen gel) rod of the present invention being applied to the severed nerve of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 11</PDAT></FGREF><HIL><ITALIC><PDAT>a; </PDAT></ITALIC></HIL></PTEXT></PARA>
<PARA ID="P-00032" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 12</PDAT></FGREF><HIL><ITALIC><PDAT>a </PDAT></ITALIC></HIL><PDAT>is a micrograph of a dorsal root ganglia (DRG) cultured in an aligned biopolymer (collagen gel) rod;</PDAT></PTEXT></PARA>
<PARA ID="P-00033" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 12</PDAT></FGREF><HIL><ITALIC><PDAT>b </PDAT></ITALIC></HIL><PDAT>is a micrograph of a dorsal root ganglia cultured in an isotropic biopolymer (collagen gel) rod;</PDAT></PTEXT></PARA>
<PARA ID="P-00034" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 13</PDAT></FGREF><HIL><ITALIC><PDAT>a </PDAT></ITALIC></HIL><PDAT>is a perspective view of a dorsal root ganglia having been placed onto one end of an aligned biopolymer (collagen gel) rod of the present invention;</PDAT></PTEXT></PARA>
<PARA ID="P-00035" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 13</PDAT></FGREF><HIL><ITALIC><PDAT>b </PDAT></ITALIC></HIL><PDAT>is a perspective view of a dorsal root ganglia having been placed onto one end of a non-aligned (isotropic) biopolymer (collagen gel) rod;</PDAT></PTEXT></PARA>
<PARA ID="P-00036" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 14</PDAT></FGREF><HIL><ITALIC><PDAT>a </PDAT></ITALIC></HIL><PDAT>is a birefringence diagram of light intensity (mean gray level) versus rotation (degrees) for the longitudinally aligned (oriented) biopolymer (collagen gel) rod of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 13</PDAT></FGREF><HIL><ITALIC><PDAT>a </PDAT></ITALIC></HIL><PDAT>of the present invention; and</PDAT></PTEXT></PARA>
<PARA ID="P-00037" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 14</PDAT></FGREF><HIL><ITALIC><PDAT>b </PDAT></ITALIC></HIL><PDAT>is a birefringence diagram of light intensity (mean gray level) versus rotation (degrees) for the isotropic biopolymer (collagen gel) rod of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 13</PDAT></FGREF><HIL><ITALIC><PDAT>b.</PDAT></ITALIC></HIL></PTEXT></PARA>
</BTEXT>
</DRWDESC>
<DETDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>DETAILED DESCRIPTION OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00038" LVL="0"><PTEXT><PDAT>As used in the present invention, &ldquo;tissue-equivalent tubes&rdquo; or &ldquo;tissue-equivalent rods&rdquo; refer to tubes or rods formed of collagen or fibrin and mammalian tissue cells. &ldquo;Biopolymer tubes&rdquo; or &ldquo;biopolymer rods&rdquo; refer to tubes or rods formed of collagen or fibrin, without the mammalian tissue cells. The term &ldquo;oriented&rdquo;, refers to the fibrils of the collagen or fibrin, which form the tissue-equivalent or biopolymer tubes, or rods, respectively, being substantially aligned in a specific direction, e.g., axially (along the longitudinal axis of the tube or rod).</PDAT></PTEXT></PARA>
<PARA ID="P-00039" LVL="0"><PTEXT><PDAT>The oriented tissue-equivalent tubes of the invention are formed of a solution comprising collagen and mammalian tissue cells, placed into a tubular mold, and subjected to a magnetic field, causing the forming collagen fibrils to become oriented in a direction substantially normal to the direction of the magnetic field. Accordingly, a filled tubular mold placed into the magnetic field, such that its longitudinal axis is parallel to the magnetic field, will have circumferentially oriented fibers, while a filled tubular mold, placed into the magnetic field such that its longitudinal axis is substantially perpendicular to the direction of the magnetic field, will have axially oriented fibrils.</PDAT></PTEXT></PARA>
<PARA ID="P-00040" LVL="0"><PTEXT><PDAT>Additionally, biopolymer tubes can be made of pure collagen. Unlike the tissue-equivalent tubes, these biopolymer tubes lack mammalian tissue cells. However, similar to the tissue-equivalent tubes made of the collagen solution (collagen and mammalian tissue cells), the collagen fibrils orient in the desired direction based upon the positioning of the filled tubular mold with respect to the direction of the magnetic field.</PDAT></PTEXT></PARA>
<PARA ID="P-00041" LVL="0"><PTEXT><PDAT>Moreover, tissue-equivalent tubes and biopolymer tubes could be made by the method of the present invention by another tissue matrix material such as fibrin. A fibrin-forming solution, prepared in accordance with conventional methods known in the art, would be placed in a tubular mold and subjected to a magnetic field. As reported by Torbet, &ldquo;Fibrin Assembly in Human Plasma and Fibrinogen/Albumin Mixtures&rdquo; in </PDAT><HIL><ITALIC><PDAT>Biochemistry</PDAT></ITALIC></HIL><PDAT>, Vol. </PDAT><HIL><ITALIC><HIL><BOLD><PDAT>25</PDAT></BOLD></HIL></ITALIC></HIL><PDAT>(1986), pp. 5309-5314, which is incorporated by reference herein, fibrin fibrils, when subjected to a magnetic field, orient in a direction substantially parallel to the direction of the magnetic field. This behavior in the presence of a magnetic field is opposite that of collagen fibrils. Accordingly, a tubular mold formed with fibrin-forming solution, and placed into the magnetic field such that its longitudinal axis is parallel to the magnetic field will have axially oriented fibers, while a filled tubular mold placed into the magnetic field such that its longitudinal axis is substantially perpendicular to the direction of the magnetic field will have circumferentially oriented fibrils.</PDAT></PTEXT></PARA>
<PARA ID="P-00042" LVL="0"><PTEXT><PDAT>The collagen referred to above is any monomeric collagen, that self-assembles into fibrils, such as Type I collagen or the like, prepared by any conventional procedures. The mammalian tissue cells referred to above could be grown by any conventional cell growth and culturing method. The tubular molds referred to above could be any mold having a solid rod concentric with an outer member. Both the solid central rod and the outer member are made of materials which will not adhere to the gelled solution, in order that a tube with an open central lumen can be removed.</PDAT></PTEXT></PARA>
<PARA ID="P-00043" LVL="0"><PTEXT><PDAT>The present invention envisions molds of single and multiple piece construction. For example, the solid central rod and outer member can be discrete members. In such a case, the outer member is preferably a cylindrical tube. However, rectangular or hexagonal shaped tubes, or the like may also be used. A separate solid rod serves as a second component of the mold. This rod can be formed as a separate member, attached to a plunger (if a syringe barrel forms the outer member) or other portion of the outer member of the mold. The solid rod can also be formed integral with the plunger. Alternately, a single piece construction, having a formed outer member, bore, barrel, or the like, with an internally positioned axial rod component is permissible. The dimensions and spatial relationships of the outer member and central rod can be varied by one skilled in the art, based on the disclosures herein. Additionally, the tubular mold, or various components thereof, can be made of materials such as Teflon&reg; polyethylene, polypropylene, polyurethane, other equivalent plastic materials, or other non-porous non-magnetic materials.</PDAT></PTEXT></PARA>
<PARA ID="P-00044" LVL="0"><PTEXT><PDAT>Turning now to the drawing figures, which show embodiments of the present invention, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT> shows a tubular mold </PDAT><HIL><BOLD><PDAT>20</PDAT></BOLD></HIL><PDAT> for making the tissue-equivalent tubes and biopolymer tubes of the invention. The tubular mold </PDAT><HIL><BOLD><PDAT>20</PDAT></BOLD></HIL><PDAT> is formed from a Teflon&reg; rod </PDAT><HIL><BOLD><PDAT>22</PDAT></BOLD></HIL><PDAT> and a cylinder </PDAT><HIL><BOLD><PDAT>24</PDAT></BOLD></HIL><PDAT>, preferably formed of a syringe barrel. The Teflon&reg; rod </PDAT><HIL><BOLD><PDAT>22</PDAT></BOLD></HIL><PDAT> is attached to a plunger </PDAT><HIL><BOLD><PDAT>26</PDAT></BOLD></HIL><PDAT> at the plunger disc </PDAT><HIL><BOLD><PDAT>28</PDAT></BOLD></HIL><PDAT>. The disc </PDAT><HIL><BOLD><PDAT>28</PDAT></BOLD></HIL><PDAT> frictionally engages the inner surface </PDAT><HIL><BOLD><PDAT>30</PDAT></BOLD></HIL><PDAT> of the cylinder </PDAT><HIL><BOLD><PDAT>24</PDAT></BOLD></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00045" LVL="0"><PTEXT><PDAT>The Teflon&reg; rod </PDAT><HIL><BOLD><PDAT>22</PDAT></BOLD></HIL><PDAT> is preferably at the center of the cylinder </PDAT><HIL><BOLD><PDAT>24</PDAT></BOLD></HIL><PDAT>. The inner surface </PDAT><HIL><BOLD><PDAT>30</PDAT></BOLD></HIL><PDAT> of the cylinder </PDAT><HIL><BOLD><PDAT>24</PDAT></BOLD></HIL><PDAT> and the outer surface </PDAT><HIL><BOLD><PDAT>32</PDAT></BOLD></HIL><PDAT> of the Teflon&reg; rod </PDAT><HIL><BOLD><PDAT>22</PDAT></BOLD></HIL><PDAT> are spaced apart such that there is a tubular cavity </PDAT><HIL><BOLD><PDAT>34</PDAT></BOLD></HIL><PDAT> in the space therebetween. The Teflon&reg; rod </PDAT><HIL><BOLD><PDAT>22</PDAT></BOLD></HIL><PDAT> is positioned in this manner to provide the resultant tubes </PDAT><HIL><BOLD><PDAT>40</PDAT></BOLD></HIL><PDAT>, </PDAT><HIL><BOLD><PDAT>50</PDAT></BOLD></HIL><PDAT>, </PDAT><HIL><BOLD><PDAT>60</PDAT></BOLD></HIL><PDAT> (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 2-4</PDAT></FGREF><PDAT>) with a central lumen </PDAT><HIL><BOLD><PDAT>44</PDAT></BOLD></HIL><PDAT>, </PDAT><HIL><BOLD><PDAT>54</PDAT></BOLD></HIL><PDAT>, </PDAT><HIL><BOLD><PDAT>64</PDAT></BOLD></HIL><PDAT> (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 2-4</PDAT></FGREF><PDAT>) upon removal from the tubular mold </PDAT><HIL><BOLD><PDAT>20</PDAT></BOLD></HIL><PDAT>. The tubular mold </PDAT><HIL><BOLD><PDAT>20</PDAT></BOLD></HIL><PDAT> includes an opening </PDAT><HIL><BOLD><PDAT>35</PDAT></BOLD></HIL><PDAT> for receiving the collagen solution and openings </PDAT><HIL><BOLD><PDAT>36</PDAT></BOLD></HIL><PDAT> for releasing air displaced by the collagen solution. The tubular mold </PDAT><HIL><BOLD><PDAT>20</PDAT></BOLD></HIL><PDAT> is designed such that a collagen solution injected therein can be easily removed as a collagen tube.</PDAT></PTEXT></PARA>
<PARA ID="P-00046" LVL="0"><PTEXT><PDAT>This tubular mold </PDAT><HIL><BOLD><PDAT>20</PDAT></BOLD></HIL><PDAT> includes a longitudinal axis </PDAT><HIL><BOLD><PDAT>38</PDAT></BOLD></HIL><PDAT> and a transverse axis </PDAT><HIL><BOLD><PDAT>39</PDAT></BOLD></HIL><PDAT>. These axes </PDAT><HIL><BOLD><PDAT>38</PDAT></BOLD></HIL><PDAT>, </PDAT><HIL><BOLD><PDAT>39</PDAT></BOLD></HIL><PDAT> will be used to illustrate the directions of fibril orientation.</PDAT></PTEXT></PARA>
<PARA ID="P-00047" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> shows a tissue-equivalent tube </PDAT><HIL><BOLD><PDAT>40</PDAT></BOLD></HIL><PDAT>, made from the tubular mold </PDAT><HIL><BOLD><PDAT>20</PDAT></BOLD></HIL><PDAT> of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>, that is used as a control. The tube </PDAT><HIL><BOLD><PDAT>40</PDAT></BOLD></HIL><PDAT> has a cylindrical body </PDAT><HIL><BOLD><PDAT>42</PDAT></BOLD></HIL><PDAT> around a central lumen </PDAT><HIL><BOLD><PDAT>44</PDAT></BOLD></HIL><PDAT>. The body </PDAT><HIL><BOLD><PDAT>42</PDAT></BOLD></HIL><PDAT> includes randomly oriented collagen fibrils </PDAT><HIL><BOLD><PDAT>45</PDAT></BOLD></HIL><PDAT> and mammalian tissue cells </PDAT><HIL><BOLD><PDAT>46</PDAT></BOLD></HIL><PDAT>. The tube </PDAT><HIL><BOLD><PDAT>40</PDAT></BOLD></HIL><PDAT> is formed from a solution of collagen and mammalian tissue cells injected into the tubular mold </PDAT><HIL><BOLD><PDAT>20</PDAT></BOLD></HIL><PDAT> (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>) and removed once the collagen has self-assembled into fibrils </PDAT><HIL><BOLD><PDAT>45</PDAT></BOLD></HIL><PDAT> entrapping the mammalian tissue cells </PDAT><HIL><BOLD><PDAT>46</PDAT></BOLD></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00048" LVL="0"><PTEXT><PDAT>The collagen used for this control tube </PDAT><HIL><BOLD><PDAT>40</PDAT></BOLD></HIL><PDAT> is preferably monomeric Type I collagen, or the like, in a cold (approximately 5&deg; C.) neutral solution. The mammalian tissue cells are preferably smooth muscle cells having been grown by conventional cell growth and culture methods, well known to those skilled in the art. The mammalian tissue cells are then dispersed into the cold collagen solution in accordance with the procedure detailed below in Example 1.</PDAT></PTEXT></PARA>
<PARA ID="P-00049" LVL="0"><PTEXT><PDAT>The cold solution is then injected into small (pinhole sized) openings </PDAT><HIL><BOLD><PDAT>35</PDAT></BOLD></HIL><PDAT> in the tubular mold </PDAT><HIL><BOLD><PDAT>20</PDAT></BOLD></HIL><PDAT>. Fibrillogenesis begins as the tubular mold </PDAT><HIL><BOLD><PDAT>20</PDAT></BOLD></HIL><PDAT> (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>) is then transferred to a constant temperature box, for incubation in the temperature range of approximately 30&deg; C. to 40&deg; C. for approximately two hours, during which firbillogenesis is normally completed. These steps, as well as additional steps required to complete the fabrication of the control tube </PDAT><HIL><BOLD><PDAT>40</PDAT></BOLD></HIL><PDAT>, are described in detail in Example 1, below.</PDAT></PTEXT></PARA>
<PARA ID="P-00050" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> shows a tissue-equivalent tube </PDAT><HIL><BOLD><PDAT>50</PDAT></BOLD></HIL><PDAT> of the invention. This tube </PDAT><HIL><BOLD><PDAT>50</PDAT></BOLD></HIL><PDAT> has a cylindrical body </PDAT><HIL><BOLD><PDAT>52</PDAT></BOLD></HIL><PDAT> around a central lumen </PDAT><HIL><BOLD><PDAT>54</PDAT></BOLD></HIL><PDAT>. The body </PDAT><HIL><BOLD><PDAT>52</PDAT></BOLD></HIL><PDAT> includes circumferentially oriented collagen fibrils </PDAT><HIL><BOLD><PDAT>55</PDAT></BOLD></HIL><PDAT> and mammalian tissue cells </PDAT><HIL><BOLD><PDAT>56</PDAT></BOLD></HIL><PDAT>. The tube </PDAT><HIL><BOLD><PDAT>50</PDAT></BOLD></HIL><PDAT> includes a longitudinal axis </PDAT><HIL><BOLD><PDAT>58</PDAT></BOLD></HIL><PDAT> and a transverse axis </PDAT><HIL><BOLD><PDAT>59</PDAT></BOLD></HIL><PDAT> and is formed from a solution of collagen, including fibrils </PDAT><HIL><BOLD><PDAT>55</PDAT></BOLD></HIL><PDAT>, with mammalian tissue cells </PDAT><HIL><BOLD><PDAT>56</PDAT></BOLD></HIL><PDAT>. The collagen fibrils </PDAT><HIL><BOLD><PDAT>55</PDAT></BOLD></HIL><PDAT> and mammalian tissue cells </PDAT><HIL><BOLD><PDAT>56</PDAT></BOLD></HIL><PDAT> of this tube </PDAT><HIL><BOLD><PDAT>50</PDAT></BOLD></HIL><PDAT> are circumferentially oriented along the transverse axis </PDAT><HIL><BOLD><PDAT>59</PDAT></BOLD></HIL><PDAT>. This circumferential orientation of fibrils </PDAT><HIL><BOLD><PDAT>55</PDAT></BOLD></HIL><PDAT> and mammalian tissue cells </PDAT><HIL><BOLD><PDAT>56</PDAT></BOLD></HIL><PDAT> in the tube </PDAT><HIL><BOLD><PDAT>50</PDAT></BOLD></HIL><PDAT> provides enhanced mechanical strength in the transverse direction, to help prevent it from longitudinal splitting. Additionally, it is believed that the mammalian tissue cells </PDAT><HIL><BOLD><PDAT>56</PDAT></BOLD></HIL><PDAT>, further mechanically strengthen the circumferentially oriented tube </PDAT><HIL><BOLD><PDAT>50</PDAT></BOLD></HIL><PDAT> by a phenomenon known as &ldquo;cell traction&rdquo;. This phenomenon of &ldquo;cell traction&rdquo; occurs as the mammalian tissue cells </PDAT><HIL><BOLD><PDAT>56</PDAT></BOLD></HIL><PDAT> place the fibrils </PDAT><HIL><BOLD><PDAT>55</PDAT></BOLD></HIL><PDAT> in tension while elaborating other reinforcing extracellular matrix molecules, such as elastin, in the collagen, as they differentiate in the tissue-equivalent environment.</PDAT></PTEXT></PARA>
<PARA ID="P-00051" LVL="0"><PTEXT><PDAT>The collagen used for the tube </PDAT><HIL><BOLD><PDAT>50</PDAT></BOLD></HIL><PDAT> of the invention is identical to that described above in reference to the control tube </PDAT><HIL><BOLD><PDAT>40</PDAT></BOLD></HIL><PDAT> of FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>. The mammalian tissue cells </PDAT><HIL><BOLD><PDAT>56</PDAT></BOLD></HIL><PDAT> are preferably smooth muscle cells, identical to those described above in reference to the control tube </PDAT><HIL><BOLD><PDAT>40</PDAT></BOLD></HIL><PDAT> of FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00052" LVL="0"><PTEXT><PDAT>The solution of collagen and mammalian tissue cells is prepared as described for the control tube </PDAT><HIL><BOLD><PDAT>40</PDAT></BOLD></HIL><PDAT> of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>, above (as described in detail in Example 1, below), except that the initiation of fibrillogenesis is substantially simultaneous with the filled tubular mold </PDAT><HIL><BOLD><PDAT>20</PDAT></BOLD></HIL><PDAT> (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>) being placed into a high strength (4.7 to 9 Tesla) magnetic field. The magnetic field is preferably a static magnetic field generated by a horizontal bore electromagnet, such as a 4.7 Tesla Model, from the Oxford Company of the United Kingdom. Specifically, the filled tubular mold </PDAT><HIL><BOLD><PDAT>20</PDAT></BOLD></HIL><PDAT> (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>) is placed into the magnetic field at an orientation such that its longitudinal axis </PDAT><HIL><BOLD><PDAT>38</PDAT></BOLD></HIL><PDAT> (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>) is parallel to the direction of the magnetic field. This incubation, where collagen fibril orientation occurs lasts approximately two hours. These steps are described in detail in Example 2, below.</PDAT></PTEXT></PARA>
<PARA ID="P-00053" LVL="0"><PTEXT><PDAT>This positioning of the filled tubular mold </PDAT><HIL><BOLD><PDAT>20</PDAT></BOLD></HIL><PDAT> (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>) in the magnetic field causes the growing collagen fibrils </PDAT><HIL><BOLD><PDAT>56</PDAT></BOLD></HIL><PDAT> to orient circumferentially in the direction of the transverse axis </PDAT><HIL><BOLD><PDAT>39</PDAT></BOLD></HIL><PDAT> (FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>). The orientation of the fibrils </PDAT><HIL><BOLD><PDAT>55</PDAT></BOLD></HIL><PDAT> is additionally aided by alteration of the parameters, one parameter being the distance between the outer surface of the Teflon&reg; rod </PDAT><HIL><BOLD><PDAT>32</PDAT></BOLD></HIL><PDAT> (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>) and the inner surface of the outer cylinder </PDAT><HIL><BOLD><PDAT>30</PDAT></BOLD></HIL><PDAT> (FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>). By having a cavity </PDAT><HIL><BOLD><PDAT>34</PDAT></BOLD></HIL><PDAT> (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>) with a short distance between the surfaces </PDAT><HIL><BOLD><PDAT>30</PDAT></BOLD></HIL><PDAT>, </PDAT><HIL><BOLD><PDAT>32</PDAT></BOLD></HIL><PDAT>, the orienting effect of the magnetic field in the growing fibrils in the circumferential direction is maximized as the surfaces of the Teflon&reg; rod </PDAT><HIL><BOLD><PDAT>22</PDAT></BOLD></HIL><PDAT> and the cylinder </PDAT><HIL><BOLD><PDAT>24</PDAT></BOLD></HIL><PDAT> (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>) assist in the alignment.</PDAT></PTEXT></PARA>
<PARA ID="P-00054" LVL="0"><PTEXT><PDAT>In the present invention, the smooth muscle cells are induced to exhibit circumferential orientation (induced by the circumferentially oriented fibrils described above), similar to that of the smooth muscle cells in the medial layer of an artery. According to the method described herein, this smooth muscle cell orientation contributes to the mechanical properties of the circumferentially oriented tube </PDAT><HIL><BOLD><PDAT>50</PDAT></BOLD></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00055" LVL="0"><PTEXT><PDAT>The circumferentially oriented tissue-equivalent tubes of the invention are useful as artificial blood vessels, and in particular arteries, as they are reinforced in a circumferential direction, providing additional strength to withstand the distension associated with pulsatile blood flow. However, these oriented tissue-equivalent tubes, along with tissue-equivalent tubes having fibrils aligned along the longitudinal axis </PDAT><HIL><BOLD><PDAT>58</PDAT></BOLD></HIL><PDAT> of the tube, known as &ldquo;axially oriented&rdquo; (produced by the method detailed in Example 2, below, except that the fibril orienting step is such that the filled mold is placed such that its longitudinal axis is substantially perpendicular to the direction of the magnetic field, during fibrillogenesis), may find use as bioartifical ureters, urethras, tracheas, an esophagus, intestines, and other tubular organs. Sheets of this material could also be produced using sheet molds instead of the tubular molds described above, in order to produce planar structures such as skin or bladders.</PDAT></PTEXT></PARA>
<PARA ID="P-00056" LVL="0"><PTEXT><PDAT>Alternately, the cold collagen solution may be kept pure (i.e., without cells) and formed into oriented biopolymer tubes in accordance with the procedures detailed below in Examples 1 and 2. If an axially oriented biopolymer tube formed from this pure cold collagen solution were desired, the orientation step (detailed in Example 2, below), would be such that the filled tubular mold would be placed into the magnetic field such that its longitudinal axis is substantially perpendicular to the direction of the magnetic field. With respect to these tubes, they would be weaker than those with the smooth muscle cells, for the smooth muscles cells enhance the mechanical properties of the tubes.</PDAT></PTEXT></PARA>
<PARA ID="P-00057" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT> shows a biopolymer tube </PDAT><HIL><BOLD><PDAT>60</PDAT></BOLD></HIL><PDAT> of the invention. This tube </PDAT><HIL><BOLD><PDAT>60</PDAT></BOLD></HIL><PDAT> has a cylindrical body </PDAT><HIL><BOLD><PDAT>62</PDAT></BOLD></HIL><PDAT> around a central lumen </PDAT><HIL><BOLD><PDAT>64</PDAT></BOLD></HIL><PDAT>. The body </PDAT><HIL><BOLD><PDAT>62</PDAT></BOLD></HIL><PDAT> includes fibrin fibrils </PDAT><HIL><BOLD><PDAT>65</PDAT></BOLD></HIL><PDAT> oriented along the longitudinal axis </PDAT><HIL><BOLD><PDAT>68</PDAT></BOLD></HIL><PDAT>, known as &ldquo;axially oriented&rdquo;. The tube </PDAT><HIL><BOLD><PDAT>60</PDAT></BOLD></HIL><PDAT> also has a transverse axis </PDAT><HIL><BOLD><PDAT>69</PDAT></BOLD></HIL><PDAT>. The tube </PDAT><HIL><BOLD><PDAT>60</PDAT></BOLD></HIL><PDAT> is formed from a fibrin-forming solution including fibrinogen and thrombin, prepared in accordance with that described in Torbet, &ldquo;Fibrin Assembly in Human Plasma and Fibrinogen/Albumin Mixtures&rdquo; in </PDAT><HIL><ITALIC><PDAT>Biochemistry</PDAT></ITALIC></HIL><PDAT>, Vol. 25 (1986), pp. 5309-5314. This fibrin-forming solution is then made into an axially oriented biopolymer tube in accordance with Examples 1 and 2 below. However, should a tissue-equivalent tube with circumferentially oriented fibrin fibrils (oriented along the transverse axis </PDAT><HIL><BOLD><PDAT>69</PDAT></BOLD></HIL><PDAT>) be desired, the orientation step would be opposite that disclosed in Example 2 below, as the filled tubular mold </PDAT><HIL><BOLD><PDAT>20</PDAT></BOLD></HIL><PDAT> (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>) would be placed into the magnetic field such that its longitudinal axis </PDAT><HIL><BOLD><PDAT>68</PDAT></BOLD></HIL><PDAT> is perpendicular to the direction of the magnetic field.</PDAT></PTEXT></PARA>
<PARA ID="P-00058" LVL="0"><PTEXT><PDAT>These axially oriented fibrin tubes, as well as axially oriented collagen biopolymer tubes (discussed above) are particularly useful as nerve regeneration conduits. This is due to the fact that the axially oriented fibrils </PDAT><HIL><BOLD><PDAT>65</PDAT></BOLD></HIL><PDAT> can serve to guide the inward growth and movement of host neurons </PDAT><HIL><BOLD><PDAT>70</PDAT></BOLD></HIL><PDAT> at opposite ends of the tube </PDAT><HIL><BOLD><PDAT>60</PDAT></BOLD></HIL><PDAT>, such that the neurons at each end ultimately grow together. Rejoining of the severed nerve would occur in less time as compared to a randomly oriented biopolymer tube.</PDAT></PTEXT></PARA>
<PARA ID="P-00059" LVL="0"><PTEXT><PDAT>Turning now to </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 5 and 6</PDAT></FGREF><PDAT>, there are shown micrographs of a control tissue-equivalent tube (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 5</PDAT></FGREF><PDAT>) and a circumferentially oriented tissue-equivalent tube (FIG. </PDAT><HIL><BOLD><PDAT>6</PDAT></BOLD></HIL><PDAT>), produced in accordance with the invention, as detailed in Examples 1 and 2 below. In </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 5 and 6</PDAT></FGREF><PDAT>, the horizontal dimension is coincident with the longitudinal direction of the tube and the vertical dimension is coincident with the circumferential (transverse) direction of the tube. In </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 5</PDAT></FGREF><PDAT>, the cells appear randomly oriented in this control tube, while in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 6</PDAT></FGREF><PDAT>, the cells appear circumferentially oriented.</PDAT></PTEXT></PARA>
<PARA ID="P-00060" LVL="0"><PTEXT><PDAT>Turning now to </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 8 and 9</PDAT></FGREF><PDAT>, there is shown a cylindrical mold </PDAT><HIL><BOLD><PDAT>120</PDAT></BOLD></HIL><PDAT> for making the tissue-equivalent and biopolymer rods </PDAT><HIL><BOLD><PDAT>130</PDAT></BOLD></HIL><PDAT> (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 10</PDAT></FGREF><PDAT>) of the present invention. These tissue-equivalent and biopolymer rods </PDAT><HIL><BOLD><PDAT>130</PDAT></BOLD></HIL><PDAT> are manufactured similarly, with the differences in the manufacturing steps noted below.</PDAT></PTEXT></PARA>
<PARA ID="P-00061" LVL="0"><PTEXT><PDAT>The cylindrical mold </PDAT><HIL><BOLD><PDAT>120</PDAT></BOLD></HIL><PDAT> for making these tissue-equivalent and biopolymer rods </PDAT><HIL><BOLD><PDAT>130</PDAT></BOLD></HIL><PDAT> is preferably formed of a TEFLON&reg; cylinder </PDAT><HIL><BOLD><PDAT>122</PDAT></BOLD></HIL><PDAT> (preferably approximately 15 mm in length) having a cavity (lumen) </PDAT><HIL><BOLD><PDAT>123</PDAT></BOLD></HIL><PDAT>, preferably of a diameter corresponding to that of a peripheral nerve (approximately 0.5-2 mm). The ends of the cylinder </PDAT><HIL><BOLD><PDAT>122</PDAT></BOLD></HIL><PDAT> receive plugs </PDAT><HIL><BOLD><PDAT>124</PDAT></BOLD></HIL><PDAT>, </PDAT><HIL><BOLD><PDAT>125</PDAT></BOLD></HIL><PDAT>. Alternately, biodegradable or bioresorbable polymer cylinders may be used as the cylindrical mold </PDAT><HIL><BOLD><PDAT>120</PDAT></BOLD></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00062" LVL="0"><PTEXT><PDAT>A first plug </PDAT><HIL><BOLD><PDAT>124</PDAT></BOLD></HIL><PDAT> is initially pushed into the cylinder </PDAT><HIL><BOLD><PDAT>122</PDAT></BOLD></HIL><PDAT> for the mold to receive collagen solution (made in accordance with the solutions described herein), preferably by injection from a syringe </PDAT><HIL><BOLD><PDAT>126</PDAT></BOLD></HIL><PDAT>. Once the cavity (lumen) </PDAT><HIL><BOLD><PDAT>123</PDAT></BOLD></HIL><PDAT> is filled, the second plug </PDAT><HIL><BOLD><PDAT>125</PDAT></BOLD></HIL><PDAT> is fitted into the cylinder </PDAT><HIL><BOLD><PDAT>122</PDAT></BOLD></HIL><PDAT> The cylindrical mold </PDAT><HIL><BOLD><PDAT>120</PDAT></BOLD></HIL><PDAT> is designed such that the collagen solution injected therein can be easily removed as a collagen gel rod. Alternately, if the biodegradable or bioresorbable cylinder is used as the cylindrical mold, the collagen gel rod is not removed from the biodegradable or bioresorbable cylinder.</PDAT></PTEXT></PARA>
<PARA ID="P-00063" LVL="0"><PTEXT><PDAT>This cylindrical mold </PDAT><HIL><BOLD><PDAT>120</PDAT></BOLD></HIL><PDAT> includes a longitudinal axis </PDAT><HIL><BOLD><PDAT>128</PDAT></BOLD></HIL><PDAT> and a transverse axis </PDAT><HIL><BOLD><PDAT>129</PDAT></BOLD></HIL><PDAT>. These axes </PDAT><HIL><BOLD><PDAT>128</PDAT></BOLD></HIL><PDAT>, </PDAT><HIL><BOLD><PDAT>129</PDAT></BOLD></HIL><PDAT> will be used to illustrate the directions of fibril alignment (orientation) in the resultant tissue-equivalent and biopolymer rods.</PDAT></PTEXT></PARA>
<PARA ID="P-00064" LVL="0"><PTEXT><PDAT>The collagen used for these tissue-equivalent or biopolymer rods is preferably monomeric Type I collagen, or the like, in a cold (approximately 5&deg; C.) neutral solution, prepared in accordance with Example 1 below. If a tissue-equivalent rod is desired, the solution includes mammalian tissue cells, that are preferably Schwann Cells and/or fiboblasts/endothelial cells, having been grown by conventional cell growth and culture methods, well known to those skilled in the art. The mammalian tissue cells are then dispersed into the cold collagen solution in accordance with the procedure detailed below in Example 1, except that the smooth muscle cells (mammalian tissue cells of Example 1) are substituted with Schwann Cells and/or fiboblasts/endothelial cells.</PDAT></PTEXT></PARA>
<PARA ID="P-00065" LVL="0"><PTEXT><PDAT>Alternately, if a biopolymer rod is desired, in a preferred step, small (approximately 10-15 micrometer diameter) biodegradable/bioresorbable polymer beads with encapsulated neurotrophic factors (such as nerve growth factor) are added to the cold collagen neutral solution. These biodegradable/bioresorbable polymer beads would be added to the collagen solution similar to the mammalian tissue cells, in accordance with Example 1 below. The polymer beads would function similar to the Schwann cells, of the tissue-equivalent rods, by releasing the encapsulated neurotropic factor(s) that serve as an additional stimulus for neural growth (e.g., neurite elongation).</PDAT></PTEXT></PARA>
<PARA ID="P-00066" LVL="0"><PTEXT><PDAT>The cold solution is then injected from the syringe </PDAT><HIL><BOLD><PDAT>126</PDAT></BOLD></HIL><PDAT> into the cavity </PDAT><HIL><BOLD><PDAT>123</PDAT></BOLD></HIL><PDAT> of the cylindrical mold </PDAT><HIL><BOLD><PDAT>120</PDAT></BOLD></HIL><PDAT>. Injection of the solution is preferably done slowly to-avoid formation of air bubbles or air pockets. In accordance with Example 2, as detailed below, fibrillogenesis begins as the filled cylindrical mold </PDAT><HIL><BOLD><PDAT>120</PDAT></BOLD></HIL><PDAT> (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 9</PDAT></FGREF><PDAT>) is then transferred to a constant temperature box, for incubation in the temperature range of approximately 30&deg; C. to 400&deg; C., and is placed in a high strength (preferably at least 4 Tesla) magnetic field, as described above and in Examples 1 and 2 below, with the longitudinal axis </PDAT><HIL><BOLD><PDAT>128</PDAT></BOLD></HIL><PDAT> oriented substantially perpendicular to the direction of the magnetic field (B) (indicated by arrows </PDAT><HIL><BOLD><PDAT>132</PDAT></BOLD></HIL><PDAT>), for approximately two hours. Additional detail for performing these steps is provided in Examples 1 and 2 below, except that the tissue-equivalent and biopolymer rods of the invention are subject to fibrillogenesis (collagen fibril self assembly) in the presence of a magnetic field.</PDAT></PTEXT></PARA>
<PARA ID="P-00067" LVL="0"><PTEXT><PDAT>Upon removal from the magnetic field, the now-formed tissue-equivalent and biopolymer rods are removed from the TEFLON&reg; cylindrical molds, by allowing the rods to slide out of the molds. If the molds are formed of biodegradable or bioresorbable polymer cylinders, these cylinders are preferably not removed, and remain as part of the rod for subsequent use. The resultant rods may be subject to further processing by steps similar to those described in Example 2 below.</PDAT></PTEXT></PARA>
<PARA ID="P-00068" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 10</PDAT></FGREF><PDAT> shows a tissue-equivalent or biopolymer rod </PDAT><HIL><BOLD><PDAT>130</PDAT></BOLD></HIL><PDAT>, made from the cylindrical mold </PDAT><HIL><BOLD><PDAT>120</PDAT></BOLD></HIL><PDAT>. (The mammalian tissue cells of the tissue-equivalent rod and the polymer beads of the biopolymer rod are too small to be observed in this drawing figure.) The tissue-equivalent or biopolymer rod </PDAT><HIL><BOLD><PDAT>130</PDAT></BOLD></HIL><PDAT> preferably includes a cylindrical body </PDAT><HIL><BOLD><PDAT>134</PDAT></BOLD></HIL><PDAT> with longitudinally aligned (oriented) collagen fibrils </PDAT><HIL><BOLD><PDAT>135</PDAT></BOLD></HIL><PDAT>, in the direction of the longitudinal axis </PDAT><HIL><BOLD><PDAT>128</PDAT></BOLD></HIL><PDAT>. (In this drawing figure, the cylindrical mold </PDAT><HIL><BOLD><PDAT>120</PDAT></BOLD></HIL><PDAT>, if a TEFLON&reg; cylinder, has been removed.)</PDAT></PTEXT></PARA>
<PARA ID="P-00069" LVL="0"><PTEXT><PDAT>As stated above, one use of the tissue-equivalent rods and biopolymer rods </PDAT><HIL><BOLD><PDAT>130</PDAT></BOLD></HIL><PDAT> of the invention is for peripheral nerve regeneration. As shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 11</PDAT></FGREF><HIL><ITALIC><PDAT>a </PDAT></ITALIC></HIL><PDAT>and </PDAT><HIL><BOLD><PDAT>11</PDAT></BOLD></HIL><HIL><ITALIC><PDAT>b</PDAT></ITALIC></HIL><PDAT>, there is a severed nerve </PDAT><HIL><BOLD><PDAT>140</PDAT></BOLD></HIL><PDAT> having a gap </PDAT><HIL><BOLD><PDAT>142</PDAT></BOLD></HIL><PDAT> between its severed ends </PDAT><HIL><BOLD><PDAT>144</PDAT></BOLD></HIL><PDAT>, </PDAT><HIL><BOLD><PDAT>145</PDAT></BOLD></HIL><PDAT>. The tissue-equivalent or biopolymer rod </PDAT><HIL><BOLD><PDAT>130</PDAT></BOLD></HIL><PDAT> is placed in the gap </PDAT><HIL><BOLD><PDAT>142</PDAT></BOLD></HIL><PDAT>, and connected to each of the severed nerve ends </PDAT><HIL><BOLD><PDAT>144</PDAT></BOLD></HIL><PDAT>, </PDAT><HIL><BOLD><PDAT>145</PDAT></BOLD></HIL><PDAT>, for example, by sutures </PDAT><HIL><BOLD><PDAT>146</PDAT></BOLD></HIL><PDAT>, </PDAT><HIL><BOLD><PDAT>147</PDAT></BOLD></HIL><PDAT>. The tissue-equivalent or biopolymer rod </PDAT><HIL><BOLD><PDAT>130</PDAT></BOLD></HIL><PDAT> comprised of longitudinally aligned (oriented) collagen fibrils serves to guide neural growth across the gap between the severed nerve endings, thereby promoting regeneration of the original neural connection. This process has been simulated with a Dorsal Root Ganglia (DRG) from a chick embryo, and is detailed below in Examples 4-6.</PDAT></PTEXT></PARA>
<PARA ID="P-00070" LVL="0"><PTEXT><PDAT>Tissue-equivalent rods and biopolymer rods of fibrin may also be made in accordance with the invention. These tissue-equivalent and biopolymer rods have a cylindrical body, that includes fibrin fibrils oriented along the longitudinal axis (the longitudinal axis defined in accordance with </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 8-10</PDAT></FGREF><PDAT> above), known as &ldquo;axially oriented&rdquo;. The rods is formed from a fibrin-forming solution including fibrinogen and thrombin, prepared in accordance with that described in Torbet, &ldquo;Fibrin Assembly in Human Plasma and Fibrinogen/Albumin Mixtures&rdquo; in </PDAT><HIL><ITALIC><PDAT>Biochemistry</PDAT></ITALIC></HIL><PDAT>, Vol. 25 (1986), pp. 5309-5314. In the case of tissue-equivalent fibrin rods, mammalian tissue cells (i.e., Schwann Cells and/or fibroblasts/endothelial cells) may be added to the fibrin-forming solution in accordance with the preparations discussed above. In the case of biopolymer fibrin rods, polymer beads (as discussed above), may be added to the fibrin-forming solution in accordance with the preparations discussed above. These fibrin-forming solutions are then placed into a cylindrical mold (of a TEFLON&reg; cylinder, or a bioresorbable or biodegradable material cylinder) and made into an axially oriented biopolymer rod (with the resultant fibrils aligned in the direction of the longitudinal axis) in accordance with Examples 1 and 2 below (such that the cylindrical molds are placed into the magnetic field parallel to the direction of the magnetic field).</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 1</PDAT></STEXT></H>
<PARA ID="P-00071" LVL="0"><PTEXT><PDAT>The control tube of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 5</PDAT></FGREF><PDAT> is prepared as follows. 20 microliters of cold (5&deg; C.) HEPES Buffer Solution (1M) (No. 4573</PDAT><HIL><ITALIC><PDAT>, The Merk Index</PDAT></ITALIC></HIL><PDAT>, 11th ed.) are mixed with 50 microliters 10&times; Gibco Minimum Essential Medium (MEM) (Gibco BRL, Gaithersburg, Md. 20877) in a disposable 15 ml sterile vial. 132 microliters of room temperature NaOH (0.1N) is then added to the HEPES-MEM solution.</PDAT></PTEXT></PARA>
<PARA ID="P-00072" LVL="0"><PTEXT><PDAT>A solution is then prepared as 60 microliters of Fetal Bovine Serum (FBS) from Hyclone Laboratories, Inc., Logan, Utah 84321, 1 microliter of Penicillin-Streptomycin solution (5000 units of Penicillin and 5000 micrograms Streptomycin per millimeter in 0.85% saline solution) (Pen-Strep), and 10 microliters L-Glutamate solution (29.2 milligrams per milliliter) in 0.85% saline solution) are obtained from separate stocks, and each is frozen &minus;20&deg; C. The separate FBS, Pen-Strep, and L-Glutamate are warmed to room temperature and individually added to the 15 ml vial.</PDAT></PTEXT></PARA>
<PARA ID="P-00073" LVL="0"><PTEXT><PDAT>677 microliters of cold (5&deg; C.) Vitrogen&reg; 100 Collagen, available from Celtrix Pharmaceuticals, Inc., 3055 Patrick Henry Drive, Santa Clara, Calif. 95054, are then added and the solution is gently mixed with a pipette.</PDAT></PTEXT></PARA>
<PARA ID="P-00074" LVL="0"><PTEXT><PDAT>A cold (5&deg; C.) cell suspension of smooth muscle cells (approximately 4&times;10</PDAT><HIL><SP><PDAT>6 </PDAT></SP></HIL><PDAT>cells/ml) suspended in 50 microliters Gibco Medium 199 (M-199) (Gibco BRL, Gatithersburg, Md. 20877) is prepared. The solution includes rat aortic smooth muscle cells prepared in accordance with the method disclosed in Diglio, et al., &ldquo;Rat Cerebral Microvascular Smooth Muscle Cells in Culture&rdquo; in </PDAT><HIL><ITALIC><PDAT>J. Cell. Physiol</PDAT></ITALIC></HIL><PDAT>., Vol. 129(2) (1986), pp. 131-141, which is incorporated by reference herein. The cells were maintained in Gibco Dulbecco&apos;s Modified Eagle Medium (DMEM) (Gibco BRL, Gaithersburg, Md. 20877) containing 10% Fetal Bovine Serum (FBS) and were subcultured twice weekly. Only cells below passage </PDAT><HIL><BOLD><PDAT>25</PDAT></BOLD></HIL><PDAT> that retain the phenotypic traits of expressing smooth muscle cell specific alpha-actin and myosin, and not the Factor VIII-related antigen were used here. This cold cell suspension is now added to the 15 ml vial.</PDAT></PTEXT></PARA>
<PARA ID="P-00075" LVL="0"><PTEXT><PDAT>The contents of the 15 ml vial are gently mixed with a pipette. The solution is kept on ice all the while. The cell and collagen solution is syringed out using standard sterile 3 milliliter syringes and is injected into a sterile mold. The mold was previously sterilized by soaking in 70% ethanol and followed by repeated rinsing with sterile water. The opening on the mold to inject the solution is covered with Parafilm&reg; (American National Can Company, Chicago, Ill.) and the mold is placed on ice. The mold has an outer diameter of 1.2 centimeters and an inner diameter (for the central solid rod) of 0.635 centimeters, and a length of 1.2 centimeters. The process is repeated until the desired amount of molds are full. The molds are then placed in an incubator at 32&deg; C. for two hours (the fibrillogenesis period).</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 2</PDAT></STEXT></H>
<PARA ID="P-00076" LVL="0"><PTEXT><PDAT>The tubes of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 6</PDAT></FGREF><PDAT> were initially prepared in accordance with Example 1 above, except that the mold(s) once full are not placed in an incubator at 32&deg; C. for the two hour fibrillogenesis period. Rather, the air and water tight molds are taken to a 4.7 Tesla magnet (Oxford Company, United Kingdom) on ice, and once there they are removed from the ice bath and placed in 1.25 inch thick styrofoam boxes filled with water at 32&deg; C. The molds-are submerged in the water. The styrofoam box, containing the submerged molds, is then placed in a plastic bag and slid into the bore of the magnet, where the collagen solution in the molds is left to self-assemble for 2 hours (the fibrillogenesis period). In order to minimize gravity-induced cell settling during fibrillogenesis, the molds are briefly removed from the magnet and carefully rotated 180&deg; and returned to the magnet. This procedure is done at 10 minute intervals.</PDAT></PTEXT></PARA>
<PARA ID="P-00077" LVL="0"><PTEXT><PDAT>When the two hours are up, the molds are removed from the magnet. Immediately, in a sterile hood, the molds are opened and the tissue-equivalent tubes are removed and placed in sterile 30 milliliter glass vials filled with 20 milliliters of M-199 cell culture medium supplemented with 5W (b y volume) L-Glutamine, Glutamine 5% (by volume) Fungizone&reg; (E. R. Squibb &amp; Sons, Inc., New York, N.Y.) (250 micrograms amphotericin B and 205 micrograms sodium deoxytcholate/milliliter in sterile/distilled water), 5% (by volume) Penicillin-Streptomycin solution (5000 units of Penicillin and 5000 micrograms steptomycin per milliliter in 0.85% saline solution), and 10% (by volume) Hyclone Fetal Bovine Serum. Smaller (&frac18; inch) diameter sterile Teflon&reg; rods are placed in the lumens of the tubes and they are subsequently placed in an incubator at 37&deg; C. for extended periods of time (as long as is desired). The M-199 cell culture medium with supplements (described above) in the 30 ml glass vials is replaced at two day intervals.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 3</PDAT></STEXT></H>
<PARA ID="P-00078" LVL="0"><PTEXT><PDAT>The control tissue-equivalent tube (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 5</PDAT></FGREF><PDAT>) and the circumferentially oriented tissue-equivalent tube (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 6</PDAT></FGREF><PDAT>) we re both subsequently cultured in an incubator at 37&deg; C. for 108 hours and then tested on a Liveco Vitrodyne&reg; 200, available from Liveco, Inc. of Burlington, Vt. The testing procedure involved first, slowly extending the tubes to a collapsed state and then allowing the tubes time to equilibrate before testing. This testing mode simulated distension in an artery. Creep compliance was measured over time and the results are plotted in FIG. </PDAT><HIL><BOLD><PDAT>7</PDAT></BOLD></HIL><PDAT>. The circumferentially oriented tissue-equivalent tube response is line </PDAT><HIL><BOLD><PDAT>100</PDAT></BOLD></HIL><PDAT> while the unoriented (control) tissue-equivalent tube response is line </PDAT><HIL><BOLD><PDAT>102</PDAT></BOLD></HIL><PDAT>. Based on these responses, the circumferentially oriented tube showed less instantaneous creep, as it was stiffer (less elastic) than the unoriented (control) tube. The creep rate at longer times is also somewhat less for the oriented tube (FIG. </PDAT><HIL><BOLD><PDAT>6</PDAT></BOLD></HIL><PDAT>), indicating that it is also more viscous.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 4</PDAT></STEXT></H>
<PARA ID="P-00079" LVL="0"><PTEXT><PDAT>Dorsal Root Ganglia (DRG) was explanted from a day </PDAT><HIL><BOLD><PDAT>12</PDAT></BOLD></HIL><PDAT> chick embryo and cultured (by direct entrapment) into an aligned biopolymer (collagen gel) rod, prepared in accordance with the above described methods for producing biopolymer rods of the present invention, except polymer beads (as described above) were not included. As illustrated in the micrograph of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 12</PDAT></FGREF><HIL><ITALIC><PDAT>a</PDAT></ITALIC></HIL><PDAT>, taken two days after the culture, the aligned biopolymer collagen gel rod </PDAT><HIL><BOLD><PDAT>150</PDAT></BOLD></HIL><HIL><ITALIC><PDAT>a </PDAT></ITALIC></HIL><PDAT>(having fibrils aligned in the direction of the arrow </PDAT><HIL><BOLD><PDAT>151</PDAT></BOLD></HIL><PDAT>) showed neurites </PDAT><HIL><BOLD><PDAT>152</PDAT></BOLD></HIL><HIL><ITALIC><PDAT>a </PDAT></ITALIC></HIL><PDAT>that elongated from the DRG </PDAT><HIL><BOLD><PDAT>154</PDAT></BOLD></HIL><HIL><ITALIC><PDAT>a </PDAT></ITALIC></HIL><PDAT>in the same direction as the fibril alignment (orientation). The neurites were imaged by antibody staining (anti-neurofilment 200 KD).</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 5</PDAT></STEXT></H>
<PARA ID="P-00080" LVL="0"><PTEXT><PDAT>Dorsal Root Ganglia (DRG) was explanted and cultured by direct entrapment from a day 12 chick embryo into an isotropic (non-aligned fibril) biopolymer (collagen gel) rod. The isotropic biopolymer (collagen gel) rod was prepared by the method described in Example 1. As illustrated by the micrograph of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 12</PDAT></FGREF><HIL><ITALIC><PDAT>b</PDAT></ITALIC></HIL><PDAT>, taken two days after the culture, the isotropic biopolymer (collagen gel) rod </PDAT><HIL><BOLD><PDAT>150</PDAT></BOLD></HIL><HIL><ITALIC><PDAT>b </PDAT></ITALIC></HIL><PDAT>showed neurites </PDAT><HIL><BOLD><PDAT>152</PDAT></BOLD></HIL><HIL><ITALIC><PDAT>b </PDAT></ITALIC></HIL><PDAT>that elongated randomly from the DRG </PDAT><HIL><BOLD><PDAT>154</PDAT></BOLD></HIL><HIL><ITALIC><PDAT>b</PDAT></ITALIC></HIL><PDAT>. The neurites were imaged by antibody staining (anti-neurofilament 200 KD).</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 6</PDAT></STEXT></H>
<PARA ID="P-00081" LVL="0"><PTEXT><PDAT>A magnetically oriented biopolymer (collagen gel) rod was produced in accordance with the present invention, except polymer beads (as described above) were not included. An invasion assay was prepared as Dorsal Root Ganglia (DRG) was explanted from a day 12 chick embryo and placed on one flat end of the rod and incubated for two days for the case of a magnetically oriented rod, prepared in a 4.7 Tesla magnetic field (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 13</PDAT></FGREF><HIL><ITALIC><PDAT>a</PDAT></ITALIC></HIL><PDAT>). In </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 13</PDAT></FGREF><HIL><ITALIC><PDAT>a </PDAT></ITALIC></HIL><PDAT>and </PDAT><HIL><BOLD><PDAT>13</PDAT></BOLD></HIL><HIL><ITALIC><PDAT>b</PDAT></ITALIC></HIL><PDAT>, as seen along the longitudinal axes of the biopolymer (collagen gel) rods </PDAT><HIL><BOLD><PDAT>162</PDAT></BOLD></HIL><HIL><ITALIC><PDAT>a</PDAT></ITALIC></HIL><PDAT>, </PDAT><HIL><BOLD><PDAT>162</PDAT></BOLD></HIL><HIL><ITALIC><PDAT>b </PDAT></ITALIC></HIL><PDAT>the neurites from the DRG </PDAT><HIL><BOLD><PDAT>164</PDAT></BOLD></HIL><HIL><ITALIC><PDAT>a</PDAT></ITALIC></HIL><PDAT>, </PDAT><HIL><BOLD><PDAT>164</PDAT></BOLD></HIL><HIL><ITALIC><PDAT>b </PDAT></ITALIC></HIL><PDAT>have advanced from their respective neurite origins </PDAT><HIL><BOLD><PDAT>166</PDAT></BOLD></HIL><HIL><ITALIC><PDAT>a</PDAT></ITALIC></HIL><PDAT>, </PDAT><HIL><BOLD><PDAT>166</PDAT></BOLD></HIL><HIL><ITALIC><PDAT>b</PDAT></ITALIC></HIL><PDAT>. The leading edge of the DRG neurite front </PDAT><HIL><BOLD><PDAT>168</PDAT></BOLD></HIL><HIL><ITALIC><PDAT>a </PDAT></ITALIC></HIL><PDAT>in the aligned biopolymer rod </PDAT><HIL><BOLD><PDAT>162</PDAT></BOLD></HIL><HIL><ITALIC><PDAT>a </PDAT></ITALIC></HIL><PDAT>(having fibrils aligned in the direction of the arrow </PDAT><HIL><BOLD><PDAT>163</PDAT></BOLD></HIL><PDAT>) has advanced further than the leading edge </PDAT><HIL><BOLD><PDAT>168</PDAT></BOLD></HIL><HIL><ITALIC><PDAT>b </PDAT></ITALIC></HIL><PDAT>of the DRG neurite front in the isotropic rod </PDAT><HIL><BOLD><PDAT>162</PDAT></BOLD></HIL><HIL><ITALIC><PDAT>b </PDAT></ITALIC></HIL><PDAT>(having non-aligned fibrils).</PDAT></PTEXT></PARA>
<PARA ID="P-00082" LVL="0"><PTEXT><PDAT>To confirm that the neurite advancement was due to magnetically aligned (oriented) collagen, the rods were analyzed in polarized light. As shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 14</PDAT></FGREF><HIL><ITALIC><PDAT>a</PDAT></ITALIC></HIL><PDAT>, the rod prepared in the 4.7 Tesla magnetic field exhibited strong birefringence (47&times;10</PDAT><HIL><SP><PDAT>&minus;6</PDAT></SP></HIL><PDAT>), indicative of highly aligned collagen fibrils, whereas little or no birefringence was measured for the non-aligned fibril control (isotropic) rod, as shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 14</PDAT></FGREF><HIL><ITALIC><PDAT>b. </PDAT></ITALIC></HIL></PTEXT></PARA>
<PARA ID="P-00083" LVL="0"><PTEXT><PDAT>While the invention has been described in connection with several embodiments, it will be understood that the invention is not limited to these embodiments. The invention is intended to cover all alternatives, modifications and equivalents as may be included within the spirit and scope thereof, as defined by the appended claims.</PDAT></PTEXT></PARA>
</BTEXT>
</DETDESC>
</SDODE>
<SDOCL>
<H LVL="1"><STEXT><PDAT>What is claimed is: </PDAT></STEXT></H>
<CL>
<CLM ID="CLM-00001">
<PARA ID="P-00084" LVL="0"><PTEXT><PDAT>1. A method for promoting nerve regeneration comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>a. providing a biopolymer rod having longitudinal and traverse dimensions and first and second ends, the rod being cylindrical and of a predetermined circumference, the rod having a body comprising a biopolymer, the biopolymer including fibrils, the fibrils aligning in a direction substantially parallel to the longitudinal dimension; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>b. positioning said biopolymer rod intermediate a first nerve ending and a second nerve ending; said first and second nerve ending formed by the severance of a nerve; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>c. attaching said first end of said biopolymer rod to said first nerve ending and said second end of said biopolymer rod to said second nerve ending. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00002">
<PARA ID="P-00085" LVL="0"><PTEXT><PDAT>2. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the biopolymer is collagen.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00003">
<PARA ID="P-00086" LVL="0"><PTEXT><PDAT>3. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the biopolymer is Type I collagen.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00004">
<PARA ID="P-00087" LVL="0"><PTEXT><PDAT>4. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the biopolymer is fibrin.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00005">
<PARA ID="P-00088" LVL="0"><PTEXT><PDAT>5. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said biopolymer rod additionally comprises an outer casing including a biodegradable or bioresorbable polymer cylinder.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00006">
<PARA ID="P-00089" LVL="0"><PTEXT><PDAT>6. A method for providing nerve regeneration comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>a. providing a biopolymer rod having longitudinal and traverse dimensions and first and second ends, the rod including a body comprising collagen, the collagen including fibrils, the fibrils being aligned in a direction substantially parallel to the longitudinal dimension; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>b. positioning said biopolymer rod intermediate a first nerve ending and a second nerve ending, said first and second nerve endings formed by the severance of a nerve; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>c. attaching said first end of said biopolymer rod to said first nerve ending and said second end of said biopolymer rod to said second nerve ending. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00007">
<PARA ID="P-00090" LVL="0"><PTEXT><PDAT>7. The method of </PDAT><CLREF ID="CLM-00006"><PDAT>claim 6</PDAT></CLREF><PDAT>, wherein said biopolymer rod further comprising an outer casing comprising a biodegradable or bioresorbable polymer cylinder.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00008">
<PARA ID="P-00091" LVL="0"><PTEXT><PDAT>8. A method for providing nerve regeneration comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>a. providing a biopolymer rod having longitudinal and traverse dimensions and first and second ends, the rod including a body comprising fibrin, the fibrin including fibrils, the fibrils being aligned in a direction substantially parallel to the longitudinal dimension; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>b. positioning said biopolymer rod intermediate a first nerve ending and a second nerve ending, said first and second nerve endings formed by the severance of a nerve; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>c. attaching said first end of said biopolymer rod to said first nerve ending and said second end of said biopolymer rod to said second nerve ending. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00009">
<PARA ID="P-00092" LVL="0"><PTEXT><PDAT>9. The method of </PDAT><CLREF ID="CLM-00008"><PDAT>claim 8</PDAT></CLREF><PDAT>, wherein said biopolymer rod further comprising an outer casing comprising a biodegradable or bioresorbable polymer cylinder.</PDAT></PTEXT></PARA>
</CLM>
</CL>
</SDOCL>
<SDODR ID="DRAWINGS">
<EMI ID="EMI-D00001" ALT="embedded image" FILE="US06461629-20021008-D00001.TIF"/>
<EMI ID="EMI-D00002" ALT="embedded image" FILE="US06461629-20021008-D00002.TIF"/>
<EMI ID="EMI-D00003" ALT="embedded image" FILE="US06461629-20021008-D00003.TIF" TYPE="HALFTONE"/>
<EMI ID="EMI-D00004" ALT="embedded image" FILE="US06461629-20021008-D00004.TIF"/>
<EMI ID="EMI-D00005" ALT="embedded image" FILE="US06461629-20021008-D00005.TIF"/>
<EMI ID="EMI-D00006" ALT="embedded image" FILE="US06461629-20021008-D00006.TIF"/>
<EMI ID="EMI-D00007" ALT="embedded image" FILE="US06461629-20021008-D00007.TIF"/>
<EMI ID="EMI-D00008" ALT="embedded image" FILE="US06461629-20021008-D00008.TIF"/>
<EMI ID="EMI-D00009" ALT="embedded image" FILE="US06461629-20021008-D00009.TIF"/>
<EMI ID="EMI-D00010" ALT="embedded image" FILE="US06461629-20021008-D00010.TIF"/>
</SDODR>
</PATDOC>

<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PATDOC SYSTEM "ST32-US-Grant-025xml.dtd" [
<!ENTITY US06461815-20021008-C00001.CDX SYSTEM "US06461815-20021008-C00001.CDX" NDATA CDX>
<!ENTITY US06461815-20021008-C00001.MOL SYSTEM "US06461815-20021008-C00001.MOL" NDATA MOL>
<!ENTITY US06461815-20021008-C00001.TIF SYSTEM "US06461815-20021008-C00001.TIF" NDATA TIF>
<!ENTITY US06461815-20021008-D00001.TIF SYSTEM "US06461815-20021008-D00001.TIF" NDATA TIF>
<!ENTITY US06461815-20021008-D00002.TIF SYSTEM "US06461815-20021008-D00002.TIF" NDATA TIF>
<!ENTITY US06461815-20021008-D00003.TIF SYSTEM "US06461815-20021008-D00003.TIF" NDATA TIF>
<!ENTITY US06461815-20021008-D00004.TIF SYSTEM "US06461815-20021008-D00004.TIF" NDATA TIF>
<!ENTITY US06461815-20021008-D00005.TIF SYSTEM "US06461815-20021008-D00005.TIF" NDATA TIF>
<!ENTITY US06461815-20021008-D00006.TIF SYSTEM "US06461815-20021008-D00006.TIF" NDATA TIF>
]>
<PATDOC DTD="2.5" STATUS="Build 20020918">
<SDOBI>
<B100>
<B110><DNUM><PDAT>06461815</PDAT></DNUM></B110>
<B130><PDAT>B1</PDAT></B130>
<B140><DATE><PDAT>20021008</PDAT></DATE></B140>
<B190><PDAT>US</PDAT></B190>
</B100>
<B200>
<B210><DNUM><PDAT>09315674</PDAT></DNUM></B210>
<B211US><PDAT>09</PDAT></B211US>
<B220><DATE><PDAT>19990520</PDAT></DATE></B220>
</B200>
<B500>
<B510>
<B511><PDAT>C12Q  168</PDAT></B511>
<B512><PDAT>C12N  121</PDAT></B512>
<B512><PDAT>C07H 2104</PDAT></B512>
<B516><PDAT>7</PDAT></B516>
</B510>
<B520>
<B521><PDAT>435  6</PDAT></B521>
<B522><PDAT>435243</PDAT></B522>
<B522><PDAT>4352528</PDAT></B522>
<B522><PDAT>536 231</PDAT></B522>
<B522><PDAT>536 241</PDAT></B522>
<B522><PDAT>536 245</PDAT></B522>
</B520>
<B540><STEXT><PDAT>Antibacterial agents and methods of screening for the same</PDAT></STEXT></B540>
<B560>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5358862</PDAT></DNUM>
<DATE><PDAT>19941000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Hardesty et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5556840</PDAT></DNUM>
<DATE><PDAT>19960900</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Suhadolnik et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5629188</PDAT></DNUM>
<DATE><PDAT>19970500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Shiba et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5674729</PDAT></DNUM>
<DATE><PDAT>19971000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Wimmer et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5712096</PDAT></DNUM>
<DATE><PDAT>19980100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Stern et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5821052</PDAT></DNUM>
<DATE><PDAT>19981000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Chen et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>2040615</PDAT></DNUM>
<DATE><PDAT>19910500</PDAT></DATE>
<CTRY><PDAT>ES</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>60-196197</PDAT></DNUM>
<DATE><PDAT>19851000</PDAT></DATE>
<CTRY><PDAT>JP</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B562><NCIT><STEXT><PDAT>Branch, A.D. TIBS, vol. 23, Feb. 1998, pp. 45-50.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Stein, C.A. Nature Biotechnology, vol. 17, Aug. 1999, pp. 751-752.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Flanagan, W.M. Et. Al. Nature Biotechnology, vol. 17, Jan. 1999, 48-52.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Crooke, S. T. Chapter 1, in Antisense Research and Application, (ed. Stanley Crooke), Springer-Verlag, New York, 1998, pp. 1-50.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Goldman, M. DTT, vol. 2, No.: 9, Sep. 1997.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Lloyd, A.W. DTT, vol. 2, No.: 10, Oct. 1997.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Wess, G. &apos;DDT, vol. 1, No.: 12, Dec. 1996.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Von Ahsen, U. et al. Identification of 2&prime;hydroxyl Groups Required for Interaction of a tRNA Anticodon Stem-Loop Region with the Ribosome. RNA, (Jan. 1997), vol. 3, pp. 49-56.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Stryer, Biochemistry, 3d edition, W.H. Freeman and Co., New York, 1988, pp. 759, Jan. 1997.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Tamura, Koji, et al., In vitro study of </PDAT><HIL><ITALIC><PDAT>E.coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Arg </PDAT></SP></HIL><PDAT>and tRNA</PDAT><HIL><SP><PDAT>Lys </PDAT></SP></HIL><PDAT>identity elements, </PDAT><HIL><ITALIC><PDAT>Nucleic Acids Research, </PDAT></ITALIC></HIL><PDAT>vol. 20, No. 9, pp. 2335-2339 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Heurgu&eacute;-Hamard, Val&eacute;rie, et al., The growth defenct in </PDAT><HIL><ITALIC><PDAT>Escherichia coli </PDAT></ITALIC></HIL><PDAT>deficient in peptidyl-tRNA hydrolase is due to starvation for Lys-tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><PDAT>, </PDAT><HIL><ITALIC><PDAT>EMBO Journal, </PDAT></ITALIC></HIL><PDAT>vol. 15, No. 11, pp. 2826-2833 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>McClain, William H.,et al., Nucleotides that determine </PDAT><HIL><ITALIC><PDAT>Escherichia coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Arg </PDAT></SP></HIL><PDAT>and tRNA</PDAT><HIL><SP><PDAT>Lys </PDAT></SP></HIL><PDAT>acceptor identities revealed by analyses of mutant opal and amber suppressor tRNAs, </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>vol. 87, pp. 9260-9264 (Dec. 1990). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kumar, Raju K,. et al., Synthesis and studies on the effect of 2-thiouridine and 4-thioruidine on sugar conformation and RNA duplex stability, </PDAT><HIL><ITALIC><PDAT>Nucleic Acids Research, </PDAT></ITALIC></HIL><PDAT>vol. 25, No. 6, pp. 1272-1280 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Penner, Michael, et al., Phase T4-coded Stp: Double-Edged Effector of Coupled DNA and tRNA-Restriction Systems, </PDAT><HIL><ITALIC><PDAT>J. Mol. Biol., </PDAT></ITALIC></HIL><PDAT>vol. 249, pp. 857-868 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Brierley, Ian, et al., Expression of a Coronavirus Ribosomal Frameshift Signal in </PDAT><HIL><ITALIC><PDAT>Escherichia coli</PDAT></ITALIC></HIL><PDAT>: Influence of tRNA Anticodon Modification on Frameshifting, </PDAT><HIL><ITALIC><PDAT>J. Mol. Biol., </PDAT></ITALIC></HIL><PDAT>vol. 270, pp. 360-373 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Baldwin, John J., et al., Recent Advances in the Generation of Small-Molecule Combinatorial Libraries: Encoded Split Synthesis and Solid-Phase Synthetic Methodology, </PDAT><HIL><ITALIC><PDAT>Medicinal Research Reviews, </PDAT></ITALIC></HIL><PDAT>vol. 16, No. 5, pp. 391-405 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Ashraf, S. Salman, et al., Single atom modification (O-&gt;S) of tRNA confers ribosome binding, </PDAT><HIL><ITALIC><PDAT>RNA, </PDAT></ITALIC></HIL><PDAT>vol. 5, pp. 188-194 (1999). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Watanbe, Kimitsuna, et al., Unusual anticodon loop structure found in </PDAT><HIL><ITALIC><PDAT>E.coli </PDAT></ITALIC></HIL><PDAT>lysine tRNA, </PDAT><HIL><ITALIC><PDAT>Nucleic Acids Research, </PDAT></ITALIC></HIL><PDAT>vol. 22, No. 1, pp. 79-87 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Sprinzl, Mathis, et al., Compilation of tRNA sequences and sequences of tRNA genes, </PDAT><HIL><ITALIC><PDAT>Nucleic Acids Research, </PDAT></ITALIC></HIL><PDAT>vol. 26. No. 1, pp. 148-153 (1998). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Agris, et al., </PDAT><HIL><ITALIC><PDAT>Unique Structure Explains Unusual Biochemical Properties of tRNA(Lys)SUU</PDAT></ITALIC></HIL><PDAT>, Presented at the ASBMB 1996 Meeting (Jan. 30, 1996) (abstract).* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Agris, et al., </PDAT><HIL><ITALIC><PDAT>Unique Structure Explains Human tRNA(LYS</PDAT></ITALIC></HIL><PDAT>3</PDAT><HIL><ITALIC><PDAT>) Selection by HIV Reverse Transcriptase</PDAT></ITALIC></HIL><PDAT>, Presented at the RNA Society 1996 Meeting (Feb. 15, 1996) (abstract).* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Guenther, et al., </PDAT><HIL><ITALIC><PDAT>Modified RNAs as potential drug targets</PDAT></ITALIC></HIL><PDAT>, </PDAT><HIL><ITALIC><PDAT>Acta Biochemica Polonica</PDAT></ITALIC></HIL><PDAT>, vol. 45, No. 1, pp. 13-18 (1998).</PDAT></STEXT></NCIT><CITED-BY-EXAMINER/></B562>
</B560>
<B570>
<B577><PDAT>4</PDAT></B577>
<B578US><PDAT>1</PDAT></B578US>
</B570>
<B580>
<B582><PDAT>435  6</PDAT></B582>
<B582><PDAT>435 911</PDAT></B582>
<B582><PDAT>435440</PDAT></B582>
<B582><PDAT>435183</PDAT></B582>
<B582><PDAT>435243</PDAT></B582>
<B582><PDAT>4352528</PDAT></B582>
<B582><PDAT>514 44</PDAT></B582>
<B582><PDAT>536 231</PDAT></B582>
<B582><PDAT>536 241</PDAT></B582>
<B582><PDAT>536 245</PDAT></B582>
</B580>
<B590><B595><PDAT>6</PDAT></B595><B596><PDAT>12</PDAT></B596></B590>
</B500>
<B600>
<B680US><DOC><DNUM><PDAT>60/086380</PDAT></DNUM><DATE><PDAT>19980522</PDAT></DATE><KIND><PDAT>00</PDAT></KIND></DOC></B680US>
</B600>
<B700>
<B720>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Paul F.</PDAT></FNM><SNM><STEXT><PDAT>Agris</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Raleigh</PDAT></CITY>
<STATE><PDAT>NC</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Salman</PDAT></FNM><SNM><STEXT><PDAT>Ashraf</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Raleigh</PDAT></CITY>
<STATE><PDAT>NC</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
</B720>
<B730>
<B731>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>North Carolina State University</PDAT></STEXT></ONM></NAM>
<ADR><CITY><PDAT>Raleigh</PDAT></CITY><STATE><PDAT>NC</PDAT></STATE></ADR>
</PARTY-US>
</B731>
<B732US>
<PDAT>02</PDAT>
</B732US>
</B730>
<B740>
<B741>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Myers Bigel Sibley &amp; Sajovec</PDAT></STEXT></ONM></NAM>
</PARTY-US>
</B741>
</B740>
<B745>
<B746>
<PARTY-US>
<NAM><FNM><PDAT>Sean</PDAT></FNM><SNM><STEXT><PDAT>McGarry</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B746>
<B747>
<PARTY-US>
<NAM><FNM><PDAT>Janet</PDAT></FNM><SNM><STEXT><PDAT>Epps</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B747>
<B748US><PDAT>1635</PDAT></B748US>
</B745>
</B700>
</SDOBI>
<SDOAB>
<BTEXT>
<PARA ID="P-00001" LVL="0"><PTEXT><PDAT>Methods of inhibiting microbial propagation, and screening for compounds that inhibit microbial propagation, are described. A method of inhibiting microbial propagation comprises inhibiting ribosomal binding of a specific microbial tRNA in the microbe by an amount sufficient to inhibit microbe propagation. A method of screening for compounds useful for inhibiting microbial propagation comprises contacting a specific microbial tRNA to a ribosome that binds that tRNA in the presence of the test compound, and then determining whether the compound inhibits the binding of that tRNA.</PDAT></PTEXT></PARA>
</BTEXT>
</SDOAB>
<SDODE>
<RELAPP>
<BTEXT>
<H LVL="1"><STEXT><PDAT>RELATED APPLICATIONS</PDAT></STEXT></H>
<PARA ID="P-00002" LVL="0"><PTEXT><PDAT>This application claims the benefit of U.S. provisional application Ser. No. 60/086,380, filed May 22, 1998, the disclosure of which is incorporated by reference herein in its entirety.</PDAT></PTEXT></PARA>
</BTEXT>
</RELAPP>
<GOVINT>
<BTEXT>
<PARA ID="P-00003" LVL="0"><PTEXT><PDAT>This invention was made with government support under grant number GM23037 from the National Institutes of Health and grant number MCB 9631103 from the National Science Foundation. The Government has certain rights to this invention.</PDAT></PTEXT></PARA>
</BTEXT>
</GOVINT>
<BRFSUM>
<BTEXT>
<H LVL="1"><STEXT><PDAT>FIELD OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00004" LVL="0"><PTEXT><PDAT>The present invention concerns antibacterial and antiviral agents that are directed against tRNA targets, and methods of screening for antibacterial and antiviral agents directed against tRNA targets.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>BACKGROUND OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00005" LVL="0"><PTEXT><PDAT>Numerous common bacteria are capable of mutating to become resistant to antibiotic agents. Viruses such as HIV are also known to mutate rapidly and thereby avoid immune defense mechanisms. Accordingly, there is a continued need for new antimicrobial agents and antiviral agents.</PDAT></PTEXT></PARA>
<PARA ID="P-00006" LVL="0"><PTEXT><PDAT>J. Hill et al., PCT Application WO 9705132, describe compounds that inhibit isoleucyl-tRNA synthetases. The compounds are stated to be useful against a broad spectrum of bacteria, fungi and parasites.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SUMMARY OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00007" LVL="0"><PTEXT><PDAT>A first aspect of the present invention is a method of inhibiting microbe propagation. The method comprises inhibiting ribosomal binding of a specific microbial tRNA such as tRNA</PDAT><HIL><SP><PDAT>lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>, tRNA</PDAT><HIL><SP><PDAT>glu</PDAT></SP></HIL><HIL><SB><PDAT>SUG </PDAT></SB></HIL><PDAT>or tRNA</PDAT><HIL><SP><PDAT>glu</PDAT></SP></HIL><HIL><SB><PDAT>SUC </PDAT></SB></HIL><PDAT>(for example, at position 27-43, most preferably position 34, thereof ) in the microbe by an amount sufficient to inhibit microbe propagation. This is achieved by a drug or compound binding to positions 27-43 (one or more positions simultaneously), most preferably position 34 or 37 of the tRNA. Additionally, the compound or drug can inactive (in the microbe) one or more enzymes that are responsible for producing the modification in the specific microbial tRNA that is responsible for the specific binding properties thereof (at positions 27 to 43, preferably positions 34 or 43).</PDAT></PTEXT></PARA>
<PARA ID="P-00008" LVL="0"><PTEXT><PDAT>A second aspect of the present invention is a method of inhibiting retrovirus propagation in a host for that retrovirus, wherein that retrovirus primes reverse transcription by binding of a specific host tRNA to retrovirus RNA at at least a pair of separate binding sites. The method comprises inhibiting the binding of the specific host tRNA to the retrovirus RNA at one of the binding sites by an amount sufficient to inhibit propagation of the retrovirus in the host. Advantageously, mutation of the retrovirus RNA to bind an alternate host tRNA for priming of reverse transcription requires a pair of mutations at at least the pair of separate tRNA binding sites in the retrovirus RNA: a low probability event.</PDAT></PTEXT></PARA>
<PARA ID="P-00009" LVL="0"><PTEXT><PDAT>A third aspect of the present invention is a method of screening for compounds useful for inhibiting microbial propagation. The method comprises contacting a specific microbial tRNA (for example, tRNA</PDAT><HIL><SP><PDAT>lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>) to a ribosome that binds that tRNA in the presence of the test compound, and then determining whether the compound inhibits the binding of that tRNA (e.g., binding of tRNA</PDAT><HIL><SP><PDAT>lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>, tRNA</PDAT><HIL><SP><PDAT>gln</PDAT></SP></HIL><HIL><SB><PDAT>SUG </PDAT></SB></HIL><PDAT>or tRNA</PDAT><HIL><SP><PDAT>glu</PDAT></SP></HIL><HIL><SB><PDAT>SUC </PDAT></SB></HIL><PDAT>at position 27-43, most preferably position 34, thereof) to the ribosome. The inhibition of binding indicates that the test compound is useful for inhibiting microbial propagation. The test compound will generally be binding to position 27-43, individually or in combination, most preferably positions 34 and or 37 of the stated tRNAs. The screening step may be carried out in a host cell, wherein the corresponding host cell tRNA (i.e., the tRNA that binds to the same amino acid) is modified differently as compared to said microbial tRNA at position 27 through 43 thereof (i.e., has a different modification, is not modified where the microbial tRNA is modified, or has the same modification but in a structure not recognized or specifically bound by the test compound).</PDAT></PTEXT></PARA>
<PARA ID="P-00010" LVL="0"><PTEXT><PDAT>A fourth aspect of the invention is a method of screening for compounds useful for inhibiting retrovirus propagation in a host for the retrovirus, wherein the retrovirus primes reverse transcription in the host by binding of a specific host tRNA to retrovirus RNA at at least a pair of separate binding sites on the host tRNA. The method comprises contacting the specific host tRNA to the retrovirus RNA in the presence of the test compound, and then determining whether the compound inhibits the binding of the specific host tRNA to the retrovirus RNA in the presence of the test compound. The inhibition of binding indicates that the test compound is useful for inhibiting propagation of the virus in the host. Again, note that mutation of the retrovirus RNA to bind an alternate host tRNA for priming of reverse transcription requires at least a pair of separate mutations at different tRNA binding sites in the retrovirus RNA.</PDAT></PTEXT></PARA>
</BTEXT>
</BRFSUM>
<DRWDESC>
<BTEXT>
<PARA ID="P-00011" LVL="0"><PTEXT><PDAT>The foregoing and other objects and aspects of the present invention are explained in detail in the drawings herein and the specification set forth below.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>BRIEF DESCRIPTION OF THE DRAWINGS</PDAT></STEXT></H>
<PARA ID="P-00012" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIGS. 1A-1B</PDAT></FGREF><PDAT>. Nucleotide sequences of human tRNA</PDAT><HIL><SP><PDAT>Lys3 </PDAT></SP></HIL><PDAT>anticodon stem/loops and structures of modified uridines. A: Nucleotide sequences of the anticodon stem/loops (ASLs) of native human tRNA</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>(SEQ ID NO: 1) and that of the chemically synthesized tRNA</PDAT><HIL><SP><PDAT>Lys </PDAT></SP></HIL><PDAT>ASLs used in the experiments: ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>(SEQ ID NO: 2) and ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>(SEQ ID NO: 3). B: Chemical structures of mcm</PDAT><HIL><SP><PDAT>5</PDAT></SP></HIL><PDAT>s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U (modified U</PDAT><HIL><SB><PDAT>34 </PDAT></SB></HIL><PDAT>in human tRNA</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>). mnm</PDAT><HIL><SP><PDAT>5</PDAT></SP></HIL><PDAT>s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U (modified U</PDAT><HIL><SB><PDAT>34 </PDAT></SB></HIL><PDAT>in </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>), and s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U in ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>. Modified nucleosides: &psgr;&equals;pseudouridine; mcm</PDAT><HIL><SP><PDAT>5</PDAT></SP></HIL><PDAT>s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U&equals;5-methoxycarbonylmethyl-2-thiouridine; mnm</PDAT><HIL><SP><PDAT>5</PDAT></SP></HIL><PDAT>s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U&equals;5-methylaminomethyl-2-thiouridine; ms</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>t</PDAT><HIL><SP><PDAT>6</PDAT></SP></HIL><PDAT>A&equals;2-methylthio-N</PDAT><HIL><SP><PDAT>6</PDAT></SP></HIL><PDAT>-threonylcarbamoyl-adenosine; s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U&equals;2-thiouridine. Human and </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>anticodon stem-loop domains have identical sequences except for the three base pairs at the top of the stem (P. Agris et al., </PDAT><HIL><ITALIC><PDAT>RNA</PDAT></ITALIC></HIL><PDAT>3: 420-428 (1997).</PDAT></PTEXT></PARA>
<PARA ID="P-00013" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIGS. 2A-2B</PDAT></FGREF><PDAT>. Binding of tRNAs and anticodon stem loops (ASLs) to programmed 30S ribosomal subunits. Ribosome binding assays were carried out as described under Materials and Methods by using </PDAT><HIL><SP><PDAT>32</PDAT></SP></HIL><PDAT>P-labeled tRNAs or ASLs and appropriately programmed 30S ribosomal subunits. A: Binding of lysine tRNAs and ASLs to poly(A)-programmed 30S ribosomal subunits: (filled square) native </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>; (open square) human tRNA</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>transcript; (filled circle) ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>; and (open circle) ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>UUU</PDAT></SB></HIL><PDAT>. B: Binding of (filled square) </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Glu</PDAT></SP></HIL><HIL><SB><PDAT>SUC</PDAT></SB></HIL><PDAT>, and (open diamond) </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Glu</PDAT></SP></HIL><HIL><SB><PDAT>UUC </PDAT></SB></HIL><PDAT>transcript to poly(AG)-programmed 30S ribosomal subunits, and (open triangle) </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Gln</PDAT></SP></HIL><HIL><SB><PDAT>UUG </PDAT></SB></HIL><PDAT>transcript to poly(AC)-programmed 30S ribosomal subunits. C: Binding of (filled square), native yeast tRNA</PDAT><HIL><SP><PDAT>Phe</PDAT></SP></HIL><HIL><SB><PDAT>GmAA </PDAT></SB></HIL><PDAT>and (opened square), ASL</PDAT><HIL><SP><PDAT>Phe</PDAT></SP></HIL><HIL><SB><PDAT>GAA </PDAT></SB></HIL><PDAT>to poly(U)-programmed 30S ribosomal subunits. G</PDAT><HIL><SB><PDAT>m</PDAT></SB></HIL><PDAT>&equals;2&prime;O-methylguanosine.</PDAT></PTEXT></PARA>
<PARA ID="P-00014" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIGS. 3A-3B</PDAT></FGREF><PDAT>. Footprinting of tRNAs and ASLs at the 16S rRNA P-site. A: Chemical probing experiments were conducted with kethoxal, as described under Materials and Methods, with: poly(U)-(lanes 1-3) or poly(A)-programmed (lanes 4-7) 30S ribosomal subunits plus native yeast tRNA</PDAT><HIL><SP><PDAT>Phe</PDAT></SP></HIL><HIL><SB><PDAT>GmAA </PDAT></SB></HIL><PDAT>(lane 2); ASL</PDAT><HIL><SP><PDAT>Phe</PDAT></SP></HIL><HIL><SB><PDAT>GAA </PDAT></SB></HIL><PDAT>(lane 3); </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>(lane 5); ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>(lane 6); or ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>(lane 7). B: Dimethyl sulfate protection experiments were conducted with poly(A)-programmed (lanes 1-4) 30S ribosomal subunits plus </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>(lane 2); ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>(lane 3); or ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>(lane 4), as described under Materials and Methods.</PDAT></PTEXT></PARA>
<PARA ID="P-00015" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIGS. 4A-4B</PDAT></FGREF><PDAT>. Thermal denaturation analyses of ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>and ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>UUU</PDAT></SB></HIL><PDAT>. A: UV thermal denaturation profiles of the ASLs (&tilde;2 &mgr;M) were obtained as described under Materials and Methods in 10 mM phosphate buffer, pH 7.2, containing 100 mM NaCl and 0.1 mM EDTA. B: Imino proton NMR spectra of ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>and ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>as a function of temperature. The spectra were collected on &tilde;0.1 mM ASLs in 10 mM phosphate buffer, pH 6.0 containing 0.1 mM EDTA.</PDAT></PTEXT></PARA>
<PARA ID="P-00016" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIGS. 5A-5B</PDAT></FGREF><PDAT>. A: Comparison of the 500-MHz DQF-COSY spectra of ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>and ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>in the region showing cross peaks between H5-H6 protons. Boxes, placed behind the cross-peaks in the ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>spectrum and in the corresponding positions in ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>spectrum facilitate comparison. B: Shaded boxes indicate stem pyrimidine H5-H6 cross-peaks that were not affected by the s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U-modification. Cross-peaks observed outside the boxes in the ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>spectrum were from the loop pyrimidines of ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>and due to a dynamic equilibrium of the loop this ASL. A small impurity of ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>(&lt;10%) in the ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>sample was responsible for weak cross-peaks inside open boxes in the ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>spectrum.</PDAT></PTEXT></PARA>
<PARA ID="P-00017" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 6</PDAT></FGREF><PDAT> is essentially the same as </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> above, but compared human ASL</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>with T</PDAT><HIL><SP><PDAT>6</PDAT></SP></HIL><PDAT>A</PDAT><HIL><SB><PDAT>37 </PDAT></SB></HIL><PDAT>with the unmodified ASL</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>with A</PDAT><HIL><SB><PDAT>37</PDAT></SB></HIL><PDAT>. Again, significantly different ribosomal binding was found.</PDAT></PTEXT></PARA>
</BTEXT>
</DRWDESC>
<DETDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>DETAILED DESCRIPTION OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00018" LVL="0"><PTEXT><PDAT>The term &ldquo;microbe&rdquo; as used herein includes bacteria, yeast, fungi and protozoans. Bacteria, including both gram positive and gram negative bacteria, are preferred. Examples of suitable bacteria include, but are not limited to, </PDAT><HIL><ITALIC><PDAT>Escherichia coli, Staphylococcus aureus</PDAT></ITALIC></HIL><PDAT>, and </PDAT><HIL><ITALIC><PDAT>Helicobacter pylori. </PDAT></ITALIC></HIL></PTEXT></PARA>
<PARA ID="P-00019" LVL="0"><PTEXT><PDAT>The term &ldquo;host&rdquo; as used herein refers to human or animal cells or tissues in vitro and human or animal subjects (e.g., avian or mammalian cells, tissues and subjects such as chickens, turkeys, mouse, rat, cats, dogs, cows, pigs, horses, etc.).</PDAT></PTEXT></PARA>
<PARA ID="P-00020" LVL="0"><PTEXT><PDAT>The term &ldquo;ribosome&rdquo; as used herein refers to both intact active ribosomes and ribosome subunits that retain tRNA binding, such as 30S subunits.</PDAT></PTEXT></PARA>
<PARA ID="P-00021" LVL="0"><PTEXT><PDAT>The specific tRNA referred to herein with respect to microbe tRNA is preferably a unique or unusual tRNA: that is, one that contains one or more modified bases other than adenine, guanine, cytosine, or uracil in the anticodon binding region (including both the stem and loop thereof), and/or preferably one that is the only tRNA available in that microbe for binding to a corresponding amino acid (e.g., lysine) during protein translation in the corresponding microbe. Preferably the modified base or bases is/are a nucleotide(s) that is/are at a binding site as described below (e.g., nucleotides 27 through 43) and participates in the binding event. Where carried out in vivo, the tRNA for the corresponding amino acid bound by the microbe tRNA preferably does not have the same modified base at the binding site or corresponding nucleotide in the host organism (i.e., pathogen specific modification). Many of these exist in the human host and in agronomically imortant animal hosts as set forth above). Examples of modified bases are set forth in Table 1 below.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00001">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 1</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Standard and modified nucleosides in tRNA and their standard</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>abbreviations.</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT></PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="offset" colwidth="14pt" align="left"/>
<colspec colname="1" colwidth="49pt" align="left"/>
<colspec colname="2" colwidth="154pt" align="left"/>
<tbody valign="top">
<row>
<entry></entry>
<entry><PTEXT><PDAT>U</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>uridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>C</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>cytidine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>adensoine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>G</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>guanosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>T</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>thymidine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>&quest;A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>unknown modified adenosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>m1A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1-methyladenosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>m2A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2-methyladenosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>i6A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N</PDAT><HIL><SP><PDAT>6</PDAT></SP></HIL><PDAT>-isopentenyladenosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>ms2i6A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2-methylthio-N</PDAT><HIL><SP><PDAT>6</PDAT></SP></HIL><PDAT>-isopentenyladenosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>m6A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N</PDAT><HIL><SP><PDAT>6</PDAT></SP></HIL><PDAT>-methyladenosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>t6A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N</PDAT><HIL><SP><PDAT>6</PDAT></SP></HIL><PDAT>-threonylcarbamoyladenosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>m6t6A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N</PDAT><HIL><SP><PDAT>6</PDAT></SP></HIL><PDAT>-methyl-N</PDAT><HIL><SP><PDAT>6</PDAT></SP></HIL><PDAT>-threonylcarbomoyladenosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>ms2t6A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2-methylthio-N</PDAT><HIL><SP><PDAT>6</PDAT></SP></HIL><PDAT>-threonylcarbamoyladenosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>Am</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2&prime;-O-methyladenosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>I</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Inosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>m1I</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1-methylinosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>Ar(p)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2&prime;-O-(5-phospho)ribosyladenosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>io6A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N</PDAT><HIL><SP><PDAT>6</PDAT></SP></HIL><PDAT>-(cis-hydroxyisopentenyl)adenosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>&quest;C</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Unknown modified cytidine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>s2C</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2-thiocytidine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>Cm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2&prime;-O-methylcytidine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>ac4C</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N</PDAT><HIL><SP><PDAT>4</PDAT></SP></HIL><PDAT>-acetylcytidine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>m5C</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5-methylcytidine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>m3C</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>3-methylcytidine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>k2C</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>lysidine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>f5C</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5-formylcytidin</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>f5Cm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2&prime;-O-methyl-5-formylcytidin</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>&quest;G</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>unknown modified guanosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>Gr(p)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2&prime;-O-(5-phospho)ribosylguanosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>m1G</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1-methylguanosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>m2G</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>-methylguanosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>Gm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2&prime;-O-methylguanosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>m22G</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>N</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>-dimethylguanosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>m22Gm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>,N</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>,2&prime;-O-trimethylguanosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>m7G</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>7-methylguanosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>fa7d7G</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>archaeosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>Q</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>queuosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>manQ</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>mannosyl-queuosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>galQ</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>galactosyl-queuosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>yW</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>wybutosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>o2yW</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>peroxywybutosine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>&quest;U</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>unknown modified uridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>mnm5U</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5-methylaminomethyluridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>s2U</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2-thiouridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>Um</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2&prime;-O-methyluridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>s4U</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4-thiouridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>ncm5U</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5-carbamoylmethyluridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>mcm5U</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5-methoxycarbonylmethyluridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>mnm5s2U</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5-methylaminomethyl-2-thiouridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>mcm5s2U</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5-methoxycarbonylmethyl-2-thiouridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>cmo5U</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>uridine 5-oxyacetic acid</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>mo5U</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5-methoxyuridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>cmnm5U</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5-carboxymethylaminomethyluridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>cmnm5s2U</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5-carboxymethylaminomethyl-2-thiouridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>acp3U</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>3-(3-amino-3-carboxypropyl)uridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>mchm5U</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5-(carboxyhydroxymethyl)uridinemethyl ester</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>cmnm5Um</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5-carboxymethylaminomethyl-2&prime;-O-methyluridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>ncm5Um</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5-carbamoylmethyl-2&prime;-O-methyluridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>D</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Dihydrouridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>&psgr;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>pseudouridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>m1&psgr;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1-methylpseudouridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>&psgr;m</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2&prime;-O-methylpseudouridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>m5U</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>ribosylthymine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>m5s2U</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5-methyl-2-thiouridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>m5Um</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5,2&prime;-O-dimethyluridine</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="left"><PTEXT><FOO ID="FOO-00001"><PTEXT><PDAT>See Sprinzl et. al., Nucleic Acids Res. 26, 148 (1998). </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00022" LVL="0"><PTEXT><PDAT>The specific tRNA referred to herein with respect to host tRNA is also preferably a unique or unusual tRNA: that is, one that contains one or more modified bases other than adenine, guanine, cytosine, or uracil in the anticodon binding region (including both the stem and loop thereof), as set forth above, and/or preferably one that is the only tRNA available in that host for binding to retroviral RNA for priming of reverse transcription of that retroviral RNA in the host.</PDAT></PTEXT></PARA>
<PARA ID="P-00023" LVL="0"><PTEXT><PDAT>The region of the tRNA to which binding occurs as described herein is, in general, the tRNA anticodon stem-loop structure, and most preferably the loop structure itself. Following conventional tRNA nucleotide numbering (see, e.g., M. Sprinzl et al., Compilation of tRNA sequences and sequences of tRNA genes, </PDAT><HIL><ITALIC><PDAT>Nucleic Acids Res</PDAT></ITALIC></HIL><PDAT>. 26, 148-153 (1998)), the site to which binding occurs is from nucleotide 27 or 32 to nucleotide 39, 41 or 43. Nucleotides 32, 34, 35, 37 and 39 are preferred binding sites, and nucleotides 34 and 37 are particularly preferred binding sites. Binding may be to a single site or combination of sites comprising nucleotides within this range.</PDAT></PTEXT></PARA>
<PARA ID="P-00024" LVL="0"><PTEXT><PDAT>As noted above, a method of screening for compounds useful for inhibiting microbial propagation is disclosed herein. The method involves contacting a specific microbial tRNA such as tRNA</PDAT><HIL><SP><PDAT>lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>, tRNA</PDAT><HIL><SP><PDAT>gln</PDAT></SP></HIL><HIL><SB><PDAT>SUG </PDAT></SB></HIL><PDAT>or tRNA</PDAT><HIL><SP><PDAT>glu</PDAT></SP></HIL><HIL><SB><PDAT>SUC </PDAT></SB></HIL><PDAT>to a ribosome that binds that tRNA in the presence of the test compound. The contacting step is typically carried out in vitro in an aqueous solution, with the tRNA, the ribosome, an appropriate messenger RNA, and the test compound in the aqueous solution. The contacting step may be carried out with a single test compound or with a library of probes or test compounds in any of a variety of combinatorial chemistry systems, as discussed in greater detail below.</PDAT></PTEXT></PARA>
<PARA ID="P-00025" LVL="0"><PTEXT><PDAT>After the contacting step, the next step involves determining whether the compound inhibits the binding of the specific tRNA to the ribosome (e.g., the binding of tRNA</PDAT><HIL><SP><PDAT>lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>at position 34 thereof to the ribosome).</PDAT></PTEXT></PARA>
<PARA ID="P-00026" LVL="0"><PTEXT><PDAT>The determining step can be carried out by any suitable means, such as the filter binding assays disclosed below, or in any of the binding detection mechanisms commonly employed with combinatorial libraries of probes or test compounds as discussed below. Inhibition of ribosomal binding by the test compound indicates that the test compound is useful for inhibiting microbial (e.g., bacterial, protozoal, fungal) propagation. Compounds identified by this technique are sometimes referred to as &ldquo;active compounds&rdquo; herein. The method is particularly useful for identifying compounds that inhibit bacterial growth, preferably bacteria that contain a single tRNA for a particular amino acid, such as a single lysine tRNA, particularly where the lysine tRNA contains a 2-thiouridine at position 34. Examples of such bacteria include, but are not limited to, </PDAT><HIL><ITALIC><PDAT>Helicobacter pylori, Escherichia coli </PDAT></ITALIC></HIL><PDAT>and </PDAT><HIL><ITALIC><PDAT>Staphylococcus aureus</PDAT></ITALIC></HIL><PDAT>. Examples of such 2-thiouridine bases include, but are not limited to: </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00001">
<CHEMCDX ID="CHEMCDX-00001" ALT="chemistry chemdraw file" FILE="US06461815-20021008-C00001.CDX"/>
<CHEMMOL ID="CHEMMOL-00001" ALT="chemistry mol file" FILE="US06461815-20021008-C00001.MOL"/>
<EMI ID="EMI-C00001" ALT="embedded image" HE="224.90055" WI="103.9311" FILE="US06461815-20021008-C00001.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00027" LVL="0"><PTEXT><PDAT>A method of screening for compounds useful for inhibiting retrovirus propagation in a host for the retrovirus, particularly where the retrovirus primes reverse transcription in the host by binding of a specific host tRNA to retrovirus RNA at a pair of separate binding sites on the host tRNA, is also disclosed herein. The method comprises contacting the specific host tRNA to the retrovirus RNA in the presence of the test compound. The contacting step is typically carried out in vitro in an aqueous solution, with the tRNA, the retroviral RNA, and the test compound in the aqueous solution. The term &ldquo;retroviral RNA&rdquo; is intended to encompass both a complete retroviral genome and fragments thereof that contain the tRNA binding portions (such fragments will typically be at least 10 or 12 to 50 or more nucleotides in length). The contacting step may again be carried out with a single test compound or with a library of probes or test compounds in any of a variety of combinatorial chemistry systems, as discussed in greater detail below.</PDAT></PTEXT></PARA>
<PARA ID="P-00028" LVL="0"><PTEXT><PDAT>After the contacting step, the next step involves determining whether the compound inhibits the binding of the specific host tRNA to the retrovirus RNA in the presence of the test compound. The determining step can be carried out by any suitable means, such as gel shift assays, chemical and enzymatic footprinting, circular dichroism and NMR spectroscopy, equilibrium dialysis, or in any of the binding detection mechanisms commonly employed with combinatorial libraries of probes or test compounds as discussed below. The inhibition of binding indicates that the test compound is useful for inhibiting propagation of the virus in the host. Such compounds are also sometimes referred to as &ldquo;active compounds&rdquo; herein. The method may be carried out with retroviruses in general, particularly lentiviruses such as HIV-1. In one embodiment the specific host tRNA is mammalian, preferably primate or specifically human, such as tRNA</PDAT><HIL><SP><PDAT>lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>, and the determining step comprises determining whether the compound inhibits the binding of tRNA</PDAT><HIL><SP><PDAT>lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>(for example at position 34 thereof) to the retrovirus RNA.</PDAT></PTEXT></PARA>
<PARA ID="P-00029" LVL="0"><PTEXT><PDAT>As noted above, the present invention can be used with test compounds (or &ldquo;probe molecules&rdquo;), or libraries (where groups of different probe molecules are employed), of any type. In general, such probe molecules (including those that are active compounds herein) are organic compounds, including oligomers such as antisense olionuleotides, non-oligomers, organo-metallic compounds, and combinations thereof, as well as bio-inorganic compounds. Non-oligomers include a wide variety of organic molecules, such as heterocyclics, aromatics, alicyclics, aliphatics and combinations thereof, comprising steroids, antibiotics, enzyme inhibitors, ligands, hormones, drugs, alkaloids, opioids, benzodiazepenes, terpenes, prophyrins, toxins, and combinations thereof. Oligomers include peptides (that is, oligopeptides) and proteins, oligonucleotides such as DNA, RNA and their derivatives such as peptide nucleic acid (PNA), oligosaccharides, polylipids, polyester, polyamides, polyurethans, polyureas, polyethers, poly(phosphorus derivatives) such ass phosphates, phosphonates, phosphoramides, phosphonamides, phosphites, phosphinamides, etc., poly(sulfur derivatives) such as sulfones, sulfonates, sulfites, sulfonamides, sulfenamides, etc., where for the phosphorous and sulfur derivatives the indicated heteroatom for the most part will be bonded to C, H, N, O or S, and combinations thereof. Numerous methods of synthesizing or applying such probe molecules on solid supports (where the probe molecules may be either covalently or non-covalently bound to the solid support) are known, and such probe molecules can be made in accordance with procedures known to those skilled in the art. See, e.g., U.S. Pat. No. 5,565,324 to Still et al., U.S. Pat. No. 5,284,514 to Ellman et al., U.S. Pat. No. 5,445,934 to Fodor et al. (the disclosures of all United States patents cited herein are to be incorporated herein by reference in their entirety); J. Baldwin and I. Henderson, </PDAT><HIL><ITALIC><PDAT>Recent Advances in the Generation of Small</PDAT></ITALIC></HIL><PDAT>-</PDAT><HIL><ITALIC><PDAT>Molecule Combinatorial Libraries: Encoded Split Synthesis and Solid</PDAT></ITALIC></HIL><PDAT>-</PDAT><HIL><ITALIC><PDAT>Phase Synthetic Methodology</PDAT></ITALIC></HIL><PDAT>, Med. Res. Reviews 16, 391-405 (1996).</PDAT></PTEXT></PARA>
<PARA ID="P-00030" LVL="0"><PTEXT><PDAT>Such probe molecules or active compounds could be used as inhibitors by contacting the tRNA, the RNA to which the tRNA binds (mRNA, viral RNA) or the modification enzyme responsible for the unique or unsual chemistry or structure of the tRNA (i.e., the modified base).</PDAT></PTEXT></PARA>
<PARA ID="P-00031" LVL="0"><PTEXT><PDAT>A method of inhibiting microbe propagation comprises inhibiting ribosomal binding of a specific microbial tRNA (e.g., tRNA</PDAT><HIL><SP><PDAT>lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>, for example at position 34 thereof) in the microbe by an amount sufficient to inhibit microbe propagation. Inhibition of ribosomal binding may be carried out by contacting an active compound to the ribosome in an amount effective to inhibit binding suffuciently to inhibit microbe propagation. The microbe is preferably a bacteria, and most preferably a bacteria that contains a single lysine tRNA, and wherein the lysine tRNA contains a 2-thiouridine (this term including derivatives thereof) at position 34 thereof. Examples include but are not limited to </PDAT><HIL><ITALIC><PDAT>Escherichia coli </PDAT></ITALIC></HIL><PDAT>and </PDAT><HIL><ITALIC><PDAT>Staphylococcus aureus</PDAT></ITALIC></HIL><PDAT>. The microbe may be in vitro, in a culture media, or on a surface to be disinfected, or may be in vivo in a host (e.g., a human or animal host in need of an antimicrobial treatment). Formulations of active compounds can be prepared and administered in accordance with known techniques, as discussed below.</PDAT></PTEXT></PARA>
<PARA ID="P-00032" LVL="0"><PTEXT><PDAT>A method of inhibiting retrovirus propagation in a host for that retrovirus, wherein the retrovirus primes reverse transcription by binding of a specific host tRNA to retrovirus RNA at a pair of separate binding sites on the host tRNA, comprises inhibiting the binding of the specific host tRNA to the retrovirus RNA at one of the binding sites by an amount sufficient to inhibit propagation of the retrovirus in the host. Note that mutation of the retrovirus RNA to bind an alternate host tRNA for priming of reverse transcription requires a pair of mutations at separate tRNA binding sites in the retrovirus RNA. Formulations of active compounds can be prepared and administered in accordance with known techniques, as discussed below. In a preferred embodiment, the specific host tRNA is tRNA</PDAT><HIL><SP><PDAT>lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>, where binding may for example be inhibited at position 34 thereof. Preferably the retrovirus primes reverse transcription in the host specifically with the specific host tRNA, such as tRNA</PDAT><HIL><SP><PDAT>lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>. The method may be carried out with retroviruses in general, particularly lentiviruses such as HIV-1. The host may be a cell in vitro, or a human or animal subject in need of such treatment.</PDAT></PTEXT></PARA>
<PARA ID="P-00033" LVL="0"><PTEXT><PDAT>Subjects to be treated by the methods of the present invention are typically human subjects although the methods may be carried out with animal subjects (dogs, cats, horses, cattle, etc.) for veterinary purposes. The present invention provides pharmaceutical formulations comprising the active compounds, including pharmaceutically acceptable salts thereof, in pharmaceutically acceptable carriers for aerosol, oral, and parenteral administration as discussed in greater detail below. The therapeutically effective dosage of any specific compound, the use of which is in the scope of present invention, will vary somewhat from compound to compound, patient to patient, and will depend upon the condition of the patient and the route of delivery.</PDAT></PTEXT></PARA>
<PARA ID="P-00034" LVL="0"><PTEXT><PDAT>In accordance with the present method, an active compound or a pharmaceutically acceptable salt thereof, may be administered orally or through inhalation as a solid, or may be administered intramuscularly or intravenously as a solution, suspension, or emulsion. Alternatively, the compound or salt may also be administered by inhalation, intravenously or intramuscularly as a liposomal suspension. When administered through inhalation the active compound or salt should be in the form of a plurality of solid particles or droplets having a particle size from about 0.5 to about 5 microns, preferably from about 1 to about 2 microns.</PDAT></PTEXT></PARA>
<PARA ID="P-00035" LVL="0"><PTEXT><PDAT>The present invention also provides new pharmaceutical compositions suitable for intravenous or intramuscular injection. The pharmaceutical compositions comprise an active compound or a pharmaceutically acceptable salt thereof, in any pharmaceutically acceptable carrier. If a solution is desired, water is the carrier of choice with respect to water-soluble compounds or salts. With respect to the water-insoluble compounds or salts, an organic vehicle, such as glycerol, propylene glycol, polyethylene glycol, or mixtures thereof, may be suitable. In the latter instance, the organic vehicle may contain a substantial amount of water. The solution in either instance may then be sterilized in any suitable manner, preferably by filtration through a 0.22 micron filter. Subsequent to sterilization, the solution may be filled into appropriate receptacles, such as depyrogenated glass vials. Of course, the filling should be done by an aseptic method. Sterilized closures may then be placed on the vials and, if desired, the vial contents may be lyophilized.</PDAT></PTEXT></PARA>
<PARA ID="P-00036" LVL="0"><PTEXT><PDAT>In addition to active compounds or their salts, the pharmaceutical compositions may contain other additives, such as pH adjusting additives. In particular, useful pH adjusting agents include acids, such as hydrochloric acid, bases or buffers, such as sodium lactate, sodium acetate, sodium phosphate, sodium citrate, sodium borate, or sodium gluconate. Further, the compositions may contain anti-microbial agents. Useful antimicrobial agents include methylparaben, propylparaben, and benzyl alcohol. The microbial preservative is typically employed when the formulation is placed in a vial designed for multidose use. Of course, as indicated, the pharmaceutical compositions of the present invention may be lyophilized using techniques well known in the art.</PDAT></PTEXT></PARA>
<PARA ID="P-00037" LVL="0"><PTEXT><PDAT>In yet another aspect of the present invention, there is provided an injectable, stable, sterile composition comprising an active compound or a salt thereof, in a unit dosage form in a sealed container. The compound or salt is provided in the form of a lyophilizate which is capable of being reconstituted with a suitable pharmaceutically acceptable carrier to form a liquid composition suitable for injection thereof into man. The unit dosage form typically comprises from about 10 mg to about 10 grams of the compound or salt. When the compound or salt is substantially water-insoluble, a sufficient amount of emulsifying agent which is physiologically acceptable may be employed in sufficient quantity to emulsify the compound or salt in an aqueous carrier. One such useful emulsifying agent is phosphatidyl choline.</PDAT></PTEXT></PARA>
<PARA ID="P-00038" LVL="0"><PTEXT><PDAT>Other pharmaceutical compositions may be prepared from the active compounds, such as aqueous base emulsions. In such an instance, the composition will contain a sufficient amount of pharmaceutically acceptable emulsifying agent to emulsify the desired amount of the active compound or salt thereof. Particularly useful emulsifying agents include phosphatidyl cholines, and lecithin.</PDAT></PTEXT></PARA>
<PARA ID="P-00039" LVL="0"><PTEXT><PDAT>Further, the present invention provides liposomal formulations of the active compounds or salts thereof. The technology for forming liposomal suspensions is well known in the art. When the active compound or salt thereof is an aqueous-soluble salt, using conventional liposome technology, the same may be incorporated into lipid vesicles. In such an instance, due to the water solubility of the compound or salt, the compound or salt will be substantially entrained within the hydrophilic center or core of the liposomes. The lipid layer employed may be of any conventional composition and may either contain cholesterol or may be cholesterol-free. When the compound or salt of interest is water-insoluble, again employing conventional liposome formation technology, the salt may be substantially entrained within the hydrophobic lipid bilayer which forms the structure of the liposome. In either instance, the liposomes which are produced may be reduced in size, as through the use of standard sonication and homogenization techniques.</PDAT></PTEXT></PARA>
<PARA ID="P-00040" LVL="0"><PTEXT><PDAT>Pharmaceutical formulations are also provided which are suitable for administration as an aerosol, by inhalation. These formulations comprise a solution or suspension of the desired active compound or a salt thereof or a plurality of solid particles of the compound or salt. The desired formulation may be placed in a small chamber and nebulized. Nebulization may be accomplished by compressed air or by ultrasonic energy to form a plurality of liquid droplets or solid particles comprising the compounds or salts. The liquid droplets or solid particles should have a particle size in the range of about 0.5 to about 5 microns. The solid particles can be obtained by processing the compound, or a salt thereof, in any appropriate manner known in the art, such as by micronization. Most preferably, the size of the solid particles or droplets will be from about 1 to about 2 microns. In this respect, commercial nebulizers are available to achieve this purpose.</PDAT></PTEXT></PARA>
<PARA ID="P-00041" LVL="0"><PTEXT><PDAT>Preferably, when the pharmaceutical formulation suitable for administration as an aerosol is in the form of a liquid, the formulation will comprise a water-soluble active compound or a salt thereof, in a carrier which comprises water. A surfactant may be present which lowers the surface tension of the formulation sufficiently to result in the formation of droplets within the desired size range when subjected to nebulization.</PDAT></PTEXT></PARA>
<PARA ID="P-00042" LVL="0"><PTEXT><PDAT>The present invention is explained in greater detail in the following non-limiting Examples.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLES</PDAT></STEXT></H>
<PARA ID="P-00043" LVL="7"><PTEXT><PDAT>1. MATERIALS AND METHODS</PDAT></PTEXT></PARA>
<PARA ID="P-00044" LVL="0"><PTEXT><PDAT>Native tRNAs, transcripts, ASLs and 30S ribosomal subunits. Native yeast tRNA</PDAT><HIL><SP><PDAT>Phe</PDAT></SP></HIL><HIL><SB><PDAT>GmAA</PDAT></SB></HIL><HIL><ITALIC><PDAT>, E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>, and </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Glu</PDAT></SP></HIL><HIL><SB><PDAT>SUC </PDAT></SB></HIL><PDAT>were purchased from Sigma Chemical Company. In vitro transcripts of human tRNA</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>UUU</PDAT></SB></HIL><HIL><ITALIC><PDAT>, E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Glu</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>and </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Gln</PDAT></SP></HIL><HIL><SB><PDAT>UUC </PDAT></SB></HIL><PDAT>were gifts from Drs. Musier-Forsyth and Rodgers and S&ouml;ll, respectively. ASLs, with and without s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U, were synthesized using an adaptation of standard solid phase chemistry for RNA synthesis and purified by HPLC (Agris et al., </PDAT><HIL><ITALIC><PDAT>Biochimie </PDAT></ITALIC></HIL><PDAT>77: 125-134 (1995); Kumar and Davis, </PDAT><HIL><ITALIC><PDAT>Nucleic Acids Res</PDAT></ITALIC></HIL><PDAT>. 25: 1272-1280 (1997)). Sequence and modification of the ASLs were confirmed by MALDI mass spectroscopy (Faulstich et al., </PDAT><HIL><ITALIC><PDAT>Anal. Chem</PDAT></ITALIC></HIL><PDAT>. 69: 4349-4353 (1997)), nucleoside composition analysis (Gehrke and Kuo, </PDAT><HIL><ITALIC><PDAT>Chromatography and modification of nucleoside </PDAT></ITALIC></HIL><PDAT>Vol. 45A, ppA3-A71 (Amsterdam: Elsevier 1990) and organomercurialgel electrophoresis (Igloi, </PDAT><HIL><ITALIC><PDAT>Biochemistry </PDAT></ITALIC></HIL><PDAT>27: 3842-3849 (1988)). Both, mass spectroscopy and HPLC analyses confirmed the purity of ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>to be greater than 90%. Thermal denaturation and renaturing of tRNA transcripts and ASLs did not alter their abilities to bind the 30S subunits. Small ribosomal subunits (30S) were prepared and activated according to Ericson et al. (</PDAT><HIL><ITALIC><PDAT>J. Mol. Biol</PDAT></ITALIC></HIL><PDAT>. 250: 407-419 (1995)).</PDAT></PTEXT></PARA>
<PARA ID="P-00045" LVL="0"><PTEXT><PDAT>Binding of tRNAs and ASLs to 30S ribosomal subunits. In order to determine the K</PDAT><HIL><SB><PDAT>d </PDAT></SB></HIL><PDAT>of tRNA and ASL binding to the ribosome, 30S subunits (10 pmol) and poly(U), poly(A), poly(AG) or poly(AC) (10 &mgr;g) were incubated for 20 minutes at 37&deg; C. with increasing amounts of </PDAT><HIL><SP><PDAT>32</PDAT></SP></HIL><PDAT>P-labeled tRNA or ASL (up to 50 pmol) in 40 ml of CMN buffer (80 mM potassium-cacodylate, pH 7.2, 20 mM MgCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>, 100 mM NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>Cl, and 3 mM &bgr;-mercaptoethanol). The reaction was incubated for another 20 minutes on ice, passed through nitrocellulose filters (0.45 &mgr;m) and the filter-bound RNA washed twice with ice-cold buffer (100 &mgr;l). The filters were then air-dried and counted. K</PDAT><HIL><SB><PDAT>d</PDAT></SB></HIL><PDAT>s and their standard deviations were determined using non-linear regression analysis on four replicates of each experiment.</PDAT></PTEXT></PARA>
<PARA ID="P-00046" LVL="0"><PTEXT><PDAT>Chemical modification and primer extension. Chemical probing and primer extension was accomplished as described by Moazed and Noller (</PDAT><HIL><ITALIC><PDAT>J. Mol. Biol</PDAT></ITALIC></HIL><PDAT>. 211: 135-145 (1990)) except that the modifications with both dimethyl sulfate and kethoxal were conducted at 20&deg; C. for 30 minutes in 40 ml of CMN buffer. Ribosomal 30S subunits (10 pmol) programmed with poly(U), poly(A), or poly(AG) (10 mg) were incubated with 50 pmoles yeast tRNA</PDAT><HIL><SP><PDAT>Phe</PDAT></SP></HIL><HIL><SB><PDAT>GmAA </PDAT></SB></HIL><PDAT>or ASL</PDAT><HIL><SP><PDAT>Phe</PDAT></SP></HIL><HIL><SB><PDAT>GAA </PDAT></SB></HIL><PDAT>or 150 pmoles of </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>, human ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>, or human ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>UUU</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00047" LVL="0"><PTEXT><PDAT>UV and NMR Spectroscopy. Thermal denaturations of tRNA</PDAT><HIL><SP><PDAT>Lys </PDAT></SP></HIL><PDAT>ASLs were monitored with UV and NMR spectroscopies. The UV samples contained &tilde;2 M (0.3 A</PDAT><HIL><SB><PDAT>260 </PDAT></SB></HIL><PDAT>units) RNA in 10 mM sodium phosphate buffer, pH 7.2, 100 mM NaCl and 0.1 mM EDTA. NMR samples contained 0.1 mM (11.5 A</PDAT><HIL><SB><PDAT>260 </PDAT></SB></HIL><PDAT>units) RNA in 10 mM phosphate buffer, pH 6.0, and 0.1 mM EDTA. Double quantum filtered COSY (DQF-COSY) experiments were conducted at 10&deg; C. with a Bruker DRX 500 MHz spectrometer using standard procedures (Rance et al., </PDAT><HIL><ITALIC><PDAT>Biochem. Biophys. Res. Commun </PDAT></ITALIC></HIL><PDAT>117: 479-485 (1983)). The exchangeable and non-exchangeable proton resonances were assigned using standard procedures except for the imino protons of U</PDAT><HIL><SB><PDAT>34</PDAT></SB></HIL><PDAT>, U</PDAT><HIL><SB><PDAT>35 </PDAT></SB></HIL><PDAT>and U</PDAT><HIL><SB><PDAT>36 </PDAT></SB></HIL><PDAT>which were assigned via site-specific incorporation of </PDAT><HIL><SP><PDAT>15</PDAT></SP></HIL><PDAT>N3-uridines. Resonances of ASL</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>were assigned by comparison to the spectra of ASL</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>UUU</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00048" LVL="7"><PTEXT><PDAT>2. RESULTS</PDAT></PTEXT></PARA>
<PARA ID="P-00049" LVL="0"><PTEXT><PDAT>Ribosomal binding of native tRNAs, unmodified tRNAs, and ASLs. The unmodified anticodon stem and loop of </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>(ASL</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>UUU</PDAT></SB></HIL><PDAT>) and that of tRNA</PDAT><HIL><SP><PDAT>Gln</PDAT></SP></HIL><HIL><SB><PDAT>UUG </PDAT></SB></HIL><PDAT>(ASL</PDAT><HIL><SP><PDAT>Gln</PDAT></SP></HIL><HIL><SB><PDAT>UUG</PDAT></SB></HIL><PDAT>) did not bind the appropriately programmed ribosomes, presumably because of lack of modified nucleosides (von Ahsen et al., RNA 3: 49-56 (1997)). However, rather than requiring one or more modified nucleosides, perhaps these particular ASLs failed to bind because their smaller sequences lacked a required structural element. Therefore, we compared the ribosome binding of the unmodified transcripts of the tRNAs to that of fully modified, native tRNAs. In vitro transcribed, full-length </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Gln</PDAT></SP></HIL><HIL><SB><PDAT>UUG </PDAT></SB></HIL><PDAT>and tRNA</PDAT><HIL><SP><PDAT>Glu</PDAT></SP></HIL><HIL><SB><PDAT>UUC </PDAT></SB></HIL><PDAT>and human tRNA</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>all failed to bind the appropriately programmed 30S ribosomal subunits (FIGS. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>A and B). Under the same conditions, native </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>effectively bound poly(A)-programmed ribosomes (FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>A), </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Glu</PDAT></SP></HIL><HIL><SB><PDAT>SUC </PDAT></SB></HIL><PDAT>bound randomly polymerized poly(AG)-programmed ribosomes (FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>B), and yeast tRNA</PDAT><HIL><SP><PDAT>Phe</PDAT></SP></HIL><HIL><SB><PDAT>GmAA </PDAT></SB></HIL><PDAT>bound poly(U)-programmed ribosomes (FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>C). Thus, the lack of ribosomal binding by unmodified </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>lysine and glutamine ASLs (von Ahsen et al., supra) was not due to the size of the RNA used in these experiments. A similar negative result was observed for the transcript of tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>when ribosomes were programmed with randomized poly(AG) containing both the AAG and AAA codons (data not shown). Thus, the inability of unmodified ASLs and tRNA transcripts of lysine, glutamine, and glutamic acid to bind the ribosome was neither due to the sequence length nor a codon preference. Because of these results and the fact that fully modified tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>, tRNA</PDAT><HIL><SP><PDAT>Gln</PDAT></SP></HIL><HIL><SB><PDAT>SUG </PDAT></SB></HIL><PDAT>and tRNA</PDAT><HIL><SP><PDAT>Glu</PDAT></SP></HIL><HIL><SB><PDAT>SUC </PDAT></SB></HIL><PDAT>have in common s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U derivatives at the wobble position 34, we postulated that s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U</PDAT><HIL><SB><PDAT>34</PDAT></SB></HIL><PDAT>-containing tRNAs are dependent on nucleoside modifications for ribosome binding.</PDAT></PTEXT></PARA>
<PARA ID="P-00050" LVL="0"><PTEXT><PDAT>In order to test this hypothesis, heptadecamer ASLs corresponding to the human tRNA</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>sequence were produced with and without s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U</PDAT><HIL><SB><PDAT>34 </PDAT></SB></HIL><PDAT>by automated oligonucleotide synthesis and then assayed for ribosome binding. Human and </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>ASLs have identical sequences except for the three base pairs at the top of the stem (Agris et al., </PDAT><HIL><ITALIC><PDAT>RNA </PDAT></ITALIC></HIL><PDAT>3: 420-428 (1997)) Surprisingly, we found that the ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>(FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>A), singularly modified with just s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U at position 34, was able to bind poly(A)- and poly(AG)-programmed ribosomes almost as effectively as native </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>(FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>A). In fact, the K</PDAT><HIL><SB><PDAT>d </PDAT></SB></HIL><PDAT>for the interaction of ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>with poly(A)-programmed 30S ribosomal subunits (176&plusmn;62 nM) was comparable to that of native </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>(70&plusmn;7 nM). As expected, the unmodified human ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>(</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1A</PDAT></FGREF><PDAT>) did not bind AAA- or AAG-programmed ribosomes (FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>A). In contrast, unmodified yeast ASL</PDAT><HIL><SP><PDAT>Phe</PDAT></SP></HIL><HIL><SB><PDAT>GAA </PDAT></SB></HIL><PDAT>bound poly(U)-programmed 30S ribosomal subunits as effectively (K</PDAT><HIL><SB><PDAT>d</PDAT></SB></HIL><PDAT>&equals;136&plusmn;49 nM) as native tRNA</PDAT><HIL><SP><PDAT>Phe</PDAT></SP></HIL><HIL><SB><PDAT>GmAA </PDAT></SB></HIL><PDAT>(K</PDAT><HIL><SB><PDAT>d</PDAT></SB></HIL><PDAT>&equals;103&plusmn;19 nM) (FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>C).</PDAT></PTEXT></PARA>
<PARA ID="P-00051" LVL="0"><PTEXT><PDAT>16S P-site footprints by tRNAs and ASLs. To determine if the ASL</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>bound the ribosome at the same site as fully modified tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>, we conducted a chemical footprinting analysis of the ASL and tRNA on 16S rRNA. Chemical protections were analyzed for five of the commonly recognized 16S P-site nucleotides (A532, G926, A794, C795, and G1338) (Moazed and Noller, supra). The ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>produced the same footprint on 16S rRNA as did the native </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>(FIGS. </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>A and B). Both ASL and tRNA protected all five P-site nucleosides. Of the five 16S rRNA nucleosides that were probed, A532, G926 and G1338 were intrinsically more reactive to chemical probes than A794 and C795. Hence, they were more easily recognized as being protected in the presence of ASL or tRNA (FIG. </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>B). The reduced chemical reactivities and the weaker protections of A794 and C795 have also been documented by others (Moazed and Noller, supra). As expected, the unmodified ASL</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>provided no substantial protection of P-site nucleotides from either kethoxal (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3A</PDAT></FGREF><PDAT>) or dimethyl sulfate (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3B</PDAT></FGREF><PDAT>) chemical probes. In contrast, the unmodified yeast ASL</PDAT><HIL><SP><PDAT>Phe</PDAT></SP></HIL><HIL><SB><PDAT>GAA </PDAT></SB></HIL><PDAT>produced the same footprint as did native yeast tRNA</PDAT><HIL><SP><PDAT>Phe</PDAT></SP></HIL><HIL><SB><PDAT>GmAA</PDAT></SB></HIL><PDAT>, the ASL</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>and native </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>. Thus, as shown by both filter binding and chemical probing, for some tRNAs, such as tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>, but not all, the nucleoside modifications are critical for ribosomal P-site binding.</PDAT></PTEXT></PARA>
<PARA ID="P-00052" LVL="0"><PTEXT><PDAT>UV and NMR Spectroscopies. The dramatic restoration of ribosomal binding activity by a single, simple base modification underscores the importance of the 2-thio group in tRNA</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>and prompted us to examine possible structural differences between the unmodified ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>and the ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>. Thermal denaturations, monitored by both UV spectroscopy and the imino proton chemical shifts of NMR spectra (FIGS. </PDAT><HIL><BOLD><PDAT>4</PDAT></BOLD></HIL><PDAT>A and B), failed to detect any significant differences in the stability of the ASLs. The ASLs had similar denaturation profiles and identical melting points (T</PDAT><HIL><SB><PDAT>m</PDAT></SB></HIL><PDAT>&equals;48&plusmn;1&deg; C.). These results were not surprising considering that the techniques employed principally monitored the stabilities of ASL stems and not the loops. However, structural and dynamic differences between the two ASL loops became apparent in analysis of NMR spectra of non-exchangeable protons (FIG. </PDAT><HIL><BOLD><PDAT>5</PDAT></BOLD></HIL><PDAT>). Examination of the DQF-COSY spectra of ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>and ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>revealed that H5-H6 cross-peaks arising from pyrimidines in the first four base pairs of the stem (U</PDAT><HIL><SB><PDAT>27</PDAT></SB></HIL><PDAT>, C</PDAT><HIL><SB><PDAT>28</PDAT></SB></HIL><PDAT>, C</PDAT><HIL><SB><PDAT>40 </PDAT></SB></HIL><PDAT>and U</PDAT><HIL><SB><PDAT>41</PDAT></SB></HIL><PDAT>) were not affected by the presence of s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U</PDAT><HIL><SB><PDAT>34 </PDAT></SB></HIL><PDAT>in the loop (FIGS. </PDAT><HIL><BOLD><PDAT>5</PDAT></BOLD></HIL><PDAT>A and B). However, the remaining six pyrimidines of the modified ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>, including five in the loop (C</PDAT><HIL><SB><PDAT>32</PDAT></SB></HIL><PDAT>, U</PDAT><HIL><SB><PDAT>33</PDAT></SB></HIL><PDAT>, s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U</PDAT><HIL><SB><PDAT>34</PDAT></SB></HIL><PDAT>, U</PDAT><HIL><SB><PDAT>35 </PDAT></SB></HIL><PDAT>and U</PDAT><HIL><SB><PDAT>36</PDAT></SB></HIL><PDAT>), produced more than six signals. These results suggest that the loop region of ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>, unlike that of the unmodified ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>UUU</PDAT></SB></HIL><PDAT>, was engaged in a slow conformational equilibrium involving two or more species. We have yet to fully describe that equilibrium. However, there is no doubt that the presence of s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U has changed the loop.</PDAT></PTEXT></PARA>
<PARA ID="P-00053" LVL="0"><PTEXT><PDAT>The results presented here are the first demonstration of a single atom modification (O&rarr;S) in tRNA that is critical for ribosomal binding. Thiolated human ASL</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>binds the ribosome, yet unmodified </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>ASL</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>UUU</PDAT></SB></HIL><PDAT>, the unmodified human tRNA</PDAT><HIL><SP><PDAT>Lys3</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>transcript and the corresponding ASL do not. In addition, the unmodified transcripts of tRNA</PDAT><HIL><SP><PDAT>Glu</PDAT></SP></HIL><HIL><SB><PDAT>UUC </PDAT></SB></HIL><PDAT>and tRNA</PDAT><HIL><SP><PDAT>Gln</PDAT></SP></HIL><HIL><SB><PDAT>UUG</PDAT></SB></HIL><PDAT>, as well as the unmodified ASL</PDAT><HIL><SP><PDAT>Glu</PDAT></SP></HIL><HIL><SB><PDAT>UUG </PDAT></SB></HIL><PDAT>(von Ahsen, supra), do not bind the ribosome. These results demonstrate the importance of the s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U</PDAT><HIL><SB><PDAT>34 </PDAT></SB></HIL><PDAT>nucleoside modification in the in vitro P-site binding of many s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U</PDAT><HIL><SB><PDAT>34</PDAT></SB></HIL><PDAT>-containing tRNAs, regardless of genus. In addition, asuE (trmU) mutants of </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>&lsqb;personal communication, Dieter S&ouml;ll&rsqb; and sin3/sin4 mutants of </PDAT><HIL><ITALIC><PDAT>Schizosaccharomyces pombe </PDAT></ITALIC></HIL><PDAT>(Grossenbacher et al., </PDAT><HIL><ITALIC><PDAT>J. biol. Chem</PDAT></ITALIC></HIL><PDAT>. 261: 16351-16355 (1986); Heyer et al., </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem</PDAT></ITALIC></HIL><PDAT>. 259: 2856-2862 (1984)) deficient in the synthesis of s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U grow very poorly, suggesting ribosomal binding of s</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>U-containing tRNAs is modification dependent in vivo, as well as in vitro.</PDAT></PTEXT></PARA>
<PARA ID="P-00054" LVL="0"><PTEXT><PDAT>To provide further evidence for nucleoside modifications being targets for antibacterial drugs, ribosome binding of ASL</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>with t</PDAT><HIL><SP><PDAT>6</PDAT></SP></HIL><PDAT>A</PDAT><HIL><SB><PDAT>37 </PDAT></SB></HIL><PDAT>was compared to the unmodified ASL</PDAT><HIL><SP><PDAT>Lys</PDAT></SP></HIL><HIL><SB><PDAT>UUU </PDAT></SB></HIL><PDAT>with A</PDAT><HIL><SB><PDAT>37</PDAT></SB></HIL><PDAT>. (t</PDAT><HIL><SP><PDAT>6</PDAT></SP></HIL><PDAT>A is N6-threonylcarbamoyladenosine). Studies were carried out in essentially the same manner as described in connection with </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> above and these data are presented in FIG. </PDAT><HIL><BOLD><PDAT>6</PDAT></BOLD></HIL><PDAT>. Again, the modified nucleotide, this time at position 37, was critical for ribosome binding. These data indicate that modified nucleoside throughout the stem-loop structure may be targeted for drug binding, interaction and screening as described above.</PDAT></PTEXT></PARA>
<PARA ID="P-00055" LVL="0"><PTEXT><PDAT>The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.</PDAT></PTEXT></PARA>
<CWU>
<SEQLST-US ID="SEQLST-1">
<SEQ-LST-NEW>
<S100>
<S160>
<PDAT>3</PDAT>
</S160>
</S100>
<S200>
<S210>
<PDAT>1</PDAT>
</S210>
<S211>
<PDAT>17</PDAT>
</S211>
<S212>
<PDAT>RNA</PDAT>
</S212>
<S213>
<PDAT>Homo sapiens</PDAT>
</S213>
<S220>
<S221>
<STEXT>
<PDAT>modified_base</PDAT>
</STEXT>
</S221>
<S222>
<STEXT>
<PDAT>(1)</PDAT>
</STEXT>
</S222>
<S223><STEXT><PDAT>p</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 1
ucagacuuuu aaucuga                                                    17
</PDAT>
</S400>
<S200>
<S210>
<PDAT>2</PDAT>
</S210>
<S211>
<PDAT>17</PDAT>
</S211>
<S212>
<PDAT>RNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequence Chemically
      synthesized tRNA anticodon stem/loop</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 2
ucagacuuuu aaucuga                                                    17
</PDAT>
</S400>
<S200>
<S210>
<PDAT>3</PDAT>
</S210>
<S211>
<PDAT>17</PDAT>
</S211>
<S212>
<PDAT>RNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequence Chemically
      synthesized tRNA anticodon stem/loop</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 3
ucagacuuuu aaucuga                                                    17
</PDAT>
</S400>
</SEQ-LST-NEW>
</SEQLST-US>
</CWU>
</BTEXT>
</DETDESC>
</SDODE>
<SDOCL>
<H LVL="1"><STEXT><PDAT>That which is claimed is: </PDAT></STEXT></H>
<CL>
<CLM ID="CLM-00001">
<PARA ID="P-00056" LVL="0"><PTEXT><PDAT>1. A method of screening for compounds useful for inhibiting microbial propagation, comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>contacting, in the presence of a test compound, a specific microbial tRNA to a ribosome that is ordinarily capable of binding said tRNA, wherein said contacting step is carried out in vitro; and then </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="3"><PTEXT><PDAT>determining whether said compound inhibits the binding of said tRNA to said ribosome; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>the inhibition of binding indicating said test compound is useful for inhibiting microbial propagation. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00002">
<PARA ID="P-00057" LVL="0"><PTEXT><PDAT>2. A method according to </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said determining step comprises determining whether said compound inhibits the binding of said tRNA to said ribosome at position 27-43 of said tRNA.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00003">
<PARA ID="P-00058" LVL="0"><PTEXT><PDAT>3. A method according to </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said tRNA is selected from the group consisting of tRNA</PDAT><HIL><SP><PDAT>lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU</PDAT></SB></HIL><PDAT>, tRNA</PDAT><HIL><SP><PDAT>gln</PDAT></SP></HIL><HIL><SB><PDAT>SUG</PDAT></SB></HIL><PDAT>, and tRNA</PDAT><HIL><SP><PDAT>glu</PDAT></SP></HIL><HIL><SB><PDAT>SUC</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00004">
<PARA ID="P-00059" LVL="0"><PTEXT><PDAT>4. A method according to </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said tRNA is tRNA</PDAT><HIL><SP><PDAT>lys</PDAT></SP></HIL><HIL><SB><PDAT>SUU </PDAT></SB></HIL><PDAT>and said binding is at position 34 thereof.</PDAT></PTEXT></PARA>
</CLM>
</CL>
</SDOCL>
<SDODR ID="DRAWINGS">
<EMI ID="EMI-D00001" ALT="embedded image" FILE="US06461815-20021008-D00001.TIF"/>
<EMI ID="EMI-D00002" ALT="embedded image" FILE="US06461815-20021008-D00002.TIF"/>
<EMI ID="EMI-D00003" ALT="embedded image" FILE="US06461815-20021008-D00003.TIF"/>
<EMI ID="EMI-D00004" ALT="embedded image" FILE="US06461815-20021008-D00004.TIF"/>
<EMI ID="EMI-D00005" ALT="embedded image" FILE="US06461815-20021008-D00005.TIF"/>
<EMI ID="EMI-D00006" ALT="embedded image" FILE="US06461815-20021008-D00006.TIF"/>
</SDODR>
</PATDOC>

<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PATDOC SYSTEM "ST32-US-Grant-025xml.dtd" [
<!ENTITY US06461838-20021008-C00001.CDX SYSTEM "US06461838-20021008-C00001.CDX" NDATA CDX>
<!ENTITY US06461838-20021008-C00001.MOL SYSTEM "US06461838-20021008-C00001.MOL" NDATA MOL>
<!ENTITY US06461838-20021008-C00001.TIF SYSTEM "US06461838-20021008-C00001.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-C00002.CDX SYSTEM "US06461838-20021008-C00002.CDX" NDATA CDX>
<!ENTITY US06461838-20021008-C00002.MOL SYSTEM "US06461838-20021008-C00002.MOL" NDATA MOL>
<!ENTITY US06461838-20021008-C00002.TIF SYSTEM "US06461838-20021008-C00002.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-C00003.CDX SYSTEM "US06461838-20021008-C00003.CDX" NDATA CDX>
<!ENTITY US06461838-20021008-C00003.MOL SYSTEM "US06461838-20021008-C00003.MOL" NDATA MOL>
<!ENTITY US06461838-20021008-C00003.TIF SYSTEM "US06461838-20021008-C00003.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-C00004.CDX SYSTEM "US06461838-20021008-C00004.CDX" NDATA CDX>
<!ENTITY US06461838-20021008-C00004.MOL SYSTEM "US06461838-20021008-C00004.MOL" NDATA MOL>
<!ENTITY US06461838-20021008-C00004.TIF SYSTEM "US06461838-20021008-C00004.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-C00005.CDX SYSTEM "US06461838-20021008-C00005.CDX" NDATA CDX>
<!ENTITY US06461838-20021008-C00005.MOL SYSTEM "US06461838-20021008-C00005.MOL" NDATA MOL>
<!ENTITY US06461838-20021008-C00005.TIF SYSTEM "US06461838-20021008-C00005.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-C00006.CDX SYSTEM "US06461838-20021008-C00006.CDX" NDATA CDX>
<!ENTITY US06461838-20021008-C00006.MOL SYSTEM "US06461838-20021008-C00006.MOL" NDATA MOL>
<!ENTITY US06461838-20021008-C00006.TIF SYSTEM "US06461838-20021008-C00006.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-C00007.CDX SYSTEM "US06461838-20021008-C00007.CDX" NDATA CDX>
<!ENTITY US06461838-20021008-C00007.MOL SYSTEM "US06461838-20021008-C00007.MOL" NDATA MOL>
<!ENTITY US06461838-20021008-C00007.TIF SYSTEM "US06461838-20021008-C00007.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-C00008.CDX SYSTEM "US06461838-20021008-C00008.CDX" NDATA CDX>
<!ENTITY US06461838-20021008-C00008.MOL SYSTEM "US06461838-20021008-C00008.MOL" NDATA MOL>
<!ENTITY US06461838-20021008-C00008.TIF SYSTEM "US06461838-20021008-C00008.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-C00009.CDX SYSTEM "US06461838-20021008-C00009.CDX" NDATA CDX>
<!ENTITY US06461838-20021008-C00009.MOL SYSTEM "US06461838-20021008-C00009.MOL" NDATA MOL>
<!ENTITY US06461838-20021008-C00009.TIF SYSTEM "US06461838-20021008-C00009.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-C00010.CDX SYSTEM "US06461838-20021008-C00010.CDX" NDATA CDX>
<!ENTITY US06461838-20021008-C00010.MOL SYSTEM "US06461838-20021008-C00010.MOL" NDATA MOL>
<!ENTITY US06461838-20021008-C00010.TIF SYSTEM "US06461838-20021008-C00010.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-C00011.CDX SYSTEM "US06461838-20021008-C00011.CDX" NDATA CDX>
<!ENTITY US06461838-20021008-C00011.MOL SYSTEM "US06461838-20021008-C00011.MOL" NDATA MOL>
<!ENTITY US06461838-20021008-C00011.TIF SYSTEM "US06461838-20021008-C00011.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00001.TIF SYSTEM "US06461838-20021008-D00001.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00002.TIF SYSTEM "US06461838-20021008-D00002.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00003.TIF SYSTEM "US06461838-20021008-D00003.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00004.TIF SYSTEM "US06461838-20021008-D00004.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00005.TIF SYSTEM "US06461838-20021008-D00005.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00006.TIF SYSTEM "US06461838-20021008-D00006.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00007.TIF SYSTEM "US06461838-20021008-D00007.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00008.TIF SYSTEM "US06461838-20021008-D00008.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00009.TIF SYSTEM "US06461838-20021008-D00009.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00010.TIF SYSTEM "US06461838-20021008-D00010.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00011.TIF SYSTEM "US06461838-20021008-D00011.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00012.TIF SYSTEM "US06461838-20021008-D00012.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00013.TIF SYSTEM "US06461838-20021008-D00013.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00014.TIF SYSTEM "US06461838-20021008-D00014.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00015.TIF SYSTEM "US06461838-20021008-D00015.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00016.TIF SYSTEM "US06461838-20021008-D00016.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00017.TIF SYSTEM "US06461838-20021008-D00017.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00018.TIF SYSTEM "US06461838-20021008-D00018.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00019.TIF SYSTEM "US06461838-20021008-D00019.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00020.TIF SYSTEM "US06461838-20021008-D00020.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00021.TIF SYSTEM "US06461838-20021008-D00021.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00022.TIF SYSTEM "US06461838-20021008-D00022.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00023.TIF SYSTEM "US06461838-20021008-D00023.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00024.TIF SYSTEM "US06461838-20021008-D00024.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00025.TIF SYSTEM "US06461838-20021008-D00025.TIF" NDATA TIF>
<!ENTITY US06461838-20021008-D00026.TIF SYSTEM "US06461838-20021008-D00026.TIF" NDATA TIF>
]>
<PATDOC DTD="2.5" STATUS="Build 20020918">
<SDOBI>
<B100>
<B110><DNUM><PDAT>06461838</PDAT></DNUM></B110>
<B130><PDAT>B2</PDAT></B130>
<B140><DATE><PDAT>20021008</PDAT></DATE></B140>
<B190><PDAT>US</PDAT></B190>
</B100>
<B200>
<B210><DNUM><PDAT>09755653</PDAT></DNUM></B210>
<B211US><PDAT>09</PDAT></B211US>
<B220><DATE><PDAT>20010105</PDAT></DATE></B220>
</B200>
<B300>
<B310><DNUM><PDAT>PCT/US94/10643</PDAT></DNUM></B310>
<B320><DATE><PDAT>19940920</PDAT></DATE></B320>
<B330><CTRY><PDAT>WO</PDAT></CTRY></B330>
</B300>
<B400>
<B472>
<B473US/>
</B472>
</B400>
<B500>
<B510>
<B511><PDAT>C12P 1934</PDAT></B511>
<B512><PDAT>C12N  900</PDAT></B512>
<B512><PDAT>C12N 1500</PDAT></B512>
<B516><PDAT>7</PDAT></B516>
</B510>
<B520>
<B521><PDAT>435 911</PDAT></B521>
<B522><PDAT>435183</PDAT></B522>
<B522><PDAT>43525231</PDAT></B522>
<B522><PDAT>43525233</PDAT></B522>
<B522><PDAT>4353201</PDAT></B522>
<B522><PDAT>435536</PDAT></B522>
<B522><PDAT>435 231</PDAT></B522>
<B522><PDAT>435 232</PDAT></B522>
</B520>
<B540><STEXT><PDAT>Recombinant production of novel polyketides</PDAT></STEXT></B540>
<B560>
<B561>
<PCIT>
<DOC><DNUM><PDAT>4935340</PDAT></DNUM>
<DATE><PDAT>19900600</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Baltz et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435  6</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5672491</PDAT></DNUM>
<DATE><PDAT>19970900</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Khosla et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435148</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5712146</PDAT></DNUM>
<DATE><PDAT>19980100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Khosla et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>43525235</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5824513</PDAT></DNUM>
<DATE><PDAT>19981000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Katz et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435183</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5830750</PDAT></DNUM>
<DATE><PDAT>19981100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Khosla et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>43525235</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5962290</PDAT></DNUM>
<DATE><PDAT>19991000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Khosla et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435183</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6004787</PDAT></DNUM>
<DATE><PDAT>19991200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Katz et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435183</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6022731</PDAT></DNUM>
<DATE><PDAT>20000200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Khosla et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>43525235</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6060234</PDAT></DNUM>
<DATE><PDAT>20000500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Katz et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435  4</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6063561</PDAT></DNUM>
<DATE><PDAT>20000500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Katz et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435  4</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6200813</PDAT></DNUM>
<DATE><PDAT>20010300</PDAT></DATE>
<KIND><PDAT>B1</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Katz et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435477</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6271255</PDAT></DNUM>
<DATE><PDAT>20010800</PDAT></DATE>
<KIND><PDAT>B1</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Leadlay et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>514 29</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>0092388</PDAT></DNUM>
<DATE><PDAT>19831000</PDAT></DATE>
<CTRY><PDAT>EP</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 93/13663</PDAT></DNUM>
<DATE><PDAT>19930700</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 98/51695</PDAT></DNUM>
<DATE><PDAT>19981100</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B562><NCIT><STEXT><PDAT>Bartel, et al., &ldquo;Biosynthesis of anthraquinones by interspecies cloning of actinorhodin biosynthesis genes in streptomycetes: Clarification of actinorhodin gene functions,&rdquo; </PDAT><HIL><ITALIC><PDAT>J Bacteriol </PDAT></ITALIC></HIL><PDAT>(1990) 172(9):4816-4826. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Beck, et al., &ldquo;The multifunctional 6-methylsalicylic acid synthase gene of </PDAT><HIL><ITALIC><PDAT>Penicillium patulum. </PDAT></ITALIC></HIL><PDAT>Its gene structure relative to that of other polyketide synthases,&rdquo; </PDAT><HIL><ITALIC><PDAT>Eur J Biochem </PDAT></ITALIC></HIL><PDAT>(1990) 192:487-498. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Bibb, et al., &ldquo;Analysis of the nucelotide sequence of the </PDAT><HIL><ITALIC><PDAT>Streptomyces glaucescens </PDAT></ITALIC></HIL><PDAT>tcml genes provides key information about the enzymology of polyketide antibiotic biosynthesis,&rdquo; </PDAT><HIL><ITALIC><PDAT>EMBO J </PDAT></ITALIC></HIL><PDAT>(1989) 8(9):2727-2735. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Caballero et al., &ldquo;Organisation and functions of the actVA region of the actinorhodin biosynthetic gene cluster of </PDAT><HIL><ITALIC><PDAT>Streptomyces coelicolor,&rdquo; Mol Gen Genet </PDAT></ITALIC></HIL><PDAT>(1991) 230:401-412. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Cortes et al., &ldquo;n unusually large multifunctional polypeptide in the erythromycin-producing polyketide synthase of </PDAT><HIL><ITALIC><PDAT>Saccharopolyspora erythraea,&rdquo; Nature </PDAT></ITALIC></HIL><PDAT>(1990) 348:176-178. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Davis, et al., &ldquo;Functional mapping of a polyketide synthase from </PDAT><HIL><ITALIC><PDAT>Aspergillus terreus </PDAT></ITALIC></HIL><PDAT>involved in lovastatin synthesis,&rdquo; </PDAT><HIL><ITALIC><PDAT>Abst of the Genetics of Industrial Microorganisms Mtg </PDAT></ITALIC></HIL><PDAT>(1994) P288:192. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Donadio et al., &ldquo;Modular organization of genes required for complex polyketide biosynthesis,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>(1991) 252:675-679. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Fernandez-Moreno et al., &ldquo;the act cluster contains regulatory and antibiotic export genes, direct targets for translational control by the bldA tRNA gene of Streptomyces,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell </PDAT></ITALIC></HIL><PDAT>(1991) 66:769-780. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Fernandez-Moreno et al., &ldquo;Nucleotide sequence and deduced functions of a set of cotranscribed genes of </PDAT><HIL><ITALIC><PDAT>Streptomyces coelicolor </PDAT></ITALIC></HIL><PDAT>A3(2) including the polyketide synthase for the antibiotic actinorhodin,&rdquo; </PDAT><HIL><ITALIC><PDAT>J Biol Chem </PDAT></ITALIC></HIL><PDAT>(1992) 267:19278-19290. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Floss, &ldquo;Genetic engineering of hybrid antibiotics&mdash;a progress report,&rdquo; </PDAT><HIL><ITALIC><PDAT>Tetrahydron </PDAT></ITALIC></HIL><PDAT>(1991) 47(31):6045-6058. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Hershberger et al., &ldquo;Genetics and molecular biology of industrial microorganisms,&rdquo; </PDAT><HIL><ITALIC><PDAT>Am Soc for Microbiol </PDAT></ITALIC></HIL><PDAT>(1989) (Washington, D.C.) pp. 68-84. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Hopwood et al., &ldquo;Antibiotics: opportunities for genetic manipulation,&rdquo; </PDAT><HIL><ITALIC><PDAT>Phil Trans R Soc Lond </PDAT></ITALIC></HIL><PDAT>(1989) B324:549-562. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Hopwood et al., &ldquo;Product of &lsquo;hybrid&rsquo;antibiotics by genetic engineering,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>(1985) 314 (6012):642-644. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Khosla, et al., &ldquo;Targeted gene replacements in a Streptomyces polyketide synthase gene cluster: role for the acyl carrier protein,&rdquo; </PDAT><HIL><ITALIC><PDAT>Mole Microbiol </PDAT></ITALIC></HIL><PDAT>(1992) 6(21):3237-3249. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Khosla, et al., &ldquo;Genetic construction and functional analysis of hybrid polyketide synthases containing heterologous acyl carrier proteins,&rdquo; </PDAT><HIL><ITALIC><PDAT>J Bacteriol </PDAT></ITALIC></HIL><PDAT>(1993) 175:2197-2204. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>MacNeil et al., &ldquo;Complex organization of the </PDAT><HIL><ITALIC><PDAT>Streptomyces avermitilis </PDAT></ITALIC></HIL><PDAT>genes encoding the avermectin polyketide synthase,&rdquo; </PDAT><HIL><ITALIC><PDAT>Gene </PDAT></ITALIC></HIL><PDAT>(1992) 115:119-125. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Malpartida et al., &ldquo;Molecular cloning of the whole biosynthetic pathway of a Streptomyces antibiotic and its expression in a heterologous host,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>(1984) 309:462-464. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Malpartida et al., &ldquo;Physical and genetic characterisation of the gene cluster for the antibiotic actinorhodin in </PDAT><HIL><ITALIC><PDAT>Streptomyces coelicolor </PDAT></ITALIC></HIL><PDAT>A3(2),&rdquo; </PDAT><HIL><ITALIC><PDAT>Mol Gen Genet </PDAT></ITALIC></HIL><PDAT>(1986) 205:66-73. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Malpartida et al., &ldquo;Homology between Streptomyces genes coding for synthesis of different polyketides used to clone antibiotic biosynthetic genes,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>(1987) 325(6107):818-821. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>McDaniel et al., &ldquo;Engineered biosynthesis of novel polyketides,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>(1993) 262:1546-1550. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Roberts, et al., &ldquo;6-Deoxyerythronolide B synthase 3 from </PDAT><HIL><ITALIC><PDAT>Saccarapolyspora erythraea: </PDAT></ITALIC></HIL><PDAT>Over-expression in </PDAT><HIL><ITALIC><PDAT>Escherichia coli, </PDAT></ITALIC></HIL><PDAT>purification and characterisation,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biochem Soc Trans </PDAT></ITALIC></HIL><PDAT>(1992) 21:325. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Roberts, et al., &ldquo;Heterologous expression in </PDAT><HIL><ITALIC><PDAT>Escherichia coli </PDAT></ITALIC></HIL><PDAT>of an intact multienzyme component of the erythromycin-producing polyketide synthase,&rdquo; </PDAT><HIL><ITALIC><PDAT>Eur J Biochem </PDAT></ITALIC></HIL><PDAT>(1993) 214:305-311. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Robinson, &ldquo;Polyketide synthase complexes: their structure and function in antibiotic biosynthesis,&rdquo; </PDAT><HIL><ITALIC><PDAT>Phil Trans R Soc Land B </PDAT></ITALIC></HIL><PDAT>(1991) 332:107-114. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Rohr, &ldquo;Combinatorial biosynthesis&mdash;an approach in the near future&quest;&rdquo; </PDAT><HIL><ITALIC><PDAT>Angew Chem Int Ed Engl </PDAT></ITALIC></HIL><PDAT>(1995) 34(8):881-885. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Sherman et al., &ldquo;Structure and deduced function of the granaticin-producing polyketide synthase gene cluster of </PDAT><HIL><ITALIC><PDAT>Streptomyces violaceoruber </PDAT></ITALIC></HIL><PDAT>T&uuml;22,&rdquo; </PDAT><HIL><ITALIC><PDAT>EMBO J </PDAT></ITALIC></HIL><PDAT>(1989) 8:2717-2725. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Sherman et al., &ldquo;Functional replacement of genes for individual polyketide synthase components in </PDAT><HIL><ITALIC><PDAT>Streptomyces coelicolor </PDAT></ITALIC></HIL><PDAT>A3(2) by heterogenous genes from a different polyketide pathway,&rdquo; </PDAT><HIL><ITALIC><PDAT>J Bacteriol </PDAT></ITALIC></HIL><PDAT>(1992) 174:6184-6190. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Strohl, et al., &ldquo;Expression of polyketide biosynthesis and regulatory genes in heterologous streptomycetes,&rdquo; </PDAT><HIL><ITALIC><PDAT>J Ind Microbiol </PDAT></ITALIC></HIL><PDAT>(1991) 7:163-174. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Strohl et al., &ldquo;Significance of anthraquinone formation resulting from the cloning of actinorhodin genes in heterologous streptomycetes,&rdquo; </PDAT><HIL><ITALIC><PDAT>Molecular Microbiology </PDAT></ITALIC></HIL><PDAT>(1992) 6(2):147-152. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Tuan et al., &ldquo;Cloning of Genes Involved in Erythromycin biosynthesis from </PDAT><HIL><ITALIC><PDAT>Saccharopolyspora erythrae </PDAT></ITALIC></HIL><PDAT>using a novel actinomycete-</PDAT><HIL><ITALIC><PDAT>Escherichia coli </PDAT></ITALIC></HIL><PDAT>cosmid,&rdquo; </PDAT><HIL><ITALIC><PDAT>Gene </PDAT></ITALIC></HIL><PDAT>(1990) 90:21-29.</PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
</B560>
<B570>
<B577><PDAT>12</PDAT></B577>
<B578US><PDAT>1</PDAT></B578US>
</B570>
<B580>
<B582><PDAT>435183</PDAT></B582>
<B582><PDAT>4352523</PDAT></B582>
<B582><PDAT>43525231</PDAT></B582>
<B582><PDAT>43525233</PDAT></B582>
<B582><PDAT>4353201</PDAT></B582>
<B582><PDAT>435 911</PDAT></B582>
<B582><PDAT>536 232</PDAT></B582>
<B582><PDAT>536 231</PDAT></B582>
</B580>
<B590><B595><PDAT>26</PDAT></B595><B596><PDAT>33</PDAT></B596></B590>
</B500>
<B600>
<B620><PARENT-US><CDOC><DOC><DNUM><PDAT>09/755653</PDAT></DNUM></DOC></CDOC><PDOC><DOC><DNUM><PDAT>09/264162</PDAT></DNUM><DATE><PDAT>19990305</PDAT></DATE><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>00</PDAT></KIND></DOC></PDOC><PSTA><PDAT>01</PDAT></PSTA><PPUB><DOC><DNUM><PDAT>6215007</PDAT></DNUM><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>A </PDAT></KIND></DOC></PPUB></PARENT-US></B620>
<B620><PARENT-US><CDOC><DOC><DNUM><PDAT>09/264162</PDAT></DNUM></DOC></CDOC><PDOC><DOC><DNUM><PDAT>08/949943</PDAT></DNUM><DATE><PDAT>19971014</PDAT></DATE><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>00</PDAT></KIND></DOC></PDOC><PSTA><PDAT>01</PDAT></PSTA><PPUB><DOC><DNUM><PDAT>5962290</PDAT></DNUM><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>A </PDAT></KIND></DOC></PPUB></PARENT-US></B620>
<B620><PARENT-US><CDOC><DOC><DNUM><PDAT>08/949943</PDAT></DNUM></DOC></CDOC><PDOC><DOC><DNUM><PDAT>08/486645</PDAT></DNUM><DATE><PDAT>19950607</PDAT></DATE><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>00</PDAT></KIND></DOC></PDOC><PSTA><PDAT>01</PDAT></PSTA><PPUB><DOC><DNUM><PDAT>5712146</PDAT></DNUM><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>A </PDAT></KIND></DOC></PPUB></PARENT-US></B620>
<B630><B632><PARENT-US><CDOC><DOC><DNUM><PDAT>08/486645</PDAT></DNUM></DOC></CDOC><PDOC><DOC><DNUM><PDAT>08/238811</PDAT></DNUM><DATE><PDAT>19940506</PDAT></DATE><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>00</PDAT></KIND></DOC></PDOC><PSTA><PDAT>01</PDAT></PSTA><PPUB><DOC><DNUM><PDAT>5672491</PDAT></DNUM><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>A </PDAT></KIND></DOC></PPUB></PARENT-US></B632></B630>
<B630><B632><PARENT-US><CDOC><DOC><DNUM><PDAT>08/238811</PDAT></DNUM></DOC></CDOC><PDOC><DOC><DNUM><PDAT>08/164301</PDAT></DNUM><DATE><PDAT>19931208</PDAT></DATE><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>00</PDAT></KIND></DOC></PDOC><PSTA><PDAT>03</PDAT></PSTA></PARENT-US></B632></B630>
<B630><B632><PARENT-US><CDOC><DOC><DNUM><PDAT>08/164301</PDAT></DNUM></DOC></CDOC><PDOC><DOC><DNUM><PDAT>08/123732</PDAT></DNUM><DATE><PDAT>19930920</PDAT></DATE><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>00</PDAT></KIND></DOC></PDOC><PSTA><PDAT>03</PDAT></PSTA></PARENT-US></B632></B630>
<B690US>
<DOC>
<DNUM><PDAT>20010039021</PDAT></DNUM>
<DATE><PDAT>20011108</PDAT></DATE>
<CTRY><PDAT>US</PDAT></CTRY>
<KIND><PDAT>A1</PDAT></KIND>
</DOC>
</B690US></B600>
<B700>
<B720>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Chaitan</PDAT></FNM><SNM><STEXT><PDAT>Khosla</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Stanford</PDAT></CITY>
<STATE><PDAT>CA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>David A.</PDAT></FNM><SNM><STEXT><PDAT>Hopwood</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Norwich</PDAT></CITY>
<CTRY><PDAT>GB</PDAT></CTRY>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Suzanne</PDAT></FNM><SNM><STEXT><PDAT>Ebert-Khosla</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Stanford</PDAT></CITY>
<STATE><PDAT>CA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Robert</PDAT></FNM><SNM><STEXT><PDAT>McDaniel</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Palo Alto</PDAT></CITY>
<STATE><PDAT>CA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Hong</PDAT></FNM><SNM><STEXT><PDAT>Fu</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Stanford</PDAT></CITY>
<STATE><PDAT>CA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Camilla</PDAT></FNM><SNM><STEXT><PDAT>Kao</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Stanford</PDAT></CITY>
<STATE><PDAT>CA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
</B720>
<B730>
<B731>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>The Leland Stanford Junior University</PDAT></STEXT></ONM></NAM>
<ADR><CITY><PDAT>Stanford</PDAT></CITY><STATE><PDAT>CA</PDAT></STATE></ADR>
</PARTY-US>
</B731>
<B732US>
<PDAT>02</PDAT>
</B732US>
</B730>
<B730>
<B731>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>The John Innes Institute</PDAT></STEXT></ONM></NAM>
<ADR><CITY><PDAT>Norwich</PDAT></CITY><CTRY><PDAT>GB</PDAT></CTRY></ADR>
</PARTY-US>
</B731>
<B732US>
<PDAT>03</PDAT>
</B732US>
</B730>
<B740>
<B741>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Morrison &amp; Foerster LLP</PDAT></STEXT></ONM></NAM>
</PARTY-US>
</B741>
</B740>
<B745>
<B746>
<PARTY-US>
<NAM><FNM><PDAT>Nashaat T.</PDAT></FNM><SNM><STEXT><PDAT>Nashed</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B746>
<B748US><PDAT>1652</PDAT></B748US>
</B745>
</B700>
</SDOBI>
<SDOAB>
<BTEXT>
<PARA ID="P-00001" LVL="0"><PTEXT><PDAT>Novel polyketides and novel methods of efficiently producing both new and known polyketides, using recombinant technology, are disclosed. In particular, a novel host-vector system is described which is used to produce polyketide synthases which in turn catalyze the production of a variety of polyketides.</PDAT></PTEXT></PARA>
</BTEXT>
</SDOAB>
<SDODE>
<RELAPP>
<BTEXT>
<H LVL="1"><STEXT><PDAT>CROSS-REFERENCE TO RELATED APPLICATIONS</PDAT></STEXT></H>
<PARA ID="P-00002" LVL="0"><PTEXT><PDAT>This application is a divisional of U.S. Ser. No. 09/264,162, filed Mar. 5, 1997, now U.S. Pat. No. 6,215,007, which is a divisional of Ser. No. 08/949,943 filed Oct. 14, 1997, now U.S. Pat. No. 5,962,290, which is a divisional of U.S. Ser. No. 08/486,645 filed Jun. 7, 1995, now U.S. Pat. No. 5,712,146 which is a continuation-in-part of U.S. patent application Ser. No. 08/238,811, filed May 6, 1994, now U.S. Pat. No. 5,672,491 which is a continuation-in-part of U.S. patent application Ser. No. 08/164,301, filed Dec. 8, 1993, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 08/123,732, filed Sep. 20, 1993, now abandoned from which priority is claimed pursuant to 35 U.S.C. &sect; 120, and which disclosures are hereby incorporated by reference in their entireties.</PDAT></PTEXT></PARA>
</BTEXT>
</RELAPP>
<GOVINT>
<BTEXT>
<H LVL="1"><STEXT><PDAT>REFERENCE TO GOVERNMENT CONTRACT</PDAT></STEXT></H>
<PARA ID="P-00003" LVL="0"><PTEXT><PDAT>This invention was made with United States Government support in the form of a grant from the National Science Foundation (BCS-9209901).</PDAT></PTEXT></PARA>
</BTEXT>
</GOVINT>
<BRFSUM>
<BTEXT>
<H LVL="1"><STEXT><PDAT>TECHNICAL FIELD</PDAT></STEXT></H>
<PARA ID="P-00004" LVL="0"><PTEXT><PDAT>The present invention relates generally to polyketides and polyketide synthases. In particular, the invention pertains to the recombinant production of polyketides using a novel host-vector system. In addition, the invention relates to the combinatorial biosynthesis of polyketides.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>BACKGROUND OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00005" LVL="0"><PTEXT><PDAT>Polyketides are a large, structurally diverse family of natural products. Polyketides possess a broad range of biological activities including antibiotic and pharmacological properties. For example, polyketides are represented by such antibiotics as tetracyclines and erythromycin, anticancer agents including daunomycin, immunosuppressants, for example FK506 and rapamycin, and veterinary products such as monensin and avermectin. Polyketides occur in most groups of organisms and are especially abundant in a class of mycelial bacteria, the actinomycetes, which produce various polyketides.</PDAT></PTEXT></PARA>
<PARA ID="P-00006" LVL="0"><PTEXT><PDAT>Polyketide synthases (PKSs) are multifunctional enzymes related to fatty acid synthases (FASs). PKSs catalyze the biosynthesis of polyketides through repeated (decarboxylative) Claisen condensations between acylthioesters, usually acetyl, propionyl, malonyl or methylmalonyl. Following each condensation, they introduce structural variability into the product by catalyzing all, part, or none of a reductive cycle comprising a ketoreduction, dehydration, and enoylreduction on the &bgr;-keto group of the growing polyketide chain. PKSs incorporate enormous structural diversity into their products, in addition to varying the condensation cycle, by controlling the overall chain length, choice of primer and extender units and, particularly in the case of aromatic polyketides, regiospecific cyclizations of the nascent polyketide chain. After the carbon chain has grown to a length characteristic of each specific product, it is released from the synthase by thiolysis or acyltransfer. Thus, PKSs consist of families of enzymes which work together to produce a given polyketide. It is the controlled variation in chain length, choice of chain-building units, and the reductive cycle, genetically programmed into each PKS, that contributes to the variation seen among naturally occurring polyketides.</PDAT></PTEXT></PARA>
<PARA ID="P-00007" LVL="0"><PTEXT><PDAT>Two general classes of PKSs exist. One class, known as Type I PKSS, is represented by the PKSs for macrolides such as erythromycin. These &ldquo;complex&rdquo; or &ldquo;modular&rdquo; PKSs include assemblies of several large multifunctional proteins carrying, between them, a set of separate active sites for each step of carbon chain assembly and modification (Cortes, J. et al. </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>(1990) 348:176; Donadio, S. et al. </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>(1991) 252:675; MacNeil, D. J. et al. </PDAT><HIL><ITALIC><PDAT>Gene </PDAT></ITALIC></HIL><PDAT>(1992) 115:119). Structural diversity occurs in this class from variations in the number and type of active sites in the PKSs. This class of PKSs displays a one-to-one correlation between the number and clustering of active sites in the primary sequence of the PKS and the structure of the polyketide backbone.</PDAT></PTEXT></PARA>
<PARA ID="P-00008" LVL="0"><PTEXT><PDAT>The second class of PKSs, called Type II PKSs, is represented by the synthases for aromatic compounds. Type II PKSs have a single set of iteratively used active sites (Bibb, M. J. et al. </PDAT><HIL><ITALIC><PDAT>EMBO J. </PDAT></ITALIC></HIL><PDAT>(1989) 8:2727;,Sherman, D. H. et al. </PDAT><HIL><ITALIC><PDAT>EMBO J. </PDAT></ITALIC></HIL><PDAT>(1989) 8:2717; Fernandez-Moreno, M. A. et al. </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>(1992) 267:19278).</PDAT></PTEXT></PARA>
<PARA ID="P-00009" LVL="0"><PTEXT><PDAT>In contrast, fungal PKSs, such as the 6-methylsalicylic acid PKS, consist of a single multi-domain polypeptide which includes all the active sites required for the biosynthesis of 6-methylsalicylic acid (Beck, J. et al. </PDAT><HIL><ITALIC><PDAT>Eur. J. Biochem. </PDAT></ITALIC></HIL><PDAT>(1990) 192:487-498; Davis, R. et al. </PDAT><HIL><ITALIC><PDAT>Abstr. of the Genetics of Industrial Microorganism Meeting, Montreal, abstr. </PDAT></ITALIC></HIL><PDAT>P288 (1994)).</PDAT></PTEXT></PARA>
<PARA ID="P-00010" LVL="0"><PTEXT><PDAT>Streptomyces is an actinomycete which is an abundant producer of aromatic polyketides. In each Streptomyces aromatic PKS so far studied, carbon chain assembly requires the products of three open reading frames (ORFs). ORF1 encodes a ketosynthase (KS) and an acyltransferase (AT) active site; ORF2 encodes a PKS chain length determining factor (CLF); and ORF3 encodes a discrete acyl carrier protein (ACP).</PDAT></PTEXT></PARA>
<PARA ID="P-00011" LVL="0"><PTEXT><HIL><ITALIC><PDAT>Streptomyces coelicolor </PDAT></ITALIC></HIL><PDAT>produces the blue-pigmented polyketide, actinorhodin. The actinorhodin gene cluster (act), has been cloned (Malpartida, F. and Hopwood, D. A. </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>(1984) 309:462; Malpartida, F. and Hopwood, D. A. </PDAT><HIL><ITALIC><PDAT>Mol. Gen. Genet. (</PDAT></ITALIC></HIL><PDAT>1986) 205:66) and completely sequenced (Fernandez-Moreno, M. A. et al. </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>(1992) 267:19278; Hallam, S. E. et al. </PDAT><HIL><ITALIC><PDAT>Gene </PDAT></ITALIC></HIL><PDAT>(1988) 74:305; Fernandez-Moreno, M. A. et al. </PDAT><HIL><ITALIC><PDAT>Cell </PDAT></ITALIC></HIL><PDAT>(1991) 66:769; Caballero, J. et al. </PDAT><HIL><ITALIC><PDAT>Mol. Gen. Genet. </PDAT></ITALIC></HIL><PDAT>(1991) 230:401). The cluster encodes the PKS enzymes described above, a cyclase and a series of tailoring enzymes involved in subsequent modification reactions leading to actinorhodin, as well as proteins involved in export of the antibiotic and at least one protein that specifically activates transcription of the gene cluster. Other genes required for global regulation of antibiotic biosynthesis, as well as for the supply of starter (acetyl CoA) and extender (malonyl CoA) units for polyketide biosynthesis, are located elsewhere in the genome.</PDAT></PTEXT></PARA>
<PARA ID="P-00012" LVL="0"><PTEXT><PDAT>The act gene cluster from </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>has been used to produce actinorhodin in </PDAT><HIL><ITALIC><PDAT>S. parvulus. </PDAT></ITALIC></HIL><PDAT>Malpartida, F. and Hopwood, D. A. </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>(1984) 309:462. Bartel et al. </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>(1990) 172:4816-4826, recombinantly produced aloesaponarin II using </PDAT><HIL><ITALIC><PDAT>S. galilaeus </PDAT></ITALIC></HIL><PDAT>transformed with an </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>act gene cluster consisting of four genetic loci, acti, actIII, actIV and actVII. Hybrid PKSs, including the basic act gene set but with ACP genes derived from granaticin, oxytetracycline, tetracenomycin and frenolicin PKSs, have also been designed which are able to express functional synthases. Khosla, C. et al. </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>(1993) 175:2197-2204. Hopwood, D. A. et al. </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>(1985) 314:642-644, describes the production of hybrid polyketides, using recombinant techniques. Sherman, D. H. et al. </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>(1992) 174:6184-6190, reports the transformation of various </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>mutants, lacking different components of the act PKS gene cluster, with the corresponding granaticin (gra) genes from </PDAT><HIL><ITALIC><PDAT>S. violaceoruber, </PDAT></ITALIC></HIL><PDAT>in trans.</PDAT></PTEXT></PARA>
<PARA ID="P-00013" LVL="0"><PTEXT><PDAT>However, no one to date has described the recombinant production of polyketides using genetically engineered host cells which substantially lack their entire native PKS gene clusters.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SUMMARY OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00014" LVL="0"><PTEXT><PDAT>The present invention provides for novel polyketides and novel methods of efficiently producing both new and known polyketides, using recombinant technology. In particular, a novel host-vector system is used to produce PKSs which in turn catalyze the production of a variety of polyketides. Furthermore, methods are provided for the combinatorial biosynthesis of polyketide libraries which can be screened for active compounds. Such polyketides are useful as antibiotics, antitumor agents, immunosuppressants and for a wide variety of other pharmacological purposes.</PDAT></PTEXT></PARA>
<PARA ID="P-00015" LVL="0"><PTEXT><PDAT>Accordingly, in one embodiment, the invention is directed to a genetically engineered cell which expresses a polyketide synthase (PKS) gene cluster in its native, nontransformed state, the genetically engineered cell substantially lacking the entire native PKS gene cluster.</PDAT></PTEXT></PARA>
<PARA ID="P-00016" LVL="0"><PTEXT><PDAT>In another embodiment, the invention is directed to the genetically engineered cell as described above, wherein the cell comprises:</PDAT></PTEXT></PARA>
<PARA ID="P-00017" LVL="2"><PTEXT><PDAT>(a) a replacement PKS gene cluster which encodes a PKS capable of catalyzing the synthesis of a polyketide; and</PDAT></PTEXT></PARA>
<PARA ID="P-00018" LVL="2"><PTEXT><PDAT>(b) one or more control sequences operatively linked to the PKS gene cluster, whereby the genes in the gene cluster can be transcribed and translated in the genetically engineered cell,</PDAT></PTEXT></PARA>
<PARA ID="P-00019" LVL="2"><PTEXT><PDAT>with the proviso that when the replacement PKS gene cluster comprises an entire PKS gene set, at least one of the PKS genes or control elements is heterologous to the cell.</PDAT></PTEXT></PARA>
<PARA ID="P-00020" LVL="0"><PTEXT><PDAT>In particularly preferred embodiments, the genetically engineered cell is </PDAT><HIL><ITALIC><PDAT>Streptomyces coelicolor, </PDAT></ITALIC></HIL><PDAT>the cell substantially lacks the entire native actinorhodin PKS gene cluster and the replacement PKS gene cluster comprises a first gene encoding a PKS ketosynthase and a PKS acyltransferase active site (KS/AT), a second gene encoding a PKS chain length determining factor (CLF), and a third gene encoding a PKS acyl carrier protein (ACP).</PDAT></PTEXT></PARA>
<PARA ID="P-00021" LVL="0"><PTEXT><PDAT>In another embodiment, the invention is directed to a method for producing a recombinant polyketide comprising:</PDAT></PTEXT></PARA>
<PARA ID="P-00022" LVL="2"><PTEXT><PDAT>(a) providing a population of cells as described above; and</PDAT></PTEXT></PARA>
<PARA ID="P-00023" LVL="2"><PTEXT><PDAT>(b) culturing the population of cells under conditions whereby the replacement PKS gene cluster present in the cells, is expressed.</PDAT></PTEXT></PARA>
<PARA ID="P-00024" LVL="0"><PTEXT><PDAT>In still another embodiment, the invention is directed to a method for producing a recombinant polyketide comprising:</PDAT></PTEXT></PARA>
<PARA ID="P-00025" LVL="2"><PTEXT><PDAT>(a) inserting a first portion of a replacement PKS gene cluster into a donor plasmid and inserting a second portion of a replacement PKS gene cluster into a recipient plasmid, wherein the first and second portions collectively encode a complete replacement PKS gene cluster, and further wherein:</PDAT></PTEXT></PARA>
<PARA ID="P-00026" LVL="3"><PTEXT><PDAT>i. the donor plasmid expresses a gene which encodes a first selection marker and is capable of replication at a first, permissive temperature and incapable of replication at a second, non-permissive temperature;</PDAT></PTEXT></PARA>
<PARA ID="P-00027" LVL="3"><PTEXT><PDAT>ii. the recipient plasmid expresses a gene which encodes a second selection marker; and</PDAT></PTEXT></PARA>
<PARA ID="P-00028" LVL="3"><PTEXT><PDAT>iii. the donor plasmid comprises regions of DNA complementary to regions of DNA in the recipient plasmid, such that homologous recombination can occur between the first portion of the replacement PKS gene cluster and the second portion of the replacement gene cluster, whereby a complete replacement gene cluster can be generated;</PDAT></PTEXT></PARA>
<PARA ID="P-00029" LVL="2"><PTEXT><PDAT>(b) transforming the donor plasmid and the recipient plasmid into a host cell and culturing the transformed host cell at the first, permissive temperature and under conditions which allow the growth of host cells which express the first and/or the second selection markers, to generate a first population of cells;</PDAT></PTEXT></PARA>
<PARA ID="P-00030" LVL="2"><PTEXT><PDAT>(c) culturing the first population of cells at the second, non-permissive temperature and under conditions which allow the growth of cells which express the first and/or the second selection markers, to generate a second population of cells which includes host cells which contain a recombinant plasmid comprising a complete PKS replacement gene cluster;</PDAT></PTEXT></PARA>
<PARA ID="P-00031" LVL="2"><PTEXT><PDAT>(d) transferring the recombinant plasmid from the second population of cells into the genetically engineered cell described above to generate transformed genetically engineered cells; and</PDAT></PTEXT></PARA>
<PARA ID="P-00032" LVL="2"><PTEXT><PDAT>(e) culturing the transformed genetically engineered cells under conditions whereby the replacement PKS gene cluster present in the cells is expressed.</PDAT></PTEXT></PARA>
<PARA ID="P-00033" LVL="0"><PTEXT><PDAT>In a further embodiment, the invention is drawn to a method for preparing a combinatorial polyketide library comprising:</PDAT></PTEXT></PARA>
<PARA ID="P-00034" LVL="2"><PTEXT><PDAT>(a) providing a population of vectors wherein the vectors comprise a random assortment of polyketide synthase (PKS) genes, modules, active sites, or portions thereof and one or more control sequences operatively linked to said genes;</PDAT></PTEXT></PARA>
<PARA ID="P-00035" LVL="2"><PTEXT><PDAT>(b) transforming a population of host cells with said population of vectors;</PDAT></PTEXT></PARA>
<PARA ID="P-00036" LVL="2"><PTEXT><PDAT>(c) culturing said population of host cells under conditions whereby the genes in said gene cluster can be transcribed and translated, thereby producing a combinatorial library of polyketides.</PDAT></PTEXT></PARA>
<PARA ID="P-00037" LVL="0"><PTEXT><PDAT>In still another embodiment, the invention is drawn to a method for producing a combinatorial polyketide library comprising:</PDAT></PTEXT></PARA>
<PARA ID="P-00038" LVL="2"><PTEXT><PDAT>a) providing one or more expression plasmids containing a random assortment of 1 or more first modules of a modular PKS gene cluster wherein the expression plasmids express a gene which encodes a first selection marker;</PDAT></PTEXT></PARA>
<PARA ID="P-00039" LVL="2"><PTEXT><PDAT>b) providing a pool of donor plasmids containing a random assortment of second modules of a modular PKS gene cluster wherein the donor plasmids express a gene which encodes a second selection marker and further wherein the donor plasmids comprise regions of DNA complementary to regions of DNA in the expression plasmids, such that homologous recombination can occur between the first and second modules;</PDAT></PTEXT></PARA>
<PARA ID="P-00040" LVL="2"><PTEXT><PDAT>c) transforming the expression plasmids and the donor plasmids into a first population of host cells to produce a first pool of transformed host cells;</PDAT></PTEXT></PARA>
<PARA ID="P-00041" LVL="2"><PTEXT><PDAT>d) culturing the first pool of transformed host cells under conditions which allow homologous recombination to occur between the first and second modules to produce recombined plasmids comprising recombined PKS gene cluster modules;</PDAT></PTEXT></PARA>
<PARA ID="P-00042" LVL="2"><PTEXT><PDAT>e) transferring the recombined plasmids into a second population of host cells to generate a second pool of transformed host cells; and</PDAT></PTEXT></PARA>
<PARA ID="P-00043" LVL="2"><PTEXT><PDAT>f) culturing the second pool of transformed host cells under conditions whereby the combinatorial polyketide library is produced.</PDAT></PTEXT></PARA>
<PARA ID="P-00044" LVL="0"><PTEXT><PDAT>In yet another embodiment, the invention is directed to a polyketide compound having the structural formula (I) </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00001">
<CHEMCDX ID="CHEMCDX-00001" ALT="chemistry chemdraw file" FILE="US06461838-20021008-C00001.CDX"/>
<CHEMMOL ID="CHEMMOL-00001" ALT="chemistry mol file" FILE="US06461838-20021008-C00001.MOL"/>
<EMI ID="EMI-C00001" ALT="embedded image" HE="104.63985" WI="91.6839" FILE="US06461838-20021008-C00001.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00045" LVL="7"><PTEXT><PDAT>wherein:</PDAT></PTEXT></PARA>
<PARA ID="P-00046" LVL="2"><PTEXT><PDAT>R</PDAT><HIL><SP><PDAT>1 </PDAT></SP></HIL><PDAT>is selected from the group consisting of hydrogen and lower alkyl and R</PDAT><HIL><SP><PDAT>2 </PDAT></SP></HIL><PDAT>is selected from the group consisting of hydrogen, lower alkyl and lower alkyl ester, or wherein R</PDAT><HIL><SP><PDAT>1 </PDAT></SP></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>2 </PDAT></SP></HIL><PDAT>together form a lower alkylene bridge optionally substituted with one to four hydroxyl or lower alkyl groups;</PDAT></PTEXT></PARA>
<PARA ID="P-00047" LVL="2"><PTEXT><PDAT>R</PDAT><HIL><SP><PDAT>3 </PDAT></SP></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>5 </PDAT></SP></HIL><PDAT>are independently selected from the group consisting of hydrogen, halogen, lower alkyl, lower alkoxy, amino, lower alkyl mono- or di-substituted amino and nitro;</PDAT></PTEXT></PARA>
<PARA ID="P-00048" LVL="2"><PTEXT><PDAT>R</PDAT><HIL><SP><PDAT>4 </PDAT></SP></HIL><PDAT>is selected from the group consisting of halogen, lower alkyl, lower alkoxy, amino, lower alkyl mono- or di-substituted amino and nitro;</PDAT></PTEXT></PARA>
<PARA ID="P-00049" LVL="2"><PTEXT><PDAT>R</PDAT><HIL><SP><PDAT>6 </PDAT></SP></HIL><PDAT>is selected from the group consisting of hydrogen, lower alkyl, and &mdash;CHR</PDAT><HIL><SP><PDAT>7</PDAT></SP></HIL><PDAT>&mdash;(CO)R</PDAT><HIL><SP><PDAT>8 </PDAT></SP></HIL><PDAT>where R</PDAT><HIL><SP><PDAT>7 </PDAT></SP></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>8 </PDAT></SP></HIL><PDAT>are independently selected from the group consisting of hydrogen and lower alkyl; and</PDAT></PTEXT></PARA>
<PARA ID="P-00050" LVL="2"><PTEXT><PDAT>i is 1, 2 or 3.</PDAT></PTEXT></PARA>
<PARA ID="P-00051" LVL="0"><PTEXT><PDAT>In another embodiment, the invention related to novel polyketides having the structures </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00002">
<CHEMCDX ID="CHEMCDX-00002" ALT="chemistry chemdraw file" FILE="US06461838-20021008-C00002.CDX"/>
<CHEMMOL ID="CHEMMOL-00002" ALT="chemistry mol file" FILE="US06461838-20021008-C00002.MOL"/>
<EMI ID="EMI-C00002" ALT="embedded image" HE="668.7198" WI="186.51465" FILE="US06461838-20021008-C00002.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00052" LVL="0"><PTEXT><PDAT>In another embodiment, the invention is directed to a polyketide compound formed by catalytic cyclization of an enzyme-bound ketide having the structure (II) </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00003">
<CHEMCDX ID="CHEMCDX-00003" ALT="chemistry chemdraw file" FILE="US06461838-20021008-C00003.CDX"/>
<CHEMMOL ID="CHEMMOL-00003" ALT="chemistry mol file" FILE="US06461838-20021008-C00003.MOL"/>
<EMI ID="EMI-C00003" ALT="embedded image" HE="57.12525" WI="130.32495" FILE="US06461838-20021008-C00003.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00053" LVL="7"><PTEXT><PDAT>wherein:</PDAT></PTEXT></PARA>
<PARA ID="P-00054" LVL="2"><PTEXT><PDAT>R</PDAT><HIL><SP><PDAT>11 </PDAT></SP></HIL><PDAT>is selected from the group consisting of methyl, &mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(CO)CH</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>and &mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(CO)CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(CO)CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>;</PDAT></PTEXT></PARA>
<PARA ID="P-00055" LVL="2"><PTEXT><PDAT>R</PDAT><HIL><SP><PDAT>1 </PDAT></SP></HIL><PDAT>is selected from the group consisting of &mdash;S&mdash;E and &mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(CO)&mdash;S&mdash;E, wherein E represents a polyketide synthase produced by the genetically engineered cells above; and</PDAT></PTEXT></PARA>
<PARA ID="P-00056" LVL="2"><PTEXT><PDAT>one of R</PDAT><HIL><SP><PDAT>13 </PDAT></SP></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>14 </PDAT></SP></HIL><PDAT>is hydrogen and the other is hydroxyl, or R</PDAT><HIL><SP><PDAT>13 </PDAT></SP></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>14 </PDAT></SP></HIL><PDAT>together represent carbonyl.</PDAT></PTEXT></PARA>
<PARA ID="P-00057" LVL="0"><PTEXT><PDAT>In still another embodiment, the invention is directed to a method for producing an aromatic polyketide, comprising effecting cyclization of an enzyme-bound ketide having the structure (II), wherein cyclization is induced by the polyketide synthase.</PDAT></PTEXT></PARA>
<PARA ID="P-00058" LVL="0"><PTEXT><PDAT>In a further embodiment, the invention is directed to a polyketide compound having the structural formula (III) </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00004">
<CHEMCDX ID="CHEMCDX-00004" ALT="chemistry chemdraw file" FILE="US06461838-20021008-C00004.CDX"/>
<CHEMMOL ID="CHEMMOL-00004" ALT="chemistry mol file" FILE="US06461838-20021008-C00004.MOL"/>
<EMI ID="EMI-C00004" ALT="embedded image" HE="153.1467" WI="103.9311" FILE="US06461838-20021008-C00004.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00059" LVL="7"><PTEXT><PDAT>wherein R</PDAT><HIL><SP><PDAT>2 </PDAT></SP></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>4 </PDAT></SP></HIL><PDAT>are as defined above and i is 0, 1 or 2.</PDAT></PTEXT></PARA>
<PARA ID="P-00060" LVL="0"><PTEXT><PDAT>In another embodiment, the invention is directed to a polyketide compound having the structural formula (IV) </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00005">
<CHEMCDX ID="CHEMCDX-00005" ALT="chemistry chemdraw file" FILE="US06461838-20021008-C00005.CDX"/>
<CHEMMOL ID="CHEMMOL-00005" ALT="chemistry mol file" FILE="US06461838-20021008-C00005.MOL"/>
<EMI ID="EMI-C00005" ALT="embedded image" HE="104.63985" WI="131.544" FILE="US06461838-20021008-C00005.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00061" LVL="7"><PTEXT><PDAT>wherein R</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>, R</PDAT><HIL><SP><PDAT>4 </PDAT></SP></HIL><PDAT>and i are as defined above for structural formula (III).</PDAT></PTEXT></PARA>
<PARA ID="P-00062" LVL="0"><PTEXT><PDAT>In still anther embodiment, the invention is directed to a polyketide compound having the structural formula (V) </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00006">
<CHEMCDX ID="CHEMCDX-00006" ALT="chemistry chemdraw file" FILE="US06461838-20021008-C00006.CDX"/>
<CHEMMOL ID="CHEMMOL-00006" ALT="chemistry mol file" FILE="US06461838-20021008-C00006.MOL"/>
<EMI ID="EMI-C00006" ALT="embedded image" HE="104.895" WI="131.544" FILE="US06461838-20021008-C00006.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00063" LVL="7"><PTEXT><PDAT>wherein R</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>, R</PDAT><HIL><SP><PDAT>4 </PDAT></SP></HIL><PDAT>and i are as defined above for structural formula (III).</PDAT></PTEXT></PARA>
<PARA ID="P-00064" LVL="0"><PTEXT><PDAT>These and other embodiments of the subject invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.</PDAT></PTEXT></PARA>
</BTEXT>
</BRFSUM>
<DRWDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BRIEF DESCRIPTION OF THE FIGURES</PDAT></STEXT></H>
<PARA ID="P-00065" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1A</PDAT></FGREF><PDAT> shows the gene clusters for act, gra, and tcm PKSS and cyclases.</PDAT></PTEXT></PARA>
<PARA ID="P-00066" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1B</PDAT></FGREF><PDAT> shows the gene clusters for act, tcm, fren, gris, and whiE PKSs and cyclases.</PDAT></PTEXT></PARA>
<PARA ID="P-00067" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> shows the strategy for making </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH999.</PDAT></PTEXT></PARA>
<PARA ID="P-00068" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2A</PDAT></FGREF><PDAT> depicts the structure of the act gene cluster present on the </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH1 chromosome.</PDAT></PTEXT></PARA>
<PARA ID="P-00069" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2B</PDAT></FGREF><PDAT> shows the structure of pLRemEts and</PDAT></PTEXT></PARA>
<PARA ID="P-00070" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2C</PDAT></FGREF><PDAT> shows the portion of the CH999 chromosome with the act gene cluster deleted.</PDAT></PTEXT></PARA>
<PARA ID="P-00071" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> is a diagram of plasmid pRM5.</PDAT></PTEXT></PARA>
<PARA ID="P-00072" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT> schematically illustrates formation of aloesaponarin II (2) and its carboxylated analog, 3,8-dihydroxy-1-methylanthraquinone-2-carboxylic acid (1) as described in Example 3.</PDAT></PTEXT></PARA>
<PARA ID="P-00073" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 5</PDAT></FGREF><PDAT> provides the structures of actinorhodin (3), granaticin (4), tetracenomycin (5) and mutactin (6), referenced in Example 4.</PDAT></PTEXT></PARA>
<PARA ID="P-00074" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 6</PDAT></FGREF><PDAT> schematically illustrates the preparation, via cyclization of the polyketide precursors, of aloesaponarin II (2), its carboxylated analog, 3,8-dihydroxy-1-methylanthraquinone-2-carboxylic acid (1), tetracenomycin (5) and new compound RM20 (9), as explained in Example 4, part (A).</PDAT></PTEXT></PARA>
<PARA ID="P-00075" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 7</PDAT></FGREF><PDAT> schematically illustrates the preparation, via cyclization of the polyketide precursors, of frenolicin (7), nanomycin (8) and actinorhodin (3).</PDAT></PTEXT></PARA>
<PARA ID="P-00076" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIGS. 8A-8C</PDAT></FGREF><PDAT> schematically illustrates the preparation, via cyclization of the polyketide precursors, of novel compounds RM20 (9), RM18 (10), RM18b (11), SEK4 (12), SEK15 (13), RM20b (14), RM20c (15) and SEK15b (16).</PDAT></PTEXT></PARA>
<PARA ID="P-00077" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 9</PDAT></FGREF><PDAT> depicts the genetic model for the 6-deoxyerythronolide B synthase (DEBS).</PDAT></PTEXT></PARA>
<PARA ID="P-00078" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 10</PDAT></FGREF><PDAT> is a representation of the overall biosynthetic pathway for a typical polyketide natural product.</PDAT></PTEXT></PARA>
<PARA ID="P-00079" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIGS. 11A-11B</PDAT></FGREF><PDAT> shows the structures of various polyketide of aromatic, modular and fungal PKSs.</PDAT></PTEXT></PARA>
<PARA ID="P-00080" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 12</PDAT></FGREF><PDAT> is a scheme for rationally engineered biosynthesis of polyketides.</PDAT></PTEXT></PARA>
<PARA ID="P-00081" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 13</PDAT></FGREF><PDAT> shows the common moieties observed in engineered polyketides formed by non-enzymatic reactions involving the uncyclized portions of the carbon chain. Hemiketals (a) and benzene rings (b) are formed at the methyl ends, whereas &ggr;-pyrone rings (c) and decarboxylations (d) occur at the carboxyl ends. The two chain ends can also co-cyclize via aldol condensations (e).</PDAT></PTEXT></PARA>
<PARA ID="P-00082" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 14</PDAT></FGREF><PDAT> illustrates the structures and proposed pathways of octaketide-derived polyketides biosynthesis including RM77 (19).</PDAT></PTEXT></PARA>
<PARA ID="P-00083" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 15</PDAT></FGREF><PDAT> illustrates the structures and proposed pathways of decaketide-derived polyketides biosynthesis including RM80 (20) and RM80b (21).</PDAT></PTEXT></PARA>
<PARA ID="P-00084" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 16</PDAT></FGREF><PDAT> shows the structures of SEK34 (22) the two novel polyketides SEK43 (23) and SEK26 (24) and other polyketides produced by genetic engineering in </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH999.</PDAT></PTEXT></PARA>
<PARA ID="P-00085" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 17</PDAT></FGREF><PDAT> is a diagram of the proposed biosynthetic pathways for the rationally designed polyketides SEK43 (23) and SEK26 (24).</PDAT></PTEXT></PARA>
<PARA ID="P-00086" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 18</PDAT></FGREF><PDAT> shows the strategy for the construction of recombinant modular PKSs.</PDAT></PTEXT></PARA>
<PARA ID="P-00087" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 19</PDAT></FGREF><PDAT> is a diagram of plasmid pCK7.</PDAT></PTEXT></PARA>
<PARA ID="P-00088" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 20</PDAT></FGREF><PDAT> schematically illustrates the preparation of 6-deoxyerythromolide B (17) from propionate and 8,8a-deoxyoleandolide (18) from an acetate starter.</PDAT></PTEXT></PARA>
<PARA ID="P-00089" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 21A</PDAT></FGREF><PDAT> shows the biosynthesis of (2R, 3S,4S, 5R)-2,4-dimethyl-3,5-dihydroxy-n-heptanoic acid S-lactone (25) by DEBS1 in </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH999.</PDAT></PTEXT></PARA>
<PARA ID="P-00090" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 21B</PDAT></FGREF><PDAT> shows the biosynthesis of (25) and (2R,3S,4S,5R)-2,4-dimethyl-3,5-dihydroxy-n-hexanoic acid 6-lactone (26) by the &ldquo;1&plus;2&plus;TE&rdquo; PKS in </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH999. The vertical line between ACP-2 and the TE represents the fusion junction in this deletion mutant.</PDAT></PTEXT></PARA>
<PARA ID="P-00091" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 22</PDAT></FGREF><PDAT> shows the biosynthesis of (8R, 9S)-8,9-dihydro-8-methyl-9-hydroxy-10-deoxymethonolide (27) by the &ldquo;1&plus;2&plus;3&plus;4&plus;5&plus;TE&rdquo; PKS in </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH999. The vertical line between KR-5 and ACP-6 represents the fusion junction in this deletion mutant.</PDAT></PTEXT></PARA>
</BTEXT>
</DRWDESC>
<DETDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>DETAILED DESCRIPTION OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00092" LVL="0"><PTEXT><PDAT>The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, microbiology, molecular biology and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, et al. </PDAT><HIL><ITALIC><PDAT>Molecular Cloning: A Laboratory Manual </PDAT></ITALIC></HIL><PDAT>(Current Edition); </PDAT><HIL><ITALIC><PDAT>DNA Cloning: A Practical Approach, </PDAT></ITALIC></HIL><PDAT>vol. I &amp; II (D. Glover, ed.); </PDAT><HIL><ITALIC><PDAT>Oligonucleotide Synthesis </PDAT></ITALIC></HIL><PDAT>(N. Gait, ed., Current Edition); </PDAT><HIL><ITALIC><PDAT>Nucleic Acid Hybridization </PDAT></ITALIC></HIL><PDAT>(B. Hames &amp; S. Higgins, eds., Current Edition); </PDAT><HIL><ITALIC><PDAT>Transcription and Translation </PDAT></ITALIC></HIL><PDAT>(B. Hames &amp; S. Higgins, eds., Current Edition).</PDAT></PTEXT></PARA>
<PARA ID="P-00093" LVL="0"><PTEXT><PDAT>All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety.</PDAT></PTEXT></PARA>
<PARA ID="P-00094" LVL="0"><PTEXT><PDAT>As used in this specification and the appended claims, the singular forms &ldquo;a,&rdquo; &ldquo;an&rdquo; and &ldquo;the&rdquo; include plural references unless the content clearly dictates otherwise. Thus, reference to &ldquo;a polyketide&rdquo; includes mixtures of polyketides, reference to &ldquo;a polyketide synthase&rdquo; includes mixtures of polyketide synthases, and the like. Ps A. Definitions</PDAT></PTEXT></PARA>
<PARA ID="P-00095" LVL="0"><PTEXT><PDAT>In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.</PDAT></PTEXT></PARA>
<PARA ID="P-00096" LVL="0"><PTEXT><PDAT>By &ldquo;replacement PKS gene cluster&rdquo; is meant any set of PKS genes capable of producing a functional PKS when under the direction of one or more compatible control elements, as defined below, in a host cell transformed therewith. A functional PKS is one which catalyzes the synthesis of a polyketide. The term &ldquo;replacement PKS gene cluster&rdquo; encompasses one or more genes encoding for the various proteins necessary to catalyze the production of a polyketide. A &ldquo;replacement PKS gene cluster&rdquo; need not include all of the genes found in the corresponding cluster in nature. Rather, the gene cluster need only encode the necessary PKS components to catalyze the production of an active polyketide. Thus, as explained further below, if the gene cluster includes, for example, eight genes in its native state and only three of these genes are necessary to provide an active polyketide, only these three genes need be present. Furthermore, the cluster can include PKS genes derived from a single species, or may be hybrid in nature with, e.g., a gene derived from a cluster for the synthesis of a particular polyketide replaced with a corresponding gene from a cluster for the synthesis of another polyketide. Hybrid clusters can include genes derived from both Type I and Type II PKSs. As explained above, Type I PKSs include several large multifunctional proteins carrying, between them, a set of separate active sites for each step of carbon chain assembly and modification. Type II PKSs, on the other hand, have a single set of iteratively used active sites. These classifications are well known. See, e.g., Hopwood, D. A. and Khosla, C. </PDAT><HIL><ITALIC><PDAT>Secondary metabolites: their function and evolution </PDAT></ITALIC></HIL><PDAT>(1992) Wiley Chichester (Ciba Foundation Symposium 171) p 88-112; Bibb, M. J. et al. </PDAT><HIL><ITALIC><PDAT>EMBO J. </PDAT></ITALIC></HIL><PDAT>(1989) 8:2727; Sherman, D. H. et al. </PDAT><HIL><ITALIC><PDAT>EMBO J. </PDAT></ITALIC></HIL><PDAT>(1989) 8:2717; Fernandez-Moreno, M. A. et al. </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>(1992) 267:19278); Cortes, J. et al. </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>(1990) 348:176; Donadio, S. et al. </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>(1991) 252:675; MacNeil, D. J. et al. </PDAT><HIL><ITALIC><PDAT>Gene </PDAT></ITALIC></HIL><PDAT>(1992) 115:119. Hybrid clusters are exemplified herein and are described further below. The genes included in the gene cluster need not be the native genes, but can be mutants or analogs thereof. Mutants or analogs may be prepared by the deletion, insertion or substitution of one or more nucleotides of the coding sequence. Techniques for modifying nucleotide sequences, such as site-directed mutagenesis, are described in, e.g., Sambrook et al., supra; </PDAT><HIL><ITALIC><PDAT>DNA Cloning, </PDAT></ITALIC></HIL><PDAT>Vols. I and II, supra; </PDAT><HIL><ITALIC><PDAT>Nucleic Acid Hybridization, </PDAT></ITALIC></HIL><PDAT>supra.</PDAT></PTEXT></PARA>
<PARA ID="P-00097" LVL="0"><PTEXT><PDAT>A &ldquo;replacement PKS gene cluster&rdquo; may also contain genes coding for modifications to the core polyketide catalyzed by the PKS, including, for example, genes encoding post-polyketide synthesis enzymes derived from natural products pathways such as O-methyl-transferases and glycosyltransferases. A &ldquo;replacement PKS gene cluster&rdquo; may further include genes encoding hydroxylases, methylases or other alkylases, oxidases, reductases, glycotransferases, lyases, ester or amide synthases, and various hydrolases such as esterases and amidases.</PDAT></PTEXT></PARA>
<PARA ID="P-00098" LVL="0"><PTEXT><PDAT>As explained further below, the genes included in the replacement gene cluster need not be on the same plasmid or if present on the same plasmid, can be controlled by the same or different control sequences.</PDAT></PTEXT></PARA>
<PARA ID="P-00099" LVL="0"><PTEXT><PDAT>A &ldquo;library&rdquo; or &ldquo;combinatorial library&rdquo; of polyketides is intended to mean a collection of polyketides catalytically produced by a PKS gene cluster capable of catalyzing the synthesis of a polyketide. The library can be produced by a PKS gene cluster that contains any combination of native, homolog or mutant genes from aromatic, modular or fungal PKSs. The combination of genes can be derived from a single PKS gene cluster, e.g., act, fren, gra, tcm, whiE, gris, ery, or the like, and may optionally include genes encoding tailoring enzymes which are capable of catalyzing the further modification of a polyketide. Alternatively, the combination of genes can be rationally or stochastically derived from an assortment of PKS gene clusters, e.g. a minimal PKS gene cluster can be constructed to contain the KS/AT component from an act PKS, the CLF component from a tcm PKS and a ACP component from a fren PKS. The combination of genes can optionally include KR, CYC and ARO components of PKS gene clusters as well. The library of polyketides thus produced can be tested or screened for biological, pharmacological or other activity.</PDAT></PTEXT></PARA>
<PARA ID="P-00100" LVL="0"><PTEXT><PDAT>By &ldquo;random assortment&rdquo; is intended any combination and/or order of genes, homologs or mutants which encode for the various PKS enzymes, modules, active sites or portions thereof derived from aromatic, modular or fungal PKS gene clusters.</PDAT></PTEXT></PARA>
<PARA ID="P-00101" LVL="0"><PTEXT><PDAT>By &ldquo;genetically engineered host cell&rdquo; is meant a host cell where the native PKS gene cluster has been deleted using recombinant DNA techniques or host cell into which a heterologous PKS gene cluster has been inserted. Thus, the term would not encompass mutational events occurring in nature. A &ldquo;host cell&rdquo; is a cell derived from a procaryotic microorganism or a eucaryotic cell line cultured as a unicellular entity, which can be, or has been, used as a recipient for recombinant vectors bearing the PKS gene clusters of the invention. The term includes the progeny of the original cell which has been transfected. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement to the original parent, due to accidental or deliberate mutation. Progeny of the parental cell which are sufficiently similar to the parent to be characterized by the relevant property, such as the presence of a nucleotide sequence encoding a desired PKS, are included in the definition, and are covered by the above terms.</PDAT></PTEXT></PARA>
<PARA ID="P-00102" LVL="0"><PTEXT><PDAT>The term &ldquo;heterologous&rdquo; as it relates to nucleic acid sequences such as coding sequences and control sequences, denotes sequences that are not normally associated with a region of a recombinant construct, and/or are not normally associated with a particular cell. Thus, a &ldquo;heterologous&rdquo; region of a nucleic acid construct is an identifiable segment of nucleic acid within or attached to another nucleic acid molecule that is not found in association with the other molecule in nature. For example, a heterologous region of a construct could include a coding sequence flanked by sequences not found in association with the coding sequence in nature. Another example of a heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., synthetic sequences having codons different from the native gene). similarly, a host cell transformed with a construct which is not normally present in the host cell would be considered heterologous for purposes of this invention. Allelic variation or naturally occurring mutational events do not give rise to heterologous DNA, as used herein.</PDAT></PTEXT></PARA>
<PARA ID="P-00103" LVL="0"><PTEXT><PDAT>A &ldquo;coding sequence&rdquo; or a sequence which &ldquo;encodes&rdquo; a particular PKS, is a nucleic acid sequence which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vitro or in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5&prime; (amino) terminus and a translation stop codon at the 3&prime; (carboxy) terminus. A coding sequence can include, but is not limited to, cDNA from procaryotic or eucaryotic mRNA, genomic DNA sequences from procaryotic or eucaryotic DNA, and even synthetic DNA sequences. A transcription termination sequence will usually be located 3&prime; to the coding sequence.</PDAT></PTEXT></PARA>
<PARA ID="P-00104" LVL="0"><PTEXT><PDAT>A &ldquo;nucleic acid&rdquo; sequence can include, but is not limited to, procaryotic sequences, eucaryotic mRNA, cDNA from eucaryotic mRNA, genomic DNA sequences from eucaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. The term also captures sequences that include any of the known base analogs of DNA and RNA such as, but not limited to 4-acetylcytosine, 8-hydroxy-N6-methyladenosine, aziridinylcytosine, pseudoisocytosine, 5-(carboxyhydroxylmethyl) uracil, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, dihydrouracil, inosine, N6-isopentenyladenine, 1-methyladenine, 1-methylpseudo-uracil, 1-methylguanine, 1-methylinosine, 2,2-dimethyl-guanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5&prime;-methoxycarbonylmethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, oxybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, N-uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, pseudouracil, queosine, 2-thiocytosine, and 2,6-diaminopurine. A transcription termination sequence will usually be located 3&prime; to the coding sequence.</PDAT></PTEXT></PARA>
<PARA ID="P-00105" LVL="0"><PTEXT><PDAT>DNA &ldquo;control sequences&rdquo; refers collectively to promoter sequences, ribosome binding sites, polyadenylation signals, transcription termination sequences, upstream regulatory domains, enhancers, and the like, which collectively provide for the transcription and translation of a coding sequence in a host cell. Not all of these control sequences need always be present in a recombinant vector so long as the desired gene is capable of being transcribed and translated.</PDAT></PTEXT></PARA>
<PARA ID="P-00106" LVL="0"><PTEXT><PDAT>&ldquo;Operably linked&rdquo; refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, control sequences operably linked to a coding sequence are capable of effecting the expression of the coding sequence. The control sequences need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered &ldquo;operably linked&rdquo; to the coding sequence.</PDAT></PTEXT></PARA>
<PARA ID="P-00107" LVL="0"><PTEXT><PDAT>By &ldquo;selection marker&rdquo; is meant any genetic marker which can be used to select a population of cells which carry the marker in their genome. Examples of selection markers include: auxotrophic markers by which cells are selected by their ability to grow on minimal media with or without a nutrient or supplement, e.g., thymidine, diaminopimelic acid or biotin; metabolic markers by which cells are selected for their ability to grow on minimal media containing the appropriate sugar as the sole carbon source or the ability of cells to form colored colonies containing the appropriate dyes or chromogenic substrates; and drug resistance markers by which cells are selected by their ability to grow on media containing one or more of the appropriate drugs, e.g., tetracycline, ampicillin, kanamycin, streptomycin or nalidixic acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00108" LVL="0"><PTEXT><PDAT>&ldquo;Recombination&rdquo; is a the reassortment of sections of DNA sequences between two DNA molecules. &ldquo;Homologous recombination&rdquo; occurs between two DNA molecules which hybridize by virtue of homologous or complementary nucleotide sequences present in each DNA molecule.</PDAT></PTEXT></PARA>
<PARA ID="P-00109" LVL="0"><PTEXT><PDAT>The term &ldquo;alkyl&rdquo; as used herein refers to a branched or unbranched saturated hydrocarbon group of 1 to 24 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, octyl, decyl, tetradecyl, hexadecyl, eicosyl, tetracosyl and the like. Preferred alkyl groups herein contain 1 to 12 carbon atoms. The term &ldquo;lower alkyl&rdquo; intends an alkyl group of one to six carbon atoms, preferably one to four carbon atoms.</PDAT></PTEXT></PARA>
<PARA ID="P-00110" LVL="0"><PTEXT><PDAT>The term &ldquo;alkylene&rdquo; as used herein refers to a difunctional saturated branched or unbranched hydrocarbon chain containing from 1 to 24 carbon atoms, and includes, for example, methylene (&mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&mdash;), ethylene (&mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&mdash;), propylene (&mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&mdash;), 2-methylpropylene &lsqb;&mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&mdash;CH(CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)&mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&mdash;&rsqb;, hexylene &lsqb;&mdash;(CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>&mdash;&rsqb; and the like. &ldquo;Lower alkylenel&rdquo; refers to an alkylene group of 1 to 6, more preferably 1 to 4, carbon atoms.</PDAT></PTEXT></PARA>
<PARA ID="P-00111" LVL="0"><PTEXT><PDAT>The term &ldquo;alkoxy&rdquo; as used herein intends an alkyl group bound through a single, terminal ether linkage; that is, an &ldquo;alkoxy&rdquo; group may be defined as &mdash;OR where R is alkyl as defined above. A &ldquo;lower alkoxy&rdquo; group intends an alkoxy group containing one to six, more preferably one to four, carbon atoms.</PDAT></PTEXT></PARA>
<PARA ID="P-00112" LVL="0"><PTEXT><PDAT>&ldquo;Halo&rdquo; or &ldquo;halogen&rdquo; refers to fluoro, chloro, bromo or iodo, and usually relates to halo substitution for a hydrogen atom in an organic compound. Of the halos, chloro and fluoro are generally preferred. &ldquo;optional&rdquo; or &ldquo;optionally&rdquo; means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. For example, the phrase &ldquo;optionally substituted alkylene&rdquo; means that an alkylene moiety may or may not be substituted and that the description includes both unsubstituted alkylene and alkylene where there is substitution.</PDAT></PTEXT></PARA>
<PARA ID="P-00113" LVL="7"><PTEXT><PDAT>B. General Methods</PDAT></PTEXT></PARA>
<PARA ID="P-00114" LVL="0"><PTEXT><PDAT>Central to the present invention is the discovery of a host-vector system for the efficient recombinant production of both novel and known polyketides. In particular, the invention makes use of genetically engineered cells which have their naturally occurring PXS genes substantially deleted. These host cells can be transformed with recombinant vectors, encoding a variety of PKS gene clusters, for the production of active polyketides. The invention provides for the production of significant quantities of product at an appropriate stage of the growth cycle. The polyketides so produced can be used as therapeutic agents, to treat a number of disorders, depending on the type of polyketide in question. For example, several of the polyketides produced by the present method will find use as immunosuppressants, as anti-tumor agents, as well as for the treatment of viral, bacterial and parasitic infections. The ability to recombinantly produce polyketides also provides a powerful tool for characterizing PKSs and the mechanism of their actions.</PDAT></PTEXT></PARA>
<PARA ID="P-00115" LVL="0"><PTEXT><PDAT>More particularly, host cells for the recombinant production of the subject polyketides can be derived from any organism with the capability of harboring a recombinant PKS gene cluster. Thus, the host cells of the present invention can be derived from either procaryotic or eucaryotic organisms. However, preferred host cells are those constructed from the actinomycetes, a class of mycelial bacteria which are abundant producers of a number of polyketides. A particularly preferred genus for use with the present system is Streptomyces. Thus, for example, </PDAT><HIL><ITALIC><PDAT>S. ambofaciens, S. avermitilis, S. azureus, S. cinnamonensis, S. coelicolor, S. curacoi, S. erythraeus, S. fradiae, S. galilaeus, S. glaucescens, S. hygroscopicus, S. lividans, S. parvulus, S. peucetius, S. rimosus, S. roseofulvus, S. thermotolerans, S. violaceoruber, </PDAT></ITALIC></HIL><PDAT>among others, will provide convenient host cells for the subject invention, with </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>being preferred. (See, e.g., Hopwood, D. A. and Sherman, D. H. </PDAT><HIL><ITALIC><PDAT>Ann. Rev. Genet. </PDAT></ITALIC></HIL><PDAT>(1990) 24:37-66; O&apos;Hagan, D. </PDAT><HIL><ITALIC><PDAT>The Polyketide Metabolites </PDAT></ITALIC></HIL><PDAT>(Ellis Horwood Limited, 1991), for a description of various polyketide-producing organisms and their natural products.)</PDAT></PTEXT></PARA>
<PARA ID="P-00116" LVL="0"><PTEXT><PDAT>The above-described cells are genetically engineered by deleting the naturally occurring PKS genes therefrom, using standard techniques, such as by homologous recombination. (See, e.g., Khosla, C. et al. </PDAT><HIL><ITALIC><PDAT>Molec. Microbiol. </PDAT></ITALIC></HIL><PDAT>(1992) 6:3237). Exemplified herein is a genetically engineered </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>host cell. Native strains of </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>produce a PKS which catalyzes the biosynthesis of the aromatic polyketide actinorhodin (structure 3, FIG. </PDAT><HIL><BOLD><PDAT>5</PDAT></BOLD></HIL><PDAT>). The novel strain, </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH999 (as described in the examples), was constructed by deleting, via homologous recombination, the entire natural act cluster from the chromosome of </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH1 (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT>) (Khosla, C. </PDAT><HIL><ITALIC><PDAT>Molec. Microbiol. </PDAT></ITALIC></HIL><PDAT>(1992) 6:3237), a strain lacking endogenous plasmids and carrying a stable mutation that blocks biosynthesis of another pigmented </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>antibiotic, undecylprodigiosin.</PDAT></PTEXT></PARA>
<PARA ID="P-00117" LVL="0"><PTEXT><PDAT>The host cells described above can be transformed with one or more vectors, collectively encoding a functional PKS set, or a cocktail comprising a random assortment of PKS genes, modules, active sites, or portions thereof. The vector(s) can include native or hybrid combinations of PKS subunits or cocktail components, or mutants thereof. As explained above, the replacement gene cluster need not correspond to the complete native gene cluster but need only encode the necessary PKS components to catalyze the production of a polyketide. For example, in each Streptomyces aromatic PKS so far studied, carbon chain assembly requires the products of three open reading frames (ORFs). ORF1 encodes a ketosynthase (KS) and an acyltransferase (AT) active site (KS/AT); as elucidated herein, ORF2 encodes a chain length determining factor (CLF), a protein similar to the ORF1 product but lacking the KS and AT motifs; and ORF3 encodes a discrete acyl carrier protein (ACP). Some gene clusters also code for a ketoreductase (KR) and a cyclase, involved in cyclization of the nascent polyketide backbone. (See </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 1A and 1B</PDAT></FGREF><PDAT> for schematic representations of six PKS gene clusters.) However, it has been found that only the KS/AT, CLF, and ACP, need be present in order to produce an identifiable polyketide. Thus, in the case of aromatic PKSs derived from Streptomyces, these three genes, without the other components of the native clusters, can be included in one or more recombinant vectors, to constitute a &ldquo;minimal&rdquo; replacement PKS gene cluster.</PDAT></PTEXT></PARA>
<PARA ID="P-00118" LVL="0"><PTEXT><PDAT>Furthermore, the recombinant vector(s) can include genes from a single PKS gene cluster, or may comprise hybrid replacement PKS gene clusters with, e.g., a gene for one cluster replaced by the corresponding gene from another gene cluster. For example, it has been found that ACPs are readily interchangeable among different synthases without an effect on product structure. Furthermore, a given KR can recognize and reduce polyketide chains of different chain lengths. Accordingly, these genes are freely interchangeable in the constructs described herein. Thus, the replacement clusters of the present invention can be derived from any combination of PKS gene sets which ultimately function to produce an identifiable polyketide.</PDAT></PTEXT></PARA>
<PARA ID="P-00119" LVL="0"><PTEXT><PDAT>Examples of hybrid replacement clusters include clusters with genes derived from two or more of the act gene cluster, the whiE gene cluster, frenolicin (fren), granaticin (gra), tetracenomycin (tcm), 6-methylsalicylic acid (6-msas), oxytetracycline (otc), tetracycline (tet), erythromycin (ery), griseusin (gris), nanaomycin, medermycin, daunorubicin, tylosin, carbomycin, spiramycin, avermectin, monensin, nonactin, curamycin, rifamycin and candicidin synthase gene clusters, among others. (For a discussion of various PKSs, see, e.g., Hopwood, D. A. and Sherman, D. H. </PDAT><HIL><ITALIC><PDAT>Ann. Rev. Genet. </PDAT></ITALIC></HIL><PDAT>(1990) 24:37-66; O&apos;Hagan, D. </PDAT><HIL><ITALIC><PDAT>The Polyketide Metabolites </PDAT></ITALIC></HIL><PDAT>(Ellis Horwood Limited, 1991).)</PDAT></PTEXT></PARA>
<PARA ID="P-00120" LVL="0"><PTEXT><PDAT>More particularly, a number of hybrid gene clusters have been constructed herein, having components derived from the act, fren, tcm, gris and gra gene clusters, as depicted in Tables 1, 2, 5 and 6. Several of the hybrid clusters were able to functionally express both novel and known polyketides in </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH999 (described above). However, other hybrid gene clusters, as described above, can easily be produced and screened using the disclosure herein, for the production of identifiable polyketides.</PDAT></PTEXT></PARA>
<PARA ID="P-00121" LVL="0"><PTEXT><PDAT>Furthermore, a library of randomly cloned ORF1, ORF2, ORF3 and homologs or mutant thereof, as well as other PKS genes and homologs or mutants thereof including ketoreductases, cyclases and aromatases from a collection of aromatic PKS gene clusters, could be constructed and screened for identifiable polyketides using methods described and exemplified herein. In addition, a considerable degree of variability exists for both the starter units (e.g., acetyl CoA, maloamyl CoA, propionyl CoA, acetate, butyrate, isobutyrate and the like) and the extender units among certain naturally occurring aromatic PKSS; thus, these units can also be used for obtaining novel polyketides via genetic engineering.</PDAT></PTEXT></PARA>
<PARA ID="P-00122" LVL="0"><PTEXT><PDAT>Additionally, a library of randomly cloned open reading frames or homologs from a collection of modular PKS gene clusters could be constructed and screened for identifiable polyketides. Such gene clusters are described in further detail below. Recombinant vectors can optionally include genes from an aromatic and a modular PKS gene cluster.</PDAT></PTEXT></PARA>
<PARA ID="P-00123" LVL="0"><PTEXT><PDAT>The recombinant vectors, harboring the gene clusters or random assortment of PKS genes, modules, active sites or portions thereof described above, can be conveniently generated using techniques known in the art. For example, the PKS subunits of interest can be obtained from an organism that expresses the same, using recombinant methods, such as by screening cDNA or genomic libraries, derived from cells expressing the gene, or by deriving the gene from a vector known to include the same. The gene can then be isolated and combined with other desired PKS subunits, using standard techniques. If the gene in question is already present in a suitable expression vector, it can be combined in situ, with, e.g., other PKS subunits, as desired. The gene of interest can also be produced synthetically, rather than cloned. The nucleotide sequence can be designed with the appropriate codons for the particular amino acid sequence desired. In general, one will select preferred codons for the intended host in which the sequence will be expressed. The complete sequence can be assembled from overlapping oligonucleotides prepared by standard methods and assembled into a complete coding sequence. See, e.g., Edge (1981) </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>292:756; Nambair et al. (1984) </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>223:1299; Jay et al. (1984) </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>259:6311.</PDAT></PTEXT></PARA>
<PARA ID="P-00124" LVL="0"><PTEXT><PDAT>Mutations can be made to the native PKS subunit sequences and such mutants used in place of the native sequence, so long as the mutants are able to function with other PKS subunits to collectively catalyze the synthesis of an identifiable polyketide. Such mutations can be made to the native sequences using conventional techniques such as by preparing synthetic oligonucleotides including the mutations and inserting the mutated sequence into the gene encoding a PKS subunit using restriction endonuclease digestion. (See, e.g., Kunkel, T. A. </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>(1985) 82:448; Geisselsoder et al. </PDAT><HIL><ITALIC><PDAT>BioTechniques </PDAT></ITALIC></HIL><PDAT>(1987) 5:786.) Alternatively, the mutations can be effected using a mismatched primer (generally 10-20 nucleotides in length) which hybridizes to the native nucleotide sequence (generally cDNA corresponding to the RNA sequence), at a temperature below the melting temperature of the mismatched duplex. The primer can be made specific by keeping primer length and base composition within relatively narrow limits and by keeping the mutant base centrally located. Zoller and Smith, </PDAT><HIL><ITALIC><PDAT>Methods Enzymol. </PDAT></ITALIC></HIL><PDAT>(1983) 100:468. Primer extension is effected using DNA polymerase, the product cloned and clones containing the mutated DNA, derived by segregation of the primer extended strand, selected. Selection can be accomplished using the mutant primer as a hybridization probe. The technique is also applicable for generating multiple point mutations. See, e.g., Dalbie-McFarland et al. </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci USA </PDAT></ITALIC></HIL><PDAT>(1982) 79:6409. PCR mutagenesis will also find use for effecting the desired mutations.</PDAT></PTEXT></PARA>
<PARA ID="P-00125" LVL="0"><PTEXT><PDAT>Random mutagenesis of the nucleotide sequences obtained as described above can be accomplished by several different techniques known in the art, such as by altering sequences within restriction endonuclease sites, inserting an oligonucleotide linker randomly into a plasmid, by irradiation with X-rays or ultraviolet light, by incorporating incorrect nucleotides during in vitro DNA synthesis, by error-prone PCR mutagenesis, by preparing synthetic mutants or by damaging plasmid DNA in vitro with chemicals. Chemical mutagens include, for example, sodium bisulfite, nitrous acid, hydroxylamine, agents which damage or remove bases thereby preventing normal base-pairing such as hydrazine or formic acid, analogues of nucleotide precursors such as nitrosoguanidine, 5-bromouracil, 2-aminopurine, or acridine intercalating agents such as proflavine, acriflavine, quinacrine, and the like. Generally, plasmid DNA or DNA fragments are treated with chemicals, transformed into </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>and propagated as a pool or library of mutant plasmids.</PDAT></PTEXT></PARA>
<PARA ID="P-00126" LVL="0"><PTEXT><PDAT>Large populations of random enzyme variants can be constructed in vivo using &ldquo;recombination-enhanced mutagenesis.&rdquo; This method employs two or more pools of, for example, 10</PDAT><HIL><SP><PDAT>6 </PDAT></SP></HIL><PDAT>mutants each of the wild-type encoding nucleotide sequence that are generated using any convenient mutagenesis technique, described more fully above, and then inserted into cloning vectors.</PDAT></PTEXT></PARA>
<PARA ID="P-00127" LVL="0"><PTEXT><PDAT>Once the mutant sequences are generated, the DNA is inserted into an appropriate cloning vector, using techniques well known in the art (see, e.g., Sambrook et al., supra). The choice of vector depends on the pool of mutant sequences, i.e., donor or recipient, with which they are to be employed. Furthermore, the choice of vector determines the host cell to be employed in subsequent steps of the claimed method. Any transducible cloning vector can be used as a cloning vector for the donor pool of mutants. It is preferred, however, that phagemids, cosmids, or similar cloning vectors be used for cloning the donor pool of mutant encoding nucleotide sequences into the host cell. Phagemids and cosmids, for example, are advantageous vectors due to the ability to insert and stably propagate therein larger fragments of DNA than in M13 phage and &lgr; phage, respectively. Phagemids which will find use in this method generally include hybrids between plasmids and filamentous phage cloning vehicles. Cosmids which will find use in this method generally include &lgr; phage-based vectors into which cos sites have been inserted. Recipient pool cloning vectors can be any suitable plasmid. The cloning vectors into which pools of mutants are inserted may be identical or may be constructed to harbor and express different genetic markers (see, e.g., Sambrook et al., supra). The utility of employing such vectors having different marker genes may be exploited to facilitate a determination of successful transduction.</PDAT></PTEXT></PARA>
<PARA ID="P-00128" LVL="0"><PTEXT><PDAT>Thus, for example, the cloning vector employed may be a phagemid and the host cell may be </PDAT><HIL><ITALIC><PDAT>E. coli. </PDAT></ITALIC></HIL><PDAT>Upon infection of the host cell which contains a phagemid, single-stranded phagemid DNA is produced, packaged and extruded from the cell in the form of a transducing phage in a manner similar to other phage vectors. Thus, clonal amplification of mutant encoding nucleotide sequences carried by phagemids is accomplished by propagating the phagemids in a suitable host cell.</PDAT></PTEXT></PARA>
<PARA ID="P-00129" LVL="0"><PTEXT><PDAT>Following clonal amplification, the cloned donor pool of mutants is infected with a helper phage to obtain a mixture of phage particles containing either the helper phage genome or phagemids mutant alleles of the wild-type encoding nucleotide sequence.</PDAT></PTEXT></PARA>
<PARA ID="P-00130" LVL="0"><PTEXT><PDAT>Infection, or transfection, of host cells with helper phage is generally accomplished by methods well known in the art (see, e.g., Sambrook et al., supra; and Russell et al. (1986) </PDAT><HIL><ITALIC><PDAT>Gene </PDAT></ITALIC></HIL><PDAT>45:333-338).</PDAT></PTEXT></PARA>
<PARA ID="P-00131" LVL="0"><PTEXT><PDAT>The helper phage may be any phage which can be used in combination with the cloning phage to produce an infective transducing phage. For example, if the cloning vector is a cosmid, the helper phage will necessarily be a &lgr; phage. Preferably, the cloning vector is a phagemid and the helper phage is a filamentous phage, and preferably phage M13.</PDAT></PTEXT></PARA>
<PARA ID="P-00132" LVL="0"><PTEXT><PDAT>If desired after infecting the phagemid with helper phage and obtaining a mixture of phage particles, the transducing phage can be separated from helper phage based on size differences (Barnes et al. (1983) </PDAT><HIL><ITALIC><PDAT>Methods Enzymol. </PDAT></ITALIC></HIL><PDAT>101:98-122), or other similarly effective technique.</PDAT></PTEXT></PARA>
<PARA ID="P-00133" LVL="0"><PTEXT><PDAT>The entire spectrum of cloned donor mutations can now be transduced into clonally amplified recipient cells into which has been transduced or transformed a pool of mutant encoding nucleotide sequences. Recipient cells which may be employed in the method disclosed and claimed herein may be, for example, </PDAT><HIL><ITALIC><PDAT>E. coli, </PDAT></ITALIC></HIL><PDAT>or other bacterial expression systems which are not recombination deficient. A recombination deficient cell is a cell in which recombinatorial events is greatly reduced, such as the rec</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT> mutants of </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>(see, Clark et al. (1965) </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>53:451-459).</PDAT></PTEXT></PARA>
<PARA ID="P-00134" LVL="0"><PTEXT><PDAT>By maintaining a high multiplicity of infection (MOI) and a ratio of &lsqb;transductant forming units (tfu)&rsqb;: &lsqb;plaque forming units (pfu)&rsqb; greater than 1, one can insure that virtually every recipient cell receives at least one mutant gene from the donor pool. The MOI is adjusted by manipulating the ratio of transducing particles to cell density. By the term &ldquo;high multiplicity of infection&rdquo; is meant a multiplicity of infection of greater than 1, preferably between 1 to 100, more preferably between 1 and 10.</PDAT></PTEXT></PARA>
<PARA ID="P-00135" LVL="0"><PTEXT><PDAT>It is preferred that the tfu:pfu ratio, as reflecting the ratio of transducing phages to helper phages, be as large as possible, at least greater than one, more preferably greater than 100 or more. By exercising the option to separate transducing phage from helper phage, as described above, the tfu:pfu ratio can be maximized.</PDAT></PTEXT></PARA>
<PARA ID="P-00136" LVL="0"><PTEXT><PDAT>These transductants can now be selected for the desired expressed protein property or characteristic and, if necessary or desirable, amplified. Optionally, if the phagemids into which each pool of mutants is cloned are constructed to express different genetic markers, as described above, transductants may be selected by way of their expression of both donor and recipient plasmid markers.</PDAT></PTEXT></PARA>
<PARA ID="P-00137" LVL="0"><PTEXT><PDAT>The recombinants generated by the above-described methods can then be subjected to selection or screening by any appropriate method, for example, enzymatic or other biological activity.</PDAT></PTEXT></PARA>
<PARA ID="P-00138" LVL="0"><PTEXT><PDAT>The above cycle of amplification, infection, transduction, and recombination may be repeated any number of times using additional donor pools cloned on phagemids. As above, the phagemids into which each pool of mutants is cloned may be constructed to express a different marker gene. Each cycle could increase the number of distinct mutants by up to a factor of 10</PDAT><HIL><SP><PDAT>6</PDAT></SP></HIL><PDAT>. Thus, if the probability of occurrence of an inter-allelic recombination event in any individual cell is f (a parameter that is actually a function of the distance between the recombining mutations), the transduced culture from two pools of 10</PDAT><HIL><SP><PDAT>6 </PDAT></SP></HIL><PDAT>allelic mutants will express up to 10</PDAT><HIL><SP><PDAT>12 </PDAT></SP></HIL><PDAT>distinct mutants in a population of 10</PDAT><HIL><SP><PDAT>12</PDAT></SP></HIL><PDAT>/f cells.</PDAT></PTEXT></PARA>
<PARA ID="P-00139" LVL="0"><PTEXT><PDAT>The gene sequences, native or mutant, which collectively encode a replacement PKS gene cluster, can be inserted into one or more expression vectors, using methods known to those of skill in the art. In order to incorporate a random assortment of PKS genes, modules, active sites or portions thereof into am expression vector, a cocktail of same can be prepared and used to generate the expression vector by techniques well known in the art and described in detail below. Expression vectors will include control sequences operably linked to the desired PKS coding sequence. Suitable expression systems for use with the present invention include systems which function in eucaryotic and procaryotic host cells. However, as explained above, procaryotic systems are preferred, and in particular, systems compatible with Streptomyces spp. are of particular interest. Control elements for use in such systems include promoters, optionally containing operator sequences, and ribosome binding sites. Particularly useful promoters include control sequences derived from PKS gene clusters which result in the production of polyketides as secondary metabolites, such as one or more act promoters, tcm promoters, spiramycin promoters, and the like. However, other bacterial promoters, such as those derived from sugar metabolizing enzymes, such as galactose, lactose (lac) and maltose, will also find use in the present constructs. Additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan (trp), the &bgr;-lactamase (bla) promoter system, bacteriophage lambda PL, and T5. In addition, synthetic promoters, such as the tac promoter (U.S. Pat. No. 4,551,433), which do not occur in nature also function in bacterial host cells.</PDAT></PTEXT></PARA>
<PARA ID="P-00140" LVL="0"><PTEXT><PDAT>Other regulatory sequences may also be desirable which allow for regulation of expression of the PKS replacement sequences relative to the growth of the host cell. Regulatory sequences are known to those of skill in the art, and examples include those which cause the expression of a gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Other types of regulatory elements may also be present in the vector, for example, enhancer sequences.</PDAT></PTEXT></PARA>
<PARA ID="P-00141" LVL="0"><PTEXT><PDAT>Selectable markers can also be included in the recombinant expression vectors. A variety of markers are known which are useful in selecting for transformed cell lines and generally comprise a gene whose expression confers a selectable phenotype on transformed cells when the cells are grown in an appropriate selective medium. Such markers include, for example, genes which confer antibiotic resistance or sensitivity to the plasmid. Alternatively, several polyketides are naturally colored and this characteristic provides a built-in marker for selecting cells successfully transformed by the present constructs.</PDAT></PTEXT></PARA>
<PARA ID="P-00142" LVL="0"><PTEXT><PDAT>The various PKS subunits of interest, or the cocktail of PKS genes, modules, active sites, or portions thereof, can be cloned into one or more recombinant vectors as individual cassettes, with separate control elements, or under the control of, e.g., a single promoter. The PKS subunits or cocktail components can include flanking restriction sites to allow for the easy deletion and insertion of other PKS subunits or cocktail components so that hybrid PKSs can be generated. The design of such unique restriction sites is known to those of skill in the art and can be accomplished using the techniques described above, such as site-directed mutagenesis and PCR.</PDAT></PTEXT></PARA>
<PARA ID="P-00143" LVL="0"><PTEXT><PDAT>Using these techniques, a novel plasmid, pRM5, (FIG. </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT> and Example 2) was constructed as a shuttle vector for the production of the polyketides described herein. Plasmid pRM5 includes the act genes encoding the KS/AT (ORF1), CLF (ORF2) and ACP (ORF3) PKS subunits, flanked by PacI, NsiI and XbaI restriction sites. Thus, analogous PKS subunits, encoded by other PKS genes, can be easily substituted for the existing act genes. (See, e.g., Example 4, describing the construction of hybrid vectors using pRM5 as the parent plasmid). The shuttle plasmid also contains the act KR gene (actIII), the cyclase gene (actVII), and a putative dehydratase gene (actIV), as well as a ColEI replicon (to allow transformation of </PDAT><HIL><ITALIC><PDAT>E. coli</PDAT></ITALIC></HIL><PDAT>), an appropriately truncated SCP2* (low copy number) Streptomyces replicon, and the actII-ORF4 activator gene from the act cluster, which induces transcription from act promoters during the transition from growth phase to stationary phase in the vegetative mycelium. pRM5 carries the divergent actII/actIII promoter pair.</PDAT></PTEXT></PARA>
<PARA ID="P-00144" LVL="0"><PTEXT><PDAT>Methods for introducing the recombinant vectors of the present invention into suitable hosts are known to those of skill in the art and typically include the use of CaCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>or other agents, such as divalent cations and DMSO. DNA can also be introduced into bacterial cells by electroporation. Once the PKSs are expressed, the polyketide producing colonies can be identified and isolated using known techniques. The produced polyketides can then be further characterized.</PDAT></PTEXT></PARA>
<PARA ID="P-00145" LVL="0"><PTEXT><PDAT>As explained above, the above-described recombinant methods also find utility in the catalytic biosynthesis of polyketides by large, modular PKSs. For example, 6-deoxyerythronolide B synthase (DEBS) catalyzes the biosynthesis of the erythromycin aglycone, 6-deoxyerythronolide B (17). Three open reading frames (eryAI, eryAII, and eryAIII) encode the DEBS polypeptides and span 32 kb in the ery gene cluster of the </PDAT><HIL><ITALIC><PDAT>Saccharopolyspora erythraea </PDAT></ITALIC></HIL><PDAT>genome. The genes are organized in six repeated units, each designated a &ldquo;module.&rdquo; Each module encodes a set of active sites that, during polyketide biosynthesis, catalyzes the condensation of an additional monomer onto the growing chain. Each module includes an acyltransferase (AT), &bgr;-ketoacyl carrier protein synthase (KS), and acyl carrier protein (ACP) as well as a subset of reductive active sites (&bgr;-ketoreductase (KR), dehydratase (DH), enoyl reductase (ER)) (FIG. </PDAT><HIL><BOLD><PDAT>9</PDAT></BOLD></HIL><PDAT>). The number of reductive sites within a module corresponds to the extent of &bgr;-keto reduction in each condensation cycle. The thioesterase (TE) encoded at the end of module appears to catalyze lactone formation.</PDAT></PTEXT></PARA>
<PARA ID="P-00146" LVL="0"><PTEXT><PDAT>Due to the large sizes of eryAI, eryAII, and eryAIII, and the presence of multiple active sites, these genes can be conveniently cloned into a plasmid suitable for expression in a genetically engineered host cell, such as CH999, using an in vivo recombination technique. This technique, described in Example 7 and summarized in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 10</PDAT></FGREF><PDAT>, utilizes derivatives of the plasmid pMAK705 (Hamilton et al. (1989) </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>171:4617) to permit in vivo recombination between a temperature-sensitive donor plasmid, which is capable of replication at a first, permissive temperature and incapable of replication at a second, non-permissive temperature, and recipient plasmid. The eryA genes thus cloned gave pCK7, a derivative of pRM5 (McDaniel et al. (1993) </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>262:1546). A control plasmid, pCK7f, was constructed to carry a frameshift mutation in eryAI. pCK7 and pCK7f possess a ColEI replicon for genetic manipulation in </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>as well as a truncated SCP2* (low copy number) Streptomyces replicon. These plasmids also contain the divergent actI/actIII promoter pair and actII-ORF4, an activator gene, which is required for transcription from these promoters and activates expression during the transition from growth to stationary phase in the vegetative mycelium. High-level expression of PKS genes occurs at the onset of stationary phase of mycelial growth; the recombinant strains therefore produce &ldquo;reporter&rdquo; polyketides as secondary metabolites in a quasi-natural manner.</PDAT></PTEXT></PARA>
<PARA ID="P-00147" LVL="0"><PTEXT><PDAT>Recombinant vectors harboring modular PKSs can also be generated using techniques known in the art. For example, the PKS of interest can be obtained from an organism that expresses the same using recombinant techniques as describe above and exemplified in Examples 7 and 8. For example, the gene can be isolated, subjected to mutation-producing protocols and reexpressed (see Example 8).</PDAT></PTEXT></PARA>
<PARA ID="P-00148" LVL="0"><PTEXT><PDAT>The method described above for producing polyketides synthesized by large, modular PKSs may be used to produce other polyketides as secondary, metabolites such as sugars, &bgr;-lactams, fatty acids, aminoglycosides, terpinoids, non-ribosomal peptides, prostanoid hormones and the like. In this manner, the polyketides can be produced after the host cell has matured, thereby reducing any potential toxic or other bioactive effects of the polyketide on the host cell.</PDAT></PTEXT></PARA>
<PARA ID="P-00149" LVL="0"><PTEXT><PDAT>As with aromatic (Type II) and modular (Type I) PKSs, the above described methods also find utility in the catalytic biosynthesis of polyketides using the PKS genes from fungi. Fungal PKSs, such as the 6-methylsalicylic acid PKS consist of a single multi-domain polypeptide which includes all active sites required for the biosynthesis of 6-methylsalicylic acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00150" LVL="0"><PTEXT><PDAT>Using the above recombinant methods, a number of polyketides have been produced. These compounds have the general structure (I) </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00007">
<CHEMCDX ID="CHEMCDX-00007" ALT="chemistry chemdraw file" FILE="US06461838-20021008-C00007.CDX"/>
<CHEMMOL ID="CHEMMOL-00007" ALT="chemistry mol file" FILE="US06461838-20021008-C00007.MOL"/>
<EMI ID="EMI-C00007" ALT="embedded image" HE="112.80465" WI="153.62865" FILE="US06461838-20021008-C00007.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00151" LVL="7"><PTEXT><PDAT>wherein R</PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>, R</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>, R</PDAT><HIL><SP><PDAT>3</PDAT></SP></HIL><PDAT>, R</PDAT><HIL><SP><PDAT>4</PDAT></SP></HIL><PDAT>, R</PDAT><HIL><SP><PDAT>5</PDAT></SP></HIL><PDAT>, R</PDAT><HIL><SP><PDAT>6</PDAT></SP></HIL><PDAT>, R</PDAT><HIL><SP><PDAT>7</PDAT></SP></HIL><PDAT>, R</PDAT><HIL><SP><PDAT>8 </PDAT></SP></HIL><PDAT>and i are as defined above. One group of such compounds are wherein: R</PDAT><HIL><SP><PDAT>1 </PDAT></SP></HIL><PDAT>is lower alkyl, preferably methyl; R</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>, R</PDAT><HIL><SP><PDAT>3 </PDAT></SP></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>6 </PDAT></SP></HIL><PDAT>are hydrogen; R is &mdash;CHR</PDAT><HIL><SP><PDAT>7</PDAT></SP></HIL><PDAT>&mdash;(CO)&mdash;R</PDAT><HIL><SP><PDAT>8</PDAT></SP></HIL><PDAT>; and i is 0. A second group of such compounds are wherein: R</PDAT><HIL><SP><PDAT>1 </PDAT></SP></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>6 </PDAT></SP></HIL><PDAT>are lower alkyl, preferably methyl; R</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>, R</PDAT><HIL><SP><PDAT>3 </PDAT></SP></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>5 </PDAT></SP></HIL><PDAT>are hydrogen; and i is 0. Still a third group of such compounds are wherein: R</PDAT><HIL><SP><PDAT>1 </PDAT></SP></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>2 </PDAT></SP></HIL><PDAT>are linked together to form a lower alkylene bridge &mdash;CHR</PDAT><HIL><SP><PDAT>9</PDAT></SP></HIL><PDAT>&mdash;CHR</PDAT><HIL><SP><PDAT>10 </PDAT></SP></HIL><PDAT>wherein R</PDAT><HIL><SP><PDAT>9 </PDAT></SP></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>10 </PDAT></SP></HIL><PDAT>are independently selected from the group consisting of hydrogen, hydroxyl and lower alkyl, e.g., &mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&mdash;CHOH&mdash;; R</PDAT><HIL><SP><PDAT>3 </PDAT></SP></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>5 </PDAT></SP></HIL><PDAT>are hydrogen; R</PDAT><HIL><SP><PDAT>6 </PDAT></SP></HIL><PDAT>is &mdash;CHR</PDAT><HIL><SP><PDAT>7</PDAT></SP></HIL><PDAT>&mdash;(CO)&mdash;R</PDAT><HIL><SP><PDAT>8 </PDAT></SP></HIL><PDAT>where R</PDAT><HIL><SP><PDAT>8 </PDAT></SP></HIL><PDAT>is hydrogen or lower alkyl, e.g., &mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&mdash;(CO)&mdash;CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>; and i is 0. Specific such compounds include the following compounds 9, 10 and 11 as follows: </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00008">
<CHEMCDX ID="CHEMCDX-00008" ALT="chemistry chemdraw file" FILE="US06461838-20021008-C00008.CDX"/>
<CHEMMOL ID="CHEMMOL-00008" ALT="chemistry mol file" FILE="US06461838-20021008-C00008.MOL"/>
<EMI ID="EMI-C00008" ALT="embedded image" HE="301.72905" WI="169.9299" FILE="US06461838-20021008-C00008.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00152" LVL="0"><PTEXT><PDAT>Other novel polyketides within the scope of the invention are those having the structure </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00009">
<CHEMCDX ID="CHEMCDX-00009" ALT="chemistry chemdraw file" FILE="US06461838-20021008-C00009.CDX"/>
<CHEMMOL ID="CHEMMOL-00009" ALT="chemistry mol file" FILE="US06461838-20021008-C00009.MOL"/>
<EMI ID="EMI-C00009" ALT="embedded image" HE="676.40265" WI="174.26745" FILE="US06461838-20021008-C00009.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00153" LVL="7"><PTEXT><PDAT>Preparation of compounds 9, 10, 11, 12, 13, 14, 15 and 16 is effected by cyclization of an enzyme-bound polyketide having the structure (II) </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00010">
<CHEMCDX ID="CHEMCDX-00010" ALT="chemistry chemdraw file" FILE="US06461838-20021008-C00010.CDX"/>
<CHEMMOL ID="CHEMMOL-00010" ALT="chemistry mol file" FILE="US06461838-20021008-C00010.MOL"/>
<EMI ID="EMI-C00010" ALT="embedded image" HE="66.7359" WI="174.9762" FILE="US06461838-20021008-C00010.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00154" LVL="7"><PTEXT><PDAT>wherein R</PDAT><HIL><SP><PDAT>11</PDAT></SP></HIL><PDAT>, R</PDAT><HIL><SP><PDAT>12</PDAT></SP></HIL><PDAT>, R</PDAT><HIL><SP><PDAT>13 </PDAT></SP></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>14 </PDAT></SP></HIL><PDAT>and E are as defined earlier herein. Examples of such compounds include: a first group wherein R</PDAT><HIL><SP><PDAT>11 </PDAT></SP></HIL><PDAT>is methyl and R</PDAT><HIL><SP><PDAT>12 </PDAT></SP></HIL><PDAT>is &mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(CO)&mdash;S&mdash;E; a second group wherein R</PDAT><HIL><SP><PDAT>11 </PDAT></SP></HIL><PDAT>is &mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(CO)CH</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>12 </PDAT></SP></HIL><PDAT>is &mdash;S&mdash;E; a third group wherein R</PDAT><HIL><SP><PDAT>11 </PDAT></SP></HIL><PDAT>is &mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>CO)CH</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>12 </PDAT></SP></HIL><PDAT>is &mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(CO)&mdash;S&mdash;E; and a fourth group wherein R</PDAT><HIL><SP><PDAT>11 </PDAT></SP></HIL><PDAT>is &mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(CO)CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(CO)CH</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>12 </PDAT></SP></HIL><PDAT>is &mdash;CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(CO)&mdash;S&mdash;E (see </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 8</PDAT></FGREF><PDAT> for structural exemplification).</PDAT></PTEXT></PARA>
<PARA ID="P-00155" LVL="0"><PTEXT><PDAT>The remaining structures encompassed by generic formula (I)&mdash;i.e., structures other than 9, 10 and 11&mdash;may be prepared from structures 9, 10 or 11 using routine synthetic organic methods well-known to those skilled in the art of organic chemistry, e.g., as described by H. O. House, </PDAT><HIL><ITALIC><PDAT>Modern Synthetic Reactions, </PDAT></ITALIC></HIL><PDAT>Second Edition (Menlo Park, CA: The Benjamin/Cummings Publishing Company, 1972), or by J. March, </PDAT><HIL><ITALIC><PDAT>Advanced organic Chemistry: Reactions, Mechanisms and Structure, </PDAT></ITALIC></HIL><PDAT>4th Ed. (New York: Wiley-Interscience, 1992), the disclosures of which are hereby incorporated by reference. Typically, as will be appreciated by those skilled in the art, incorporation of substituents on the aromatic rings will involve simple electrophilic aromatic addition reactions. Structures 12 and 13 may be modified in a similar manner to produce polyketides which are also intended to be within the scope of the present invention.</PDAT></PTEXT></PARA>
<PARA ID="P-00156" LVL="0"><PTEXT><PDAT>In addition, the above recombinant methods have been used to produce polyketide compound having the </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00011">
<CHEMCDX ID="CHEMCDX-00011" ALT="chemistry chemdraw file" FILE="US06461838-20021008-C00011.CDX"/>
<CHEMMOL ID="CHEMMOL-00011" ALT="chemistry mol file" FILE="US06461838-20021008-C00011.MOL"/>
<EMI ID="EMI-C00011" ALT="embedded image" HE="401.57775" WI="199.4706" FILE="US06461838-20021008-C00011.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00157" LVL="7"><PTEXT><PDAT>Particularly preferred compounds of structural formulas (III), (IV) and (V) are wherein: R</PDAT><HIL><SP><PDAT>2 </PDAT></SP></HIL><PDAT>is hydrogen and i is 0.</PDAT></PTEXT></PARA>
<PARA ID="P-00158" LVL="0"><PTEXT><PDAT>As disclosed hereinabove and in the Examples which follow, a system has been developed to functionally express recombinant PKSs and to produce novel aromatic polyketides (Examples 1-6). This technology has been extrapolated to larger gene clusters using an in vivo recombination strategy (Kao et al. </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>(1994) 265:509-512; see Examples 7 and 8). These systems may be used to genetically manipulate polyketide biosynthesis to generate libraries of synthetic products.</PDAT></PTEXT></PARA>
<PARA ID="P-00159" LVL="0"><PTEXT><PDAT>A typical pathway for polyketide biosynthesis is shown in FIG. </PDAT><HIL><BOLD><PDAT>10</PDAT></BOLD></HIL><PDAT>. Generally, polyketide synthesis occurs in three stages. In the first stage, catalyzed by the PKS, a nascent polyketide backbone is generated from monomeric CoA thioesters. In the second stage this backbone is regiospecifically cyclized. While some cyclization reactions are controlled by the PKS itself, others result from activities of downstream enzymes. In the final stage, the cyclized intermediate is modified further by the action of mechanistically diverse &ldquo;tailoring enzymes,&rdquo; giving rise to the natural product.</PDAT></PTEXT></PARA>
<PARA ID="P-00160" LVL="0"><PTEXT><PDAT>More particularly, polyketide biosynthesis begins with a primer unit loading on to the active site of the condensing enzyme, &bgr;-keto acyl synthase (KS). An extender unit (usually malonate) is then transferred to the pathetheinyl arm of the acyl carrier protein (ACP). The KS catalyzes the condensation between the ACP-bound malonate and the starter unit. Additional extender units are added sequentially until the nascent polyketide chain has grown to a desired chain length determined by the protein chain length factor (CLF), perhaps together with the KS. Thus, the KS, CLF and the ACP form a minimal set to generate a polyketide backbone, and are together called the &ldquo;minimal PKS.&rdquo; The nascent polyketide chain is then subjected to regiospecific ketoreduction by a ketoreductase (KR) if it exists. Cyclases (CYC) and aromatases (ARO) later catalyze regiospecific ring formation events through intramolecular aldol condensations. The cyclized intermediate may then undergo additional regiospecific and/or stereospecific modifications (e.g., O-methylation, hydroxylation, glycosylation, etc.) controlled by downstream tailoring enzymes).</PDAT></PTEXT></PARA>
<PARA ID="P-00161" LVL="0"><PTEXT><PDAT>Acetyl CoA is the usual starter unit for most aromatic polyketides. However, maloamyl CoA (Gatenbeck, S. </PDAT><HIL><ITALIC><PDAT>Biochem. Biophy. Res. Commun. </PDAT></ITALIC></HIL><PDAT>(1961) 6:422-426) and propionyl CoA (Paulick, R. C. et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1976) 98:3370-3371) are primers for many members of the tetracycline and anthracycline classes of polyketides, respectively (FIG. </PDAT><HIL><BOLD><PDAT>11</PDAT></BOLD></HIL><PDAT>). Daunorubicin PKS can also accept acetate, butyrate, and isobutyrate as starter units. (Oki, T. et al. </PDAT><HIL><ITALIC><PDAT>J. Antibiot. </PDAT></ITALIC></HIL><PDAT>(1981) 34:783-790; Yoshimoto, A. et al. </PDAT><HIL><ITALIC><PDAT>J. Antiobiot. </PDAT></ITALIC></HIL><PDAT>(1993) 46:1758-1761).</PDAT></PTEXT></PARA>
<PARA ID="P-00162" LVL="0"><PTEXT><PDAT>The act KR can productively interact with all minimal PKSs studied thus far and is both necessary and sufficient to catalyze a C-9 ketoreduction. Although homologous KRs have been found in other PKS clusters, they catalyze ketoreduction with the same regiospecificity. However, the structures of frenolicin, griseusin and daunorubicin (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 11</PDAT></FGREF><PDAT>) suggest that an additional C-17 ketoreduction occurs in these biosynthetic pathways. Likewise, several angucyclines undergo a C-15 ketoreduction, which occurs before the nascent polyketide chain is cyclized (Gould, S. J. et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1992) 114:10066-10068). The ketoreductases responsible for C-15 and C-17 reductions have not yet been identified; however, two homologous KRs have been found in the daunorubicin PKS cluster (Grimm, A. et al. </PDAT><HIL><ITALIC><PDAT>Gene </PDAT></ITALIC></HIL><PDAT>(1994) 151:1-10; Ye, J. et al. </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>(1994) 176:6270-6280). It is likely that they catalyze the C-9 and C-17 reductions. Thus, KRs responsible for regiospecific reduction of the carbon chain backbone at positions other than C-9 may also be targets for use in the construction of combinatorial libraries.</PDAT></PTEXT></PARA>
<PARA ID="P-00163" LVL="0"><PTEXT><PDAT>The formation of the first two six-membered rings in the biosynthesis of most naturally occurring bacterial aromatic polyketides is controlled by PKS subunits; further ring closures are controlled by additional cyclases and modifying enzymes. The structural diversity introduced via these reactions appears to be greater than via the first two cyclizations. However, certain preferred patterns are observed, which suggests that at least some of these downstream cyclases may be useful for the construction of combinatorial libraries. For example, the pyran ring in isochromanequinones (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 11</PDAT></FGREF><PDAT>) is invariably formed via cyclization between C-3 and C-15; two stereochemically distinct classes of products are observed (see, for example, the structures of actinorhodin and frenolicin in (FIG. </PDAT><HIL><BOLD><PDAT>11</PDAT></BOLD></HIL><PDAT>)). In anthracyclines and tetracyclines a third aldol condensation usually occurs between C-3 and C-16, whereas in unreduced tetracenomycins (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 11</PDAT></FGREF><PDAT>) and related compounds it occurs between C-5 and C-18, and in angucyclines (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 11</PDAT></FGREF><PDAT>) it occurs between C-4 and C-17. Representative gene(s) encoding a few of these enzymes have already been cloned (Fernandez-Moreno, M. A., et al. </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>(1994) 269:24854-24863; Shen, B. et al. </PDAT><HIL><ITALIC><PDAT>Biochemistry </PDAT></ITALIC></HIL><PDAT>(1993) 32:11149-11154). At least some cyclases might recognize chains of altered lengths and/or degrees of reduction, thereby increasing the diversity of aromatic polyketide combinatorial libraries.</PDAT></PTEXT></PARA>
<PARA ID="P-00164" LVL="0"><PTEXT><PDAT>In the absence of downstream cyclases, polyketide chains undergo non-enzymatic reactions. Recently, some degree of predictability has emerged within this repertoire of possibilities. For instance, hemiketals and benzene rings are two common moieties seen on the methyl end. Hemiketals are formed with an appropriately-positioned enol and can be followed by a dehydration. Benzene rings are formed with longer uncyclized methyl terminus. On the carboxyl terminus, a &ggr;-pyrone ring formed by three ketide units is frequently observed. Spontaneous decarboxylations occur on free carboxyl ends activated by the existence of a &bgr;-carbonyl.</PDAT></PTEXT></PARA>
<PARA ID="P-00165" LVL="0"><PTEXT><PDAT>A cyclized intermediate can undergo various types of modifications to generate the final natural product. The recurrence of certain structural motifs among naturally occurring aromatic polyketides suggests that some tailoring enzymes, particularly group transferases, may be combinatorially useful. Two examples are discussed below.</PDAT></PTEXT></PARA>
<PARA ID="P-00166" LVL="0"><PTEXT><PDAT>O-methylation is a common downstream modification. Although several SAM-dependent O-methyltransferase genes have been found in PKS gene clusters (Decker, H. et al. </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>(1993) 175:3876-3886), their specificities have not been systematically studied as yet. Perhaps some of them could be useful for combinatorial biosynthesis. For instance, O-11-methylation occurs in several members of the anthracycline, tetracenomycin, and angucycline classes of aromatic polyketides (FIG. </PDAT><HIL><BOLD><PDAT>11</PDAT></BOLD></HIL><PDAT>).</PDAT></PTEXT></PARA>
<PARA ID="P-00167" LVL="0"><PTEXT><PDAT>Both aromatic and complex polyketides are often glycosylated. In many cases (e.g. doxorubicin and erythromycin) absence of the sugar group(s) results in considerably weaker bioactivity. There is tremendous diversity in both the types and numbers of sugar units attached to naturally occurring polyketide aglycones. In particular, deoxy- and aminosugars are commonly found. Regiochemical preferences can be detected in many glycosylated natural products. Among anthracyclines, O-17 is frequently glycosylated, whereas among angucyclines, C-10 is usually glycosylated. Glycosyltransferases involved in erythromycin biosynthesis may have relaxed specificities for the aglycone moiety (Donadio, S. et al. </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>(1991) 252:675-679). An elloramycin glycosyltransferase may be able to recognize an unnatural NDP-sugar unit and attach it regiospecifically to an aromatic polyketide aglycone (Decker, H. et al. </PDAT><HIL><ITALIC><PDAT>Angew. Chem. </PDAT></ITALIC></HIL><PDAT>(1995), in press). These early results suggest that glycosyltransferases derived from secondary metabolic pathways have unique properties and may be attractive targets for use in the generation of combinatorial libraries.</PDAT></PTEXT></PARA>
<PARA ID="P-00168" LVL="0"><PTEXT><PDAT>Although modular PKSs have not been extensively analyzed, the one-to-one correspondence between active sites and product structure (FIG. </PDAT><HIL><BOLD><PDAT>9</PDAT></BOLD></HIL><PDAT>), together with the incredible chemical diversity observed among naturally occurring &ldquo;complex&rdquo; polyketides, indicates that the combinatorial potential within these multienzyme systems could be considerably greater than that for aromatic PKSs. For example, a wider range of primer units including aliphatic monomers (acetate, propionate, butyrate, isovalerate, etc.), aromatics (aminohydroxybenzoic acid), alicyclics (cyclohexanoic acid), and heterocyclics (pipecolic acid) are found in various macrocyclic polyketides. Recent studies have shown that modular PKSs have relaxed specificity for their starter units (Kao et al. Science (1994), supra). The degree of &bgr;-ketoreduction following a condensation reaction can also be altered by genetic manipulation (Donadio et al. </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>(1991), supra; Donadio, S. et al. </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>(1993) 90:7119-7123). Likewise, the size of the polyketide product can be varied by designing mutants with the appropriate number of modules (Kao, C. M. et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1994) 116:11612-11613). Modular PKSs also exhibit considerable variety with regards to the choice of extender units in each condensation cycle, although it remains to be seen to what extent this property can be manipulated. Lastly, these enzymes are particularly well-known for generating an impressive range of asymmetric centers in their products in a highly controlled manner. Thus, the combinatorial potential within modular PKS pathways could be virtually unlimited.</PDAT></PTEXT></PARA>
<PARA ID="P-00169" LVL="0"><PTEXT><PDAT>Like the actinomycetes, filamentous fungi are a rich source of polyketide natural products. The fact that fungal PKSs, such as the 6-methylsalicylic acid synthase (6-MSAS) and the mevinolin synthase, are encoded by single multi-domain proteins (Beck et al. </PDAT><HIL><ITALIC><PDAT>Eur. J. Biochem. </PDAT></ITALIC></HIL><PDAT>(1990), supra; Davis, R. et al. </PDAT><HIL><ITALIC><PDAT>Abstr. Genet. Ind. Microorg. Meeting, </PDAT></ITALIC></HIL><PDAT>supra) indicates that they may also be targeted for combinatorial mutagenesis. Moreover, fungal PKSs can be functionally expressed in </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH999 using the genetic strategy outlined above. Chain lengths not observed in bacterial aromatic polyketides (e.g. tetraketides, pentaketides and hexaketides) have been found among fungal aromatic polyketides (O&apos;Hagan, D. </PDAT><HIL><ITALIC><PDAT>The Polyketide Metabolites </PDAT></ITALIC></HIL><PDAT>(Ellis Horwood, Chichester, U.K., 1991). Likewise, the cyclization patterns of fungal aromatic polyketides are quite different from those observed in bacterial aromatic polyketides (Id.). In contrast with modular PKSs from bacteria, branched methyl groups are introduced into fungal polyketide backbones by S-adenosylmethionine-dependent methyltransferases; in the case of the mevinolin PKS (Davis, R. et al. </PDAT><HIL><ITALIC><PDAT>Abstr. Genet. Ind. Microorg. Meeting, </PDAT></ITALIC></HIL><PDAT>supra), this activity is encoded as one domain within a monocistronic PKS. It is now possible to experimentally evaluate whether these and other sources of chemical diversity in fungal polyketides are indeed amenable to combinatorial manipulation.</PDAT></PTEXT></PARA>
<PARA ID="P-00170" LVL="0"><PTEXT><PDAT>Based on the above-discussed state of the art, and the results presented in Examples 1-8 hereinbelow, the inventors herein have developed the following set of design rules for rationally or stochastically manipulating early biosynthetic steps in aromatic polyketide pathways including chain synthesis, C-9 ketoreduction, and the formation of the first two aromatic rings. If each biosynthetic degree of freedom was independent of all others, then it should be possible to design a single combinatorial library of N</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&times;N</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&times; . . . N</PDAT><HIL><SB><PDAT>i</PDAT></SB></HIL><PDAT>&times; . . . N</PDAT><HIL><SB><PDAT>n-1</PDAT></SB></HIL><PDAT>&times;N</PDAT><HIL><SB><PDAT>n </PDAT></SB></HIL><PDAT>clones, where Ni is the number of ways in which the ith degree of freedom can be exploited. In practice however, not all enzymatic degrees of freedom are independent. Therefore, to minimize redundancy, it is preferable to design several sub-libraries of aromatic polyketide-producing clones.</PDAT></PTEXT></PARA>
<PARA ID="P-00171" LVL="0"><PTEXT><PDAT>(1) Chain length. Polyketide carbon chain length is dictated by the minimal PKS (FIG. </PDAT><HIL><BOLD><PDAT>12</PDAT></BOLD></HIL><PDAT>). Within the minimal PKS, the acyl carrier protein can be interchanged without affecting specificity, whereas the chain length factor is crucial. Although some ketosynthase/chain length factor combinations are functional, others are not; therefore, biosynthesis of a polyketide chain of specified length can be insured with a minimal PKS in which both the ketosynthase and chain length factor originate from the same PKS gene cluster. So far, chain lengths of 16 (octaketide), 18 (nonaketide), 20 (decaketide), and 24 carbons (dodecaketide) can be generated with minimal PKSs from the act, fren, tcm, and, whiE PKS clusters, respectively (McDaniel et al. </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>(1993), supra; McDaniel et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1993), supra; McDaniel et al. </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>(1994), supra). The whiE minimal PKS can also generate 22-carbon backbones in the presence of a KR, suggesting a degree of relaxed chain length control as found for the fren PKS.</PDAT></PTEXT></PARA>
<PARA ID="P-00172" LVL="0"><PTEXT><PDAT>(2) Ketoreduction. Ketoreduction requires a ketoreductase (FIG. </PDAT><HIL><BOLD><PDAT>12</PDAT></BOLD></HIL><PDAT>). The act KR can catalyze reduction of the C-9 carbonyl (counting from the carboxyl end) of a nascent polyketide backbone of any length studied so far. Furthermore, the act KR is compatible with all the minimal PKSs mentioned above. Homologous ketoreductases have been identified in other PKS clusters (Sherman, D. H., et al. </PDAT><HIL><ITALIC><PDAT>EMBO J. </PDAT></ITALIC></HIL><PDAT>(1989) 8:2717-2725; Yu, T. -W. et al. </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>(1994) 176:2627-2534; Bibb, M. J. et al. </PDAT><HIL><ITALIC><PDAT>Gene </PDAT></ITALIC></HIL><PDAT>(1994) 142:31-39). These enzymes may catalyze ketoreduction at C-9 as well since all the corresponding natural products undergo this modification. In unusual circumstances, C-7 ketoreductions have also been observed with the act KR.</PDAT></PTEXT></PARA>
<PARA ID="P-00173" LVL="0"><PTEXT><PDAT>(3) Cyclization of the first ring. Although the minimal PKS alone can control formation of the first ring, the regiospecific course of this reaction may be influenced by other PKS proteins. For example, most minimal PKSs studied so far produce polyketides with C-7/C-12 cyclizations when present alone (FIG. </PDAT><HIL><BOLD><PDAT>12</PDAT></BOLD></HIL><PDAT>). In contrast, the tcm minimal PKS alone generates both C-7/C-12 and C-9/C-14 cyclized products. The presence of a ketoreductase with any minimal PKS restricts the nascent polyketide chain to cyclize exclusively with respect to the position of ketoreduction: C-7/C-12 cyclization for C-9 ketoreduction and C-5/C-10 cyclization for C-7 ketoreduction (McDaniel, R. et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1993) 115:11671-11675; McDaniel, R. et al. </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>(1994) 91:11542-11546; McDaniel, R. et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1994) 116:10855-10859). Likewise, use of the TcmN enzyme alters the regiospecificity to C-9/C-14 cyclizations for unreduced polyketides of different lengths, but has no effect on reduced molecules (see Example 5 below).</PDAT></PTEXT></PARA>
<PARA ID="P-00174" LVL="0"><PTEXT><PDAT>(4) First ring aromatization. The first ring in unreduced polyketides aromatizes non-catalytically. In contrast, an aromatizing subunit is required for reduced polyketides (FIG. </PDAT><HIL><BOLD><PDAT>12</PDAT></BOLD></HIL><PDAT>). There appears to be a hierarchy in the chain length specificity of these subunits from different PKS clusters. For example, the act ARO will recognize only 16-carbon chains (McDaniel et al. </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>(1994), supra), the fren ARO recognizes both 16- and 18-carbon chains, while the gris ARO recognizes chains of 16, 18, and 20 carbons.</PDAT></PTEXT></PARA>
<PARA ID="P-00175" LVL="0"><PTEXT><PDAT>(5) Second ring cyclization. C-5/C-14 cyclization of the second ring of reduced polyketides may be achieved with an appropriate cyclase (FIG. </PDAT><HIL><BOLD><PDAT>12</PDAT></BOLD></HIL><PDAT>). While the act CYC can cyclize octa- and nonaketides, it does not recognize longer chains. No equivalent C-5/C-14 cyclase with specificity for decaketides or longer chains has been identified, although the structures of natural products such as griseusin imply their existence. In the case of sufficiently long unreduced chains with a C-9/C-14 first ring, formation of a C-7/C-16 second ring is catalyzed by the minimal PKS (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 12</PDAT></FGREF><PDAT>) (McDaniel et al. </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>(1994), supra).</PDAT></PTEXT></PARA>
<PARA ID="P-00176" LVL="0"><PTEXT><PDAT>(6) Additional cyclizations. The KS, CLF, ACP, KR, ARO, and CYC subunits of the PKS together catalyze the formation of an intermediate with a defined chain length, reduction pattern, and first two cyclizations. While the biosynthesis of naturally occurring polyketides typically requires the activity of downstream cyclases and other modifying enzymes to generate the characteristic biologically active product, subsequent reactions in the biosynthesis of engineered polyketides described here and in our earlier work occur in the absence of specific enzymes and are determined by the different physical and chemical properties of the individual molecules. Presumably reflecting such chemical possibilities and constraints, consistent patterns have been observed, leading to some degree of predictability. Two common moieties formed by the uncyclized methyl terminus of polyketide chains are hemiketals and benzene rings. Formation of a hemiketal occurs in the presence of an appropriately positioned enol and can be followed by a dehydration since both the hydrated and dehydrated forms are often isolated (FIG. </PDAT><HIL><BOLD><PDAT>13</PDAT></BOLD></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>a</PDAT></ITALIC></HIL><PDAT>)) (McDaniel, R. et al. </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>(1993) 262:15461550; McDaniel, R. et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1994) 116:10855-10859; Fu, H. et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1994) 116:4166-4170), while benzene ring formation occurs with longer unprocessed methyl ends (FIG. </PDAT><HIL><BOLD><PDAT>13</PDAT></BOLD></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>b</PDAT></ITALIC></HIL><PDAT>)) (Fu et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1994), supra). The most frequently observed moiety at the carboxyl terminus of the chain is a 7-pyrone ring formed by three ketide units (FIG. </PDAT><HIL><BOLD><PDAT>13</PDAT></BOLD></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>c</PDAT></ITALIC></HIL><PDAT>)) (McDaniel et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1994), supra; Fu et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1994), supra; Fu, H., et al. </PDAT><HIL><ITALIC><PDAT>Biochemistry </PDAT></ITALIC></HIL><PDAT>(1994) 33:9321-9326; Fu, H. et al. </PDAT><HIL><ITALIC><PDAT>Chem. </PDAT></ITALIC></HIL><PDAT>&amp; </PDAT><HIL><ITALIC><PDAT>Biol. </PDAT></ITALIC></HIL><PDAT>(1994) 1:205-210; Zhang, H. -l. et al. </PDAT><HIL><ITALIC><PDAT>J. Org. Chem. </PDAT></ITALIC></HIL><PDAT>(1990) 55:1682-1684); if a free carboxylic acid remains, decarboxylation typically occurs if a &bgr;-carbonyl exists (FIG. </PDAT><HIL><BOLD><PDAT>13</PDAT></BOLD></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>d</PDAT></ITALIC></HIL><PDAT>)) (McDaniel et al. </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>(1993), supra; McDaniel, R., Ebert-Khosla, S., Hopwood, D. A. &amp; Khosla, C. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1993), supra; Kao, C. M. et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1994) 116:11612-11613). Many aldol condensations can be predicted as well, bearing in mind that the methyl and carboxyl ends tend preferentially to cyclize independently but will co-cyclize if no alternative exists (FIG. </PDAT><HIL><BOLD><PDAT>13</PDAT></BOLD></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>e</PDAT></ITALIC></HIL><PDAT>)) (McDaniel et al. </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>(1994), supra. These non-enzymatic cyclization patterns observed in vivo are also consistent with earlier biomimetic studies (Griffin, D. A. et al. </PDAT><HIL><ITALIC><PDAT>J. Chem. Soc. Perkin Trans. </PDAT></ITALIC></HIL><PDAT>(1984) 1:1035-1042).</PDAT></PTEXT></PARA>
<PARA ID="P-00177" LVL="0"><PTEXT><PDAT>Taken together with the structures of other naturally occurring bacterial aromatic polyketides, the design rules presented above can be extrapolated to estimate the extent of molecular diversity that might be generated via in vivo combinatorial biosynthesis of, for example, reduced and unreduced polyketides. For reduced polyketides, the identified degrees of freedom include chain length, aromatization of the first ring, and cyclization of the second ring. For unreduced ones, these include chain length and regiospecificity of the first ring cyclization. The number of accessible structures is the product of the number of ways in which each degree of freedom can be varied. Chains of five different lengths have so far been manipulated (16-, 18- 20-, 22- and 24-carbon lengths). From the structure and deduced biosynthetic pathways of the dynemicin anthraquinone (Tokiwa, Y. et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1992) 114:4107-4110), simaomicin (Carter, G. T. et al. </PDAT><HIL><ITALIC><PDAT>J. Org. Chem. </PDAT></ITALIC></HIL><PDAT>(1989) 54:4321-4323), and benastatin (Aoyama, T. et al. </PDAT><HIL><ITALIC><PDAT>J. Antibiot. </PDAT></ITALIC></HIL><PDAT>(1992) 45:1767-1772), the isolation of minimal PKSs that generate 14-, 26-, and possibly 28-carbon backbones, respectively, is anticipated, bringing the potential number to eight. Cloning of such minimal PKSs can be accomplished using the genes for minimal PKSs which have previously been isolated, such as the acti genes (Sherman et al. </PDAT><HIL><ITALIC><PDAT>EMBO J. </PDAT></ITALIC></HIL><PDAT>(1989), supra; Yu et al. </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>(1994), supra; Bibb et al. </PDAT><HIL><ITALIC><PDAT>Gene </PDAT></ITALIC></HIL><PDAT>(1994), supra; Malpartida, F. et al. </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>(1987) 325:818-821). Reduced chains can either be aromatized or not; a second ring cyclase is optional where the first ring is aromatized (FIG. </PDAT><HIL><BOLD><PDAT>12</PDAT></BOLD></HIL><PDAT>). The regiospecificity of the first cyclization of an unreduced chain can be varied, depending on the presence of an enzyme like TcmN.</PDAT></PTEXT></PARA>
<PARA ID="P-00178" LVL="0"><PTEXT><PDAT>For example, for reduced polyketides the relevant degrees of freedom include the chain length (which can be manipulated in at least seven ways), the first ring aromatization (which can be manipulated in at least two ways), and the second ring cyclization (which can be manipulated in at least two ways for aromatized intermediates only). For unreduced polyketides, the regiospecificity of the first cyclization can also be manipulated. Thus, the combinatorial potential for reduced polyketides is at least 7&times;3&equals;21; for unreduced polyketides the combinatorial potential is at least 7&times;2&equals;14. Moreover, these numbers do not include additional minor products, on the order of 5 to 10 per major product, that are produced in the recombinant strains through non-enzymatic or non-specific enzyme catalyzed steps. Thus, the number of polyketides that can be generated from combinatorial manipulation of only the first few steps in aromatic polyketide biosynthesis is on the order of a few hundred. Thus, genetically engineered biosynthesis represents a potentially unlimited source of chemical diversity for drug discovery.</PDAT></PTEXT></PARA>
<PARA ID="P-00179" LVL="0"><PTEXT><PDAT>The number of potential novel polyketides increase geometrically as new degrees of freedom are exploited and/or protein engineering strategies are brought to bear on the task of creating enzyme subunits with specificities not observed in nature. For example, non-acetate starter units can be incorporated into polyketide backbones (e.g. propionate in daunorubicin and malonamide in oxytetracycline). Furthermore, enzymes that catalyze downstream cyclizations and late-step modifications, such as group transfer reactions and oxidoreductions commonly seen in naturally occurring polyketides, can be studied along the lines presented here and elsewhere. It is therefore possible that at least some of these degrees of freedom can be combinatorially exploited to generate libraries of synthetic products with structural diversity that is comparable to that observed in nature.</PDAT></PTEXT></PARA>
<PARA ID="P-00180" LVL="7"><PTEXT><PDAT>C. Experimental</PDAT></PTEXT></PARA>
<PARA ID="P-00181" LVL="0"><PTEXT><PDAT>Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.</PDAT></PTEXT></PARA>
<PARA ID="P-00182" LVL="0"><PTEXT><PDAT>Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>Materials and Methods</PDAT></STEXT></H>
<PARA ID="P-00183" LVL="0"><PTEXT><PDAT>Bacterial strains, plasmids, and culture conditions. </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH999 was used as a host for transformation by all plasmids. The construction of this strain is described below. DNA manipulations were performed in </PDAT><HIL><ITALIC><PDAT>Escherichia coli </PDAT></ITALIC></HIL><PDAT>MC1061. Plasmids were passaged through </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>ET12567 (dam dcm hsds Cm</PDAT><HIL><SP><PDAT>r</PDAT></SP></HIL><PDAT>) (MacNeil, D. J. </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>(1988) 170:5607) to generate unmethylated DNA prior to transformation of </PDAT><HIL><ITALIC><PDAT>S. coelicolor. E. coli </PDAT></ITALIC></HIL><PDAT>strains were grown under standard conditions. </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>strains were grown on R2YE agar plates (Hopwood, D. A. et al. </PDAT><HIL><ITALIC><PDAT>Genetic manipulation of Streptomyces. A laboratory manual. </PDAT></ITALIC></HIL><PDAT>The John Innes Foundation: Norwich, 1985).</PDAT></PTEXT></PARA>
<PARA ID="P-00184" LVL="0"><PTEXT><PDAT>Manipulation of DNA and organisms. Polymerase chain reaction (PCR) was performed using Taq polymerase (Perkin Elmer Cetus) under conditions recommended by the enzyme manufacturer. Standard in vitro techniques were used for DNA manipulations (Sambrook, et al. </PDAT><HIL><ITALIC><PDAT>Molecular Cloning: A Laboratory Manual </PDAT></ITALIC></HIL><PDAT>(Current Edition)). E. coli was transformed with a Bio-Rad E. Coli Pulsing apparatus using protocols provided by Bio-Rad. </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>was transformed by standard procedures (Hopwood, D. A. et al. </PDAT><HIL><ITALIC><PDAT>Genetic manipulation of Streptomyces. A laboratory manual. </PDAT></ITALIC></HIL><PDAT>The John Innes Foundation: Norwich, 1985) and transformants were selected using 2 ml of a 500 mg/ml thiostrepton overlay.</PDAT></PTEXT></PARA>
<PARA ID="P-00185" LVL="0"><PTEXT><PDAT>Construction of plasmids containing recombinant PKSs. All plasmids are derivatives of pRM5, described below. fren PKS genes were amplified via PCR with 5&prime; and 3&prime; restriction sites flanking the genes in accordance with the location of cloning sites on pRM5 (i.e. PacI-NsiI for ORF1, NsiI-XbaI for ORF2, and XbaI-PstI for ORF3). Following subcloning and sequencing, the amplified fragments were cloned in place of the corresponding fragments in pRM5 to generate the plasmids for transformation.</PDAT></PTEXT></PARA>
<PARA ID="P-00186" LVL="0"><PTEXT><PDAT>Production and purification of polyketides. For initial screening, all strains were grown at 30&deg; C. as confluent lawns on 10-30 plates each containing approximately 30 ml of agar medium for 6-8 days. Additional plates were made as needed to obtain sufficient material for complete characterization. CH999 was a negative control when screening for potential polyketides. The agar was finely chopped and extracted with ethyl acetate/1% acetic acid or ethyl acetate:methanol (4:1)/1% acetic acid. The concentrated extract was then flashed through a silica gel (Baker 40 mm) chromatography column in ethyl acetate/1% acetic acid. Alternatively, the extract was applied to a Florisil column (Fisher Scientific) and eluted with ethyl acetate:ethanol:acetic acid (17:2:1). The primary yellow fraction was further purified via high-performance liquid chromatography (HPLC) using a 20-60% acetonitrile/water/1% acetic acid gradient on a preparative reverse phase (C-18) column (Beckman). Absorbance was monitored at 280 nm and 410 nm. In general, the yield of purified product from these strains was approximately 10 mg/l for compounds 1 and 2 (FIG. </PDAT><HIL><BOLD><PDAT>4</PDAT></BOLD></HIL><PDAT>), and 5 mg/l for compounds 7 and 8 (FIG. </PDAT><HIL><BOLD><PDAT>7</PDAT></BOLD></HIL><PDAT>).</PDAT></PTEXT></PARA>
<PARA ID="P-00187" LVL="0"><PTEXT><PDAT>SEK4, (12), was produced and purified as follows. CH999/pSEK4 was grown on 90 agar plates (&minus;34 ml/plate) at 30&deg; C. for 7 days. The agar was chopped and extracted with ethyl acetate/methanol (4/1) in the presence of 1% acetic acid (3&times;1000 ml). Following removal of the solvent under vacuum, 200 ml of ethyl acetate containing 1% acetic acid were added. The precipitate was filtered and discarded, and the solvent was evaporated to dryness. The product mixture was applied to a Florisil column (Fisher Scientific), and eluted with ethyl acetate containing 3% acetic acid. The first 100 ml fraction was collected, and concentrated down to 5 ml. 1 ml methanol was added, and the mixture was kept at 4&deg; C. overnight. The precipitate was collected by filtration, and washed with ethyl acetate to give 850 mg of pure product. R</PDAT><HIL><SB><PDAT>f</PDAT></SB></HIL><PDAT>&equals;0.48 (ethyl acetate with 1% acetic acid). Results from NMR spectroscopy on SEK4 are reported in Table 4. FAB HRMS (NBA), M&plus;H</PDAT><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>, calculated m/e 319.0818, observed m/e 319.0820.</PDAT></PTEXT></PARA>
<PARA ID="P-00188" LVL="0"><PTEXT><PDAT>To produce SEK15 (13) and SEK15b (16), CH999/pSEK15 was grown on 90 agar plates, and the product was extracted in the same manner as SEK4. The mixture was applied to a Florisil column (ethyl acetate with 5% acetic acid), and fractions containing the major products were combined and evaporated to dryness. The products were further purified using preparative C-18 reverse phase HPLC (Beckman) (mobile phase: acetonitrile/water&equals;1/10 to 3/5 gradient in the presence of 1% acetic acid). The yield of SEK15, (13), was 250 mg. R</PDAT><HIL><SB><PDAT>f</PDAT></SB></HIL><PDAT>&equals;0.41 (ethyl acetate with 1% acetic acid). Results from NMR spectroscopy on SEK4 are reported in Table 4. FAB HRMS (NBA), M&plus;H</PDAT><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>, calculated m/e 385.0923, observed m/e 385.0920.</PDAT></PTEXT></PARA>
<PARA ID="P-00189" LVL="0"><PTEXT><PDAT>&lsqb;1,2-</PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&rsqb; acetate feeding experiments. Two 2 1 flasks each containing 400 ml of modified NMP medium (Strauch, E. et al. </PDAT><HIL><ITALIC><PDAT>Mol. Microbiol. </PDAT></ITALIC></HIL><PDAT>(1991) 5:289) were inoculated with spores of </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH999/pRM18, CH999/pSEK4 or CH999/pSEK15, and incubated in a shaker at 30 degrees C and 300 rpm. To each flask, 50 mg of sodium &lsqb;1,2-</PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&rsqb; acetate (Aldrich) was added at 72 and 96 hrs. After 120 hrs, the cultures were pooled and extracted with two 500 ml volumes of ethyl acetate/1% acetic acid. The organic phase was kept and purification proceeded as described above. </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C NMR data indicate approximately a 2-3% enrichment for the CH999/pRM18 product; a 0.5-1% enrichment for SEK4 and a 1-2% enrichment for SEK15.</PDAT></PTEXT></PARA>
<PARA ID="P-00190" LVL="0"><PTEXT><PDAT>NMR Spectroscopy. All spectra were recorded on a Varian XL-400 except for HETCOR analysis of RM18 (10) (FIG. </PDAT><HIL><BOLD><PDAT>8</PDAT></BOLD></HIL><PDAT>), which was performed on a Nicolet NT-360. </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C spectra were acquired with continuous broadband proton decoupling. For NOE studies of RM18 (10), the one-dimensional difference method was employed. All compounds were dissolved in DMSO-d</PDAT><HIL><SB><PDAT>6 </PDAT></SB></HIL><PDAT>(Sigma, 99&plus;atom % D) and spectra were referenced internally to the solvent. Hydroxyl resonances were identified by adding D</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (Aldrich, 99 atom % D) and checking for disappearance of signal.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 1</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Production of </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH999</PDAT></STEXT></H>
<PARA ID="P-00191" LVL="0"><PTEXT><PDAT>An </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>host cell, genetically engineered to remove the native act gene cluster, and termed CH999, was constructed using </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH1 (Khosla, C. </PDAT><HIL><ITALIC><PDAT>Molec. Microbiol. </PDAT></ITALIC></HIL><PDAT>(1992) 6:3237), using the strategy depicted in FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>. (CH1 is derived from </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>B385 (Rudd, B. A. M. Genetics of Pigmented Secondary Metabolites in </PDAT><HIL><ITALIC><PDAT>Streptomyces coelicolor </PDAT></ITALIC></HIL><PDAT>(1978) Ph.D. Thesis, University of East Anglia, Norwich, England.) CH1 includes the act gene cluster which codes for enzymes involved in the biosynthesis and export of the polyketide antibiotic actinorhodin. The cluster is made up of the PKS genes, flanked by several post-PKS biosynthetic genes including those involved in cyclization, aromatization, and subsequent chemical tailoring (FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>A). Also present are the genes responsible for transcriptional activation of the act genes. The act gene cluster was deleted from CH1 using homologous recombination as described in Khosla, C. et al. </PDAT><HIL><ITALIC><PDAT>Molec. Microbiol. </PDAT></ITALIC></HIL><PDAT>(1992) 6:3237.</PDAT></PTEXT></PARA>
<PARA ID="P-00192" LVL="0"><PTEXT><PDAT>In particular, plasmid pLRermEts (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2B</PDAT></FGREF><PDAT>) was constructed with the following features: a ColEI replicon from pBR322, the temperature sensitive replicon from pSG5 (Muth, G. et al. </PDAT><HIL><ITALIC><PDAT>Mol. Gen. Genet. </PDAT></ITALIC></HIL><PDAT>(1989) 219:341), ampicillin and thiostrepton resistance markers, and a disruption cassette including a 2 kb BamHI/XhoI fragment from the 5&prime; end of the act cluster, a 1.5 kb ermE fragment (Khosla, C. et al. </PDAT><HIL><ITALIC><PDAT>Molec. Microbiol. </PDAT></ITALIC></HIL><PDAT>(1992) 6:3237), and a 1.9 kb SphI/PstI fragment from the 3&prime; end of the act cluster. The 5&prime; fragment extended from the BamHI site 1 (Malpartida, F. and Hopwood, D. A. </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>(1984) 309:462; Malpartida, F. and Hopwood, D. A. </PDAT><HIL><ITALIC><PDAT>Mol. Gen. Genet. </PDAT></ITALIC></HIL><PDAT>(1986) 205:66) downstream to a XhoI site. The 3&prime; fragment extended from PstI site 20 upstream to SphI site 19.2 (Fernandez-Moreno, M. A. et al. </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>(1992) 267:19278). The 5&prime; and 3&prime; fragments (shown as hatched DNA in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT>) were cloned in the same relative orientation as in the act cluster. CH1 was transformed with pLRermEts. The plasmid was subsequently cured from candidate transformants by streaking non-selectively at 39&deg; C. Several colonies that were lincomycin resistant, thiostrepton sensitive, and unable to produce actinorhodin, were isolated and checked via Southern blotting. One of them was designated CH999.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 2</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Production of the Recombinant Vector pRM5</PDAT></STEXT></H>
<PARA ID="P-00193" LVL="0"><PTEXT><PDAT>Shuttle plasmids are used to express recombinant PKSs in CH999. Such plasmids typically include a colEI replicon, an appropriately truncated SCP2* Streptomyces replicon, two act-promoters to allow for bidirectional cloning, the gene encoding the actII-ORF4 activator which induces transcription from act promoters during the transition from growth phase to stationary phase, and appropriate marker genes. Restriction sites have been engineered into these vectors to facilitate the combinatorial construction of PKS gene clusters starting from cassettes encoding individual subunits (or domains) of naturally occurring PKSs. The primary advantages of this method are that (i) all relevant biosynthetic genes are plasmid-borne and therefore amenable to facile manipulation and mutagenesis in </PDAT><HIL><ITALIC><PDAT>E. coli, </PDAT></ITALIC></HIL><PDAT>(ii) the entire library of PKS gene clusters can be expressed in the same bacterial host which is genetically and physiologically well-characterized and presumably contains most, if not all, ancillary activities required for in vivo production of polyketides, (iii) polyketides are produced in a secondary metabolite-like manner, thereby alleviating the toxic effects of synthesizing potentially bioactive compounds in vivo, and (iv) molecules thus produced undergo fewer side reactions than if the same pathways were expressed in wild-type organisms or blocked mutants.</PDAT></PTEXT></PARA>
<PARA ID="P-00194" LVL="0"><PTEXT><PDAT>pRM5 (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT>) was the shuttle plasmid used for expressing PKSs in CH999. It includes a ColEI replicon to allow genetic engineering in </PDAT><HIL><ITALIC><PDAT>E. coli, </PDAT></ITALIC></HIL><PDAT>an appropriately truncated SCP2* (low copy number) Streptomyces replicon, and the actII-ORF4 activator gene from the act cluster, which induces transcription from act promoters during the transition from growth phase to stationary phase in the vegetative mycelium. As shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT>, pRM5 carries the divergent actI/actIII promoter pair, together with convenient cloning sites to facilitate the insertion of a variety of engineered PKS genes downstream of both promoters. pRM5 lacks the par locus of SCP2*; as a result the plasmid is slightly unstable (approx. 2% loss in the absence of thiostrepton). This feature was deliberately introduced in order to allow for rapid confirmation that a phenotype of interest could be unambiguously assigned to the plasmid-borne mutant PKS. The recombinant PKSs from pRM5 are expressed approximately at the transition from exponential to stationary phase of growth, in good yields.</PDAT></PTEXT></PARA>
<PARA ID="P-00195" LVL="0"><PTEXT><PDAT>pRM5 was constructed as follows. A 10.5 kb SphI/HindIII fragment from pIJ903 (containing a portion of the fertility locus and the origin of replication of SCP2* as well as the colEI origin of replication and the &bgr;-lactamase gene from pBR327) (Lydiate, D. J. </PDAT><HIL><ITALIC><PDAT>Gene </PDAT></ITALIC></HIL><PDAT>(1985) 35:223) was ligated with a 1.5 kb HindIII/sphI tsr gene cassette to yield pRM1. pRM5 was constructed by inserting the following two fragments between the unique HindIII and EcoRI sites of pRM1: a 0.3 kb HindIII/HpaI(blunt) fragment carrying a transcription terminator from phage fd (Khosla, C. et al. </PDAT><HIL><ITALIC><PDAT>Molec. Microbiol. </PDAT></ITALIC></HIL><PDAT>(1992) 6:3237), and a 10 kb fragment from the act cluster extending from the NcoI site (1 kb upstream of the actII-ORF4 activator gene) (Hallam, S. E. et al. </PDAT><HIL><ITALIC><PDAT>Gene </PDAT></ITALIC></HIL><PDAT>(1988) 74:305; Fernandez-Moreno, M. A. et al. </PDAT><HIL><ITALIC><PDAT>Cell </PDAT></ITALIC></HIL><PDAT>(1991) 66:769; Caballero, J. L. </PDAT><HIL><ITALIC><PDAT>Mol. Gen. Genet. </PDAT></ITALIC></HIL><PDAT>(1991) 230:401) to the PstI site downstream of the actI-VII-IV genes (Fernandez-Moreno, M. A. et al. </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>(1992) 267:19278).</PDAT></PTEXT></PARA>
<PARA ID="P-00196" LVL="0"><PTEXT><PDAT>To facilitate the expression of any desired recombinant PKS under the control of the acti promoter (which is activated by the actII-ORF4 gene product), restriction sites for PacI, NsiI, XbaI, and PstI were engineered into the act DNA in intercistronic positions. In pRM5, as well as in all other PKS expression plasmids described here, ORF1, 2, and 3 alleles were cloned between these sites as cassettes engineered with their own RBSs.</PDAT></PTEXT></PARA>
<PARA ID="P-00197" LVL="0"><PTEXT><PDAT>In particular, in most naturally occurring aromatic polyketide synthase gene clusters in actinomycetes, ORF1 and ORF2 are translationally coupled. In order to facilitate construction of recombinant PKSs, the ORF1 and ORF2 alleles used here were cloned as independent (uncoupled) cassettes. For act ORF1, the following sequence was engineered into pRM5: CCACCGGACGAACGCATCGATTAATTAAGGAGGACCATCATG, where the boldfaced sequence corresponds to upstream DNA from the acti region, TTAATTAA is the PacI recognition site, and ATG is the start codon of act ORF1. The following sequence was engineered between act ORF1 and ORF2: NTGAATGCATGGAGGAGCCATCATG, where TGA and ATG are the stop and start codons of ORF1 and ORF2, respectively, ATGCAT is the NsiI recognition site, and the replacement of N (A in act DNA, A or G in alleles from other PKSs) with a C results in translational decoupling. The following sequence was engineered downstream of act ORF2: TAATCTAGA, where TAA is the stop codon, and TCTAGA is the XbaI recognition site. This allowed fusion of act ORF1 and ORF2 (engineered as above) to an XbaI site that had been engineered upstream of act ORF3 (Khosla, C. et al. </PDAT><HIL><ITALIC><PDAT>Molec. Microbiol. </PDAT></ITALIC></HIL><PDAT>(1992) 6:3237). As a control, pRM2 was constructed, identical to pRM5, but lacking any of the engineered sequences. ORF1 and ORF2 in pRM2 are translationally coupled. Comparison of the product profiles of CH999/pRM2 and CH999/pRM5 revealed that the decoupling strategy described here had no detectable influence on product distribution or product levels.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 3</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Polyketides Produced using CH999 Transformed with pRM5</PDAT></STEXT></H>
<PARA ID="P-00198" LVL="0"><PTEXT><PDAT>Plasmid pRM5 was introduced into </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH999 using standard techniques. (See, e.g., Sambrook, et al. </PDAT><HIL><ITALIC><PDAT>Molecular Cloning: A Laboratory Manual </PDAT></ITALIC></HIL><PDAT>(Current Edition.) CH999 transformed with pRM5 produced a large amount of yellowish-brown material. The two most abundant products were characterized by NMR and mass spectroscopy as aloesaponarin II (2) (Bartel, P. L. et al. </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>(1990) 172:4816) and its carboxylated analog, 3,8-dihydroxy-1-methylanthraquinone-2-carboxylic acid (1) (Cameron, D. W. et al. </PDAT><HIL><ITALIC><PDAT>Liebigs Ann. Chem. </PDAT></ITALIC></HIL><PDAT>(1989) 7:699) (FIG. </PDAT><HIL><BOLD><PDAT>4</PDAT></BOLD></HIL><PDAT>). It is presumed that 2 is derived from 1 by non-enzymatic decarboxylation (Bartel, P. L. et al. </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>(1990) 172:4816). Compounds 1 and 2 were present in approximately a 1:5 molar ratio. Approximately 100 mg of the mixture could be easily purified from 1 l of culture. The CH999/pRM5 host-vector system was therefore functioning as expected to produce significant amounts of a stable, only minimally modified polyketide metabolite. The production of 1 and 2 is consistent with the proposed pathway of actinorhodin biosynthesis (Bartel, P. L. et al. </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>(1990) 172:4816). Both metabolites, like the actinorhodin backbone, are derived from a 16-carbon polyketide with a single ketoreduction at C-9.</PDAT></PTEXT></PARA>
<PARA ID="P-00199" LVL="0"><PTEXT><PDAT>When CH999 was transformed with pSEK4, identical to pRM5 except for replacement of a 140 bp SphI/SalI fragment within the act KR gene by the SphI/SalI fragment from pUC19, the resulting strain produced abundant quantities of the aromatic polyketide SEK4 (12). The exact structure of this product is slightly different from desoxyerythrolaccin (Bartel, P. L. et al. </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>(1990) 172:4816). However, in vivo isotopic labeling studies using 1,2-</PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>-labeled acetate confirmed that the polyketide backbone is derived from 8 acetates. Moreover, the aromatic region of the </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H spectrum, as well as the </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C NMR spectrum of this product, are consistent with a tricyclic structure similar to 1, but lacking any ketoreduction (see Table 4).</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 4</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Construction and Analysis of Hybrid Polyketide Synthases</PDAT></STEXT></H>
<PARA ID="P-00200" LVL="7"><PTEXT><PDAT>A. Construction of Hybrid PKSs Including Components from act. gra and tcm PKSs</PDAT></PTEXT></PARA>
<PARA ID="P-00201" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1A</PDAT></FGREF><PDAT> shows the PKSs responsible for synthesizing the carbon chain backbones of actinorhodin (3), granaticin (4), and tetracenomycin (5) (structures shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 5</PDAT></FGREF><PDAT>) which contain homologous putative KS/AT and ACP subunits, as well as the ORF2 product. The act and gra PKSs also have KRs, lacking in the tcm PKS. Corresponding proteins from each cluster show a high degree of sequence identity. The percentage identities between corresponding PKS proteins in the three clusters are as follows: KS/AT: act/gra 76, act/tcm 64, gra/tcm 70; CLF: act/gra 60, act/tcm 58, gra/tcm 54; ACP: act/gra 60, act/tcm 43, gra/tcm 44. The act and gra PKSs synthesize identical 16-carbon backbones derived from 8 acetate residues with a ketoreduction at C-9 (FIG. </PDAT><HIL><BOLD><PDAT>6</PDAT></BOLD></HIL><PDAT>). In contrast, also as shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 6</PDAT></FGREF><PDAT>, the tcm polyketide backbone differs in overall carbon chain length (20 instead of 16 carbons), lack of any ketoreduction, and regiospecificity of the first cyclization, which occurs between carbons 9 and 14, instead of carbons 7 and 12 for act and gra.</PDAT></PTEXT></PARA>
<PARA ID="P-00202" LVL="0"><PTEXT><PDAT>In an attempt to generate novel polyketides, differing in a range of properties, as well as to elucidate aspects of the programming of aromatic PKSs, a systematic series of minimal PKS gene clusters, using various permutations of the ORF1 (encoding the KS/AT subunit), ORF2 (encoding the CLF subunit) and ORF3 (encoding the ACP subunit) gene products from the act, gra and tcm gene clusters were cloned into pRM5 in place of the existing act genes, as shown in Table 1. The resulting plasmids were used to transform CH999 as above.</PDAT></PTEXT></PARA>
<PARA ID="P-00203" LVL="0"><PTEXT><PDAT>Analysis of the products of the recombinant PKSs containing various permutations among the KS/AT, ORF2 product, and ACP subunits of the PKSs (all constructs also containing the act KR, cyclase, and dehydratase genes) indicated that the synthases could be grouped into three categories (Table 1): those that did not produce any polyketide; those that produced compound 1 (in addition to a small amount of 2); and those that produced a novel polyketide 9 (designated RM20) (FIG. </PDAT><HIL><BOLD><PDAT>6</PDAT></BOLD></HIL><PDAT>). The structure of 9 suggests that the polyketide backbone precursor of this molecule is derived from 10 acetate residues with a single ketoreduction at the C-9 position.</PDAT></PTEXT></PARA>
<PARA ID="P-00204" LVL="0"><PTEXT><PDAT>In order to investigate the influence of the act KR on the reduction and cyclization patterns of a heterologous polyketide chain, pSEK15 was also constructed, which included tam ORFs 1-3, but lacked the act KR. (The deletion in the act KR gene in this construct was identical to that in pSEK4.) Analysis of CH999/pSEK15 showed the 20 carbon chain product, SEK15 (13) which resembled, but was not identical to, tetracenomycin C or its shunt products. NMR spectroscopy was also consistent with a completely unreduced decaketide backbone (see Table 4).</PDAT></PTEXT></PARA>
<PARA ID="P-00205" LVL="0"><PTEXT><PDAT>All act/gra hybrids produced compound 1, consistent with the identical structures of the presumed actinorhodin and granaticin polyketides. In each case where a product could be isolated from a tcm/act hybrid, the chain length of the polyketide was identical to that of the natural product corresponding to the source of ORF2. This implies that the ORF2 product, and not the ACP or KS/AT, controls carbon chain length. Furthermore, since all polyketides produced by the hybrids described here, except the ones lacking the KR (CH999/pSEK4 and CH999/pSEK15), underwent a single ketoreduction, it can be concluded that: (i) the KR is both necessary and sufficient for ketoreduction to occur; (ii) this reduction always occurs at the C-9 position in the final polyketide backbone (counting from the carboxyl end of the chain); and (iii) while unreduced polyketides may undergo alternative cyclization patterns, in nascent polyketide chains that have undergone ketoreduction, the regiochemistry of the first cyclization is dictated by the position of the resulting hydroxyl, irrespective of how this cyclization occurs in the non-reduced product. In other words, the tam PKS could be engineered to exhibit new cyclization specificity by including a ketoreductase.</PDAT></PTEXT></PARA>
<PARA ID="P-00206" LVL="0"><PTEXT><PDAT>A striking feature of RM20 (9) is the pattern of cyclizations following the first cyclization. Isolation of mutactin (6) from an actVII mutant suggested that the actVII product and its tcm homolog catalyze the cyclization of the second ring in the biosynthesis of actinorhodin (3) and tetracenomycin (5), respectively (Sherman, D. H. et al. </PDAT><HIL><ITALIC><PDAT>Tetrahedron </PDAT></ITALIC></HIL><PDAT>(1991) 47:6029; Summers, R. G. et al. </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>(1992) 174:1810). The cyclization pattern of RM20 (9) is different from that of 1 and tetracenomycin F1, despite the presence of the actVII gene on pRM20 (9). It therefore appears that the act cyclase cannot cyclize longer polyketide chains.</PDAT></PTEXT></PARA>
<PARA ID="P-00207" LVL="0"><PTEXT><PDAT>Unexpectedly, the strain containing the minimal tcm PKS alone (CH999/pSEK33) produced two polyketides, SEK15 (13) and SEK15b (16), as depicted in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 8</PDAT></FGREF><PDAT>, in approximately equal quantities. Compounds (13) and (16) were also isolated from CH999/pSEK15, however, greater quantities of compound (13) were isolated this construct than of compound (16).</PDAT></PTEXT></PARA>
<PARA ID="P-00208" LVL="0"><PTEXT><PDAT>SEK15b is a novel compound, the structure of which was elucidated through a combination of NMR spectroscopy, sodium &lsqb;1,2-</PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&rsqb; acetate feeding experiments and mass spectroscopy. Results from </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H and </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C N indicated that SEK15b consisted of an unreduced anthraquinone moiety and a pyrone moiety. Sodium &lsqb;1,2-</PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&rsqb;-acetate feeding experiments confirmed that the carbon chain of SEK15b was derived from 10 acetate units. The coupling constants calculated from the </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C NMR spectrum of the enriched SEK15b sample facilitated peak assignment. Fast atom bombardment (FAB) mass spectroscopy gave a molecular weight of 381 (M&plus;H</PDAT><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>), consistent with C</PDAT><HIL><SB><PDAT>20</PDAT></SB></HIL><PDAT>H</PDAT><HIL><SB><PDAT>12</PDAT></SB></HIL><PDAT>O</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>. Deuterium exchange was used to confirm the presence of each hydroxyl in SEK15b.</PDAT></PTEXT></PARA>
<PARA ID="P-00209" LVL="0"><PTEXT><PDAT>In order to identify the degrees of freedom available in vivo to a nascent polyketide chain for cyclizing in the absence of an active cyclase, polyketides produced by recombinant </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH999/pRM37 (McDaniel et al. (1993), supra) were analyzed. The biosynthetic enzymes encoded by pRM37 are the tcm ketosynthase/acyltransferase (KS/AT), the tcm chain length determining factor (CLF), the tcm acyl carrier protein (ACP), and the act ketoreductase (KR).</PDAT></PTEXT></PARA>
<PARA ID="P-00210" LVL="0"><PTEXT><PDAT>Two novel compounds, RM20b (14) and RM20c (15) (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 8</PDAT></FGREF><PDAT>) were discovered in the culture medium of CH999/pRM37, which had previously yielded RM20 (9). The relative quantities of the three compounds recovered were 3:7:1 (RM20:RM20b:RM20c). The structures of (14) and (15) were elucidated through a combination of mass spectroscopy, NMR spectroscopy and isotope labeling experiments. </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H and </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C NMR spectra suggested that RM20b and RM20c were diastereomers, each containing a pyrone moiety. Optical rotations (&lsqb;&agr;&rsqb;</PDAT><HIL><SB><PDAT>D</PDAT></SB></HIL><HIL><SP><PDAT>20 </PDAT></SP></HIL><PDAT>were found to by &plus;210.8&deg; for RM20b (EtOH, 0.55%) and &plus;78.0&deg; for RM20c (EtOH, 0.33%). Sodium &lsqb;1,2-</PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&rsqb;-acetate feeding experiments confirmed that the carbon chain of RM20b (and by inference RM20c) was derived from 10 acetate units. Deuterium exchange studies were carried out in order to identify </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR peaks corresponding to potential hydroxyl groups on both RM20b and RM20c. Proton coupling constants were calculated from the results of </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR and one-dimensional decoupling experiments. In particular, the coupling pattern in the upfield region of the spectrum indicated a 5-proton spin system of two methylene groups surrounding a central carbinol methine proton. High resolution fast atom bombardment (FAB) mass spectroscopy gave molecular weights of (519.0056) (M&equals;Cs</PDAT><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>) for RM20b and 387.1070 (M&plus;H</PDAT><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>) for RM20c, which is consistent with C</PDAT><HIL><SB><PDAT>20</PDAT></SB></HIL><PDAT>H</PDAT><HIL><SB><PDAT>18</PDAT></SB></HIL><PDAT>O</PDAT><HIL><SB><PDAT>8 </PDAT></SB></HIL><PDAT>(M&plus;Cs</PDAT><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>, 519.0056; M&plus;H</PDAT><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>, 387.1080). Based on theses data, structures (14) and (15) (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 8</PDAT></FGREF><PDAT>) were assigned to RM20b and RM20c, respectively.</PDAT></PTEXT></PARA>
<PARA ID="P-00211" LVL="0"><PTEXT><PDAT>Data from 1H and </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C NMR indicated that the coupling constants between H-9 and the geminal protons on C-8 were 12.1 or 12.2 and 2.5 or 2.2 Hz for RM20b or RM20c, respectively. The coupling constants between H-9 and the geminal protons on C-10 were 9.6 or 9.7 and 5.7 or 5.8 Hz for Rm20b or RM20c, respectively. These values are typical of a J</PDAT><HIL><SB><PDAT>a,a </PDAT></SB></HIL><PDAT>(J</PDAT><HIL><SB><PDAT>9a,8a </PDAT></SB></HIL><PDAT>or J</PDAT><HIL><SB><PDAT>9a,10a</PDAT></SB></HIL><PDAT>) and J</PDAT><HIL><SB><PDAT>a,e </PDAT></SB></HIL><PDAT>(J</PDAT><HIL><SB><PDAT>9a,8e </PDAT></SB></HIL><PDAT>or J</PDAT><HIL><SB><PDAT>9a,10e</PDAT></SB></HIL><PDAT>) coupling pattern, and indicate an axial position for H-9 in both RM20b and Rm20c. In contrast, the chemical shifts of the C-7 hydroxyls on the two molecules were 16.18 and 6.14 ppm for RM20b and RM20c, respectively. These values indicate a hydrogen bond between the C-7 hydroxyl and a suitably positioned acceptor atom in RM20b, but not in RM20c. The most likely candidate acceptor atoms for such hydrogen bonding are the C-13 carbonyl oxygen in the conjugated pyrone ring system, or the bridge oxygen in the isolate pyrone ring. The former appears to be likely as it would be impossible to discriminate between (14) and (15) if the latter were the case. Furthermore, comparison of </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C NHR spectra of RM20b and RM20c revealed that the greatest differences between (14) and (15) were in the chemical shifts of the carbons that make up the conjugated pyrone ring (&plus;5.9, &minus;6.1, &plus;8.9, &minus;7.8 and &plus;2.0 ppm for C-11, C-12, C-13, C-14 and C-15, respectively). Such a pattern of alternating upfield and downfield shifts can be explained by the fact that the C-7 hydroxyl is hydrogen-bonded to the C-13 carbonyl, since hydrogen bonding would be expected to reduce the electron density around C-11, C-13 and C-15, but increase the electron density around C-12 and C-14. To confirm the C-7/C-13 hydrogen bond assignment, the exchangeable protons RM20b and RM20c were replaced with deuterium (by incubating in the presence of D</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O), and the samples were analyzed by </PDAT><HIL><SP><PDAT>13 </PDAT></SP></HIL><PDAT>C NMR. The C-13 peak in RM20b, but not RM20c, underwent an upfield shift (1.7 ppm), which can be explained by a weaker C-7/C-13 non-covalent bond in RM20b when hydrogen is replace with deuterium. In order to form a hydrogen bond with the C-13 carbonyl, the C-7 hydroxyl of RM20b must occupy the equatorial position. Thus, it can be inferred that the C-7 and C-9 hydroxyls are on the same face (syn) of the conjugated ring system in the major isomer (RM20b), whereas they are on opposite sides (anti) in the minor isomer (RM20c).</PDAT></PTEXT></PARA>
<PARA ID="P-00212" LVL="0"><PTEXT><PDAT>No polyketide could be detected in CH999/pRM15, /pRM35, and /pRM36. Thus, only some ORF1-ORF2 combinations are functional. Since each subunit was functional in at least one recombinant synthase, protein expression/folding problems are unlikely to be the cause. Instead, imperfect or inhibitory association between the different subunits of these enzyme complexes, or biosynthesis of (aborted) short chain products that are rapidly degraded, are plausible explanations.</PDAT></PTEXT></PARA>
<PARA ID="P-00213" LVL="7"><PTEXT><PDAT>B. Construction of Hybrid PKSs Including Components from act and fren PKSs</PDAT></PTEXT></PARA>
<PARA ID="P-00214" LVL="0"><PTEXT><HIL><ITALIC><PDAT>Streptomyces roseofulvus </PDAT></ITALIC></HIL><PDAT>produces both frenolicin B (7) (Iwai, Y. et al. </PDAT><HIL><ITALIC><PDAT>J. Antibiot. </PDAT></ITALIC></HIL><PDAT>(1978) 31:959) and nanaomycin A (8) (Tsuzuki, K. et al. </PDAT><HIL><ITALIC><PDAT>J. Antibiot. </PDAT></ITALIC></HIL><PDAT>(1986) 39:1343). A 10 kb DNA fragment (referred to as the fren locus hereafter) was cloned from a genomic library of S. roseofulvus (Bibb, M. J. et al. submitted) using DNA encoding the KS/AT and KR components of the act PKS of </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>A3(2) as a probe (Malpartida, F. et al. </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>(1987) 325:818). (See </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 7</PDAT></FGREF><PDAT> for structural representations.) DNA sequencing of the fren locus revealed the existence of (among others) genes with a high degree of identity to those encoding the act KS/AT, CLF, ACP, KR, and cyclase.</PDAT></PTEXT></PARA>
<PARA ID="P-00215" LVL="0"><PTEXT><PDAT>To produce the novel polyketides, the ORF1, 2 and 3 act genes present in pRM5 were replaced with the corresponding fren genes, as shown in Table 2. </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH999, constructed as described above, was transformed with these plasmids. (The genes encoding the act KR, and the act cyclase were also present on each of these genetic constructs.) Based on results from similar experiments with act and tcm PKSs, described above, it was expected that the act KR would be able to reduce the products of all functional recombinant PKSs, whereas the ability of the act cyclase to catalyze the second cyclization would depend upon the chain length of the product of the fren PKS.</PDAT></PTEXT></PARA>
<PARA ID="P-00216" LVL="0"><PTEXT><PDAT>The results summarized in Table 2 indicate that most of the transformants expressed functional PKSs, as assayed by their ability to produce aromatic polyketides. Structural analysis of the major products revealed that the producer strains could be grouped into two categories: those that synthesized compound 1 (together with a smaller amount of its decarboxylated side-product (2), and those that synthesized a mixture of compounds 1, 10 and 11 in a roughly 1:2:2 ratio. (Small amounts of 2 were also found in all strains producing 1.) Compounds 1 and 2 had been observed before as natural products, and were the metabolites produced by a PKS consisting entirely of act subunits, as described in Example 3. Compounds 10 and 11 (designated RM18 and RM18b, respectively) are novel structures whose chemical synthesis or isolation as natural products has not been reported previously.</PDAT></PTEXT></PARA>
<PARA ID="P-00217" LVL="0"><PTEXT><PDAT>The structures of 10 and 11 were elucidated through a combination of mass spectroscopy, NMR spectroscopy, and isotope labeling experiments. The </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H and </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C spectral assignments are shown in Table 3, along with </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C-</PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C coupling constants for 10 obtained through sodium &lsqb;1,2-</PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&rsqb; acetate feeding experiments (described below). Unequivocal assignments for compound 10 were established with 1D nuclear Overhauser effect (NOE) and long range heteronuclear correlation (HETCOR) studies. Deuterium exchange confirmed the presence of hydroxyls at C-15 of compound 10 and C-13 of compound 11. Field desorption mass spectrometry (FD-MS) of 2 revealed a molecular weight of 282, consistent with C</PDAT><HIL><SB><PDAT>17</PDAT></SB></HIL><PDAT>H</PDAT><HIL><SB><PDAT>14</PDAT></SB></HIL><PDAT>O</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(282.2952).</PDAT></PTEXT></PARA>
<PARA ID="P-00218" LVL="0"><PTEXT><PDAT>Earlier studies showed that the polyketide backbone of 2 (Bartel, P. L. et al. </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>(1990) 172:4816) (and by inference, 1) is derived from iterative condensations of 8 acetate residues with a single ketoreduction at C-9. It may also be argued that nanaomycin (8) arises from an identical carbon chain backbone. Therefore, it is very likely that nanaomycin is a product of the fren PKS genes in </PDAT><HIL><ITALIC><PDAT>S. roseofulvus. </PDAT></ITALIC></HIL><PDAT>Regiospecificity of the first cyclization leading to the formation of 1 is guided by the position of the ketoreduction, whereas that of the second cyclization is controlled by the act cyclase (Zhang, H. L. et al. </PDAT><HIL><ITALIC><PDAT>J. Org. Chem. </PDAT></ITALIC></HIL><PDAT>(1990) 55:1682).</PDAT></PTEXT></PARA>
<PARA ID="P-00219" LVL="0"><PTEXT><PDAT>In order to trace the carbon chain backbone of RM18 (10), in vivo feeding experiments using &lsqb;1,2-</PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C2&rsqb; acetate were performed on CH999/pRM18, followed by NMR analysis of labelled RM18 (10). The </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C coupling data (summarized in Table 3) indicate that the polyketide backbone of RM18 (10) is derived from 9 acetate residues, followed by a terminal decarboxylation (the C-2 </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C resonance appears as an enhanced singlet), which presumably occurs non-enzymatically. Furthermore, the absence of a hydroxyl group at the C-9 position suggests that a ketoreduction occurs at this carbon. Since these two features would be expected to occur in the putative frenolicin (7) backbone, the results suggest that, in addition to synthesizing nanaomycin, the fren PKS genes are responsible for the biosynthesis of frenolicin in </PDAT><HIL><ITALIC><PDAT>S. roseofulvus. </PDAT></ITALIC></HIL><PDAT>This appears to be the first unambiguous case of a PKS with relaxed chain length specificity. However, unlike the putative backbone of frenolicin, the C-17 carbonyl of RM18 (10) is not reduced. This could either reflect the absence from pRM18 of a specific ketoreductase, dehydratase, and an enoylreductase (present in the fren gene cluster in </PDAT><HIL><ITALIC><PDAT>S. roseofulvus</PDAT></ITALIC></HIL><PDAT>), or it could reflect a different origin for carbons 15-18 in frenolicin.</PDAT></PTEXT></PARA>
<PARA ID="P-00220" LVL="0"><PTEXT><PDAT>Regiospecificity of the first cyclization leading to the formation of RM18 (10) is guided by the position of the ketoreduction; however the second cyclization occurs differently from that in 7 or 1, and is similar to the cyclization pattern observed in RM20 (9), a decaketide produced by the tcm PKS, as described above. Therefore, as in the case of RM20 (9), it could be argued that the act cyclase cannot catalyze the second cyclization of the RM18 precursor, and that its subsequent cyclizations, which presumably occur non-enzymatically, are dictated by temporal differences in release of different portions of the nascent polyketide chain into an aqueous environment. In view of the ability of CH999/pRM18 (and CH999/pRM34) to produce 1, one can rule out the possibility that the cyclase cannot associate with the fren PKS (KS/AT, CLF, and ACP). A more likely explanation is that the act cyclase cannot recognize substrates of altered chain lengths. This would also be consistent with the putative biosynthetic scheme for RM20 (9).</PDAT></PTEXT></PARA>
<PARA ID="P-00221" LVL="0"><PTEXT><PDAT>A comparison of the product profiles of the hybrid synthases reported in Table 2 with analogous hybrids between act and tcm PKS components (Table 1) support the hypothesis that the ORF2 product is the chain length determining factor (CLF). Preparation of compounds 9, 10 and 11 via cyclization of enzyme-bound ketides is schematically illustrated in FIG. </PDAT><HIL><BOLD><PDAT>8</PDAT></BOLD></HIL><PDAT>.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 5</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>The Role of tcmJ and tcmN in Polyketide Synthesis</PDAT></STEXT></H>
<PARA ID="P-00222" LVL="0"><PTEXT><PDAT>To evaluate the specific catalytic roles of the PKS enzymes encoded by tcmJ and tcmN, tcmJ and tcmN were expressed in the presence of additional act and tcm PKS components in the </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH999 host-vector system described in Examples 1 through 3. The isolation of three novel polyketides from these genetic constructs has allowed the assignment of two distinct catalytic functions to tcmN.</PDAT></PTEXT></PARA>
<PARA ID="P-00223" LVL="0"><PTEXT><PDAT>The series of recombinant gene clusters shown in Table 5 was constructed. Each plasmid contained either tcmJ, tcmN, or both in addition to the minimal PKS genes responsible for the biosynthesis of 16 (act) or 20 (tcm) carbon backbones. Half of the plasmids also contained the gene encoding the act ketoreductase (KR, actIII), which catalyzes ketoreduction at the C-9 position of the nascent polyketide backbone. The plasmids were introduced by transformation into </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH999. The major polyketides produced by the transformed strains were isolated and structurally characterized using a combination of NMR, isotopic labelling and mass spectroscopy experiments. All of the polyketides isolated have been previously structurally characterized with the exception of the novel polyketides RM77 (19) (FIG. </PDAT><HIL><BOLD><PDAT>14</PDAT></BOLD></HIL><PDAT>), RM80 (20), and RM80b (21) (FIG. </PDAT><HIL><BOLD><PDAT>15</PDAT></BOLD></HIL><PDAT>).</PDAT></PTEXT></PARA>
<PARA ID="P-00224" LVL="0"><PTEXT><PDAT>A comparative analysis of the cyclization patterns of these molecules, together with those reported earlier, reveals two functions for tcmN. The first can be illustrated by differences in the proposed pathways for RM77 (19; produced by the act minimal PKS&plus;tcmN; pRM77) and SEK4 (12; produced by the act minimal PKS alone; pSEK24). As shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 14</PDAT></FGREF><PDAT>, tcmN influences the regiospecificity of the cyclization of the first ring. In SEK4 (12), an intramolecular aldol condensation occurs between the C-7 carbonyl and the C-12 methylene. In contrast, a similar reaction occurs between the C-9 carbonyl and the C-14 methylene in RM77 (19); this represents a shift of one acetate unit in the polyketide backbone. Thus, while earlier results indicated that the course of this reaction is primarily controlled by the minimal PKS, RM77 (19) clearly illustrates the effect of tcmN on the act minimal PKS, which otherwise exclusively catalyzes C-7/C-12 cyclizations in the absence of tcmN. The absence of any significant amount of SEK15 (13) or other C-7/C-12 cyclized molecules in CH999/pRM80 and CH999/pRM81 also supports the conclusion that regiospecificity of the first aldol condensation can be controlled by enzymes downstream of the minimal PKS.</PDAT></PTEXT></PARA>
<PARA ID="P-00225" LVL="0"><PTEXT><PDAT>An important consequence of the designation the tcmN function is the temporal relationship between the catalytic ketoreduction and cyclization of the first ring. In all naturally occurring and recombinant polyketides undergoing a C-9 ketoreduction studied to date, initial cyclization occurs between carbons 7 and 12. Therefore, the inability of strains expressing tcmN to produce significant quantities of a polyketide with a C-9/C-14 cyclization in the presence of the act KR (pRM71, pRM72, pRM74, pRM75; Table 5) indicates that ketoreduction occurs prior to formation of the first ring (FIG. </PDAT><HIL><BOLD><PDAT>14</PDAT></BOLD></HIL><PDAT>).</PDAT></PTEXT></PARA>
<PARA ID="P-00226" LVL="0"><PTEXT><PDAT>The second function of tcmN is apparent from comparison between the proposed cyclization pathways of RM80 (20; produced by the tcm minimal PKS&plus;tcmN; pRM80) and SEK15b (16; produced by the tcm minimal PKS alone; pSEK33). Production of these two molecules is mutually exclusive in these strains. As seen in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 15</PDAT></FGREF><PDAT>, the regiospecificities of the first and second intramolecular aldol condensations in both molecules are identical. However, in SEK15b (16) the third ring forms via an aldol condensation between C-6 and C-19, whereas in RM80 (20) it forms via hemiketalization between C-15 and C-19. The difference in these two cyclization pathways can be attributed to enolization of the C-15 carbonyl in RM80 (20), but not in SEK15b (16). This is reminiscent of the related polyketides SEK34 (22) and mutactin (6), shunt products from the early stages of actinorhodin biosynthesis which led to the hypothesis that the act aromatase (ARO) catalyzes the enolization of the C-11 carbonyl. Therefore, it is not surprising that tcmN, a homolog of the act ARO, should catalyze the same reaction; however, the specificities of the two proteins differ. Whereas the act ARO acts on the first ring, tcmN appears to act on the second ring.</PDAT></PTEXT></PARA>
<PARA ID="P-00227" LVL="0"><PTEXT><PDAT>TcmN provides an additional tool for the design and biosynthesis of novel polyketides through the genetic manipulation of PKSs. RM77 (19) represents the first example of a 16-carbon polyketide with an engineered first cyclization different from that of the expected &ldquo;natural&rdquo; one. Therefore, it is likely that other heterologous PKS complexes containing tcmN (or homologs) along with various minimal PKSs will produce polyketides of different chain length with the alternative first cyclization. This biosynthetic degree of freedom may be limited to unreduced molecules.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 6</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Rationally Designed Aromatic Polyketides</PDAT></STEXT></H>
<PARA ID="P-00228" LVL="0"><PTEXT><PDAT>All identified gene clusters for actinomycete aromatic polyketides contain a set of three genes encoding a so-called &lsquo;minimal PKS&rsquo; which consists of a ketosynthase (KS), which also carries a putative acyltransferase (AT) domain, a chain length factor (CLF), and an acyl carrier protein (ACP) (FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>). A 16-carbon molecule, for example SEK4 (12), can be synthesized from the act minimal PKS alone. In order to produce the C-9 reduced analogue of SEK4, SEK34 (22) (FIG. </PDAT><HIL><BOLD><PDAT>16</PDAT></BOLD></HIL><PDAT>), two additional activities are needed: a ketoreductase (KR) and an aromatizing subunit (ARO) (compare the genes present on pSEK24 and pSEK34; Table 6). The following experiments were designed to determine whether analogous pairs of molecules could be generated from backbones of alternative chain length, for example, 20 carbons using a suitable combination of a minimal PKS, a KR, and an ARO.</PDAT></PTEXT></PARA>
<PARA ID="P-00229" LVL="0"><PTEXT><PDAT>The tcm minimal PKS (on pSEK33; Table 6) is both necessary and sufficient for synthesis of an unreduced 20 carbon backbone (McDaniel, R. et al. </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>(1994) 91:11542-11546), which forms SEK15 (13). In addition, the act KR can reduce the C-9 carbonyl on such a backbone to a hydroxyl, which is subsequently lost upon spontaneous aromatization of the first carbocyclic ring (Fu, H. et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1994) 116:4166-4170). Aromatization of the reduced ring, in contrast, requires an ARO (McDaniel, R. et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1994) 116:10855-10859). However, the act ARO cannot aromatize 20-carbon chains (McDaniel, R., et al. </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>(1994) 262:1546-1550; McDaniel et al. </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>(1994), supra). Furthermore, the tcm PKS cluster (which lacks a KR gene) does not appear to encode a first ring ARO which would be a suitable candidate. Accordingly, an ARO gene homologous to the one in the act cluster was chosen from the gene cluster that encodes the PKS for the 20-carbon polyketide griseusin (gris) (Yu, T. -W. et al. </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>(1994) 176:2627-2534).</PDAT></PTEXT></PARA>
<PARA ID="P-00230" LVL="0"><PTEXT><PDAT>The plasmid pSEK43 (Table 6), containing the tcm minimal PKS, the act KR, and the gris ARO, was constructed and introduced into the CH999 host. Analysis of the transformed strain revealed the anticipated polyketide SEK43 (23), whose structure was determined by NMR, mass spectroscopy, and isotopic labelling studies.</PDAT></PTEXT></PARA>
<PARA ID="P-00231" LVL="0"><PTEXT><PDAT>The biosynthesis of SEK43 (23) (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 17</PDAT></FGREF><PDAT>) reaffirms the conclusion that the act ARO and its homologues aromatize the first ring (McDaniel et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1994), supra). Without a functional ARO, the tcm minimal PKS and act KR (pSEK23; Table 6) produce RM20b (14) (FIG. </PDAT><HIL><BOLD><PDAT>16</PDAT></BOLD></HIL><PDAT>), which contains a non-aromatized first ring. Replacement of the tcm minimal PKS in pSEK43 with either the act or fren minimal PKSs (pSEK41 and pSEK42; Table 6) resulted in production of the 16-carbon aromatized compound SEK34 (22), demonstrating that the gris ARO can also recognize shorter carbon chains. It was unexpected, however, that a corresponding 18-carbon polyketide was not detected in the construct containing the fren minimal PKS, which has been shown to synthesize both 18- and 16-carbon chains (McDaniel et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1993), supra). This is probably due to decomposition of the molecule, since CH999/pSEK42 produced small quantities of an uncharacterized molecule not present in CH999/pSEK34. More significantly, evidence for an aromatized 18-carbon intermediate is described below.</PDAT></PTEXT></PARA>
<PARA ID="P-00232" LVL="0"><PTEXT><PDAT>A second test of the concept of rational design arose from the previous isolation of the 16-carbon polyketide DMAC (28) (FIG. </PDAT><HIL><BOLD><PDAT>16</PDAT></BOLD></HIL><PDAT>). The PKS subunits required for DMAC (28) biosynthesis are a &ldquo;16-carbon&rdquo; minimal PKS, a KR, and suitable ARO and CYC components (pRM5; Table 6). CYC catalyzes cyclization of the second ring between carbons 4 and 15, leading eventually to the formation of an anthraquinone (McDaniel et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1994), supra). These observations suggested that an analogous anthraquinone, with 18 carbons, could be generated. To achieve this, the plasmid pSEK26 (Table 6) containing the fren minimal PKS with the act KR, the fren ARO, and the act CYC was constructed. The fren minimal PKS and act KR were selected for their ability to produce an 18-carbon, C-9 reduced backbone (McDaniel et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1993), supra; McDaniel et al. </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>(1994), supra). The fren ARO was chosen since the act ARO cannot aromatize 18-carbon chains (McDaniel et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1993), supra; McDaniel et al. </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>(1994), supra).</PDAT></PTEXT></PARA>
<PARA ID="P-00233" LVL="0"><PTEXT><PDAT>Introduction of the plasmid into CH999 resulted in the production of both DMAC (28) and SEK26 (24). The latter is a novel 18-carbon anthraquinone whose structure was confirmed by NMR, mass spectroscopy, and isotopic labelling studies. Formation of SEK26 (24) (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 17</PDAT></FGREF><PDAT>) occurs through a second ring cyclization at C5/C14 presumably catalyzed by the act CYC. The production also of DMAC (28) is consistent with the relaxed chain length specificity of the fren minimal PKS (McDaniel et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1993), supra).</PDAT></PTEXT></PARA>
<PARA ID="P-00234" LVL="0"><PTEXT><PDAT>In order to evaluate further the specificity of ARO and CYC subunits towards carbon chains of various lengths, several other PKS combinations were constructed (Table 6). For example, pSEK25 and pSEK26 demonstrate that the fren ARO can aromatize both 16- and 18-carbon chains. However, the fren ARO cannot handle 20-carbon chains; instead the combination of the fren ARO with the tcm minimal PKS, act KR, and act CYC (pSEK27) resulted in biosynthesis of RM20b (14), the non-aromatized 20-carbon polyketide (FIG. </PDAT><HIL><BOLD><PDAT>16</PDAT></BOLD></HIL><PDAT>). As expected, replacing the fren ARO with the gris ARO (pRM51) in pSEK26 yielded DMAC (28) and SEK26 (24). However, attempts to generate a 20-carbon reduced polyketide with a C-5/C-14 second ring cyclization were unsuccessful; replacing the fren minimal PKS in pRM51 with the tcm minimal PKS (pRM52) resulted in production of SEK43 (23), indicating that the act CYC cannot cyclize 20-carbon chains. Finally, the plasmids pSEK44-47, pRM51, and pRM52 (Table 6), all lacking KRs, failed to cause production of polyketides different from those produced by the minimal PKS alone (McDaniel et al. </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>(1994), supra), despite the presence of ARO and CYC components. This is consistent with previous observations that ARO and CYC subunits do not alter the biosynthetic pathways of unreduced polyketides (McDaniel et al. </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>(1994), supra; Fu, H., McDaniel, R., Hopwood, D. A. &amp; Khosla, C. </PDAT><HIL><ITALIC><PDAT>Biochemistry </PDAT></ITALIC></HIL><PDAT>33:9321-9326 (1994)).</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 7</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Construction and Analysis of Modular Polyketide Synthases</PDAT></STEXT></H>
<PARA ID="P-00235" LVL="0"><PTEXT><PDAT>Expression plasmids containing recombinant modular DEBS PKS genes were constructed by transferring DNA incrementally from a temperature-sensitive &ldquo;donor&rdquo; plasmid, i.e., a plasmid capable of replication at a first, permissive temperature and incapable of replication at a second, non-permissive temperature, to a &ldquo;recipient&rdquo; shuttle vector via a double recombination event, as depicted in FIG. </PDAT><HIL><BOLD><PDAT>18</PDAT></BOLD></HIL><PDAT>. pCK7 (FIG. </PDAT><HIL><BOLD><PDAT>12</PDAT></BOLD></HIL><PDAT>), a shuttle plasmid containing the complete eryA genes, which were originally cloned from pS1 (Tuan et al. (1990) </PDAT><HIL><ITALIC><PDAT>Gene </PDAT></ITALIC></HIL><PDAT>90:21), was constructed as follows. A 25.6 kb SphI fragment from pS1 was inserted into the SphI site of pMAK705 (Hamilton et al. (1989) </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>171:4617) to give pCK6 (Cm</PDAT><HIL><SP><PDAT>R</PDAT></SP></HIL><PDAT>), a donor plasmid containing eryAII, eryAIII, and the 3&prime; end of eryAI. Replication of this temperature-sensitive pSC101 derivative occurs at 30&deg; C. but is arrested at 44&deg; C. The recipient plasmid, pCK5 (Ap</PDAT><HIL><SP><PDAT>R</PDAT></SP></HIL><PDAT>, TC</PDAT><HIL><SP><PDAT>R</PDAT></SP></HIL><PDAT>), includes a 12.2 kb eryA fragment from the eryAI start codon (Caffrey et al. (1992) </PDAT><HIL><ITALIC><PDAT>FEBS Lett. </PDAT></ITALIC></HIL><PDAT>304:225) to the XcmI site near the beginning of eryAII, a 1.4 kb EcoRI&mdash;BsmI pBR322 fragment encoding the tetracycline resistance gene (Tc), and a 4.0 kb NotI&mdash;EcoRI fragment from the end of eryAIII. PacI, NdeI, and ribosome binding sites were engineered at the eryAI start codon in pCK5. pCK5 is a derivative of pRM5 (McDaniel et al. (1993), supra). The 5&prime; and 3&prime; regions of homology (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 18</PDAT></FGREF><PDAT>, striped and unshaded areas) are 4.1 kb and 4.0 kb, respectively. MC1061 </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>was transformed (see, Sambrook et al., supra) with pCK5 and pCK6 and subjected to carbenicillin and chloramphenicol selection at 30&deg; C. Colonies harboring both plasmids (Ap</PDAT><HIL><SP><PDAT>R</PDAT></SP></HIL><PDAT>, Cm</PDAT><HIL><SP><PDAT>R</PDAT></SP></HIL><PDAT>) were then restreaked at 44&deg; C. on carbenicillin and chloramphenicol plates. Only cointegrates formed by a single recombination event between the two plasmids were viable surviving colonies were propagated at 30&deg; C. under carbenicillin selection, forcing the resolution of the cointegrates via a second recombination event. To enrich for pCK7 recombinants, colonies were restreaked again on carbenicillin plates at 44&deg; C. Approximately 20% of the resulting colonies displayed the desired phenotype (Ap</PDAT><HIL><SP><PDAT>R</PDAT></SP></HIL><PDAT>, Tc</PDAT><HIL><SP><PDAT>S</PDAT></SP></HIL><PDAT>,Cm</PDAT><HIL><SP><PDAT>S</PDAT></SP></HIL><PDAT>). The final pCK7 candidates were thoroughly checked via restriction mapping. A control plasmid, pCK7f, which contains a frameshift error in eryAI, was constructed in a similar manner. pCK7 and pCK7f were transformed into </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>ET12567 (MacNeil (1988) </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>170:5607) to generate unmethylated plasmid DNA and subsequently moved into </PDAT><HIL><ITALIC><PDAT>Streptomyces coelicolor </PDAT></ITALIC></HIL><PDAT>CH999 using standard protocols (Hopwood et al. (1985) </PDAT><HIL><ITALIC><PDAT>Genetic manipulation of Streptomyces. A laboratory manual. </PDAT></ITALIC></HIL><PDAT>The John Innes Foundation: Norwich).</PDAT></PTEXT></PARA>
<PARA ID="P-00236" LVL="0"><PTEXT><PDAT>Upon growth of CH999/pCK7 on R2YE medium, the organism produced abundant quantities of two polyketides (FIG. </PDAT><HIL><BOLD><PDAT>20</PDAT></BOLD></HIL><PDAT>). The addition of propionate (300 mg/L) to the growth medium resulted in approximately a two-fold increase in yield of polyketide product. Proton and </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C NMR spectroscopy, in conjunction with propionic-1-</PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C acid feeding experiments, confirmed the major product as 6dEB (17) (&gt;40 mg/L). The minor product was identified as 8,8a-deoxyoleandolide (18) (&gt;10 mg/L), which apparently originates from an acetate starter unit instead of propionate in the 6dEB biosynthetic pathway. </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>sodium acetate feeding experiments confirmed the incorporation of acetate into (18). Three high molecular weight proteins (&gt;200 kDa), presumably DEBS1, DEBS2,.and DEBS3 (Caffrey et al. (1992) </PDAT><HIL><ITALIC><PDAT>FEBS Lett. </PDAT></ITALIC></HIL><PDAT>304:225), were also observed in crude extracts of CH999/pCK7 via SDS-polyacrylamide gel electrophoresis. No polyketide products were observed from CH999/pCK7f. The inventors hereby acknowledge support provided by the American Cancer Society (IRG-32-34).</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 8</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Manipulation of Macrolide Ring Size by Directed Mutagenesis of DEBS</PDAT></STEXT></H>
<PARA ID="P-00237" LVL="0"><PTEXT><PDAT>In order to investigate the relationship between structure and function in modular PKSs and to apply this knowledge towards the rational and stochastic design of novel polyketides, a host-vector expression system was designed to study DEBS (Kao, C. M. et al. </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>(1994) 265:509-512). Using this expression system, the expression of DEBS1 alone, in the absence of DEBS2 and DEBS3, resulted in the production of (2R,3S,4S,5R)-2,4-dimethyl-3,5-dihydroxy-n-heptanoic acid 6-lactone (&ldquo;the heptanoic acid 6-lactone&rdquo; (25)) (1-3 mg/L), the expected triketide product of the first two modules (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 21A</PDAT></FGREF><PDAT>) (Kao, C. M. et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1994) 116:11612-11613). The synthesis of the heptanoic acid &dgr;-lactone (25) provided further biochemical evidence for the modular PKS model of Katz and coworkers (Donadio, S. et al. </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>(1991), supra) and showed that a thioesterase is not essential for release of a triketide from the enzyme complex.</PDAT></PTEXT></PARA>
<PARA ID="P-00238" LVL="0"><PTEXT><PDAT>In this Example the role of the thioesterase (TE) domain in DEBS was analyzed by constructing two additional deletion mutant PKSs that consist of different subsets of the DEBS modules and the TE. The first PKS contained DEBS1 fused to the TE, whereas the second PKS included the first five DEBS modules with the TE; plasmids pCK12 and pCK15 contained the genes encoding the bimodular (&ldquo;1&plus;2&plus;TE&rdquo;) and pentamodular (&ldquo;1&plus;2&plus;3&plus;4&plus;5&plus;TE&rdquo;) PKSs.</PDAT></PTEXT></PARA>
<PARA ID="P-00239" LVL="0"><PTEXT><PDAT>The 1&plus;2&plus;TE PKS contained a fusion of the carboxy-terminal end of the acyl carrier protein of module 2 (ACP-2) to the carboxy-terminal end of the acyl carrier protein of module 6 (ACP-6). Thus ACP-2 is essentially intact in this PKS and is followed by the amino acid sequence naturally found between ACP-6 and the TE (FIG. </PDAT><HIL><BOLD><PDAT>21</PDAT></BOLD></HIL><PDAT>B). Plasmid pCK12 contained eryA DNA originating from pS1 (Tuan, J. S. et al. </PDAT><HIL><ITALIC><PDAT>Gene </PDAT></ITALIC></HIL><PDAT>(1990) 90:21). pCK12 is identical to pCK7 (Kao et al. </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>(1994), supra) with the exception of a deletion between the carboxy-terminal ends of ACP-2 and ACP-6. The fusion occurs between residues L3455 of DEBS1 and Q2891 of DEBS3. An SpeI site is present between these two residues so that the DNA sequence at the fusion is CTCACTAGTCAG.</PDAT></PTEXT></PARA>
<PARA ID="P-00240" LVL="0"><PTEXT><PDAT>The 1&plus;2&plus;3&plus;4&plus;5&plus;TE PKS contained a fusion 76 amino acids downstream of the &bgr;-ketoreductase of module 5 (KR-5) and five amino acids upstream of ACP-6. Thus, the fusion occurs towards the carboxy-terminal end of the non-conserved region between KR-5 and ACP-5, and the recombinant module 5 was essentially a hybrid between the wild type modules 5 and 6 (FIG. </PDAT><HIL><BOLD><PDAT>22</PDAT></BOLD></HIL><PDAT>). Plasmid pCK15 contained eryA DNA originating from pS1 (Tuan et al. </PDAT><HIL><ITALIC><PDAT>Gene </PDAT></ITALIC></HIL><PDAT>(1990), supra). pCK15 is a derivative of pCK7 (Kao et al. </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>(1994), supra) and was constructed using an in vivo recombination strategy described earlier (Kao et al. </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>(1994), supra). pCK15 is identical to pCK7 with the exceptions of a deletion between KR-5 and ACP-6, which occurs between residues G1372 and A2802 of DEBS3, and the insertion of a blunted a SalI fragment containing a kanamycin resistance gene (Oka A. et al. </PDAT><HIL><ITALIC><PDAT>J. Mol. Biol. </PDAT></ITALIC></HIL><PDAT>(1981) 147:217) into the blunted HindIII site of pCK7. An arginine residue is present between G1372 and A2802 so that the DNA sequence at the fusion is GGCCGCGCC.</PDAT></PTEXT></PARA>
<PARA ID="P-00241" LVL="0"><PTEXT><PDAT>Plasmids pCK12 and pCK15 were introduced into </PDAT><HIL><ITALIC><PDAT>S. coelicolor </PDAT></ITALIC></HIL><PDAT>CH999 and polyketide products purified from the transformed strains according to methods previously described (Kao et al. </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>(1994), supra).</PDAT></PTEXT></PARA>
<PARA ID="P-00242" LVL="0"><PTEXT><PDAT>CH999/pCK12 produced the heptanoic acid &dgr;-lactone (25) (20 mg/L) as determined by </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H and </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C NM spectroscopy. This triketide product is identical to that produced by CH999/pCK9, which expresses the unmodified DEBS1 protein alone (Kao </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1994), supra. However, CH999/pCK12 produced the heptanoic acid 6-lactone (25) in significantly greater quantities than CH999/pCK9 (&gt;10 mg/L vs. &minus;1 mg/L), indicating the ability of the TE to catalyze thiolysis of a triketide chain attached to the ACP domain of module 2. CH999/pCK12 also produced significant quantities of a novel analog of (2R,3S,4S,5R)-2,4-dimethyl-3,5-dihydroxy-n-hexanoic acid &dgr;-lactone (&ldquo;the hexanoic acid &dgr;-lactone (26)) (10 mg/L), that resulted from the incorporation of an acetate start unit instead of propionate. This is reminiscent of the ability of CH999/pCK7, which expresses intact DEBS, to produce 8,8a-deoxyoleandolide (18) in addition to 6dEB (17) (Kao et al. </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>(1994), supra).</PDAT></PTEXT></PARA>
<PARA ID="P-00243" LVL="0"><PTEXT><PDAT>Since the hexanoic acid &dgr;-lactone (26) was not detected in CH999/pCK9, its facile isolation from CH999/pCK12 provides additional evidence for the increased turnover rate of DEBS1 due to the presence of the TE. In other words, the TE can effectively recognize an intermediate bound to a &ldquo;foreign&rdquo; module that is four acyl units shorter than its natural substrate, 6dEB (17). However, since the triketide products can probably cyclize spontaneously into the heptanoic acid 6-lactone (25) and the hexanoic acid 6-lactone (26) under typical fermentation conditions (pH 7), it is not possible to discriminate between a biosynthetic model involving enzyme-catalyzed lactonization and one involving enzyme-catalyzed hydrolysis followed by spontaneous lactonization. Thus, the ability of the 1&plus;2&plus;TE PKS to recognize the C-5 hydroxyl of a triketide as an incoming nucleophile is unclear.</PDAT></PTEXT></PARA>
<PARA ID="P-00244" LVL="0"><PTEXT><PDAT>The second recombinant strain, CH999/pCK15, produced abundant quantities of (8R,9S)-8,9-dihydro-8-methyl-9-hydroxy-10-deoxymethonolide (&ldquo;the 10-deoxymethonolide (27); </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 22</PDAT></FGREF><PDAT>) (10 mg/L), demonstrating that the pentamodular PKS is active. The 10-deoxymethonolide (27) was characterized using </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H and </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C NMR spectroscopy of natural abundance and </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C-enriched material, homonuclear correlation spectroscopy (COSY), heteronuclear correlation spectroscopy (HETCOR), mass spectrometry, and molecular modeling. The 10-deaxymethonolide (27) is an analog of 10-deoxymethonolide (Lambalot, R. H. et al. </PDAT><HIL><ITALIC><PDAT>J. Antibiotics </PDAT></ITALIC></HIL><PDAT>(1992) 45:1981-1982), the aglycone of the macrolide antibiotic methymycin. The production of the 10-deoxymethonolide (27) by a pentamodular enzyme demonstrates that active site domains in modules 5 and 6 in DEBS can be joined without loss of activity. If this proves to be a general feature of the multimodular proteins that constitute modular PKSS, then any structural model for module assembly must account for the fact that individual modules as well as active sites are independent entities which do not depend on association with neighboring modules to be functional. Most remarkably, the 12-membered lactone ring, formed by esterification of the terminal carboxyl with the C-11 hydroxyl of the hexaketide product, indicated the ability of the 1&plus;2&plus;3&plus;4&plus;5&plus;TE PKS, and possibly the TE itself, to catalyze lactonization of a polyketide chain one acyl unit shorter than the natural product of DEBS, 6dEB (17). Indeed, the formation of the 10-deoxymethonolide (27) may mimic the biosynthesis of the closely related 12-membered hexaketide macrolide, methymycin, which frequently occurs with the homologous 14-membered heptaketide macrolides, picromycin and/or narbomycin (Cane, D. E. et al. </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>(1993) 115:522-566). A modular PKS such as DEBS could thus be used to generate a wide range of macrolactones with shorter as well as longer chain lengths. The latter products would require the introduction of additional heterologous modules into DEBS.</PDAT></PTEXT></PARA>
<PARA ID="P-00245" LVL="0"><PTEXT><PDAT>The construction of the 1&plus;2&plus;3&plus;4&plus;5&plus;TE PKS resulted in the biosynthesis of a previously uncharacterized 12-membered macrolactone that closely resembles, but is distinct from, the aglycone of a biologically active macrolide. The apparent structural and functional independence of active site domains and modules as well as relaxed lactonization specificity suggest the existence of many degrees of freedom for manipulating these enzymes to produce new modular PKSs. Libraries of new macrolides can be generated by altering the association of active site domains and entire modules, the subset of reductive domains within each module, the activity of the TE, and possibly even downstream modification reactions such as hydroxylation and glycosylation. Such libraries could prove to be rich sources of new leads for drug discovery.</PDAT></PTEXT></PARA>
<PARA ID="P-00246" LVL="0"><PTEXT><PDAT>Thus, novel polyketides, as well as methods for recombinantly producing the polyketides, are disclosed. Although preferred embodiments of the subject invention have been described in some detail, it is understood that obvious variations can be made without departing from the spirit and the scope of the invention as defined by the appended claims.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00001">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="6">
<colspec colname="1" colwidth="35pt" align="left"/>
<colspec colname="2" colwidth="42pt" align="left"/>
<colspec colname="3" colwidth="28pt" align="left"/>
<colspec colname="4" colwidth="28pt" align="left"/>
<colspec colname="5" colwidth="42pt" align="center"/>
<colspec colname="6" colwidth="42pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="6" rowsep="1"><PTEXT><PDAT>TABLE 1</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="6" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Backbone</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>ORF1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>ORF2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>ORF3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Major</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Carbon</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Plasmid</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(KS/AT)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(CLDF)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(ACP)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Product(s)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Length</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="6" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>pRM5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1,2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>16</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>pRM7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>gra</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1,2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>16</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>pRM12</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>gra</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1,2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>16</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>pRM22</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>gra</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1,2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>16</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>pRM10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1,2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>16</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>pRM15</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>NP</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>pRM20</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>20</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>pRM25</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1,2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>16</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>pRM35</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>NP</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>pRM36</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>NP</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>pRM37</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>9,14,15</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>20</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>pSEK15</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>13,16</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>20</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>pSEK33</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>13,16</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>20</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="6" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<CWU>
<TABLE-US ID="TABLE-US-00002">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="6">
<colspec colname="offset" colwidth="14pt" align="left"/>
<colspec colname="1" colwidth="35pt" align="left"/>
<colspec colname="2" colwidth="42pt" align="left"/>
<colspec colname="3" colwidth="42pt" align="left"/>
<colspec colname="4" colwidth="28pt" align="left"/>
<colspec colname="5" colwidth="56pt" align="center"/>
<thead>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="5" rowsep="1"><PTEXT><PDAT>TABLE 2</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="5" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>ORF1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>ORF2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>ORF3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Major</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>Plasmid</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(KS/AT)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(CLDF)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(ACP)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Product(s)</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="5" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1,2</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1,2</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM13</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>NP</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM23</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1,2</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM18</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1,2,10,11</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM32</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>NP</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM33</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>NP</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM34</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0001,2,10,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>11</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="5" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<CWU>
<TABLE-US ID="TABLE-US-00003">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0" pgwide="1">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="287pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 3</PDAT></PTEXT></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H(400 MHz) and </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C(100 MHz) NMR data from RM18(10) and RM18b(11)</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="161pt" align="center"/>
<colspec colname="2" colwidth="126pt" align="center"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>RM18</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>RM18b</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="7">
<colspec colname="1" colwidth="28pt" align="center"/>
<colspec colname="2" colwidth="35pt" align="center"/>
<colspec colname="3" colwidth="35pt" align="center"/>
<colspec colname="4" colwidth="63pt" align="center"/>
<colspec colname="5" colwidth="28pt" align="center"/>
<colspec colname="6" colwidth="35pt" align="center"/>
<colspec colname="7" colwidth="63pt" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H&dgr;(ppm)</PDAT></PTEXT></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H&dgr;(ppm)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>carbon</PDAT><HIL><SP><PDAT>&agr;</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C&dgr;(ppm)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(J</PDAT><HIL><SB><PDAT>CC</PDAT></SB></HIL><PDAT>(Hz))</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(m,J</PDAT><HIL><SB><PDAT>HH</PDAT></SB></HIL><PDAT>(Hz),area))</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>carbon</PDAT><HIL><SP><PDAT>&agr;</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C&dgr;(ppm)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(m,J</PDAT><HIL><SB><PDAT>HH</PDAT></SB></HIL><PDAT>(Hz),area))</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="7" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="7">
<colspec colname="1" colwidth="28pt" align="char" char="."/>
<colspec colname="2" colwidth="35pt" align="char" char="."/>
<colspec colname="3" colwidth="35pt" align="center"/>
<colspec colname="4" colwidth="63pt" align="center"/>
<colspec colname="5" colwidth="28pt" align="char" char="."/>
<colspec colname="6" colwidth="35pt" align="char" char="."/>
<colspec colname="7" colwidth="63pt" align="center"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>29.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>NC</PDAT><HIL><SP><PDAT>b</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>2.2(s,3H)</PDAT></PTEXT></entry>
<entry></entry>
<entry></entry>
<entry></entry>
</row>
<row>
<entry><PTEXT><PDAT>3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>203.7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>37.7</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>47.0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>36.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>3.6(s,2H)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>18.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2.1(s,3H)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>149.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>77.2</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>152.3</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>106.7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>77.4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6.2(s,1H)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>104.0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6.1(s,1H)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>129.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>61.9</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>130.0</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>114.4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>62.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6.7(d,7.2,1H)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>113.5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6.7(d,7.0)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>130.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>58.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>7.3(dd,8.4,7.4,1H)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>130.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>7.3(dd,7.1,8.7,1H)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>120.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>59.2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>7.6(d,8.9,1H)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>120.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>7.6(d,8.6,1H)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>11</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>132.7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>56.0</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>132.8</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>12</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>116.7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>55.7</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>116.6</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>13</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>155.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>74.7</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>11</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>155.9</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>14</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>98.4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>74.9</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>12</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>98.2</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>15</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>158.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>69.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6.4(s,1H)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>13</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>159.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6.4(s,1H)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>16</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>113.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>69.3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>11.2(s,1OH)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>14</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>113.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>11.2(s,1OH)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>17</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>201.7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>41.9</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>15</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>201.7</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>18</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>32.4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>41.7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2.5(s,3H)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>16</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>32.4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2.5(s,3H)</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="7" align="center" rowsep="1"></entry>
</row>
<row>
<entry namest="1" nameend="7" align="left"><PTEXT><FOO ID="FOO-00001"><PTEXT><HIL><SP><PDAT>&agr;</PDAT></SP></HIL><PDAT>carbons are labelled according to their number in the polyketide backbone </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="7" align="left"><PTEXT><FOO ID="FOO-00002"><PTEXT><HIL><SP><PDAT>b</PDAT></SP></HIL><PDAT>NC, not coupled </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<CWU>
<TABLE-US ID="TABLE-US-00004">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0" pgwide="1">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="322pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 4</PDAT></PTEXT></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H and </PDAT><HIL><SP><PDAT>12</PDAT></SP></HIL><PDAT>C NMR data for SEK4 (12) and SEK15 (13)</PDAT><HIL><SP><PDAT>a</PDAT></SP></HIL></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="161pt" align="center"/>
<colspec colname="2" colwidth="161pt" align="center"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>SEK4 (12)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>SEK15 (13)</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="8">
<colspec colname="1" colwidth="28pt" align="center"/>
<colspec colname="2" colwidth="35pt" align="center"/>
<colspec colname="3" colwidth="28pt" align="center"/>
<colspec colname="4" colwidth="70pt" align="left"/>
<colspec colname="5" colwidth="28pt" align="center"/>
<colspec colname="6" colwidth="35pt" align="center"/>
<colspec colname="7" colwidth="28pt" align="center"/>
<colspec colname="8" colwidth="70pt" align="left"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>carbon</PDAT><HIL><SP><PDAT>b</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C&dgr;(ppm)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>J</PDAT><HIL><SB><PDAT>CC</PDAT></SB></HIL><PDAT>(Hz)</PDAT></PTEXT></entry>
<entry><PTEXT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H&dgr;(ppm)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>carbon</PDAT></PTEXT></entry>
<entry><PTEXT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C&dgr;(ppm)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>J</PDAT><HIL><SB><PDAT>CC</PDAT></SB></HIL><PDAT>(Hz)</PDAT></PTEXT></entry>
<entry><PTEXT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H&dgr;(ppm)</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="8" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="8">
<colspec colname="1" colwidth="28pt" align="char" char="."/>
<colspec colname="2" colwidth="35pt" align="char" char="."/>
<colspec colname="3" colwidth="28pt" align="center"/>
<colspec colname="4" colwidth="70pt" align="left"/>
<colspec colname="5" colwidth="28pt" align="char" char="."/>
<colspec colname="6" colwidth="35pt" align="char" char="."/>
<colspec colname="7" colwidth="28pt" align="center"/>
<colspec colname="8" colwidth="70pt" align="left"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT> 1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>165.4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>78.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>11.60(s,1OH)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>164.0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>79.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>12.20(s,1OH)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>88.2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>79.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6.26(d,J&equals;2.28Hz,1H)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>88.2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>79.4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6.20(d,J&equals;1.88 Hz,1H)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>170.5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>55.3</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>172.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>57.9</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>111.3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>61.3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6.33(d,J&equals;2.24 Hz,1H)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>101.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>53.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6.20(d,J&equals;1.88 Hz,1H)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>163.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>51.0</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>163.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>50.4</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>37.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>50.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4.07(d,J&equals;15.7 Hz,1H)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>36.7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>50.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1.90(s,2H)</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>4.16(d,J&equals;16.0 Hz,1H)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>138.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>60.7</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>135.4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>60.7</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>102.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>60.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5.66(d,J&equals;1.6 Hz,1H)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>109.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>61.7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5.66 (s,1H)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>161.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>71.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10.50(s,1OH)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>159.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>66.2</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>70.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5.19(d,J&equals;1.96 Hz,1H)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>101.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>66.5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5.08 (s,1H)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>11</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>162.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>60.8</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>11</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>157.4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>67.3</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>12</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>112.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>61.6</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>12</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>121.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>67.6</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>13</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>191.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>39.1</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>13</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200.3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>58.1</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>14</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>49.3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>39.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2.54(d,J&equals;15.9 Hz,1H)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>14</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>117.2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>58.6</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>4.92(d,J&equals;16.0 Hz,1H)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>15</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>99.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>46.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6.90(s,1OH)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>15</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>163.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>68.5</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>16</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>27.5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>46.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1.56(s,3H)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>16</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>68.0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6.08 (s,1H)</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>17</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>162.2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>62.6</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>18</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>111.0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>62.0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6.12 (s,1H)</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>19</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>141.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>43.3</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>20</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>21.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>42.7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1.86 (s,3H)</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="8" align="center" rowsep="1"></entry>
</row>
<row>
<entry namest="1" nameend="8" align="left"><PTEXT><FOO ID="FOO-00003"><PTEXT><HIL><SP><PDAT>a</PDAT></SP></HIL><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H and </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C NMR&apos;s were recorded in DMSO-d</PDAT><HIL><SB><PDAT>6 </PDAT></SB></HIL><PDAT>(400 MHz for </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H and 100 MHz for </PDAT><HIL><SP><PDAT>13</PDAT></SP></HIL><PDAT>C) </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="8" align="left"><PTEXT><FOO ID="FOO-00004"><PTEXT><HIL><SP><PDAT>b</PDAT></SP></HIL><PDAT>carbons are labelled according to their number in the polyketide backbone </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<CWU>
<TABLE-US ID="TABLE-US-00005">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="6">
<colspec colname="offset" colwidth="14pt" align="left"/>
<colspec colname="1" colwidth="42pt" align="left"/>
<colspec colname="2" colwidth="49pt" align="left"/>
<colspec colname="3" colwidth="28pt" align="left"/>
<colspec colname="4" colwidth="28pt" align="center"/>
<colspec colname="5" colwidth="56pt" align="center"/>
<thead>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="5" rowsep="1"><PTEXT><PDAT>TABLE 5</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="5" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Minimal</PDAT></PTEXT></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Major</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>Plasmid</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>PKS*</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>KR</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcmJ,N</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Product(s)</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="5" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
<entry><PTEXT><PDAT>pSEK21</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;6</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM70</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>J</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;6</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM71</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;6</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM72</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>J,N</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;6</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pSEK23</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM73</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>J</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM74</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM75</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>J,N</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pSEK24</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>12</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM76</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>J</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>12</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM77</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>19</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM78</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>J,N</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>19</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pSEK33</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>13,16</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM79</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>J</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>13,16</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM80</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>20,21</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM81</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>J,N</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>20,21</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="5" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="5" align="left"><PTEXT><FOO ID="FOO-00005"><PTEXT><PDAT>*The minimal PKS contains the ketosynthase/putative acyl transferase, chain length factor, and act acyl carrier protein. </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<CWU>
<TABLE-US ID="TABLE-US-00006">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="7">
<colspec colname="offset" colwidth="14pt" align="left"/>
<colspec colname="1" colwidth="35pt" align="left"/>
<colspec colname="2" colwidth="42pt" align="left"/>
<colspec colname="3" colwidth="21pt" align="left"/>
<colspec colname="4" colwidth="28pt" align="left"/>
<colspec colname="5" colwidth="21pt" align="left"/>
<colspec colname="6" colwidth="56pt" align="center"/>
<thead>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="6" rowsep="1"><PTEXT><PDAT>TABLE 6</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="6" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Minimal</PDAT></PTEXT></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Major</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>Plasmid</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>PKS*</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>KR</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>ARO</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>CYC</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Product</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="6" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
<entry><PTEXT><PDAT>pSEK24</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>12</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pSEK34</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>22</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>28</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pSEK33</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>13</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pSEK23</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>14</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pSEK41</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>gris</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>22</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pSEK42</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>gris</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>22</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pSEK43</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>gris</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>23</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pSEK25</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>28</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pSEK26</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>28/24</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pSEK27</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>14</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM51</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>gris</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>28/24</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM52</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>gris</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>23</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pSEK44</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>gris</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>12</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pSEK45</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>gris</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>13</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pSEK46</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>12</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pSEK47</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fren</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>13</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM53</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>gris</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>12</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>pRM54</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tcm</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>gris</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>act</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>13</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="6" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="6" align="left"><PTEXT><FOO ID="FOO-00006"><PTEXT><PDAT>*The minimal PKS contains the ketosynthase/putative acyl transferase, chain length factor, and act acyl carrier protein. </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<CWU>
<SEQLST-US ID="SEQLST-1">
<SEQ-LST-NEW>
<S100>
<S160>
<PDAT>2</PDAT>
</S160>
</S100>
<S200>
<S210>
<PDAT>1</PDAT>
</S210>
<S211>
<PDAT>42</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Synthetic construct</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 1
ccaccggacg aacgcatcga ttaattaagg aggaccatca tg                        42
</PDAT>
</S400>
<S200>
<S210>
<PDAT>2</PDAT>
</S210>
<S211>
<PDAT>25</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Synthetic construct</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 2
ntgaatgcat ggaggagcca tcatg                                           25
</PDAT>
</S400>
</SEQ-LST-NEW>
</SEQLST-US>
</CWU>
</BTEXT>
</DETDESC>
</SDODE>
<SDOCL>
<H LVL="1"><STEXT><PDAT>What is claimed is: </PDAT></STEXT></H>
<CL>
<CLM ID="CLM-00001">
<PARA ID="P-00247" LVL="0"><PTEXT><PDAT>1. A recombinant expression system which comprises a first nucleotide sequence that encodes modules derived from a native modular polyketide synthase (PKS) encoded by the first nucleotide sequence fused to a second nucleotide sequence downstream thereof which second nucleotide sequence encodes a thioesterase derived from said native PKS, said first and second nucleotide sequences operably linked to control sequences which effect their expression,</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>wherein said modules consist of fewer than the modules natively contained in said native modular PKS, </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>wherein said native modular PKS produces deoxyerythronolide B (6-dEB). </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00002">
<PARA ID="P-00248" LVL="0"><PTEXT><PDAT>2. The expression system of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein the modules encoded by the first nucleotide sequence consist of a single open reading frame of said modular 6-dEB PKS.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00003">
<PARA ID="P-00249" LVL="0"><PTEXT><PDAT>3. The expression system of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein the modules encoded by the first nucleotide sequence consist of one less than the complete number of modules contained in said native 6-dEB PKS.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00004">
<PARA ID="P-00250" LVL="0"><PTEXT><PDAT>4. The expression system of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein the modules encoded by the first nucleotide sequence consist of modules 1 and 2 of said 6-dEB PKS.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00005">
<PARA ID="P-00251" LVL="0"><PTEXT><PDAT>5. The expression system of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein the modules encoded by the first nucleotide sequence consist of modules 1-5 of said 6-dEB PKS.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00006">
<PARA ID="P-00252" LVL="0"><PTEXT><PDAT>6. Recombinant host cells modified to contain the expression system of any of claims </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT> and </PDAT><HIL><BOLD><PDAT>4</PDAT></BOLD></HIL><PDAT>-</PDAT><HIL><BOLD><PDAT>5</PDAT></BOLD></HIL><PDAT>.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00007">
<PARA ID="P-00253" LVL="0"><PTEXT><PDAT>7. A method to produce a functional PKS containing less than the number of modules contained in the native form of said PKS which method comprises culturing the cells of </PDAT><CLREF ID="CLM-00006"><PDAT>claim 6</PDAT></CLREF><PDAT> under conditions wherein said PKS is produced.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00008">
<PARA ID="P-00254" LVL="0"><PTEXT><PDAT>8. A method to prepare a recombinant expression system for production of a PKS containing less than the number of modules than a native modular PKS from which it is derived which method comprises modifying the nucleotide sequence encoding said native modular PKS so as to fuse a first nucleotide sequence that encodes fewer than the modules natively contained in said native modular PKS to a second nucleotide sequence which second nucleotide sequence encodes the thioesterase of said native modular PKS wherein said first and second nucleotide sequences are operably linked to control sequences which effect their expression;</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>wherein said native modular PKS produces 6-dEB. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00009">
<PARA ID="P-00255" LVL="0"><PTEXT><PDAT>9. The method of </PDAT><CLREF ID="CLM-00008"><PDAT>claim 8</PDAT></CLREF><PDAT>, wherein the modules encoded by the first nucleotide sequence consist of a single open reading frame of said 6-dEB PKS.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00010">
<PARA ID="P-00256" LVL="0"><PTEXT><PDAT>10. The expression system of </PDAT><CLREF ID="CLM-00008"><PDAT>claim 8</PDAT></CLREF><PDAT>, wherein the modules encoded by the first nucleotide sequence consist of one less than the complete number of modules contained in said native 6-dEB PKS.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00011">
<PARA ID="P-00257" LVL="0"><PTEXT><PDAT>11. The method of </PDAT><CLREF ID="CLM-00008"><PDAT>claim 8</PDAT></CLREF><PDAT>, wherein the modules encoded by the first nucleotide sequence consist of modules 1 and 2 of said 6-dEB PKS.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00012">
<PARA ID="P-00258" LVL="0"><PTEXT><PDAT>12. The method of </PDAT><CLREF ID="CLM-00008"><PDAT>claim 8</PDAT></CLREF><PDAT>, wherein the modules encoded by the first nucleotide sequence consist of modules 1-5 of said 6-dEB PKS.</PDAT></PTEXT></PARA>
</CLM>
</CL>
</SDOCL>
<SDODR ID="DRAWINGS">
<EMI ID="EMI-D00001" ALT="embedded image" FILE="US06461838-20021008-D00001.TIF"/>
<EMI ID="EMI-D00002" ALT="embedded image" FILE="US06461838-20021008-D00002.TIF"/>
<EMI ID="EMI-D00003" ALT="embedded image" FILE="US06461838-20021008-D00003.TIF"/>
<EMI ID="EMI-D00004" ALT="embedded image" FILE="US06461838-20021008-D00004.TIF"/>
<EMI ID="EMI-D00005" ALT="embedded image" FILE="US06461838-20021008-D00005.TIF"/>
<EMI ID="EMI-D00006" ALT="embedded image" FILE="US06461838-20021008-D00006.TIF"/>
<EMI ID="EMI-D00007" ALT="embedded image" FILE="US06461838-20021008-D00007.TIF"/>
<EMI ID="EMI-D00008" ALT="embedded image" FILE="US06461838-20021008-D00008.TIF"/>
<EMI ID="EMI-D00009" ALT="embedded image" FILE="US06461838-20021008-D00009.TIF"/>
<EMI ID="EMI-D00010" ALT="embedded image" FILE="US06461838-20021008-D00010.TIF"/>
<EMI ID="EMI-D00011" ALT="embedded image" FILE="US06461838-20021008-D00011.TIF"/>
<EMI ID="EMI-D00012" ALT="embedded image" FILE="US06461838-20021008-D00012.TIF"/>
<EMI ID="EMI-D00013" ALT="embedded image" FILE="US06461838-20021008-D00013.TIF"/>
<EMI ID="EMI-D00014" ALT="embedded image" FILE="US06461838-20021008-D00014.TIF"/>
<EMI ID="EMI-D00015" ALT="embedded image" FILE="US06461838-20021008-D00015.TIF"/>
<EMI ID="EMI-D00016" ALT="embedded image" FILE="US06461838-20021008-D00016.TIF"/>
<EMI ID="EMI-D00017" ALT="embedded image" FILE="US06461838-20021008-D00017.TIF"/>
<EMI ID="EMI-D00018" ALT="embedded image" FILE="US06461838-20021008-D00018.TIF"/>
<EMI ID="EMI-D00019" ALT="embedded image" FILE="US06461838-20021008-D00019.TIF"/>
<EMI ID="EMI-D00020" ALT="embedded image" FILE="US06461838-20021008-D00020.TIF"/>
<EMI ID="EMI-D00021" ALT="embedded image" FILE="US06461838-20021008-D00021.TIF"/>
<EMI ID="EMI-D00022" ALT="embedded image" FILE="US06461838-20021008-D00022.TIF"/>
<EMI ID="EMI-D00023" ALT="embedded image" FILE="US06461838-20021008-D00023.TIF"/>
<EMI ID="EMI-D00024" ALT="embedded image" FILE="US06461838-20021008-D00024.TIF"/>
<EMI ID="EMI-D00025" ALT="embedded image" FILE="US06461838-20021008-D00025.TIF"/>
<EMI ID="EMI-D00026" ALT="embedded image" FILE="US06461838-20021008-D00026.TIF"/>
</SDODR>
</PATDOC>

<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PATDOC SYSTEM "ST32-US-Grant-025xml.dtd" [
<!ENTITY US06462849-20021008-M00001.NB SYSTEM "US06462849-20021008-M00001.NB" NDATA NB>
<!ENTITY US06462849-20021008-M00001.TIF SYSTEM "US06462849-20021008-M00001.TIF" NDATA TIF>
<!ENTITY US06462849-20021008-M00002.NB SYSTEM "US06462849-20021008-M00002.NB" NDATA NB>
<!ENTITY US06462849-20021008-M00002.TIF SYSTEM "US06462849-20021008-M00002.TIF" NDATA TIF>
<!ENTITY US06462849-20021008-M00003.NB SYSTEM "US06462849-20021008-M00003.NB" NDATA NB>
<!ENTITY US06462849-20021008-M00003.TIF SYSTEM "US06462849-20021008-M00003.TIF" NDATA TIF>
<!ENTITY US06462849-20021008-D00000.TIF SYSTEM "US06462849-20021008-D00000.TIF" NDATA TIF>
<!ENTITY US06462849-20021008-D00001.TIF SYSTEM "US06462849-20021008-D00001.TIF" NDATA TIF>
<!ENTITY US06462849-20021008-D00002.TIF SYSTEM "US06462849-20021008-D00002.TIF" NDATA TIF>
<!ENTITY US06462849-20021008-D00003.TIF SYSTEM "US06462849-20021008-D00003.TIF" NDATA TIF>
<!ENTITY US06462849-20021008-D00004.TIF SYSTEM "US06462849-20021008-D00004.TIF" NDATA TIF>
]>
<PATDOC DTD="2.5" STATUS="Build 20020918">
<SDOBI>
<B100>
<B110><DNUM><PDAT>06462849</PDAT></DNUM></B110>
<B130><PDAT>B1</PDAT></B130>
<B140><DATE><PDAT>20021008</PDAT></DATE></B140>
<B190><PDAT>US</PDAT></B190>
</B100>
<B200>
<B210><DNUM><PDAT>09151387</PDAT></DNUM></B210>
<B211US><PDAT>09</PDAT></B211US>
<B220><DATE><PDAT>19980910</PDAT></DATE></B220>
</B200>
<B500>
<B510>
<B511><PDAT>H04B 1000</PDAT></B511>
<B516><PDAT>7</PDAT></B516>
</B510>
<B520>
<B521><PDAT>359161</PDAT></B521>
<B522><PDAT>385 24</PDAT></B522>
</B520>
<B540><STEXT><PDAT>Optimizing launch points for dispersion-managed solitons</PDAT></STEXT></B540>
<B560>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5140656</PDAT></DNUM>
<DATE><PDAT>19920800</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Hasegawa et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>385 24</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5471333</PDAT></DNUM>
<DATE><PDAT>19951100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Taga et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>359173</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5504829</PDAT></DNUM>
<DATE><PDAT>19960400</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Evans et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>385123</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5508845</PDAT></DNUM>
<DATE><PDAT>19960400</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Frisken</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>359161</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5559920</PDAT></DNUM>
<DATE><PDAT>19960900</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Chraplyvy et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>385123</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5574590</PDAT></DNUM>
<DATE><PDAT>19961100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Edagawa et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>359179</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5612808</PDAT></DNUM>
<DATE><PDAT>19970300</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Audouin et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>359161</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5642215</PDAT></DNUM>
<DATE><PDAT>19970600</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Suzuki et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>359161</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5737460</PDAT></DNUM>
<DATE><PDAT>19980400</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Damen et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>385 24</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5877879</PDAT></DNUM>
<DATE><PDAT>19990300</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Naito</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>359161 X</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6137604</PDAT></DNUM>
<DATE><PDAT>20001000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Bergano</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>359124</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>13588</PDAT></DNUM>
<DATE><PDAT>19990300</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-EXAMINER/>
</B561>
<B562><NCIT><STEXT><PDAT>Devaney Et Al., &ldquo;WDM of Enhanced Power Solitons in Strongly Dispersion-Managed Systems&rdquo;, Conference on Optical Fiber Communications Technical Digest, vol. 6, Feb. 1997.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Yang Et Al., &ldquo;Optimal Dispersion Maps for Wavelength-Division-Multiplexed Soliton-Transmission&rdquo;, Optics Letters, vol. 23, No. 8, pp. 597-599, Apr. 1998.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Charbonnier et al., Continuum Generated by Chromatic Dispersion and Power Variations in Periodically Amplified Solition Links. </PDAT><HIL><ITALIC><PDAT>Optics Letters, </PDAT></ITALIC></HIL><PDAT>(1996) vol. 21, No. 16, p. 1232-1234. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Charbonnier et al., Reduction of the Dispersive Wave in Periodically Amplified Links with Initially Chirped Solutions. </PDAT><HIL><ITALIC><PDAT>IEEE Photonics Technology Letters, </PDAT></ITALIC></HIL><PDAT>(1997) vol. 9, No. 1, p. 127-129. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kodama et al., Optimal Design of Dispersion Management for a Solition-Wavelength-Division-Multiplexed System. </PDAT><HIL><ITALIC><PDAT>Optic Letters, </PDAT></ITALIC></HIL><PDAT>(1997) vol. 22, No. 22, pp. 1692-1694. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Guen et al. 200Gbit/s 100km-span Soliton WDM Transmission over 1000 km of Standard Fiber with Dispersion Compensation and Pre-Chirping. Optical Fiber Communications Conf., (1997) Post Deadline Paper, p. PD17-1-PD17-3. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Wald et al., Optimization of Soliton Transmission in Dispersion-Managed Fibers Links, </PDAT><HIL><ITALIC><PDAT>Optics Cummunications, </PDAT></ITALIC></HIL><PDAT>145 (1998) 48-52.</PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
</B560>
<B570>
<B577><PDAT>9</PDAT></B577>
<B578US><PDAT>1</PDAT></B578US>
</B570>
<B580>
<B582><PDAT>359124</PDAT></B582>
<B582><PDAT>359161</PDAT></B582>
<B582><PDAT>359173</PDAT></B582>
<B582><PDAT>359179</PDAT></B582>
<B582><PDAT>385 24</PDAT></B582>
<B582><PDAT>385 27</PDAT></B582>
<B582><PDAT>385 31</PDAT></B582>
<B582><PDAT>385115</PDAT></B582>
<B582><PDAT>385122</PDAT></B582>
<B582><PDAT>385123</PDAT></B582>
<B582><PDAT>372  6</PDAT></B582>
</B580>
<B590><B595><PDAT>4</PDAT></B595><B596><PDAT>4</PDAT></B596><B597US/>
</B590>
</B500>
<B700>
<B720>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>William L.</PDAT></FNM><SNM><STEXT><PDAT>Kath</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Evanston</PDAT></CITY>
<STATE><PDAT>IL</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Tian-Siang</PDAT></FNM><SNM><STEXT><PDAT>Yang</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Evanston</PDAT></CITY>
<STATE><PDAT>IL</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Sergei K.</PDAT></FNM><SNM><STEXT><PDAT>Turitsyn</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Dusseldorf</PDAT></CITY>
<CTRY><PDAT>DE</PDAT></CTRY>
</ADR>
</PARTY-US>
</B721>
</B720>
<B730>
<B731>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Northwestern University</PDAT></STEXT></ONM></NAM>
<ADR><CITY><PDAT>Evanston</PDAT></CITY><STATE><PDAT>IL</PDAT></STATE></ADR>
</PARTY-US>
</B731>
<B732US>
<PDAT>02</PDAT>
</B732US>
</B730>
<B740>
<B741>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Welsh &amp; Katz. Ltd.</PDAT></STEXT></ONM></NAM>
</PARTY-US>
</B741>
</B740>
<B745>
<B746>
<PARTY-US>
<NAM><FNM><PDAT>Thomas</PDAT></FNM><SNM><STEXT><PDAT>Mullen</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B746>
<B748US><PDAT>2632</PDAT></B748US>
</B745>
</B700>
</SDOBI>
<SDOAB>
<BTEXT>
<PARA ID="P-00001" LVL="0"><PTEXT><PDAT>There is described an asymptotic theory for predicting the evolution of dispersion-managed solitons with loss and gain. Optimal launch points for dispersion-managed solitons where the pulses do not need to be prechirped can be readily located. Numerical results demonstrate that launching the pulses with proper phase chirp and power significantly reduces pulse amplitude and width oscillations and the amount of dispersive radiation, without regard to wavelength.</PDAT></PTEXT></PARA>
</BTEXT>
</SDOAB>
<SDODE>
<GOVINT>
<BTEXT>
<PARA ID="P-00002" LVL="0"><PTEXT><PDAT>This invention is made with government support under Grant No. F49620-97-1-0008 awarded by the Air Force Office of Scientific Research (Air Force Materials Command, USAF) and Grant No. DMS-9500615 awarded by the National Science Foundation. The government has certain rights in the invention.</PDAT></PTEXT></PARA>
</BTEXT>
</GOVINT>
<BRFSUM>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BACKGROUND OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00003" LVL="0"><PTEXT><PDAT>The present invention relates to a transmission system using optical fibers and, more particularly, to a long-distance, large-capacity optical transmission system employing return-to-zero lightwave pulses, such as soliton lightwave pulses, and optical amplifiers.</PDAT></PTEXT></PARA>
<PARA ID="P-00004" LVL="0"><PTEXT><PDAT>With the development of optical amplifying techniques, optical fiber communication technology has made rapid-paced progress toward ultra-long-distance communication, now allowing implementation of a long-range communication system without the need of using regenerative repeaters. At increased transmission rates, however, conventional transmission systems suffer serious degradation of their transmission characteristics caused by the wavelength dispersion and nonlinear effect of optical fibers, imposing severe limitations on the realization of a high-speed, high-capacity transmission system.</PDAT></PTEXT></PARA>
<PARA ID="P-00005" LVL="0"><PTEXT><PDAT>Usually, when lightwave pulses are transmitted over an optical fiber, their pulse width broadens by the wavelength dispersion characteristic of the optical fiber owing to the frequency spread inherent in data-modulated lightwave pulses. The freedom of a soliton lightwave signal from variation in its pulse waveform by transmission is achieved when the pulse width compression, caused by frequency chirping of the lightwave pulses owing to optical nonlinearities of the optical fiber forming the transmission line, balances with the aforementioned pulse width broadening. To accomplish an optical soliton transmission which maintains the above-mentioned balance and is substantially free from variations in the lightwave pulse waveform, it is necessary that the zero dispersion wavelength of the transmission line be shorter than the wavelength of the lightwave signal to hold a desired (anomalous) wavelength dispersion characteristic.</PDAT></PTEXT></PARA>
<PARA ID="P-00006" LVL="0"><PTEXT><PDAT>In an optical soliton transmission which is generally free from waveform degradation by transmission, timing jitter brought about by various causes during transmission is a main factor determining the transmission characteristic, along with degradation of the signal to noise ratio by accumulated optical noises. The Gordon-Haus jitter forms a main part of such timing jitter. In an optically amplified transmission system, the optical soliton carrier frequency which randomly fluctuates due to optical noises produced by optical repeater-amplifiers, is converted mainly by the wavelength dispersion characteristic of the fiber optic transmission line into fluctuations in the system. The Gordon-Haus jitter increases with distance and, hence, exerts a great influence on long-distance soliton transmission. The pulse spacing reduced by the Gordon-Haus jitter also increases the interaction between adjacent optical soliton pulses, newly causing timing jitter. Thus, the Gordon-Haus jitter is an important problem which must be solved in order to transmit long distances.</PDAT></PTEXT></PARA>
<PARA ID="P-00007" LVL="0"><PTEXT><PDAT>Since the amount of Gordon-Haus jitter is proportional to the group-velocity dispersion present in the transmission line, decreasing the fiber&apos;s average dispersion reduces the timing jitter. This leads to additional complications, however, as distortions due to four-wave mixing become more pronounced at low dispersion values.</PDAT></PTEXT></PARA>
<PARA ID="P-00008" LVL="0"><PTEXT><PDAT>Dispersion management has proven to be an effective technique to reduce both effects simultaneously. The idea of dispersion management is to concatenate fibers of both normal and anomalous dispersion to form a transmission line having both a high local group-velocity dispersion (GVD) and a low path-averaged GVD. This is beneficial since high local dispersion significantly reduces the efficiency of four-wave mixing, decreasing both the modulational instability gain and bandwidth. In addition, lowering the average dispersion also reduces the Gordon-Haus timing jitter of soliton transmission systems. Furthermore, dispersion management has been found to enhance the soliton energy; this additionally reduces the timing jitter below the amount that would be obtained in a system with constant dispersion equal to the path-averaged value.</PDAT></PTEXT></PARA>
<PARA ID="P-00009" LVL="0"><PTEXT><PDAT>In high-rate terrestrial soliton transmission systems, intersymbol interference produced by the generation of dispersive waves (or, continuum radiation) shed by propagating pulses is a major limitation. It is therefore important to diminish the shedding of energy from the input pulse into a dispersive pedestal, which can be achieved by launching properly shaped and chirped pulses with optimum power into the fiber. In practice, typical optical sources generate unchirped pulses and input pulse chirping is realized by using an additional piece of fiber preceding the beginning of the transmission line. It is therefore convenient to identify points in each dispersion-map period where pulses are naturally unchirped, and use one such location as the launch point. The partial map period preceding the first complete map period then plays the role of the prechirping fiber.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SUMMARY OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00010" LVL="0"><PTEXT><PDAT>Therefore, an object of the subject invention is an efficient, fiber-optic communication system.</PDAT></PTEXT></PARA>
<PARA ID="P-00011" LVL="0"><PTEXT><PDAT>A further object of the subject invention is a manner of optimizing a dispersion map for use in decreasing dispersive radiation in a fiber-optic system.</PDAT></PTEXT></PARA>
<PARA ID="P-00012" LVL="0"><PTEXT><PDAT>These and other objects are attained by the subject invention, which includes dispersion maps with zero-chirp point positions independent of the dispersion values of the types of fiber comprising the map. A zero-chirp point can be used as a special launching point for optical pulses; the subsequent evolution of the pulses is much cleaner than if other launching points are used since there is less dispersive radiation shed by the pulse as it evolves. Because these optimized dispersion maps identify zero-chirp launching points which are independent of the dispersion values of the types of fiber comprising the map, the launching points are, therefore, also independent of the wavelength since the second-order dispersion varies with wavelength. As a result, such a dispersion map allows minimal shedding of dispersive radiation at several frequencies simultaneously, a situation that is ideal for wavelength-division-multiplexing. With this optimized map, one need only choose the appropriate length of the fiber segments, locate the zero chirp point, and cut the combined fiber segments at the zero-chirp point location to form an optimal prechirping fiber. Optimum lengths are chosen by using a theoretical estimate for the imbalance between the effects of the group velocity dispersion and nonlinear index of refraction.</PDAT></PTEXT></PARA>
</BTEXT>
</BRFSUM>
<DRWDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BRIEF DESCRIPTION OF THE DRAWINGS</PDAT></STEXT></H>
<PARA ID="P-00013" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT> is a dispersion profile of a lightwave system which uses dispersion management.</PDAT></PTEXT></PARA>
<PARA ID="P-00014" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> is a pulse profile showing the reduction in the amount of dispersive radiation shed when a zero-chirp launch point is used (solid and dashed lines) versus other launching points (dot-dashed lines and long dashed lines).</PDAT></PTEXT></PARA>
<PARA ID="P-00015" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> is a chirp produced in a dispersion managed system showing the local imbalance between linear dispersion and the nonlinear refractive index.</PDAT></PTEXT></PARA>
<PARA ID="P-00016" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT> is a pulse profile showing that the reduction in the amount of dispersive radiation shed can be optimized at two different frequencies when a specially-chosen dispersion map is used (solid and dashed lines) versus other launching points (dot-dashed lines and long dashed lines).</PDAT></PTEXT></PARA>
</BTEXT>
</DRWDESC>
<DETDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>DESCRIPTION OF THE PREFERRED EMBODIMENTS</PDAT></STEXT></H>
<PARA ID="P-00017" LVL="0"><PTEXT><PDAT>It is fundamental that any signal must have more than one frequency present in order to carry information. Dispersion is the effect that occurs when the propagation speed is dependent upon frequency; this process tends to break up signals and can pose a severe limitation upon the information capacity of optical communication systems. There are several techniques that have been proposed to alleviate this difficulty. For traditional, low-intensity information encoding schemes, it is possible to work near the zero-dispersion point of optical fibers (at either 1.3 microns for standard single mode fiber or 1.5 microns for dispersion shifted fiber). Near the zero dispersion point, however, other effects such as four-wave mixing tend to degrade the signal. In such situations, dispersion management can be particularly helpful.</PDAT></PTEXT></PARA>
<PARA ID="P-00018" LVL="0"><PTEXT><PDAT>Another technique to alleviate the effects of dispersion is to encode the information using optical solitons. Optical solitons exploit the intensity-dependent index of refraction to compensate the dispersion. Essentially, the intensity-dependent refractive index produces an intensity-dependent pulse phase velocity, which can compensate for the frequency-dependent velocity produced by the group velocity dispersion. In this way, it is possible in theory to produce an optical pulse which can propagate for thousands of kilometers without significant distortion in an optically amplified transmission system.</PDAT></PTEXT></PARA>
<PARA ID="P-00019" LVL="0"><PTEXT><PDAT>In practice, other effects such as four-wave mixing also distort solitons and degrade the performance of systems employing them. Dispersion management has been shown to significantly improve the performance of soliton-based communication systems. Dispersion management arises when fibers with different dispersion parameters are concatenated to form a transmission line that has both low path-averaged group velocity dispersion and high local group velocity dispersion, as shown in FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00020" LVL="0"><PTEXT><PDAT>Optimizing dispersion managed systems is also desirable. In high bit-rate terrestrial soliton communication systems, for example, the generation of dispersive radiation by non-ideal starting conditions imposes a limit on the amplifier spacing. It is beneficial, therefore, to minimize the amount of dispersive radiation by either pre-chirping the pulses or by launching the pulses at the zero-chirp point of the dispersion map as shown in FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00021" LVL="0"><PTEXT><PDAT>The chirp can be explained as an imbalance between the phase advance produced by the nonlinear index of refraction and the linear dispersion. In a dispersion-managed soliton, these balance on average, but in one part of the fiber the dispersion will be too small and the nonlinear index will dominate, while in another part of the fiber the dispersion will be larger and will dominate. An example of this is shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3. A</PDAT></FGREF><PDAT> zero-chirp point is a point at which the accumulations of the two effects are locally balanced.</PDAT></PTEXT></PARA>
<PARA ID="P-00022" LVL="0"><PTEXT><PDAT>One difficulty of using such dispersion maps is when one considers wavelength-division-multiplexed (WDM) systems. WDM systems employ two or more channels operating at different wavelengths to increase the total system capacity. Since the group-velocity dispersion parameter of an optical fiber depends upon wavelength or frequency, this means that a dispersion map&apos;s parameters will be different for each channel. This can necessitate independently adjusting and modulating each channel&apos;s laser transmitter to pre-chirp each channel to compensate for the differences.</PDAT></PTEXT></PARA>
<PARA ID="P-00023" LVL="0"><PTEXT><PDAT>A dispersion map constructed according to the subject invention renders the zero-chirp locations independent of the dispersion values of the two types of fiber comprising the map, thus making the ideal launching points independent of frequency. Such special dispersion maps allow the amount of dispersive radiation shed by solitons in a WDM system to be reduced simultaneously over a range of frequencies without independent external adjustment or modulation, as shown in FIG. </PDAT><HIL><BOLD><PDAT>4</PDAT></BOLD></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00024" LVL="0"><PTEXT><PDAT>The design of such an optimized map follows by choosing the lengths of the fiber segments appropriately. The optimum lengths are chosen by using a theoretical estimate for the imbalance between the effects of the group velocity dispersion and nonlinear index of refraction and noting that when a particular ratio of lengths is chosen the result becomes independent of the group velocity dispersion of the fibers.</PDAT></PTEXT></PARA>
<PARA ID="P-00025" LVL="0"><PTEXT><PDAT>Recent laboratory and numerical experiments have demonstrated that dispersion management significantly improves soliton transmission system performance. This is mainly because concatenating fibers of both anomalous and normal dispersion to form a transmission line produces both a low path-averaged group-velocity dispersion (GVD) and a high local GVD; Gordon-Haus timing jitter and the four-wave mixing efficiency can then be reduced simultaneously. Considerable work has been devoted to understanding the potential performance gains to be obtained with dispersion-managed solitons and the optimization of systems employing them. System optimization involves many practical factors and is, therefore, a rather complicated issue. One important fact, however, is that pulses launched into the fiber should be properly shaped and chirped to minimize the shedding of dispersive radiation. From a practical point of view, of course, it is preferable to eliminate the need for pulse prechirping.</PDAT></PTEXT></PARA>
<PARA ID="P-00026" LVL="0"><PTEXT><PDAT>Generally, for a two-step dispersion map, dispersion-managed solitons in lossless fibers are unchirped at the midpoints of the fiber segments. In realistic systems, of course, pulses need to be amplified repeatedly due to fiber loss. A good understanding of the effects of various amplification schemes on the dynamics of dispersion-managed solitons is, therefore, very useful. The subject analytic approach is suitable for cases where there are a finite number of amplifiers in each dispersion-map period. The goal is to locate the optimal launch points for dispersion-managed solitons where no pulse prechirping is needed.</PDAT></PTEXT></PARA>
<PARA ID="P-00027" LVL="0"><PTEXT><PDAT>Pulse evolution in dispersion-managed optical fibers with loss and gain is governed by the nonlinear Schr&ouml;dinger equation: </PDAT>
<CWU>
<MATH-US ID="MATH-US-00001">
<MATHEMATICA ID="MATHEMATICA-00001" ALT="mathematica file" FILE="US06462849-20021008-M00001.NB"/>
<MATHML>
<math>
<mtable>
  <mtr>
    <mtd>
      <mrow>
        <mrow>
          <mrow>
            <mi>i</mi>
            <mo>&it;</mo>
            <mfrac>
              <mrow>
                <mo>&PartialD;</mo>
                <mi>u</mi>
              </mrow>
              <mrow>
                <mo>&PartialD;</mo>
                <mi>x</mi>
              </mrow>
            </mfrac>
          </mrow>
          <mo>-</mo>
          <mrow>
            <mfrac>
              <mn>1</mn>
              <mn>2</mn>
            </mfrac>
            <mo>&it;</mo>
            <mi>&sigma;</mi>
            <mo>&it;</mo>
            <mstyle>
              <mtext>&emsp;</mtext>
            </mstyle>
            <mo>&it;</mo>
            <mrow>
              <mo>(</mo>
              <mfrac>
                <mi>z</mi>
                <mi>&varepsilon;</mi>
              </mfrac>
              <mo>)</mo>
            </mrow>
            <mo>&it;</mo>
            <mfrac>
              <mrow>
                <msup>
                  <mo>&PartialD;</mo>
                  <mn>2</mn>
                </msup>
                <mo>&it;</mo>
                <mi>u</mi>
              </mrow>
              <mrow>
                <mo>&PartialD;</mo>
                <msup>
                  <mi>t</mi>
                  <mn>2</mn>
                </msup>
              </mrow>
            </mfrac>
          </mrow>
          <mo>+</mo>
          <mrow>
            <mrow>
              <mi>g</mi>
              <mo>&af;</mo>
              <mrow>
                <mo>(</mo>
                <mfrac>
                  <mi>z</mi>
                  <mi>&varepsilon;</mi>
                </mfrac>
                <mo>)</mo>
              </mrow>
            </mrow>
            <mo>&it;</mo>
            <msup>
              <mrow>
                <mo>&LeftBracketingBar;</mo>
                <mi>u</mi>
                <mo>&RightBracketingBar;</mo>
              </mrow>
              <mn>2</mn>
            </msup>
            <mo>&it;</mo>
            <mi>u</mi>
          </mrow>
        </mrow>
        <mo>=</mo>
        <mn>0</mn>
      </mrow>
    </mtd>
    <mtd>
      <mrow>
        <mo>(</mo>
        <mn>1</mn>
        <mo>)</mo>
      </mrow>
    </mtd>
  </mtr>
</mtable>
</math>
</MATHML>
<EMI ID="EMI-M00001" ALT="embedded image" FILE="US06462849-20021008-M00001.TIF"/>
</MATH-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00028" LVL="7"><PTEXT><PDAT>We apply a perturbation method in the limit when &egr;</PDAT><HIL><SB><PDAT>&egr;</PDAT></SB></HIL><PDAT> the ratio of the dispersion map period to the soliton dispersion length, is small in order to evaluate the local imbalance between the effects of dispersion and the nonlinear index of refraction (also known as self-phase modulation). From the explicit formula obtained, the positions may be calculated at which the local imbalance is zero and, thus, where the pulse is locally chirp-free.</PDAT></PTEXT></PARA>
<PARA ID="P-00029" LVL="0"><PTEXT><PDAT>Assuming that the group-velocity dispersion parameter of the segment after (before) the amplifier is &sgr;</PDAT><HIL><SB><PDAT>1 </PDAT></SB></HIL><PDAT>(&sgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>), that the ratio of the first (second) segment length l</PDAT><HIL><SB><PDAT>1 </PDAT></SB></HIL><PDAT>(l</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>) to the map&apos;s period l is &zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&equals;l</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>/l(&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&equals;l</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>/l&equals;1&minus;&zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>), that the path-averaged group-velocity dispersion has been normalized to be &minus;1, and that the amplifier gain is G&equals;exp(</PDAT><HIL><SB><PDAT>&agr;</PDAT></SB></HIL><PDAT>l) where </PDAT><HIL><SB><PDAT>&agr;</PDAT></SB></HIL><PDAT> is the fiber loss, we find that the distance between the amplifier and a chirp-free point on the segment after the amplifier, &zgr;</PDAT><HIL><SB><PDAT>a</PDAT></SB></HIL><PDAT>, can be determined as the solution of </PDAT>
<CWU>
<MATH-US ID="MATH-US-00002">
<MATHEMATICA ID="MATHEMATICA-00002" ALT="mathematica file" FILE="US06462849-20021008-M00002.NB"/>
<MATHML>
<math>
<mtable>
  <mtr>
    <mtd>
      <mrow>
        <mrow>
          <mrow>
            <mn>1</mn>
            <mo>+</mo>
            <msub>
              <mi>&sigma;</mi>
              <mn>1</mn>
            </msub>
          </mrow>
          <mo>=</mo>
          <mfrac>
            <mrow>
              <mrow>
                <mn>2</mn>
                <mo>&it;</mo>
                <mstyle>
                  <mtext>&emsp;</mtext>
                </mstyle>
                <mo>&it;</mo>
                <mi>&Lambda;</mi>
                <mo>&it;</mo>
                <mstyle>
                  <mtext>&emsp;</mtext>
                </mstyle>
                <mo>&it;</mo>
                <mi>G</mi>
                <mo>&it;</mo>
                <mstyle>
                  <mtext>&emsp;</mtext>
                </mstyle>
                <mo>&it;</mo>
                <mrow>
                  <mi>exp</mi>
                  <mo>&af;</mo>
                  <mrow>
                    <mo>(</mo>
                    <mrow>
                      <mrow>
                        <mo>-</mo>
                        <mn>2</mn>
                      </mrow>
                      <mo>&it;</mo>
                      <mi>&Lambda;</mi>
                      <mo>&it;</mo>
                      <mstyle>
                        <mtext>&emsp;</mtext>
                      </mstyle>
                      <mo>&it;</mo>
                      <msub>
                        <mi>&zeta;</mi>
                        <mn>1</mn>
                      </msub>
                      <mo>&it;</mo>
                      <mi>d</mi>
                    </mrow>
                    <mo>)</mo>
                  </mrow>
                </mrow>
              </mrow>
              <mo>+</mo>
              <mrow>
                <mrow>
                  <mo>(</mo>
                  <mrow>
                    <mrow>
                      <mn>2</mn>
                      <mo>&it;</mo>
                      <mi>&Lambda;</mi>
                      <mo>&it;</mo>
                      <mstyle>
                        <mtext>&emsp;</mtext>
                      </mstyle>
                      <mo>&it;</mo>
                      <msub>
                        <mi>&zeta;</mi>
                        <mn>1</mn>
                      </msub>
                      <mo>&it;</mo>
                      <mstyle>
                        <mtext>&emsp;</mtext>
                      </mstyle>
                      <mo>&it;</mo>
                      <mi>d</mi>
                    </mrow>
                    <mo>-</mo>
                    <mn>1</mn>
                    <mo>-</mo>
                    <mi>&Lambda;</mi>
                  </mrow>
                  <mo>)</mo>
                </mrow>
                <mo>&it;</mo>
                <mrow>
                  <mo>(</mo>
                  <mrow>
                    <mi>G</mi>
                    <mo>-</mo>
                    <mn>1</mn>
                  </mrow>
                  <mo>)</mo>
                </mrow>
              </mrow>
            </mrow>
            <mrow>
              <mrow>
                <mn>2</mn>
                <mo>&it;</mo>
                <mi>&Lambda;</mi>
                <mo>&it;</mo>
                <mstyle>
                  <mtext>&emsp;</mtext>
                </mstyle>
                <mo>&it;</mo>
                <msub>
                  <mi>&zeta;</mi>
                  <mn>1</mn>
                </msub>
                <mo>&it;</mo>
                <mrow>
                  <mi>d</mi>
                  <mo>&af;</mo>
                  <mrow>
                    <mo>(</mo>
                    <mrow>
                      <mi>G</mi>
                      <mo>-</mo>
                      <mn>1</mn>
                    </mrow>
                    <mo>)</mo>
                  </mrow>
                </mrow>
              </mrow>
              <mo>-</mo>
              <mi>G</mi>
              <mo>+</mo>
              <mrow>
                <mrow>
                  <mo>[</mo>
                  <mrow>
                    <mrow>
                      <mi>exp</mi>
                      <mo>&af;</mo>
                      <mrow>
                        <mo>(</mo>
                        <mrow>
                          <mn>2</mn>
                          <mo>&it;</mo>
                          <mi>&Lambda;</mi>
                          <mo>&it;</mo>
                          <mstyle>
                            <mtext>&emsp;</mtext>
                          </mstyle>
                          <mo>&it;</mo>
                          <msub>
                            <mi>&zeta;</mi>
                            <mn>2</mn>
                          </msub>
                        </mrow>
                        <mo>)</mo>
                      </mrow>
                    </mrow>
                    <mo>-</mo>
                    <msub>
                      <mi>&zeta;</mi>
                      <mn>1</mn>
                    </msub>
                  </mrow>
                  <mo>]</mo>
                </mrow>
                <mo>/</mo>
                <msub>
                  <mi>&zeta;</mi>
                  <mn>2</mn>
                </msub>
              </mrow>
            </mrow>
          </mfrac>
        </mrow>
        <mo>,</mo>
      </mrow>
    </mtd>
    <mtd>
      <mrow>
        <mo>(</mo>
        <mn>2</mn>
        <mo>)</mo>
      </mrow>
    </mtd>
  </mtr>
</mtable>
</math>
</MATHML>
<EMI ID="EMI-M00002" ALT="embedded image" FILE="US06462849-20021008-M00002.TIF"/>
</MATH-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00030" LVL="7"><PTEXT><PDAT>where d&equals;&zgr;</PDAT><HIL><SB><PDAT>a</PDAT></SB></HIL><PDAT>/&zgr;</PDAT><HIL><SB><PDAT>1 </PDAT></SB></HIL><PDAT>(0&lt;d&lt;1) and &Lgr;&equals;</PDAT><HIL><SB><PDAT>&agr;</PDAT></SB></HIL><PDAT>l/2 is the dimensionless loss coefficient. Similarly, the distance between the amplifier and a chirp-free point on the segment before the amplifier, &zgr;</PDAT><HIL><SB><PDAT>b</PDAT></SB></HIL><PDAT>, is given by the solution of </PDAT>
<CWU>
<MATH-US ID="MATH-US-00003">
<MATHEMATICA ID="MATHEMATICA-00003" ALT="mathematica file" FILE="US06462849-20021008-M00003.NB"/>
<MATHML>
<math>
<mtable>
  <mtr>
    <mtd>
      <mrow>
        <mrow>
          <mrow>
            <msub>
              <mi>&sigma;</mi>
              <mn>1</mn>
            </msub>
            <mo>+</mo>
            <mn>1</mn>
          </mrow>
          <mo>=</mo>
          <mfrac>
            <mrow>
              <mrow>
                <mn>2</mn>
                <mo>&it;</mo>
                <mstyle>
                  <mtext>&emsp;</mtext>
                </mstyle>
                <mo>&it;</mo>
                <mi>&Lambda;</mi>
                <mo>&it;</mo>
                <mstyle>
                  <mtext>&emsp;</mtext>
                </mstyle>
                <mo>&it;</mo>
                <mrow>
                  <mi>exp</mi>
                  <mo>&af;</mo>
                  <mrow>
                    <mo>(</mo>
                    <mrow>
                      <mrow>
                        <mo>-</mo>
                        <mn>2</mn>
                      </mrow>
                      <mo>&it;</mo>
                      <mi>&Lambda;</mi>
                      <mo>&it;</mo>
                      <mstyle>
                        <mtext>&emsp;</mtext>
                      </mstyle>
                      <mo>&it;</mo>
                      <msub>
                        <mi>&zeta;</mi>
                        <mn>2</mn>
                      </msub>
                      <mo>&it;</mo>
                      <mi>d</mi>
                    </mrow>
                    <mo>)</mo>
                  </mrow>
                </mrow>
              </mrow>
              <mo>+</mo>
              <mrow>
                <mrow>
                  <mo>(</mo>
                  <mrow>
                    <mrow>
                      <mn>2</mn>
                      <mo>&it;</mo>
                      <mi>&Lambda;</mi>
                      <mo>&it;</mo>
                      <mstyle>
                        <mtext>&emsp;</mtext>
                      </mstyle>
                      <mo>&it;</mo>
                      <msub>
                        <mi>&zeta;</mi>
                        <mn>2</mn>
                      </msub>
                      <mo>&it;</mo>
                      <mstyle>
                        <mtext>&emsp;</mtext>
                      </mstyle>
                      <mo>&it;</mo>
                      <mi>d</mi>
                    </mrow>
                    <mo>-</mo>
                    <mn>1</mn>
                    <mo>-</mo>
                    <mi>&Lambda;</mi>
                  </mrow>
                  <mo>)</mo>
                </mrow>
                <mo>&it;</mo>
                <mrow>
                  <mo>(</mo>
                  <mrow>
                    <mi>G</mi>
                    <mo>-</mo>
                    <mn>1</mn>
                  </mrow>
                  <mo>)</mo>
                </mrow>
              </mrow>
            </mrow>
            <mrow>
              <mrow>
                <mrow>
                  <mo>-</mo>
                  <mn>2</mn>
                </mrow>
                <mo>&it;</mo>
                <mi>&Lambda;</mi>
                <mo>&it;</mo>
                <mstyle>
                  <mtext>&emsp;</mtext>
                </mstyle>
                <mo>&it;</mo>
                <msub>
                  <mi>&zeta;</mi>
                  <mn>1</mn>
                </msub>
                <mo>&it;</mo>
                <mrow>
                  <mi>d</mi>
                  <mo>&af;</mo>
                  <mrow>
                    <mo>(</mo>
                    <mrow>
                      <mi>G</mi>
                      <mo>-</mo>
                      <mn>1</mn>
                    </mrow>
                    <mo>)</mo>
                  </mrow>
                </mrow>
              </mrow>
              <mo>-</mo>
              <mi>G</mi>
              <mo>+</mo>
              <mrow>
                <mrow>
                  <mo>[</mo>
                  <mrow>
                    <mrow>
                      <mi>exp</mi>
                      <mo>&af;</mo>
                      <mrow>
                        <mo>(</mo>
                        <mrow>
                          <mn>2</mn>
                          <mo>&it;</mo>
                          <mi>&Lambda;</mi>
                          <mo>&it;</mo>
                          <mstyle>
                            <mtext>&emsp;</mtext>
                          </mstyle>
                          <mo>&it;</mo>
                          <msub>
                            <mi>&zeta;</mi>
                            <mn>2</mn>
                          </msub>
                        </mrow>
                        <mo>)</mo>
                      </mrow>
                    </mrow>
                    <mo>-</mo>
                    <msub>
                      <mi>&zeta;</mi>
                      <mn>1</mn>
                    </msub>
                  </mrow>
                  <mo>]</mo>
                </mrow>
                <mo>/</mo>
                <msub>
                  <mi>&zeta;</mi>
                  <mn>2</mn>
                </msub>
              </mrow>
            </mrow>
          </mfrac>
        </mrow>
        <mo>,</mo>
      </mrow>
    </mtd>
    <mtd>
      <mrow>
        <mo>(</mo>
        <mn>3</mn>
        <mo>)</mo>
      </mrow>
    </mtd>
  </mtr>
</mtable>
</math>
</MATHML>
<EMI ID="EMI-M00003" ALT="embedded image" FILE="US06462849-20021008-M00003.TIF"/>
</MATH-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00031" LVL="7"><PTEXT><PDAT>where d&equals;&minus;&zgr;</PDAT><HIL><SB><PDAT>b</PDAT></SB></HIL><PDAT>/&zgr;</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(&minus;1&lt;d&lt;0). For a given dispersion map, there are, in general, two optimal launch points in each map period, but three or four optimal launch points are also possible for weaker dispersion maps.</PDAT></PTEXT></PARA>
<PARA ID="P-00032" LVL="0"><PTEXT><PDAT>The optical length of &zgr;</PDAT><HIL><SB><PDAT>1 </PDAT></SB></HIL><PDAT>and chirp-free location d in the first fiber segment are found by simultaneously solving for them in the equation:</PDAT></PTEXT></PARA>
<PARA ID="P-00033" LVL="0"><PTEXT><F><PTEXT><PDAT>2</PDAT><HIL><ITALIC><PDAT>&Lgr;G </PDAT></ITALIC></HIL><PDAT>exp(&minus;2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><HIL><ITALIC><PDAT>d</PDAT></ITALIC></HIL><PDAT>)&plus;(2&Lgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><HIL><ITALIC><PDAT>d&minus;</PDAT></ITALIC></HIL><PDAT>1&minus;&Lgr;)(</PDAT><HIL><ITALIC><PDAT>G&minus;</PDAT></ITALIC></HIL><PDAT>1)&equals;0,</PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00034" LVL="0"><PTEXT><F><PTEXT><PDAT>2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><HIL><ITALIC><PDAT>d</PDAT></ITALIC></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>G&minus;</PDAT></ITALIC></HIL><PDAT>1)&minus;</PDAT><HIL><ITALIC><PDAT>G</PDAT></ITALIC></HIL><PDAT>&plus;&lsqb;exp(2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>)&minus;&zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&rsqb;/&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&equals;0</PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00035" LVL="2"><PTEXT><PDAT>where the optimal length &zgr;</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>and chirp-free location d in the second fiber segment are found simultaneously solving for them in equations.</PDAT></PTEXT></PARA>
<PARA ID="P-00036" LVL="0"><PTEXT><F><PTEXT><PDAT>2&Lgr; exp(&minus;2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><HIL><ITALIC><PDAT>d</PDAT></ITALIC></HIL><PDAT>)&plus;(2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><HIL><ITALIC><PDAT>d</PDAT></ITALIC></HIL><PDAT>&minus;1&minus;&Lgr;)(</PDAT><HIL><ITALIC><PDAT>G</PDAT></ITALIC></HIL><PDAT>&minus;1)&equals;0,</PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00037" LVL="0"><PTEXT><F><PTEXT><PDAT>&minus;2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><HIL><ITALIC><PDAT>d</PDAT></ITALIC></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>G&minus;</PDAT></ITALIC></HIL><PDAT>1)&minus;</PDAT><HIL><ITALIC><PDAT>G</PDAT></ITALIC></HIL><PDAT>&plus;&lsqb;exp(2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>)&minus;&zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&rsqb;/&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&equals;0</PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00038" LVL="0"><PTEXT><PDAT>As an example, with the attenuation constant and dispersion-map period taken to be &agr;&equals;0.04605 km</PDAT><HIL><SP><PDAT>&minus;1 </PDAT></SP></HIL><PDAT>(i.e., a 0.2 dB/km power loss) and l&equals;120 km, the loss coefficient is then &Lgr;&equals;2.763. For &zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&equals;0.225 and &sgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&equals;&minus;3.33, Eqs. (2) and (3) predict that there are four optimal launch points, namely d&equals;0.7099, 0.1442, &minus;0.2587 and &minus;0.8688. </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> shows the evolution of the chirp parameter b, which is a measure of the local imbalance between the dispersion and nonlinear self-phase modulation, when an unchirped hyperbolic-secant pulse is launched at the optimal point d&equals;0.1442, taking &egr;&equals;0.5. Both the numerical (circles) and asymptotic (solid line) results are plotted in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> for comparison. Clearly, the asymptotic theory provides a good prediction of the soliton behavior when this map is used.</PDAT></PTEXT></PARA>
<PARA ID="P-00039" LVL="0"><PTEXT><PDAT>Next consider a dispersion map using 100 km of normal dispersion fiber and 20 km of anomalous dispersion fiber with GVD coefficients of 2.76 and &minus;20.1 ps</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>/km, respectively, so that the averaged GVD is &lt;&bgr;&gt;&equals;&minus;1.05 ps</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>/km. Suppose that the amplifier is deployed at the starting point of the anomalous dispersion segment; we then have &zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&equals;&frac16;, &sgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&equals;&minus;19.1. For a 35 ps FWHM pulse, it can be calculated that &egr;&equals;0.406 and taking &Lgr;&equals;2.763, we find from Eqs. (2) and (3) that d&equals;0.567 and &minus;0.611. This means that there are two optimal launch points: one at 11.3 km after the amplifier and the other at 61.1 km before the amplifier (on the anomalous dispersion and the normal dispersion segments, respectively).</PDAT></PTEXT></PARA>
<PARA ID="P-00040" LVL="0"><PTEXT><PDAT>A practical implementation exploiting the use of these optimal chirp-free points can be constructed merely by using a portion of one dispersion map period before the first amplifier to aid in the launching of the optical pulses. In the previous example, the dispersion map period is 120 km (20 km of anomalous dispersion fiber and 100 km of normal dispersion fiber), and for the parameters chosen there are two optimal chirp-free points, one at 11.3 km after the amplifier (in the anomalous dispersion fiber) and the other at 61.1 km before the amplifier (in the normal dispersion fiber). If the first chirp-free point is chosen as the launch point, one merely constructs a partial dispersion map period of total length 108.7 km comprising of 8.7 km (&equals;20&minus;11.3) of anomalous dispersion fiber and 100 km of normal dispersion fiber. If the second chirp-free point is chosen as the launch point, the partial dispersion map has total length 61.1 km and comprises just 61.1 km of normal dispersion fiber. Either of these fiber lengths or partial dispersion maps can be used as a passive device to be installed before the first amplifier to reduce the amount of dispersive radiation generated by the propagating pulses, as shown in FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00041" LVL="0"><PTEXT><PDAT>Furthermore, when optimal lengths of fiber used to construct the map are chosen optimally so as to make the numerator and denominator of Eqs. (2) or (3) zero simultaneously, then one obtains a special dispersion map in which the position of one of the chirp-free points becomes independent of the dispersion parameters of the fiber making up the dispersion map and, therefore independent of the signal wavelength, since the group velocity dispersion depends upon the wavelength. In the example given previous with an amplifier spacing of 120 km and a loss parameter of &Lgr;&equals;2.763, requiring the numerator and denominator of Eq. (2) to be zero simultaneously gives &zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&equals;0.1762 and d&equals;0.5593, meaning that if the first length of fiber is taken to be 0.1762&times;120&equals;21.1 km long, then a wavelength-independent chirp-free point is located 0.5593&times;21.1&equals;11.8 km into this first length of fiber. A similar wavelength-independent chirp-free point results in the second fiber segment by requiring the numerator and denominator of Eq. (3) to be zero simultaneously. By employing one of these specially-constructed dispersion maps, it is, therefore, possible to optimize the transmission of several wavelengths simultaneously, as shown in FIG. </PDAT><HIL><BOLD><PDAT>4</PDAT></BOLD></HIL><PDAT>. Such special dispersion maps are particularly suited for use as passive performance-enhancing devices in systems employing wavelength division multiplexing.</PDAT></PTEXT></PARA>
<PARA ID="P-00042" LVL="0"><PTEXT><PDAT>Thus, the invention involves a method of minimizing dispersive radiation in an optical fiber transmission system utilizing solitons with at least a first and a second type of optical fibers and an amplifier. The method comprises first, determining a first optimal length of said first type optical fiber to form a first length of optical fiber; then determining a second optimal length of said second type optical fiber to form a second length of optical fibers to form a first dispersion map. The first and second optimal lengths are those lengths where the net amount of chirp accumulated before and the net amount of chirp accumulated after said zero chirp point balance one another for all wavelengths and may be determined by the formula set forth above. An amplifier is then located after every said dispersion map. Points in the dispersion map connected to the amplifier are then located where the pulse chirp is zero. A plurality of dispersion maps and amplifiers are connected to form in a transmission line; the first dispersion map is said transmission line is then cut at the zero chirp point to create an optimal launch point for all wavelengths in the transmission line.</PDAT></PTEXT></PARA>
<PARA ID="P-00043" LVL="0"><PTEXT><PDAT>A prechirping fiber may be prepared by first determining a first optimal length of a first type of optical fiber and a second optimal length of a second type optical fiber; the first and second optimal lengths are, as before, those lengths where the net amount of chirp accumulated before and the net amount of chirp accumulated after the zero chirp point balance one another for all wavelengths. The first length is connected to the second length to form a dispersion map. An amplifier is located after the dispersion map, and the pulse chirp zero points in the dispersion map connected to the amplifier is determined. The dispersion map is cut at a zero chirp point to create an optimal prechirping fiber for all wavelengths.</PDAT></PTEXT></PARA>
<PARA ID="P-00044" LVL="0"><PTEXT><PDAT>While the invention has been described with reference to a preferred embodiment, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from the essential scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out this invention, but that the invention will include all embodiments and equivalents falling within the scope of the to appended claims.</PDAT></PTEXT></PARA>
</BTEXT>
</DETDESC>
</SDODE>
<SDOCL>
<H LVL="1"><STEXT><PDAT>We claim: </PDAT></STEXT></H>
<CL>
<CLM ID="CLM-00001">
<PARA ID="P-00045" LVL="0"><PTEXT><PDAT>1. A method of minimizing dispersive radiation in an optical fiber transmission system utilizing solitons and having at least a first and second type of optical fibers and an amplifier comprising the steps of:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>1.) determining a first optimal length of said first type optical fiber to form a first length of optical fiber; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>2.) determining a second optimal length of said second type optical fiber to form a second length of optical fiber, </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>3.) connecting the optimal lengths of said first and second type of optical fibers to form a first dispersion map; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>4.) locating an amplifier after every said dispersion map; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>5.) locating points in the dispersion map connected to the amplifier where the pulse chirp is zero; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>6.) said first and second optimal lengths being those lengths where the net amount of chirp accumulated before and the net amount of chirp accumulated after said zero chirp point balance one another for all wavelengths; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>7.) repeating steps 3 and 4 to form a plurality of dispersion maps and amplifiers in a transmission line; and, </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>8.) cutting the first dispersion map in said transmission line at said zero chirp point to create an optimal launch point for all wavelengths in said transmission line. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00002">
<PARA ID="P-00046" LVL="0"><PTEXT><PDAT>2. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein said optimal length &zgr;</PDAT><HIL><SB><PDAT>1 </PDAT></SB></HIL><PDAT>and chirp-free location d in the first fiber segment are found by simultaneously solving for them in the equations:</PDAT></PTEXT></PARA>
<PARA ID="P-00047" LVL="0"><PTEXT><F><PTEXT><PDAT>2&Lgr;</PDAT><HIL><ITALIC><PDAT>G </PDAT></ITALIC></HIL><PDAT>exp(&minus;2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><HIL><ITALIC><PDAT>d</PDAT></ITALIC></HIL><PDAT>)&plus;(2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><HIL><ITALIC><PDAT>d</PDAT></ITALIC></HIL><PDAT>&minus;1&minus;&Lgr;)(</PDAT><HIL><ITALIC><PDAT>G&minus;</PDAT></ITALIC></HIL><PDAT>1)&equals;0, </PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00048" LVL="0"><PTEXT><F><PTEXT><PDAT>2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><HIL><ITALIC><PDAT>d</PDAT></ITALIC></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>G</PDAT></ITALIC></HIL><PDAT>&minus;1)&minus;</PDAT><HIL><ITALIC><PDAT>G</PDAT></ITALIC></HIL><PDAT>&plus;&lsqb;exp(2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>)&minus;&zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&rsqb;/&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&equals;0, </PDAT></PTEXT></F></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>where the optimal length &zgr;</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>and chirp-free location d in the second fiber segment are found by simultaneously solving for them in the equations </PDAT></PTEXT></CLMSTEP>
<PARA ID="P-00049" LVL="0"><PTEXT><F><PTEXT><PDAT>2&Lgr;exp(&minus;2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><HIL><ITALIC><PDAT>d</PDAT></ITALIC></HIL><PDAT>)&plus;(2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><HIL><ITALIC><PDAT>d</PDAT></ITALIC></HIL><PDAT>&minus;1&minus;&Lgr;)(</PDAT><HIL><ITALIC><PDAT>G&minus;</PDAT></ITALIC></HIL><PDAT>1)&equals;0, </PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00050" LVL="0"><PTEXT><F><PTEXT><PDAT>&minus;2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><HIL><ITALIC><PDAT>d</PDAT></ITALIC></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>G</PDAT></ITALIC></HIL><PDAT>&minus;1)&minus;</PDAT><HIL><ITALIC><PDAT>G</PDAT></ITALIC></HIL><PDAT>&plus;&lsqb;exp(2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>)&minus;&zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&rsqb;/&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&equals;0 </PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00051" LVL="7"><PTEXT><PDAT>where</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>&Lgr; is the dimensionless fiber loss &Lgr;&equals;&agr;l/2; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>G is the amplifier gain, G&equals;exp(&agr;l) where &agr; is fiber loss and l is the spacing between amplifiers. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00003">
<PARA ID="P-00052" LVL="0"><PTEXT><PDAT>3. A method of managing dispersion in a wavelength division multiplexed soliton transmission system comprising the steps of:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>1.) determining a first optimal length of a first type of optical fiber; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>2.) determining a second optimal length of a second type optical fiber; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>3.) connecting said first length to said second length to form a dispersion map; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>4.) locating an amplifier after said dispersion map; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>5.) determining the pulse chirp zero point in said dispersion map; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>6.) said first and second optimal lengths are those where the net amount of chirp accumulated before and the net amount of chirp accumulated after said zero chirp point balance one another for all wavelengths; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>7.) cutting the dispersion map at said zero chirp point to create an optimal prechirping fiber for all wavelengths. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00004">
<PARA ID="P-00053" LVL="0"><PTEXT><PDAT>4. The method of </PDAT><CLREF ID="CLM-00003"><PDAT>claim 3</PDAT></CLREF><PDAT>, wherein the prechirping fiber is connected to the beginning of a transmission line comprising a plurality of said dispersion maps and said amplifiers.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00005">
<PARA ID="P-00054" LVL="0"><PTEXT><PDAT>5. The method of </PDAT><CLREF ID="CLM-00004"><PDAT>claim 4</PDAT></CLREF><PDAT>, wherein said plurality of dispersion maps are constructed as in steps 1-6 of </PDAT><CLREF ID="CLM-00003"><PDAT>claim 3</PDAT></CLREF><PDAT>.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00006">
<PARA ID="P-00055" LVL="0"><PTEXT><PDAT>6. A method of managing dispersion in a wavelength division multiplexed soliton transmission system comprising the steps of:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>1. determining a first optimal length of a first type of optical fiber; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>2. determining a second optimal length of a second type optical fiber; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>3. connecting said first length to said second length to form a dispersion map; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>4. locating an amplifier after said dispersion map; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>5. determining the pulse chirp zero point in said dispersion map; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>6. said first and second optimal lengths being those of said lengths where the net amount of chirp accumulated before and the net amount of chirp accumulated after said zero chirp point balance one another for all wavelengths; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>7. cutting the dispersion map at said zero chirp point to create an optimal launch point for all wavelengths. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00007">
<PARA ID="P-00056" LVL="0"><PTEXT><PDAT>7. The method of </PDAT><CLREF ID="CLM-00006"><PDAT>claim 6</PDAT></CLREF><PDAT> further including the steps of repeating steps 3 and 4 connecting said dispersion maps to form a transmission line.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00008">
<PARA ID="P-00057" LVL="0"><PTEXT><PDAT>8. The method of </PDAT><CLREF ID="CLM-00007"><PDAT>claim 7</PDAT></CLREF><PDAT> further including the step of connecting said optimal prechirped fiber to said transmission line.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00009">
<PARA ID="P-00058" LVL="0"><PTEXT><PDAT>9. The method of </PDAT><CLREF ID="CLM-00007"><PDAT>claim 7</PDAT></CLREF><PDAT> wherein said optimal length is found by solving for d in the equation:</PDAT></PTEXT></PARA>
<PARA ID="P-00059" LVL="0"><PTEXT><F><PTEXT><PDAT>2&Lgr;</PDAT><HIL><ITALIC><PDAT>G </PDAT></ITALIC></HIL><PDAT>exp(&minus;2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><HIL><ITALIC><PDAT>d</PDAT></ITALIC></HIL><PDAT>)&plus;(2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><HIL><ITALIC><PDAT>d</PDAT></ITALIC></HIL><PDAT>&minus;1&minus;&Lgr;)(</PDAT><HIL><ITALIC><PDAT>G&minus;</PDAT></ITALIC></HIL><PDAT>1)&equals;0 </PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00060" LVL="0"><PTEXT><F><PTEXT><PDAT>2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><HIL><ITALIC><PDAT>d</PDAT></ITALIC></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>G&minus;</PDAT></ITALIC></HIL><PDAT>1)&minus;</PDAT><HIL><ITALIC><PDAT>G</PDAT></ITALIC></HIL><PDAT>&plus;&lsqb;exp(2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>)&minus;&zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&rsqb;/&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&equals;0 </PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00061" LVL="7"><PTEXT><PDAT>or where optimal length &zgr;</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>and chirp-free location d in the second fiber segment are found by simultaneously solving for them in equations</PDAT></PTEXT></PARA>
<PARA ID="P-00062" LVL="7"><PTEXT><PDAT>&emsp;2&Lgr; exp(&minus;2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><HIL><ITALIC><PDAT>d</PDAT></ITALIC></HIL><PDAT>)&plus;(2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><HIL><ITALIC><PDAT>d</PDAT></ITALIC></HIL><PDAT>&minus;1&minus;&Lgr;)(</PDAT><HIL><ITALIC><PDAT>G</PDAT></ITALIC></HIL><PDAT>&minus;1)&equals;0,</PDAT></PTEXT></PARA>
<PARA ID="P-00063" LVL="0"><PTEXT><F><PTEXT><PDAT>&minus;2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><HIL><ITALIC><PDAT>d</PDAT></ITALIC></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>G&minus;</PDAT></ITALIC></HIL><PDAT>1)&minus;</PDAT><HIL><ITALIC><PDAT>G&plus;</PDAT></ITALIC></HIL><PDAT>&lsqb;exp(2&Lgr;&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>)&minus;&zgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&rsqb;/&zgr;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&equals;0 </PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00064" LVL="7"><PTEXT><PDAT>where</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>&Lgr; is the dimensionless fiber loss &Lgr;&equals;&agr;l/2; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>G is the amplifier gain, G&equals;exp(&agr;l) where &agr; is fiber loss and l is the spacing between amplifiers.</PDAT></PTEXT></CLMSTEP>
</CLM>
</CL>
</SDOCL>
<SDODR ID="DRAWINGS">
<EMI ID="EMI-D00000" ALT="embedded image" FILE="US06462849-20021008-D00000.TIF"/>
<EMI ID="EMI-D00001" ALT="embedded image" FILE="US06462849-20021008-D00001.TIF"/>
<EMI ID="EMI-D00002" ALT="embedded image" FILE="US06462849-20021008-D00002.TIF"/>
<EMI ID="EMI-D00003" ALT="embedded image" FILE="US06462849-20021008-D00003.TIF"/>
<EMI ID="EMI-D00004" ALT="embedded image" FILE="US06462849-20021008-D00004.TIF"/>
</SDODR>
</PATDOC>

<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PATDOC SYSTEM "ST32-US-Grant-025xml.dtd" [
<!ENTITY US06463200-20021008-M00001.NB SYSTEM "US06463200-20021008-M00001.NB" NDATA NB>
<!ENTITY US06463200-20021008-M00001.TIF SYSTEM "US06463200-20021008-M00001.TIF" NDATA TIF>
<!ENTITY US06463200-20021008-M00002.NB SYSTEM "US06463200-20021008-M00002.NB" NDATA NB>
<!ENTITY US06463200-20021008-M00002.TIF SYSTEM "US06463200-20021008-M00002.TIF" NDATA TIF>
<!ENTITY US06463200-20021008-M00003.NB SYSTEM "US06463200-20021008-M00003.NB" NDATA NB>
<!ENTITY US06463200-20021008-M00003.TIF SYSTEM "US06463200-20021008-M00003.TIF" NDATA TIF>
<!ENTITY US06463200-20021008-M00004.NB SYSTEM "US06463200-20021008-M00004.NB" NDATA NB>
<!ENTITY US06463200-20021008-M00004.TIF SYSTEM "US06463200-20021008-M00004.TIF" NDATA TIF>
<!ENTITY US06463200-20021008-M00005.NB SYSTEM "US06463200-20021008-M00005.NB" NDATA NB>
<!ENTITY US06463200-20021008-M00005.TIF SYSTEM "US06463200-20021008-M00005.TIF" NDATA TIF>
<!ENTITY US06463200-20021008-D00000.TIF SYSTEM "US06463200-20021008-D00000.TIF" NDATA TIF>
<!ENTITY US06463200-20021008-D00001.TIF SYSTEM "US06463200-20021008-D00001.TIF" NDATA TIF>
<!ENTITY US06463200-20021008-D00002.TIF SYSTEM "US06463200-20021008-D00002.TIF" NDATA TIF>
<!ENTITY US06463200-20021008-D00003.TIF SYSTEM "US06463200-20021008-D00003.TIF" NDATA TIF>
<!ENTITY US06463200-20021008-D00004.TIF SYSTEM "US06463200-20021008-D00004.TIF" NDATA TIF>
<!ENTITY US06463200-20021008-D00005.TIF SYSTEM "US06463200-20021008-D00005.TIF" NDATA TIF>
<!ENTITY US06463200-20021008-D00006.TIF SYSTEM "US06463200-20021008-D00006.TIF" NDATA TIF>
<!ENTITY US06463200-20021008-D00007.TIF SYSTEM "US06463200-20021008-D00007.TIF" NDATA TIF>
]>
<PATDOC DTD="2.5" STATUS="Build 20020918">
<SDOBI>
<B100>
<B110><DNUM><PDAT>06463200</PDAT></DNUM></B110>
<B130><PDAT>B2</PDAT></B130>
<B140><DATE><PDAT>20021008</PDAT></DATE></B140>
<B190><PDAT>US</PDAT></B190>
</B100>
<B200>
<B210><DNUM><PDAT>09418344</PDAT></DNUM></B210>
<B211US><PDAT>09</PDAT></B211US>
<B220><DATE><PDAT>19991014</PDAT></DATE></B220>
</B200>
<B500>
<B510>
<B511><PDAT>G02B  616</PDAT></B511>
<B516><PDAT>7</PDAT></B516>
</B510>
<B520>
<B521><PDAT>385123</PDAT></B521>
<B522><PDAT>385126</PDAT></B522>
</B520>
<B540><STEXT><PDAT>Omnidirectional multilayer device for enhanced optical waveguiding</PDAT></STEXT></B540>
<B560>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5661839</PDAT></DNUM>
<DATE><PDAT>19970800</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Whitehead</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>385131</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5814367</PDAT></DNUM>
<DATE><PDAT>19980900</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Hubbard et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>427162</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5995696</PDAT></DNUM>
<DATE><PDAT>19991100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Miyagi et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>385125</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6043914</PDAT></DNUM>
<DATE><PDAT>20000300</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Cook et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>359124</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6080467</PDAT></DNUM>
<DATE><PDAT>20000600</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Weber et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>428212</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6101032</PDAT></DNUM>
<DATE><PDAT>20000800</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Wortman et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>359500</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>0 195 630</PDAT></DNUM>
<DATE><PDAT>19860300</PDAT></DATE>
<CTRY><PDAT>EP</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>0 426 203</PDAT></DNUM>
<DATE><PDAT>19870100</PDAT></DATE>
<CTRY><PDAT>EP</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>2 288 469</PDAT></DNUM>
<DATE><PDAT>19951000</PDAT></DATE>
<CTRY><PDAT>GB</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 94/09393</PDAT></DNUM>
<DATE><PDAT>19940400</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO97/01774</PDAT></DNUM>
<DATE><PDAT>19970100</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO99/47465</PDAT></DNUM>
<DATE><PDAT>19990900</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B562><NCIT><STEXT><PDAT>&ldquo;Current Status of Flexible Waveguides for IR Laser Radiation Transmission&rdquo; by Gannot et al., IEEE Journal of Selected Topics In Quantum Electronics, vol.2, No. 4, Dec. 1996, pp. 880-888. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Doran et al., &ldquo;Cylindrical Bragg Fibers: A Design and Feasibility Study for Optical Communications,&rdquo; Journal of Lightwave Technology, vol. LT-1, No. 4, pp. 588-590, Dec. 1983,. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Miyagi et al., &ldquo;Transmission Characteristics of Dielectric-Coated Metallic Waveguide for Infrared Transmission: Slab Waveguide Model,&rdquo; IEEE Journal of Quantum Electronics, vol. QE-19, No. 2, pp. 136-145, Feb. 1983. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Miyagi et al., &ldquo;Design Theory of Dielectric-Coated Circular Metallic Waveguides for Infrared Transmission,&rdquo; Journal of Lightwave Technology, vol. LT-2, No. 2, pp. 116-126, Apr. 1984. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Marcatili et al., &ldquo;Hollow Metallic and Dielectric Waveguides for Long Distance Optical Transmission and Lasers,&rdquo; The Bell System Technical Journal, pp. 1783-1809, Jul. 1964. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Martijn et al., &ldquo;Differential Losses in Bragg Fibers,&rdquo; J.Appl.Phys., 76(2), pp. 680-688, Jul. 15, 1994. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Lazarchik, &ldquo;Bragg Fiber Lightguides,&rdquo; originally published in Radiotekhnika I Elektronika, No. 1, 1988, pp. 36-43. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Fink et al., &ldquo;A Dielectric Omnidirectional Reflector,&rdquo; Science, vol. 282, pp. 1679-1682, Nov. 27, 1998. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Brechet et al., &ldquo;Singlemode Propagation into Depressed-core-index Photonic-bandgap Fibre Designed for Zero-dispersion Propagation at Short Wavelengths,&rdquo; Electronics Letters, vol. 36, No. 6, pp. 514-515, Mar. 16, 2000. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Brechet et al., &ldquo;Analysis of Bandpass Filtering Behaviour of Singlemode Depressed-core-index Photonic-bandgap Fibre,&rdquo; Electronics Letters, vol. 36, No. 10, pp. 870-871, May 11, 2000. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Yeh et al., &ldquo;Theory of Bragg Fiber,&rdquo; Journal of the Optical Society of America, vol. 68, No. 9, pp. 1196-1201, Sep. 1978.</PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
</B560>
<B570>
<B577><PDAT>23</PDAT></B577>
<B578US><PDAT>1</PDAT></B578US>
</B570>
<B580>
<B582><PDAT>385123</PDAT></B582>
<B582><PDAT>385129</PDAT></B582>
<B583US><PDAT>385122-133</PDAT></B583US>
<B582><PDAT>428212</PDAT></B582>
<B582><PDAT>428480</PDAT></B582>
<B582><PDAT>428483</PDAT></B582>
<B582><PDAT>428522</PDAT></B582>
<B582><PDAT>359500</PDAT></B582>
</B580>
<B590><B595><PDAT>7</PDAT></B595><B596><PDAT>9</PDAT></B596><B597US/>
</B590>
</B500>
<B600>
<B680US><DOC><DNUM><PDAT>60/104153</PDAT></DNUM><DATE><PDAT>19981014</PDAT></DATE><KIND><PDAT>00</PDAT></KIND></DOC></B680US>
<B690US>
<DOC>
<DNUM><PDAT>20020025130</PDAT></DNUM>
<DATE><PDAT>20020228</PDAT></DATE>
<CTRY><PDAT>US</PDAT></CTRY>
<KIND><PDAT>A1</PDAT></KIND>
</DOC>
</B690US></B600>
<B700>
<B720>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Yoel</PDAT></FNM><SNM><STEXT><PDAT>Fink</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Cambridge</PDAT></CITY>
<STATE><PDAT>MA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Shanhui</PDAT></FNM><SNM><STEXT><PDAT>Fan</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Somerville</PDAT></CITY>
<STATE><PDAT>MA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Edwin</PDAT></FNM><SNM><STEXT><PDAT>Thomas</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Natick</PDAT></CITY>
<STATE><PDAT>MA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Chiping</PDAT></FNM><SNM><STEXT><PDAT>Chen</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Needham</PDAT></CITY>
<STATE><PDAT>MA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>John</PDAT></FNM><SNM><STEXT><PDAT>Joannopoulos</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Belmont</PDAT></CITY>
<STATE><PDAT>MA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
</B720>
<B730>
<B731>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Massachusetts Institute of Technology</PDAT></STEXT></ONM></NAM>
<ADR><CITY><PDAT>Cambridge</PDAT></CITY><STATE><PDAT>MA</PDAT></STATE></ADR>
</PARTY-US>
</B731>
<B732US>
<PDAT>02</PDAT>
</B732US>
</B730>
<B740>
<B741>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Fish &amp; Richardson P.C.</PDAT></STEXT></ONM></NAM>
</PARTY-US>
</B741>
</B740>
<B745>
<B746>
<PARTY-US>
<NAM><FNM><PDAT>Phan T. H.</PDAT></FNM><SNM><STEXT><PDAT>Palmer</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B746>
<B748US><PDAT>2874</PDAT></B748US>
</B745>
</B700>
</SDOBI>
<SDOAB>
<BTEXT>
<PARA ID="P-00001" LVL="0"><PTEXT><PDAT>A device having at least one dielectric inner core region in which electromagnetic radiation is confined, and at least two dielectric outer regions surrounding the inner core region, each with a distinct refractive index. The outer regions confine electromagnetic radiation within the inner core region. The refractive indices, the number of outer regions, and thickness of the outer regions result in a reflectivity for a planar geometry that is greater than 95% for angles of incidence ranging from 0&deg; to at least 80&deg; for all polarizations for a range of wavelengths of the electromagnetic radiation. In exemplary embodiments, the inner core region is made of a low dielectric material, and the outer regions include alternating layers of low and high dielectric materials. In one aspect of the invention, the device is a waveguide, and in another aspect the device is a microcavity.</PDAT></PTEXT></PARA>
</BTEXT>
</SDOAB>
<SDODE>
<RELAPP>
<BTEXT>
<H LVL="1"><STEXT><PDAT>PRIORITY INFORMATION</PDAT></STEXT></H>
<PARA ID="P-00002" LVL="0"><PTEXT><PDAT>This application claims priority from provisional application Ser. No. 60/104,153 filed Oct. 14, 1998.</PDAT></PTEXT></PARA>
</BTEXT>
</RELAPP>
<GOVINT>
<BTEXT>
<PARA ID="P-00003" LVL="0"><PTEXT><PDAT>This invention was made with government support under Grant No. DMR-9400334 awarded by the National Science Foundation, Grant No. DAAG55-97-1-0366 awarded by the U.S. Army and Grant No. F49620-97-0-0325 awarded by the U.S. Air Force. The government has certain rights in the invention.</PDAT></PTEXT></PARA>
</BTEXT>
</GOVINT>
<BRFSUM>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BACKGROUND OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00004" LVL="0"><PTEXT><PDAT>The invention relates to the field of optical waveguiding, and in particular to an omnidirectional multilayered device for enhanced waveguiding of electromagnetic radiation.</PDAT></PTEXT></PARA>
<PARA ID="P-00005" LVL="0"><PTEXT><PDAT>Mirrors are probably the most prevalent of optical devices. Known to the ancients and used by them as objects of worship and beauty, mirrors are currently employed for imaging, solar energy collection and in laser cavities. Their intriguing optical properties have captured the imagination of scientists as well as artists and writers.</PDAT></PTEXT></PARA>
<PARA ID="P-00006" LVL="0"><PTEXT><PDAT>One can distinguish between two types of mirrors, the age-old metallic, and more recent dielectric. Metallic mirrors reflect light over a broad range of frequencies incident from arbitrary angles, i.e., omnidirectional reflectance. However, at infrared and optical frequencies, a few percent of the incident power is typically lost due to absorption. Multilayer dielectric mirrors are used primarily to reflect a narrow range of frequencies incident from a particular angle or particular angular range. Unlike their metallic counterparts, dielectric reflectors can be extremely low loss.</PDAT></PTEXT></PARA>
<PARA ID="P-00007" LVL="0"><PTEXT><PDAT>The ability to reflect light of arbitrary angle of incidence for all-dielectric structures has been associated with the existence of a complete photonic bandgap, which can exist only in a system with a dielectric function that is periodic along three orthogonal directions. In fact, a recent theoretical analysis predicted that a sufficient condition for the achievement of omnidirectional reflection in a periodic system with an interface is the existence of an overlapping bandgap regime in phase space above the light cone of the ambient media.</PDAT></PTEXT></PARA>
<PARA ID="P-00008" LVL="0"><PTEXT><PDAT>The theoretical analysis is now extended to provide experimental realization of a multilayer omnidirectional reflector operable in infrared frequencies. The structure is made of thin layers of materials with different dielectric constants (polystyrene and tellurium) and combines characteristic features of both the metallic and dielectric mirrors. It offers metallic-like omnidirectional reflectivity together with frequency selectivity and low-loss behavior typical of multilayer dielectrics.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SUMMARY OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00009" LVL="0"><PTEXT><PDAT>Accordingly, in accordance with the invention there is provided a device having at least one inner core region in which electromagnetic radiation is confined, and at least two outer regions surrounding the inner core region, each with a distinct isotropic refractive index. The outer regions confine electromagnetic radiation within the inner core region. The refractive indices, the number of outer regions, and thickness of the outer regions result in a reflectivity for a planar geometry that is greater than 95% for angles of incidence ranging from 0&deg; to at least 80&deg; for all polarizations for a range of wavelengths of the electromagnetic radiation. In exemplary embodiments, the inner core region is made of a low dielectric material, and the outer regions include alternating layers of low and high dielectric materials. In one aspect of the invention, the device is a waveguide, and in another aspect the device is a microcavity.</PDAT></PTEXT></PARA>
</BTEXT>
</BRFSUM>
<DRWDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BRIEF DESCRIPTION OF THE DRAWINGS</PDAT></STEXT></H>
<PARA ID="P-00010" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT> is a simplified block diagram of an exemplary embodiment of a multilayer periodic dielectric film structure in accordance with the invention;</PDAT></PTEXT></PARA>
<PARA ID="P-00011" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2A</PDAT></FGREF><PDAT> is a graph of the projected band structure of a multilayer film with a light line and Brewster line, exhibiting a reflectivity range of limited angular acceptance;</PDAT></PTEXT></PARA>
<PARA ID="P-00012" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2B</PDAT></FGREF><PDAT> is a graph of the projected band structure of a multilayer film together with the light line and Brewster line, showing an omnidirectional reflectance range at the first and second harmonic;</PDAT></PTEXT></PARA>
<PARA ID="P-00013" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> is a graph of the range to midrange ratio for the fundamental frequency range of omnidirectional reflection plotted as contours;</PDAT></PTEXT></PARA>
<PARA ID="P-00014" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT> is a series of graphs showing the calculated (solid line) and measured (dashed line) reflectance (%) as a function of wavelength for TM and TE modes at normal, 45&deg;, and 80&deg; angles of incidence, thus showing an omnidirectional reflectivity band;</PDAT></PTEXT></PARA>
<PARA ID="P-00015" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 5</PDAT></FGREF><PDAT> is a table showing that &xgr; is a monotonically increasing function of the incident angle for the TM mode of an omnidirectional reflector;</PDAT></PTEXT></PARA>
<PARA ID="P-00016" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 6A</PDAT></FGREF><PDAT> is a simplified block diagram cross section of an exemplary structure;</PDAT></PTEXT></PARA>
<PARA ID="P-00017" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 6B</PDAT></FGREF><PDAT> is a corresponding cross section radial index of refraction profile of the structure in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 6A</PDAT></FGREF><PDAT>; and</PDAT></PTEXT></PARA>
<PARA ID="P-00018" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 7</PDAT></FGREF><PDAT> is a cross section of a simplified schematic diagram of a coextrusion assembly in accordance with the invention.</PDAT></PTEXT></PARA>
</BTEXT>
</DRWDESC>
<DETDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>DETAILED DESCRIPTION OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00019" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT> is a simplified block diagram of an exemplary embodiment of a multilayer periodic dielectric film structure </PDAT><HIL><BOLD><PDAT>100</PDAT></BOLD></HIL><PDAT> in accordance with the invention. The structure is made of an array of alternating dielectric layers </PDAT><HIL><BOLD><PDAT>102</PDAT></BOLD></HIL><PDAT>, </PDAT><HIL><BOLD><PDAT>104</PDAT></BOLD></HIL><PDAT> coupled to a homogeneous medium, characterized by n</PDAT><HIL><SB><PDAT>0 </PDAT></SB></HIL><PDAT>(such as air with n</PDAT><HIL><SB><PDAT>0</PDAT></SB></HIL><PDAT>&equals;1), at the interfaces. Electromagnetic waves are incident upon the multilayer film from the homogeneous medium. The possibility of omnidirectional reflectivity for such a system has now been recognized. h</PDAT><HIL><SB><PDAT>1 </PDAT></SB></HIL><PDAT>and h</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>are the layer thickness , and n</PDAT><HIL><SB><PDAT>1 </PDAT></SB></HIL><PDAT>and n</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>are the indices of refraction of the respective layers </PDAT><HIL><BOLD><PDAT>104</PDAT></BOLD></HIL><PDAT> and </PDAT><HIL><BOLD><PDAT>102</PDAT></BOLD></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00020" LVL="0"><PTEXT><PDAT>An exemplary incident wave has a wave vector {right arrow over (k)}&equals;k</PDAT><HIL><SB><PDAT>x</PDAT></SB></HIL><PDAT>&ecirc;</PDAT><HIL><SB><PDAT>x</PDAT></SB></HIL><PDAT>&plus;k</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>&ecirc;</PDAT><HIL><SB><PDAT>y </PDAT></SB></HIL><PDAT>and frequency of &ohgr;&equals;c&verbar;k&verbar;.The wave vector together with the normal to the periodic structure </PDAT><HIL><BOLD><PDAT>100</PDAT></BOLD></HIL><PDAT> defines a mirror plane of symmetry that allows distinguishing between two independent electromagnetic modes: transverse electric (TE) modes and transverse magnetic (TM) modes. For the TE mode, the electric field is perpendicular to the plane, as is the magnetic field for the TM mode. The distribution of the electric field of the TE mode (or the magnetic field in the TM mode) in a particular layer within the stratified structure can be written as a sum of two plane waves traveling in opposite directions. The amplitudes of the two plane waves in a particular layer &agr; of one cell are related to the amplitudes in the same layer of an adjacent cell by a unitary 2&times;2 translation matrix U</PDAT><HIL><SP><PDAT>(&agr;)</PDAT></SP></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00021" LVL="0"><PTEXT><PDAT>General features of the transport properties of the finite structure can be understood when the properties of the infinite structure are elucidated. In a structure with infinite number of layers, translational symmetry along the direction perpendicular to the layers leads to Bloch wave solutions of the form</PDAT></PTEXT></PARA>
<PARA ID="P-00022" LVL="7"><PTEXT><PDAT>&emsp;</PDAT><HIL><ITALIC><PDAT>E</PDAT></ITALIC></HIL><HIL><SB><PDAT>K</PDAT></SB></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>x,y</PDAT></ITALIC></HIL><PDAT>)&equals;</PDAT><HIL><ITALIC><PDAT>E</PDAT></ITALIC></HIL><HIL><SB><PDAT>K</PDAT></SB></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>X</PDAT></ITALIC></HIL><PDAT>)</PDAT><HIL><ITALIC><PDAT>e</PDAT></ITALIC></HIL><HIL><SP><PDAT>ikx</PDAT></SP></HIL><HIL><ITALIC><PDAT>e</PDAT></ITALIC></HIL><HIL><SP><PDAT>ik</PDAT></SP></HIL><HIL><SP><HIL><SB><PDAT>y</PDAT></SB></HIL></SP></HIL><HIL><SP><PDAT>y</PDAT></SP></HIL><PDAT>,&emsp;&emsp;(1)</PDAT></PTEXT></PARA>
<PARA ID="P-00023" LVL="7"><PTEXT><PDAT>where E</PDAT><HIL><SB><PDAT>K</PDAT></SB></HIL><PDAT>(x) is periodic, with a period of length a, and K is the Bloch wave number given by</PDAT></PTEXT></PARA>
<PARA ID="P-00024" LVL="0"><PTEXT><F><PTEXT><HIL><ITALIC><PDAT>K&equals;i/a ln &lsqb;</PDAT></ITALIC></HIL><PDAT>1/2</PDAT><HIL><ITALIC><PDAT>Tr</PDAT></ITALIC></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>U</PDAT></ITALIC></HIL><HIL><SP><PDAT>(&agr;)</PDAT></SP></HIL><PDAT>)&plusmn;&lsqb;1/4(</PDAT><HIL><ITALIC><PDAT>Tr</PDAT></ITALIC></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>U</PDAT></ITALIC></HIL><HIL><SP><PDAT>(&agr;)</PDAT></SP></HIL><PDAT>))</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>&minus;1&rsqb;</PDAT><HIL><SP><PDAT>{fraction (1/2 )}</PDAT></SP></HIL><PDAT>&rsqb;.&emsp;&emsp;(2)</PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00025" LVL="7"><PTEXT><PDAT>Solutions of the infinite system can be propagating or evanescent, corresponding to real or imaginary Bloch wave numbers, respectively. The solution of Eq. 2 defines the band structure for the infinite system, &ohgr; (K,k</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>).</PDAT></PTEXT></PARA>
<PARA ID="P-00026" LVL="0"><PTEXT><PDAT>It is convenient to display the solutions of the infinite structure by projecting the &ohgr; (K,k</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>) function onto the &ohgr;&minus;k</PDAT><HIL><SB><PDAT>y </PDAT></SB></HIL><PDAT>plane. </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 2A and 2B</PDAT></FGREF><PDAT> are examples of such projected structures.</PDAT></PTEXT></PARA>
<PARA ID="P-00027" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2A</PDAT></FGREF><PDAT> is a graph of the projected band structure of a multilayer film with a light line </PDAT><HIL><BOLD><PDAT>200</PDAT></BOLD></HIL><PDAT> and Brewster line </PDAT><HIL><BOLD><PDAT>202</PDAT></BOLD></HIL><PDAT>, exhibiting a reflectivity range of limited angular acceptance with n</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&equals;2.2 and n</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&equals;1.7, and a thickness ratio of h</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>/h</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&equals;2.2/1.7.</PDAT></PTEXT></PARA>
<PARA ID="P-00028" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2B</PDAT></FGREF><PDAT> is a graph of the projected band structure of a multilayer film together with the light line </PDAT><HIL><BOLD><PDAT>204</PDAT></BOLD></HIL><PDAT> and Brewster line </PDAT><HIL><BOLD><PDAT>206</PDAT></BOLD></HIL><PDAT>, showing an omnidirectional reflectance range at the first and second harmonic. The film parameters are n</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&equals;4.6 and n</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&equals;1.6 with a thickness ratio of h</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>h/</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&equals;1.6/0.8. These parameters are similar to the actual polymer-tellurium film parameters measured in the experiment.</PDAT></PTEXT></PARA>
<PARA ID="P-00029" LVL="0"><PTEXT><PDAT>The area </PDAT><HIL><BOLD><PDAT>208</PDAT></BOLD></HIL><PDAT> and </PDAT><HIL><BOLD><PDAT>210</PDAT></BOLD></HIL><PDAT> (light gray) highlight phase space where K is strictly real, i.e., regions of propagating states. The area </PDAT><HIL><BOLD><PDAT>212</PDAT></BOLD></HIL><PDAT> (white) represents regions containing evanescent states. The areas </PDAT><HIL><BOLD><PDAT>214</PDAT></BOLD></HIL><PDAT> and </PDAT><HIL><BOLD><PDAT>216</PDAT></BOLD></HIL><PDAT> represent omnidirectional reflectance ranges.</PDAT></PTEXT></PARA>
<PARA ID="P-00030" LVL="0"><PTEXT><PDAT>The shape of the projected band structures for the multilayer film structure can be understood intuitively. At k</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>&equals;0 the bandgap for waves travelling normal to the layers is recovered. For k</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>&gt;0 the bands curve upward in frequency. As k</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>&rarr;&infin;, the modes become largely confined to the slabs with the high index of refraction and do not couple between layers (and are therefore independent of k</PDAT><HIL><SB><PDAT>x</PDAT></SB></HIL><PDAT>).</PDAT></PTEXT></PARA>
<PARA ID="P-00031" LVL="0"><PTEXT><PDAT>For a finite structure, the translational symmetry in the directions parallel to the layers is preserved, hence k</PDAT><HIL><SB><PDAT>y </PDAT></SB></HIL><PDAT>remains a conserved quantity. In the direction perpendicular to the layers, the translational symmetry no longer exists. Nevertheless, the K-number, as defined in Eq. 2, is still relevant, because it is determined purely by the dielectric and structural property of a single bilayer. In regions where K is imaginary, the electromagnetic field is strongly attenuated. As the number of layers is increased, the transmission coefficient decreases exponentially, while the reflectivity approaches unity.</PDAT></PTEXT></PARA>
<PARA ID="P-00032" LVL="0"><PTEXT><PDAT>Since the primary interest is in waves originating from the homogeneous medium external to the periodic structure, the focus will be only on the portion of phase space lying above the light line. Waves originating from the homogeneous medium satisfy the condition &ohgr;&gE;ck</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>/n</PDAT><HIL><SB><PDAT>0</PDAT></SB></HIL><PDAT>, where n</PDAT><HIL><SB><PDAT>0 </PDAT></SB></HIL><PDAT>is the refractive index of the homogeneous medium, and therefore they must reside above the light line. States of the homogeneous medium with k</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>&equals;0 are normal incident, and those lying on the &ohgr;&equals;ck</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>/n</PDAT><HIL><SB><PDAT>0 </PDAT></SB></HIL><PDAT>line with k</PDAT><HIL><SB><PDAT>x</PDAT></SB></HIL><PDAT>&equals;0 are incident at an angle of 90&deg;.</PDAT></PTEXT></PARA>
<PARA ID="P-00033" LVL="0"><PTEXT><PDAT>The states in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2A</PDAT></FGREF><PDAT> that are lying in the restricted phase space defined by the light line </PDAT><HIL><BOLD><PDAT>200</PDAT></BOLD></HIL><PDAT> and that have a (&ohgr;,k</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>) corresponding to the propagating solutions (gray areas </PDAT><HIL><BOLD><PDAT>208</PDAT></BOLD></HIL><PDAT>) of the structure can propagate in both the homogeneous medium and in the structure. These waves will partially or entirely transmit through the film. Those with (&ohgr;, k</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>) in the evanescent regions (white areas </PDAT><HIL><BOLD><PDAT>212</PDAT></BOLD></HIL><PDAT>) can propagate in the homogeneous medium, but will decay in the structure. Waves corresponding to this portion of phase space will be reflected off the structure.</PDAT></PTEXT></PARA>
<PARA ID="P-00034" LVL="0"><PTEXT><PDAT>The multilayer system leading to </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2A</PDAT></FGREF><PDAT> represents a structure with a limited reflectivity cone since for any frequency one can always find a k</PDAT><HIL><SB><PDAT>y </PDAT></SB></HIL><PDAT>vector for which a wave at that frequency can propagate in the structure, and hence transmit through the film. For example, a wave with &ohgr;&equals;0.285 2 &pgr;c/a (dashed horizontal line </PDAT><HIL><BOLD><PDAT>218</PDAT></BOLD></HIL><PDAT>) will be reflected for a range of k</PDAT><HIL><SB><PDAT>y </PDAT></SB></HIL><PDAT>values ranging from 0 (normal incidence) to 0.285 2 &pgr;/a (90&deg; incidence) in the TE mode, while in the TM mode it begins to transmit at a value of k</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>&equals;0.187 2 &pgr;/a (&tilde;41&deg; incidence). The necessary and sufficient criterion for omnidirectional reflectivity at a given frequency is that there exist no transmitting states of the structure inside the light cone. This criterion is satisfied by frequency ranges </PDAT><HIL><BOLD><PDAT>214</PDAT></BOLD></HIL><PDAT> and </PDAT><HIL><BOLD><PDAT>216</PDAT></BOLD></HIL><PDAT> in FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>B. In fact, the system leading to </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2B</PDAT></FGREF><PDAT> exhibits two omnidirectional reflectivity ranges.</PDAT></PTEXT></PARA>
<PARA ID="P-00035" LVL="0"><PTEXT><PDAT>A necessary condition for omnidirectional reflectivity is that light from outside of the structure cannot be allowed to access the Brewster angle &thgr;</PDAT><HIL><SB><PDAT>B</PDAT></SB></HIL><PDAT>&equals;tan</PDAT><HIL><SP><PDAT>&minus;1</PDAT></SP></HIL><PDAT>(n</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>/n</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>) of the multilayer structure because at this angle, the TM mode will be transmitted through. This condition is met when the Brewster line lies outside of the light line, or, terms of the refractive indices of the layers, sin</PDAT><HIL><SP><PDAT>&minus;1</PDAT></SP></HIL><PDAT>(n</PDAT><HIL><SB><PDAT>0</PDAT></SB></HIL><PDAT>/n</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>)&lt;&thgr;</PDAT><HIL><SB><PDAT>B</PDAT></SB></HIL><PDAT>. A sufficient condition is the existence of a particular frequency at which no propagating mode within the crystal exists between k</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>&equals;0 and k</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>&equals;&ohgr;/c.</PDAT></PTEXT></PARA>
<PARA ID="P-00036" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2A</PDAT></FGREF><PDAT> is an example of a structure, which does not have an omnidirectional reflectivity range even though its Brewster crossing is inaccessible to light coming from the homogeneous medium (the Brewster crossing lies outside of the light cone). This is due to the large group velocity of modes in the lower band edge of the TM mode which allow every frequency to couple to a propagating state in the crystal. This should be contrasted with </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2B</PDAT></FGREF><PDAT>, which exhibits an omnidirectional reflectivity range (area </PDAT><HIL><BOLD><PDAT>214</PDAT></BOLD></HIL><PDAT>). The high indices of refraction actually allow for the opening of an additional omnidirectional reflectivity range (area </PDAT><HIL><BOLD><PDAT>216</PDAT></BOLD></HIL><PDAT>) in the higher harmonic as well.</PDAT></PTEXT></PARA>
<PARA ID="P-00037" LVL="0"><PTEXT><PDAT>The omnidirectional range is defined from above by the normal incidence band edge &ohgr;</PDAT><HIL><SB><PDAT>h</PDAT></SB></HIL><PDAT>&lsqb;(k</PDAT><HIL><SB><PDAT>x</PDAT></SB></HIL><PDAT>&equals;&pgr;/a, k</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>&equals;0&rsqb;(point </PDAT><HIL><BOLD><PDAT>220</PDAT></BOLD></HIL><PDAT>), and below by the intersection of the top of the TM allowed band edge with the light line &ohgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&lsqb;k</PDAT><HIL><SB><PDAT>x</PDAT></SB></HIL><PDAT>&equals;&pgr;/a,k</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>&equals;&ohgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>/c&rsqb;(point </PDAT><HIL><BOLD><PDAT>222</PDAT></BOLD></HIL><PDAT>).</PDAT></PTEXT></PARA>
<PARA ID="P-00038" LVL="0"><PTEXT><PDAT>The exact expression for the band edges is </PDAT>
<CWU>
<MATH-US ID="MATH-US-00001">
<MATHEMATICA ID="MATHEMATICA-00001" ALT="mathematica file" FILE="US06463200-20021008-M00001.NB"/>
<MATHML>
<math>
<mtable>
  <mtr>
    <mtd>
      <mrow>
        <mrow>
          <mrow>
            <mrow>
              <mfrac>
                <mrow>
                  <mn>1</mn>
                  <mo>+</mo>
                  <mi>&Lambda;</mi>
                </mrow>
                <mn>2</mn>
              </mfrac>
              <mo>&it;</mo>
              <mrow>
                <mi>cos</mi>
                <mo>&af;</mo>
                <mrow>
                  <mo>(</mo>
                  <mrow>
                    <mrow>
                      <msubsup>
                        <mi>k</mi>
                        <mi>x</mi>
                        <mrow>
                          <mo>(</mo>
                          <mn>1</mn>
                          <mo>)</mo>
                        </mrow>
                      </msubsup>
                      <mo>&it;</mo>
                      <msub>
                        <mi>h</mi>
                        <mn>1</mn>
                      </msub>
                    </mrow>
                    <mo>+</mo>
                    <mrow>
                      <msubsup>
                        <mi>k</mi>
                        <mi>x</mi>
                        <mrow>
                          <mo>(</mo>
                          <mn>2</mn>
                          <mo>)</mo>
                        </mrow>
                      </msubsup>
                      <mo>&it;</mo>
                      <msub>
                        <mi>h</mi>
                        <mn>2</mn>
                      </msub>
                    </mrow>
                  </mrow>
                  <mo>)</mo>
                </mrow>
              </mrow>
            </mrow>
            <mo>+</mo>
            <mrow>
              <mfrac>
                <mrow>
                  <mn>1</mn>
                  <mo>-</mo>
                  <mi>&Lambda;</mi>
                </mrow>
                <mn>2</mn>
              </mfrac>
              <mo>&it;</mo>
              <mrow>
                <mi>cos</mi>
                <mo>&af;</mo>
                <mrow>
                  <mo>(</mo>
                  <mrow>
                    <mrow>
                      <msubsup>
                        <mi>k</mi>
                        <mi>x</mi>
                        <mrow>
                          <mo>(</mo>
                          <mn>1</mn>
                          <mo>)</mo>
                        </mrow>
                      </msubsup>
                      <mo>&it;</mo>
                      <msub>
                        <mi>h</mi>
                        <mn>1</mn>
                      </msub>
                    </mrow>
                    <mo>-</mo>
                    <mrow>
                      <msubsup>
                        <mi>k</mi>
                        <mi>x</mi>
                        <mrow>
                          <mo>(</mo>
                          <mn>2</mn>
                          <mo>)</mo>
                        </mrow>
                      </msubsup>
                      <mo>&it;</mo>
                      <msub>
                        <mi>h</mi>
                        <mn>2</mn>
                      </msub>
                    </mrow>
                  </mrow>
                  <mo>)</mo>
                </mrow>
              </mrow>
            </mrow>
            <mo>+</mo>
            <mn>1</mn>
          </mrow>
          <mo>=</mo>
          <mn>0</mn>
        </mrow>
        <mo>,</mo>
      </mrow>
    </mtd>
    <mtd>
      <mrow>
        <mo>(</mo>
        <mn>3</mn>
        <mo>)</mo>
      </mrow>
    </mtd>
  </mtr>
</mtable>
</math>
</MATHML>
<EMI ID="EMI-M00001" ALT="embedded image" FILE="US06463200-20021008-M00001.TIF"/>
</MATH-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00039" LVL="7"><PTEXT><PDAT>where k</PDAT><HIL><SB><PDAT>x</PDAT></SB></HIL><HIL><SP><PDAT>(&agr;)</PDAT></SP></HIL><PDAT>&equals;{square root over (&lsqb;&ohgr;n</PDAT><HIL><SB><PDAT>&agr;</PDAT></SB></HIL><PDAT>/c&rsqb;</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>&minus;k</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT></PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>)}(&agr;&equals;1,2) and </PDAT>
<CWU>
<MATH-US ID="MATH-US-00002">
<MATHEMATICA ID="MATHEMATICA-00002" ALT="mathematica file" FILE="US06463200-20021008-M00002.NB"/>
<MATHML>
<math>
<mtable>
  <mtr>
    <mtd>
      <mrow>
        <mi>&Lambda;</mi>
        <mo>&Congruent;</mo>
        <mrow>
          <mo>{</mo>
          <mtable>
            <mtr>
              <mtd>
                <mrow>
                  <mfrac>
                    <mn>1</mn>
                    <mn>2</mn>
                  </mfrac>
                  <mo>&it;</mo>
                  <mrow>
                    <mo>(</mo>
                    <mrow>
                      <mfrac>
                        <msubsup>
                          <mi>k</mi>
                          <mi>x</mi>
                          <mrow>
                            <mo>(</mo>
                            <mn>2</mn>
                            <mo>)</mo>
                          </mrow>
                        </msubsup>
                        <msubsup>
                          <mi>k</mi>
                          <mi>x</mi>
                          <mrow>
                            <mo>(</mo>
                            <mn>1</mn>
                            <mo>)</mo>
                          </mrow>
                        </msubsup>
                      </mfrac>
                      <mo>+</mo>
                      <mfrac>
                        <msubsup>
                          <mi>k</mi>
                          <mi>x</mi>
                          <mrow>
                            <mo>(</mo>
                            <mn>1</mn>
                            <mo>)</mo>
                          </mrow>
                        </msubsup>
                        <msubsup>
                          <mi>k</mi>
                          <mi>x</mi>
                          <mrow>
                            <mo>(</mo>
                            <mn>2</mn>
                            <mo>)</mo>
                          </mrow>
                        </msubsup>
                      </mfrac>
                    </mrow>
                    <mo>)</mo>
                  </mrow>
                </mrow>
              </mtd>
              <mtd>
                <mrow>
                  <mi>TE</mi>
                  <mo>,</mo>
                </mrow>
              </mtd>
            </mtr>
            <mtr>
              <mtd>
                <mrow>
                  <mfrac>
                    <mn>1</mn>
                    <mn>2</mn>
                  </mfrac>
                  <mo>&it;</mo>
                  <mrow>
                    <mo>(</mo>
                    <mrow>
                      <mfrac>
                        <mrow>
                          <msubsup>
                            <mi>n</mi>
                            <mn>1</mn>
                            <mn>2</mn>
                          </msubsup>
                          <mo>&it;</mo>
                          <msubsup>
                            <mi>k</mi>
                            <mi>x</mi>
                            <mrow>
                              <mo>(</mo>
                              <mn>2</mn>
                              <mo>)</mo>
                            </mrow>
                          </msubsup>
                        </mrow>
                        <mrow>
                          <msubsup>
                            <mi>n</mi>
                            <mn>2</mn>
                            <mn>2</mn>
                          </msubsup>
                          <mo>&it;</mo>
                          <msubsup>
                            <mi>k</mi>
                            <mi>x</mi>
                            <mrow>
                              <mo>(</mo>
                              <mn>1</mn>
                              <mo>)</mo>
                            </mrow>
                          </msubsup>
                        </mrow>
                      </mfrac>
                      <mo>+</mo>
                      <mfrac>
                        <mrow>
                          <msubsup>
                            <mi>n</mi>
                            <mn>2</mn>
                            <mn>2</mn>
                          </msubsup>
                          <mo>&it;</mo>
                          <msubsup>
                            <mi>k</mi>
                            <mi>x</mi>
                            <mrow>
                              <mo>(</mo>
                              <mn>1</mn>
                              <mo>)</mo>
                            </mrow>
                          </msubsup>
                        </mrow>
                        <mrow>
                          <msubsup>
                            <mi>n</mi>
                            <mn>1</mn>
                            <mn>2</mn>
                          </msubsup>
                          <mo>&it;</mo>
                          <msubsup>
                            <mi>k</mi>
                            <mi>x</mi>
                            <mrow>
                              <mo>(</mo>
                              <mn>2</mn>
                              <mo>)</mo>
                            </mrow>
                          </msubsup>
                        </mrow>
                      </mfrac>
                    </mrow>
                    <mo>)</mo>
                  </mrow>
                </mrow>
              </mtd>
              <mtd>
                <mrow>
                  <mi>TM</mi>
                  <mo>.</mo>
                </mrow>
              </mtd>
            </mtr>
          </mtable>
        </mrow>
      </mrow>
    </mtd>
    <mtd>
      <mrow>
        <mo>(</mo>
        <mn>4</mn>
        <mo>)</mo>
      </mrow>
    </mtd>
  </mtr>
</mtable>
</math>
</MATHML>
<EMI ID="EMI-M00002" ALT="embedded image" FILE="US06463200-20021008-M00002.TIF"/>
</MATH-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00040" LVL="7"><PTEXT><PDAT>A dimensionless parameter used to quantify the extent of the omnidirectional reflection range is the range to midrange ratio defined as &lsqb;&ohgr;</PDAT><HIL><SB><PDAT>h</PDAT></SB></HIL><PDAT>&minus;&ohgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>)/1/2(&ohgr;</PDAT><HIL><SB><PDAT>h</PDAT></SB></HIL><PDAT>&plus;&ohgr;</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>). </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> is a a plot of this ratio as a function of n</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>/n</PDAT><HIL><SB><PDAT>1 </PDAT></SB></HIL><PDAT>and n</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>/n</PDAT><HIL><SB><PDAT>0 </PDAT></SB></HIL><PDAT>where &ohgr;</PDAT><HIL><SB><PDAT>h </PDAT></SB></HIL><PDAT>and &ohgr;</PDAT><HIL><SB><PDAT>1 </PDAT></SB></HIL><PDAT>are determined by solutions of Eq. 3 with quarter wave layer thickness, and n</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&gt;n</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>. The contours in this figure represent various equi-omnidirectional ranges for different material index parameters and could be useful for design purposes. The ratio for the exemplary materials is approximately 45% (n</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>/n</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&equals;2.875, n</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>/n</PDAT><HIL><SB><PDAT>0</PDAT></SB></HIL><PDAT>&equals;1.6), and it is located at the intersection of the dashed lines at point </PDAT><HIL><BOLD><PDAT>300</PDAT></BOLD></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00041" LVL="0"><PTEXT><PDAT>It may also be useful to have an approximate analytical expression for the extent of the gap. This can be obtained by setting cos&lsqb;k</PDAT><HIL><SB><PDAT>x</PDAT></SB></HIL><HIL><SP><PDAT>(1)</PDAT></SP></HIL><PDAT>h</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&minus;k</PDAT><HIL><SB><PDAT>x</PDAT></SB></HIL><HIL><SP><PDAT>(2)</PDAT></SP></HIL><PDAT>h</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&rsqb;&equiv;1 in Eq. 3. It is found that that for a given incident angle &thgr;</PDAT><HIL><SB><PDAT>0</PDAT></SB></HIL><PDAT>, the approximate width in frequency is </PDAT>
<CWU>
<MATH-US ID="MATH-US-00003">
<MATHEMATICA ID="MATHEMATICA-00003" ALT="mathematica file" FILE="US06463200-20021008-M00003.NB"/>
<MATHML>
<math>
<mtable>
  <mtr>
    <mtd>
      <mrow>
        <mrow>
          <mi>&Delta;</mi>
          <mo>&it;</mo>
          <mstyle>
            <mtext>&emsp;</mtext>
          </mstyle>
          <mo>&it;</mo>
          <mrow>
            <mi>&omega;</mi>
            <mo>&af;</mo>
            <mrow>
              <mo>(</mo>
              <msub>
                <mi>&theta;</mi>
                <mn>0</mn>
              </msub>
              <mo>)</mo>
            </mrow>
          </mrow>
        </mrow>
        <mo>=</mo>
        <mrow>
          <mrow>
            <mfrac>
              <mrow>
                <mn>2</mn>
                <mo>&it;</mo>
                <mi>c</mi>
              </mrow>
              <mrow>
                <mrow>
                  <msub>
                    <mi>h</mi>
                    <mn>1</mn>
                  </msub>
                  <mo>&it;</mo>
                  <msqrt>
                    <mrow>
                      <msubsup>
                        <mi>n</mi>
                        <mn>1</mn>
                        <mn>2</mn>
                      </msubsup>
                      <mo>-</mo>
                      <mrow>
                        <msubsup>
                          <mi>n</mi>
                          <mn>0</mn>
                          <mn>2</mn>
                        </msubsup>
                        <mo>&it;</mo>
                        <msup>
                          <mi>sin</mi>
                          <mn>2</mn>
                        </msup>
                        <mo>&it;</mo>
                        <msub>
                          <mi>&theta;</mi>
                          <mn>0</mn>
                        </msub>
                      </mrow>
                    </mrow>
                  </msqrt>
                </mrow>
                <mo>+</mo>
                <mrow>
                  <msub>
                    <mi>h</mi>
                    <mn>2</mn>
                  </msub>
                  <mo>&it;</mo>
                  <msqrt>
                    <mrow>
                      <msubsup>
                        <mi>n</mi>
                        <mn>2</mn>
                        <mn>2</mn>
                      </msubsup>
                      <mo>-</mo>
                      <mrow>
                        <msubsup>
                          <mi>n</mi>
                          <mn>0</mn>
                          <mn>2</mn>
                        </msubsup>
                        <mo>&it;</mo>
                        <msup>
                          <mi>sin</mi>
                          <mn>2</mn>
                        </msup>
                        <mo>&it;</mo>
                        <msub>
                          <mi>&theta;</mi>
                          <mn>0</mn>
                        </msub>
                      </mrow>
                    </mrow>
                  </msqrt>
                </mrow>
              </mrow>
            </mfrac>
            <mo>[</mo>
            <mstyle>
              <mtext>&emsp;</mtext>
            </mstyle>
            <mo>&it;</mo>
            <mrow>
              <mrow>
                <msup>
                  <mi>cos</mi>
                  <mrow>
                    <mo>-</mo>
                    <mn>1</mn>
                  </mrow>
                </msup>
                <mo>&af;</mo>
                <mrow>
                  <mo>(</mo>
                  <mrow>
                    <mo>-</mo>
                    <msqrt>
                      <mfrac>
                        <mrow>
                          <mi>&Lambda;</mi>
                          <mo>-</mo>
                          <mn>1</mn>
                        </mrow>
                        <mrow>
                          <mi>&Lambda;</mi>
                          <mo>+</mo>
                          <mn>1</mn>
                        </mrow>
                      </mfrac>
                    </msqrt>
                  </mrow>
                  <mo>)</mo>
                </mrow>
              </mrow>
              <mo>-</mo>
              <mrow>
                <msup>
                  <mi>cos</mi>
                  <mrow>
                    <mo>-</mo>
                    <mn>1</mn>
                  </mrow>
                </msup>
                <mo>&af;</mo>
                <mrow>
                  <mo>(</mo>
                  <msqrt>
                    <mfrac>
                      <mrow>
                        <mi>&Lambda;</mi>
                        <mo>-</mo>
                        <mn>1</mn>
                      </mrow>
                      <mrow>
                        <mi>&Lambda;</mi>
                        <mo>+</mo>
                        <mn>1</mn>
                      </mrow>
                    </mfrac>
                  </msqrt>
                  <mo>)</mo>
                </mrow>
              </mrow>
            </mrow>
            <mo>]</mo>
          </mrow>
          <mo>.</mo>
        </mrow>
      </mrow>
    </mtd>
    <mtd>
      <mrow>
        <mo>(</mo>
        <mn>5</mn>
        <mo>)</mo>
      </mrow>
    </mtd>
  </mtr>
</mtable>
</math>
</MATHML>
<EMI ID="EMI-M00003" ALT="embedded image" FILE="US06463200-20021008-M00003.TIF"/>
</MATH-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00042" LVL="7"><PTEXT><PDAT>At normal incidence there is no distinction between TM and TE modes. At increasingly oblique angles the gap of the TE mode increases, whereas the gap of the TM mode decreases. In addition, the center of the gap shifts to higher frequencies. Therefore, the criterion for the existence of omnidirectional reflectivity can be restated as the occurrence of a frequency overlap between the gap at normal incidence and the gap of the TM mode at 90&deg;. Analytical expressions for the range to midrange ratio can be obtained by setting </PDAT>
<CWU>
<MATH-US ID="MATH-US-00004">
<MATHEMATICA ID="MATHEMATICA-00004" ALT="mathematica file" FILE="US06463200-20021008-M00004.NB"/>
<MATHML>
<math>
<mtable>
  <mtr>
    <mtd>
      <mrow>
        <mrow>
          <msub>
            <mi>&omega;</mi>
            <mi>h</mi>
          </msub>
          <mo>=</mo>
          <mrow>
            <mfrac>
              <mrow>
                <mn>2</mn>
                <mo>&it;</mo>
                <mi>c</mi>
              </mrow>
              <mrow>
                <mrow>
                  <msub>
                    <mi>h</mi>
                    <mn>2</mn>
                  </msub>
                  <mo>&it;</mo>
                  <msub>
                    <mi>n</mi>
                    <mn>2</mn>
                  </msub>
                </mrow>
                <mo>+</mo>
                <mrow>
                  <msub>
                    <mi>h</mi>
                    <mn>1</mn>
                  </msub>
                  <mo>&it;</mo>
                  <msub>
                    <mi>n</mi>
                    <mn>1</mn>
                  </msub>
                </mrow>
              </mrow>
            </mfrac>
            <mo>&it;</mo>
            <mrow>
              <msup>
                <mi>cos</mi>
                <mrow>
                  <mo>-</mo>
                  <mn>1</mn>
                </mrow>
              </msup>
              <mo>&af;</mo>
              <mrow>
                <mo>(</mo>
                <mrow>
                  <mo>-</mo>
                  <mrow>
                    <mo>&LeftBracketingBar;</mo>
                    <mfrac>
                      <mrow>
                        <msub>
                          <mi>n</mi>
                          <mn>1</mn>
                        </msub>
                        <mo>-</mo>
                        <msub>
                          <mi>n</mi>
                          <mn>2</mn>
                        </msub>
                      </mrow>
                      <mrow>
                        <msub>
                          <mi>n</mi>
                          <mn>1</mn>
                        </msub>
                        <mo>+</mo>
                        <msub>
                          <mi>n</mi>
                          <mn>2</mn>
                        </msub>
                      </mrow>
                    </mfrac>
                    <mo>&RightBracketingBar;</mo>
                  </mrow>
                </mrow>
                <mo>)</mo>
              </mrow>
            </mrow>
          </mrow>
        </mrow>
        <mo>,</mo>
        <mstyle>
          <mtext>&NewLine;</mtext>
        </mstyle>
        <mo>&it;</mo>
        <mrow>
          <msub>
            <mi>&omega;</mi>
            <mi>l</mi>
          </msub>
          <mo>=</mo>
          <mrow>
            <mfrac>
              <mrow>
                <mn>2</mn>
                <mo>&it;</mo>
                <mi>c</mi>
              </mrow>
              <mrow>
                <mrow>
                  <msub>
                    <mi>h</mi>
                    <mn>2</mn>
                  </msub>
                  <mo>&it;</mo>
                  <msqrt>
                    <mrow>
                      <msubsup>
                        <mi>n</mi>
                        <mn>2</mn>
                        <mn>2</mn>
                      </msubsup>
                      <mo>-</mo>
                      <mn>1</mn>
                    </mrow>
                  </msqrt>
                </mrow>
                <mo>+</mo>
                <mrow>
                  <msub>
                    <mi>h</mi>
                    <mn>1</mn>
                  </msub>
                  <mo>&it;</mo>
                  <msqrt>
                    <mrow>
                      <msubsup>
                        <mi>n</mi>
                        <mn>1</mn>
                        <mn>2</mn>
                      </msubsup>
                      <mo>-</mo>
                      <mn>1</mn>
                    </mrow>
                  </msqrt>
                </mrow>
              </mrow>
            </mfrac>
            <mo>&it;</mo>
            <mrow>
              <mrow>
                <msup>
                  <mi>cos</mi>
                  <mrow>
                    <mo>-</mo>
                    <mn>1</mn>
                  </mrow>
                </msup>
                <mo>&af;</mo>
                <mrow>
                  <mo>(</mo>
                  <mrow>
                    <mo>&LeftBracketingBar;</mo>
                    <mfrac>
                      <mrow>
                        <mrow>
                          <msubsup>
                            <mi>n</mi>
                            <mn>1</mn>
                            <mn>2</mn>
                          </msubsup>
                          <mo>&it;</mo>
                          <msqrt>
                            <mrow>
                              <msubsup>
                                <mi>n</mi>
                                <mn>2</mn>
                                <mn>2</mn>
                              </msubsup>
                              <mo>-</mo>
                              <mn>1</mn>
                            </mrow>
                          </msqrt>
                        </mrow>
                        <mo>-</mo>
                        <mrow>
                          <msubsup>
                            <mi>n</mi>
                            <mn>2</mn>
                            <mn>2</mn>
                          </msubsup>
                          <mo>&it;</mo>
                          <msqrt>
                            <mrow>
                              <msubsup>
                                <mi>n</mi>
                                <mn>1</mn>
                                <mn>2</mn>
                              </msubsup>
                              <mo>-</mo>
                              <mn>1</mn>
                            </mrow>
                          </msqrt>
                        </mrow>
                      </mrow>
                      <mrow>
                        <mrow>
                          <msubsup>
                            <mi>n</mi>
                            <mn>1</mn>
                            <mn>2</mn>
                          </msubsup>
                          <mo>&it;</mo>
                          <msqrt>
                            <mrow>
                              <msubsup>
                                <mi>n</mi>
                                <mn>2</mn>
                                <mn>2</mn>
                              </msubsup>
                              <mo>-</mo>
                              <mn>1</mn>
                            </mrow>
                          </msqrt>
                        </mrow>
                        <mo>+</mo>
                        <mrow>
                          <msubsup>
                            <mi>n</mi>
                            <mn>2</mn>
                            <mn>2</mn>
                          </msubsup>
                          <mo>&it;</mo>
                          <msqrt>
                            <mrow>
                              <msubsup>
                                <mi>n</mi>
                                <mn>1</mn>
                                <mn>2</mn>
                              </msubsup>
                              <mo>-</mo>
                              <mn>1</mn>
                            </mrow>
                          </msqrt>
                        </mrow>
                      </mrow>
                    </mfrac>
                    <mo>&RightBracketingBar;</mo>
                  </mrow>
                  <mo>)</mo>
                </mrow>
              </mrow>
              <mo>.</mo>
            </mrow>
          </mrow>
        </mrow>
      </mrow>
    </mtd>
    <mtd>
      <mrow>
        <mo>(</mo>
        <mn>6</mn>
        <mo>)</mo>
      </mrow>
    </mtd>
  </mtr>
</mtable>
</math>
</MATHML>
<EMI ID="EMI-M00004" ALT="embedded image" FILE="US06463200-20021008-M00004.TIF"/>
</MATH-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00043" LVL="0"><PTEXT><PDAT>Moreover, the maximum range width is attained for thickness values that are not equal to the quarter wave stack though the increase in bandwidth gained by deviating from the quarter wave stack is typically only a few percent.</PDAT></PTEXT></PARA>
<PARA ID="P-00044" LVL="0"><PTEXT><PDAT>In general, the TM mode defines the lower frequency edge of the omnidirectional range. An example can be seen in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2B</PDAT></FGREF><PDAT> for a particular choice of the indices of refraction. This can be proven by showing that </PDAT>
<CWU>
<MATH-US ID="MATH-US-00005">
<MATHEMATICA ID="MATHEMATICA-00005" ALT="mathematica file" FILE="US06463200-20021008-M00005.NB"/>
<MATHML>
<math>
<mtable>
  <mtr>
    <mtd>
      <mrow>
        <msub>
          <mrow>
            <mo>&AutoLeftMatch;</mo>
            <mfrac>
              <mrow>
                <mo>&PartialD;</mo>
                <mi>&omega;</mi>
              </mrow>
              <mrow>
                <mo>&PartialD;</mo>
                <msub>
                  <mi>k</mi>
                  <mi>y</mi>
                </msub>
              </mrow>
            </mfrac>
            <mo>&RightBracketingBar;</mo>
          </mrow>
          <mi>TM</mi>
        </msub>
        <mo>&GreaterEqual;</mo>
        <msub>
          <mrow>
            <mo>&AutoLeftMatch;</mo>
            <mfrac>
              <mrow>
                <mo>&PartialD;</mo>
                <mi>&omega;</mi>
              </mrow>
              <mrow>
                <mo>&PartialD;</mo>
                <msub>
                  <mi>k</mi>
                  <mi>y</mi>
                </msub>
              </mrow>
            </mfrac>
            <mo>&RightBracketingBar;</mo>
          </mrow>
          <mi>TE</mi>
        </msub>
      </mrow>
    </mtd>
    <mtd>
      <mrow>
        <mo>(</mo>
        <mn>7</mn>
        <mo>)</mo>
      </mrow>
    </mtd>
  </mtr>
</mtable>
</math>
</MATHML>
<EMI ID="EMI-M00005" ALT="embedded image" FILE="US06463200-20021008-M00005.TIF"/>
</MATH-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00045" LVL="7"><PTEXT><PDAT>in the region that resides inside the light line. The physical reason for Eq. 7 lies in the vectorial nature of the electric field. In the upper portion of the first band the electric field concentrates its energy in the high dielectric regions.</PDAT></PTEXT></PARA>
<PARA ID="P-00046" LVL="0"><PTEXT><PDAT>Away from normal incidence the electric field in the TM mode has a component in the direction of periodicity. This component forces a larger portion of the electric field into the low dielectric regions. The group velocity of the TM mode is therefore enhanced. In contrast, the electric field of the TE mode is always perpendicular to the direction of periodicity and can concentrate its energy primarily in the high dielectric region.</PDAT></PTEXT></PARA>
<PARA ID="P-00047" LVL="0"><PTEXT><PDAT>A polystyrene-tellurium (PS-Te) materials system was chosen to demonstrate omnidirectional reflectivity. Tellurium has a high index of refraction and low loss characteristics in the frequency range of interest. In addition, its relatively low latent heat of condensation together with the high glass transition temperature of the PS minimizes diffusion of Te into the polymer layer. The choice of PS, which has a series of absorption peaks in the measurement range, demonstrates the competition between reflectivity and absorption that occurs when an absorption peak is located in the evanescent state region. The Te(0.8 &mgr;m) and PS (1.65 &mgr;m) films were deposited sequentially to create a nine-layer film.</PDAT></PTEXT></PARA>
<PARA ID="P-00048" LVL="0"><PTEXT><PDAT>A 0.8&plusmn;0.09 &mgr;m thick layer of tellurium (99.99&plus;%, Strem Chemicals) was vacuum evaporated at 10</PDAT><HIL><SP><PDAT>&minus;6 </PDAT></SP></HIL><PDAT>torr and 7A (Ladd Industries 30000) onto a NaCl 25 mm salt substrate (polished NaCl window, Wilmad Glass). The layer thickness and deposition rate were monitored in-situ using a crystal thickness monitor (Sycon STM 100). A 10% solution of polystyrene (Goodyear PS standard, 110,000 g/mol) in toluene was spin cast at 1000 RPM onto the tellurium coated substrate and allowed to dry for a few hours, the polymer layer thickness is 1.65&plusmn;0.09 &mgr;m . The nine layer film sequence was Te/PS/Te/PS/Te/PS/Te/PS/Te.</PDAT></PTEXT></PARA>
<PARA ID="P-00049" LVL="0"><PTEXT><PDAT>The optical response of this particular multilayer film was designed to have a high reflectivity region in the 10 to 15 &mgr;m range for any angle of incidence (in the experiment we measure from 0&deg; to 80&deg;). The optical response at oblique angles of incidence was measured using a Fourier Transform Infrared Spectrometer (Nicolet 860) fitted with a polarizer (ZnS SpectraTech) and an angular reflectivity stage (VeeMax by SpectraTech). At normal incidence, the reflectivity was measured using a Nicolet Infrared Microscope. A freshly evaporated aluminum mirror was used as a background for the reflectance measurements.</PDAT></PTEXT></PARA>
<PARA ID="P-00050" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT> is a series of graphs showing the calculated (solid line) and measured (dashed line) reflectance (%) as a function of wavelength for TM and TE modes at normal, 45&deg;, and 80&deg; angles of incidence, thus showing an omnidirectional reflectivity band. </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT> illustrates the good agreement between the calculated and measured reflectance spectra. The calculations were done using the transfer matrix method described in F. Abeles, Ann. De Physique 5, 706 (1950), incorporated herein by reference, using the film parameters.</PDAT></PTEXT></PARA>
<PARA ID="P-00051" LVL="0"><PTEXT><PDAT>The regimes of high reflectivity at the different angles of incidence overlap, thus forming a reflective range of frequencies for light of any angle of incidence. The frequency location of the omnidirectional range is determined by the layer thickness and can be tuned to meet specifications. The range is calculated from Eq. 6 to be 5.6 &mgr;m and the center wavelength is 12.4 &mgr;m corresponding to a 45% range to midrange ratio shown in dashed lines in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> for the experimental index of refraction parameters. These values are in agreement with the measured data. The calculations are for lossless media and therefore do not predict the PS absorption band at&tilde;13 and 14 microns. The PS absorption peak is seen to increase at larger angles of incidence for the TM mode, and decrease for the TE mode.</PDAT></PTEXT></PARA>
<PARA ID="P-00052" LVL="0"><PTEXT><PDAT>The physical basis for this phenomena lies in the relation between the penetration depth and the amount of absorption. The penetration length is &xgr;&prop;Im(1/K), with K the Bloch wave number. It can be shown that &xgr; is a monotonically increasing function of the incident angle for the TM mode of an omnidirectional reflector, and is relatively constant for the TE mode. Thus, the TM mode penetrates deeper into the structure at increasing angles of incidence and is more readily absorbed, as is shown in the table of FIG. </PDAT><HIL><BOLD><PDAT>5</PDAT></BOLD></HIL><PDAT>. The magnitude of the imaginary part of the Bloch wave number for a mode lying in the gap is related to its distance from the band edges. This distance increases in the TE mode due to the widening of the gap at increasing angles of incidence and decreases in the TM mode due to the shrinking of the gap.</PDAT></PTEXT></PARA>
<PARA ID="P-00053" LVL="0"><PTEXT><PDAT>The PS-Te structure does not have a complete photonic bandgap. Its omnidirectional reflectivity is due instead to the restricted phase space available to the propagating states of the system. The materials and processes were chosen for their low cost and applicability to large area coverage. In addition to omnidirectionality, the measurements show that a polymer, while lossy in the infrared, can still be used for reflection applications without a considerable sacrifice of performance. The possibility of achieving omnidirectional reflectivity itself is not associated with any particular choice of materials and can be applied to many wavelengths of interest. The structure of the invention offers metallic-like omnidirectional reflectivity for a wide range of frequencies, and at the same time is of low loss. In addition, it allows the flexibility of frequency selection.</PDAT></PTEXT></PARA>
<PARA ID="P-00054" LVL="0"><PTEXT><PDAT>In accordance with the invention, the confinement of light in cavities and wave guides using an omnidirectional multilayer film will now be described. The multilayer film structure has been described in co-pending applications Ser. No. 09/253,379 now U.S Pat. No. 6,130,780 filed Feb. 19, 1999 and Ser. No. 09/267,854 filed Mar. 12, 1999, of common assignee, and incorporated herein by reference. Specifically, a method is presented for creating very low loss broad band optical fibers, which are capable of transmitting around Rha* bends. In addition, a design is presented for improving the delivering power of a near field optical fiber tip.</PDAT></PTEXT></PARA>
<PARA ID="P-00055" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 6A</PDAT></FGREF><PDAT> is a simplified block diagram cross section of an exemplary structure </PDAT><HIL><BOLD><PDAT>600</PDAT></BOLD></HIL><PDAT>. </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 6B</PDAT></FGREF><PDAT> is a corresponding cross section radial index of refraction profile of the structure </PDAT><HIL><BOLD><PDAT>600</PDAT></BOLD></HIL><PDAT>. The structure consists of concentric cylindrical layers </PDAT><HIL><BOLD><PDAT>604</PDAT></BOLD></HIL><PDAT>-</PDAT><HIL><BOLD><PDAT>616</PDAT></BOLD></HIL><PDAT> with alternating indices of refraction n</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>, n</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>centered on a core </PDAT><HIL><BOLD><PDAT>602</PDAT></BOLD></HIL><PDAT> of low dielectric material n</PDAT><HIL><SB><PDAT>0</PDAT></SB></HIL><PDAT>, such as air. The radius of the core is h</PDAT><HIL><SB><PDAT>0 </PDAT></SB></HIL><PDAT>and the layer thicknesses are h</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>, h</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>. Note that an exemplary embodiment would involve each layer consisting of different material and corresponding different layer thickness. The parameters of the multilayer film are chosen such that light from any incident angle and polarization is completely reflected by the multilayer for the range of signal frequencies.</PDAT></PTEXT></PARA>
<PARA ID="P-00056" LVL="0"><PTEXT><PDAT>For example, for values of n</PDAT><HIL><SB><PDAT>0</PDAT></SB></HIL><PDAT>, n</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>, n</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>, h</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>, and h</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>as in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2B</PDAT></FGREF><PDAT>, light can be guided for any frequency within the two broadband omnidirectional reflection ranges </PDAT><HIL><BOLD><PDAT>214</PDAT></BOLD></HIL><PDAT> and </PDAT><HIL><BOLD><PDAT>216</PDAT></BOLD></HIL><PDAT>. As is generally the case, the electromagnetic radiation will be multi-mode or single-mode depending on the size of the region in which it is confined. Thus, within each broadband range the electromagnetic radiation can be multi-mode or single mode depending on the size of the inner core region. For large core radii, the light will be multi-mode and for very small radii the light will be single mode.</PDAT></PTEXT></PARA>
<PARA ID="P-00057" LVL="0"><PTEXT><PDAT>Conventional optical fibers confine a propagating EM pulse by total internal reflection where the electromagnetic (EM) wave travels through a high index fiber core surrounded by low-index cladding. In accordance with the invention, the method of confinement in the Omniguide&trade; waveguide structure is the polarization independent omnidirectional reflectance of EM waves at the walls of the hollow fiber. The advantages of this mode of confinement are numerous.</PDAT></PTEXT></PARA>
<PARA ID="P-00058" LVL="0"><PTEXT><PDAT>There is very low loss associated with material absorption since the wave travels essentially through air, which is extremely low loss when compared with any dense medium. This enables low loss propagation which is of importance in basically every device that involves light guiding for communication, lasers and more.</PDAT></PTEXT></PARA>
<PARA ID="P-00059" LVL="0"><PTEXT><PDAT>Conventional optical communication fibers need amplification to compensate for absorption losses in the material, and to this end, the fiber is periodically doped with erbium. The use of erbium severely limits the bandwidth of the fiber. Since the structure of the invention is very low loss and does not need amplification, orders of magnitude increase in the usable bandwidth is possible. In addition, the omnidirectional multilayer structure provides a strong confinement mechanism and will propagate signals around very sharp bends as demonstrated in other systems with strong confinement mechanisms.</PDAT></PTEXT></PARA>
<PARA ID="P-00060" LVL="0"><PTEXT><PDAT>Such a multilayer coated fiber will also be important for improving the delivering power of a fiber tip in a near-field scanning optical microscope. The tip is used to deliver optical power with a spot size far smaller than the wavelength of light. Metal coating is currently employed in order to confine light to such a small length scale. Metal coatings have material absorption losses, which in this case limits the maximum delivery power. The fiber tip with a multilayer coating overcomes this problem since it is essentially lossless.</PDAT></PTEXT></PARA>
<PARA ID="P-00061" LVL="0"><PTEXT><PDAT>The ultimate goal is to create a hollow structure with walls made of a multilayer coating in accordance with the structure described heretofore. The structure may be of, but is not limited to, a cylindrical geometry. One method to produce such a structure is to take a thin wall hollow fiber made of glass or polymer and coat it with alternating layers of dielectrics. The layers could be made of a polymer or glass as the low refractive index component, and Germanium or Tellurium as the high index material. One would then take the fiber and evaporate a layer of prescribed thickness using a thermal evaporator or sputtering device. The subsequent low index layer would be deposited by dipping the fiber in a dilute solution of the polymer, or by evaporating a monomer followed by a rapid polymerization.</PDAT></PTEXT></PARA>
<PARA ID="P-00062" LVL="0"><PTEXT><PDAT>Another exemplary method would be the coextrusion of the entire structure using a combination of immiscible polymers, one loaded with a high index component in a fine powder form the other without additives as in FIG. </PDAT><HIL><BOLD><PDAT>7</PDAT></BOLD></HIL><PDAT>. </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 7</PDAT></FGREF><PDAT> is a cross section of a simplified schematic diagram of a coextrusion assembly </PDAT><HIL><BOLD><PDAT>700</PDAT></BOLD></HIL><PDAT> in accordance with the invention. An extruding device </PDAT><HIL><BOLD><PDAT>702</PDAT></BOLD></HIL><PDAT> provides a structure </PDAT><HIL><BOLD><PDAT>704</PDAT></BOLD></HIL><PDAT> of alternating layers of high and low index polymer surrounding an air core </PDAT><HIL><BOLD><PDAT>706</PDAT></BOLD></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00063" LVL="0"><PTEXT><PDAT>Although the present invention has been shown and described with respect to several preferred embodiments thereof, various changes, omissions and additions to the form and detail thereof, may be made therein, without departing from the spirit and scope of the invention.</PDAT></PTEXT></PARA>
</BTEXT>
</DETDESC>
</SDODE>
<SDOCL>
<H LVL="1"><STEXT><PDAT>What is claimed is: </PDAT></STEXT></H>
<CL>
<CLM ID="CLM-00001">
<PARA ID="P-00064" LVL="0"><PTEXT><PDAT>1. A device comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>at least one dielectric inner core region in which electromagnetic radiation is confined; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>at least two outer regions comprising dielectric material surrounding the inner core region, each with a distinct isotropic refractive index, said outer regions confining electromagnetic radiation within said inner core region, wherein the refractive indices, the number of outer regions, and thickness of the outer regions result in a reflectivity for a planar geometry that is greater than 95% for angles of incidence ranging from 0&deg; to at least 80&deg; for all polarizations for a range of wavelengths of said electromagnetic radiation, and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>wherein during operation the outer regions guide the electromagnetic radiation within the dielectric inner core region. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00002">
<PARA ID="P-00065" LVL="0"><PTEXT><PDAT>2. The device of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said device is utilized to guide electromagnetic radiation in a plurality of broadband region.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00003">
<PARA ID="P-00066" LVL="0"><PTEXT><PDAT>3. The device of </PDAT><CLREF ID="CLM-00002"><PDAT>claim 2</PDAT></CLREF><PDAT>, wherein the electromagnetic radiation in said broadband regions is single mode.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00004">
<PARA ID="P-00067" LVL="0"><PTEXT><PDAT>4. The device of </PDAT><CLREF ID="CLM-00002"><PDAT>claim 2</PDAT></CLREF><PDAT>, wherein the electromagnetic radiation in said broadband regions is multi-mode.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00005">
<PARA ID="P-00068" LVL="0"><PTEXT><PDAT>5. The device of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said device comprises a hexagonal cross section.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00006">
<PARA ID="P-00069" LVL="0"><PTEXT><PDAT>6. The device of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said inner core region comprises a low dielectric material.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00007">
<PARA ID="P-00070" LVL="0"><PTEXT><PDAT>7. The device of </PDAT><CLREF ID="CLM-00006"><PDAT>claim 6</PDAT></CLREF><PDAT>, wherein said inner core region comprises a gas.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00008">
<PARA ID="P-00071" LVL="0"><PTEXT><PDAT>8. The device of </PDAT><CLREF ID="CLM-00007"><PDAT>claim 7</PDAT></CLREF><PDAT>, wherein said inner core region comprises air.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00009">
<PARA ID="P-00072" LVL="0"><PTEXT><PDAT>9. The device of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the outer regions comprise alternating layers of low and high dielectric materials.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00010">
<PARA ID="P-00073" LVL="0"><PTEXT><PDAT>10. The device of </PDAT><CLREF ID="CLM-00009"><PDAT>claim 9</PDAT></CLREF><PDAT>, wherein said low dielectric material comprises a polymer or a glass.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00011">
<PARA ID="P-00074" LVL="0"><PTEXT><PDAT>11. The device of </PDAT><CLREF ID="CLM-00009"><PDAT>claim 9</PDAT></CLREF><PDAT>, wherein said high dielectric material comprises germanium or tellurium.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00012">
<PARA ID="P-00075" LVL="0"><PTEXT><PDAT>12. The device of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the outer regions comprise alternating layers of dielectric and thin metal materials.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00013">
<PARA ID="P-00076" LVL="0"><PTEXT><PDAT>13. The device of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said inner core region has dimensions on the order of the wavelength of said electromagnetic radiation.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00014">
<PARA ID="P-00077" LVL="0"><PTEXT><PDAT>14. The device of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said inner core region has dimensions larger than the wavelength of said electromagnetic radiation.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00015">
<PARA ID="P-00078" LVL="0"><PTEXT><PDAT>15. The device of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said device is utilized to guide high power electromagnetic radiation.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00016">
<PARA ID="P-00079" LVL="0"><PTEXT><PDAT>16. The device of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said device is utilized to guide high power electromagnetic radiation around bends.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00017">
<PARA ID="P-00080" LVL="0"><PTEXT><PDAT>17. The device of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said device is utilized to guide electromagnetic radiation in at least one broadband region.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00018">
<PARA ID="P-00081" LVL="0"><PTEXT><PDAT>18. The device of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said device is utilized as a microcavity to confine electromagnetic radiation.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00019">
<PARA ID="P-00082" LVL="0"><PTEXT><PDAT>19. The device of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said device comprises a circular cross section.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00020">
<PARA ID="P-00083" LVL="0"><PTEXT><PDAT>20. The device of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said device comprises a rectangular cross section.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00021">
<PARA ID="P-00084" LVL="0"><PTEXT><PDAT>21. The device of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said device comprises a triangular cross section.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00022">
<PARA ID="P-00085" LVL="0"><PTEXT><PDAT>22. A waveguide which exhibits omnidirectional reflection, comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>at least one dielectric inner core region in which light is confined; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>at least two outer regions comprising dielectric material surrounding the inner core region, each with a distinct isotropic refractive index, said outer regions confining light within said inner core region, wherein </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>the refractive indices, the number of outer regions, and thickness of the outer regions result in a reflectivity for a planar geometry that is greater than 95% for angles of incidence ranging from 0&deg; to at least 80&deg; for all polarizations for a range of wavelengths of said light, and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>wherein during operation the outer regions guide the electromagnetic radiation within the dielectric inner core region. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00023">
<PARA ID="P-00086" LVL="0"><PTEXT><PDAT>23. A microcavity comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>at least one dielectric inner core region in which light is confined; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>at least two outer regions comprising dielectric material surrounding the inner core region, each with a distinct isotropic refractive index, said outer regions confining light within said inner core region, wherein </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>the refractive indices, the number of outer regions, and thickness of the outer regions result in a reflectivity for a planar geometry that is greater than 95% for angles of incidence ranging from 0&deg; to at least 80&deg; for all polarizations for a range of wavelengths of said light.</PDAT></PTEXT></CLMSTEP>
</CLM>
</CL>
</SDOCL>
<SDODR ID="DRAWINGS">
<EMI ID="EMI-D00000" ALT="embedded image" FILE="US06463200-20021008-D00000.TIF"/>
<EMI ID="EMI-D00001" ALT="embedded image" FILE="US06463200-20021008-D00001.TIF"/>
<EMI ID="EMI-D00002" ALT="embedded image" FILE="US06463200-20021008-D00002.TIF"/>
<EMI ID="EMI-D00003" ALT="embedded image" FILE="US06463200-20021008-D00003.TIF"/>
<EMI ID="EMI-D00004" ALT="embedded image" FILE="US06463200-20021008-D00004.TIF"/>
<EMI ID="EMI-D00005" ALT="embedded image" FILE="US06463200-20021008-D00005.TIF"/>
<EMI ID="EMI-D00006" ALT="embedded image" FILE="US06463200-20021008-D00006.TIF"/>
<EMI ID="EMI-D00007" ALT="embedded image" FILE="US06463200-20021008-D00007.TIF"/>
</SDODR>
</PATDOC>

